TW202325848A - 用於基因體編輯之多核苷酸、組合物及方法 - Google Patents
用於基因體編輯之多核苷酸、組合物及方法 Download PDFInfo
- Publication number
- TW202325848A TW202325848A TW111141875A TW111141875A TW202325848A TW 202325848 A TW202325848 A TW 202325848A TW 111141875 A TW111141875 A TW 111141875A TW 111141875 A TW111141875 A TW 111141875A TW 202325848 A TW202325848 A TW 202325848A
- Authority
- TW
- Taiwan
- Prior art keywords
- polynucleotide
- nucleotides
- sequence
- orf
- seq
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 291
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 291
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 291
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 73
- 238000010362 genome editing Methods 0.000 title abstract description 8
- 108091033409 CRISPR Proteins 0.000 claims abstract description 125
- 230000004568 DNA-binding Effects 0.000 claims abstract description 47
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 15
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 499
- 125000003729 nucleotide group Chemical group 0.000 claims description 408
- 239000002773 nucleotide Substances 0.000 claims description 380
- 108700026244 Open Reading Frames Proteins 0.000 claims description 345
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 223
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 223
- 229940045145 uridine Drugs 0.000 claims description 223
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 222
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 182
- 229930024421 Adenine Natural products 0.000 claims description 173
- 229960000643 adenine Drugs 0.000 claims description 173
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 172
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 157
- 229920001184 polypeptide Polymers 0.000 claims description 152
- 108020005004 Guide RNA Proteins 0.000 claims description 143
- 150000002632 lipids Chemical class 0.000 claims description 122
- -1 lipid nucleic acid Chemical class 0.000 claims description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 102
- 108020004999 messenger RNA Proteins 0.000 claims description 101
- 102000039446 nucleic acids Human genes 0.000 claims description 101
- 108020004707 nucleic acids Proteins 0.000 claims description 101
- 108020004705 Codon Proteins 0.000 claims description 96
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 94
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 94
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 claims description 93
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 86
- 230000014509 gene expression Effects 0.000 claims description 69
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 54
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 46
- 108091026890 Coding region Proteins 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 40
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 29
- 229940035893 uracil Drugs 0.000 claims description 27
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 26
- 229930185560 Pseudouridine Natural products 0.000 claims description 26
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 25
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 24
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 24
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 24
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 23
- 239000003316 glycosidase inhibitor Substances 0.000 claims description 21
- 238000013519 translation Methods 0.000 claims description 21
- 229940122069 Glycosidase inhibitor Drugs 0.000 claims description 20
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 101150065592 NME2 gene Proteins 0.000 claims description 12
- 101150001372 Nme1 gene Proteins 0.000 claims description 11
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 claims description 10
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 210000002706 plastid Anatomy 0.000 claims description 9
- 101150077194 CAP1 gene Proteins 0.000 claims description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 8
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims description 8
- 101150014715 CAP2 gene Proteins 0.000 claims description 7
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 230000008488 polyadenylation Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 239000002777 nucleoside Substances 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002479 lipoplex Substances 0.000 claims description 3
- 108020004513 Bacterial RNA Proteins 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 102100026846 Cytidine deaminase Human genes 0.000 claims 8
- 102100031726 Endoplasmic reticulum junction formation protein lunapark Human genes 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract description 51
- 230000002829 reductive effect Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 150000007523 nucleic acids Chemical group 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 64
- 235000018102 proteins Nutrition 0.000 description 62
- 108020004414 DNA Proteins 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 48
- 241000282414 Homo sapiens Species 0.000 description 47
- 229920001223 polyethylene glycol Polymers 0.000 description 46
- 229940024606 amino acid Drugs 0.000 description 40
- 102000005381 Cytidine Deaminase Human genes 0.000 description 38
- 101710163270 Nuclease Proteins 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 25
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000001939 inductive effect Effects 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 102200097286 rs199472825 Human genes 0.000 description 16
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 16
- 108020004566 Transfer RNA Proteins 0.000 description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108090000856 Lyases Proteins 0.000 description 13
- 102000004317 Lyases Human genes 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 11
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 11
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000005782 double-strand break Effects 0.000 description 11
- 229920002401 polyacrylamide Polymers 0.000 description 11
- 238000012384 transportation and delivery Methods 0.000 description 11
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 10
- 230000000712 assembly Effects 0.000 description 10
- 238000000429 assembly Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 102000044159 Ubiquitin Human genes 0.000 description 8
- 108090000848 Ubiquitin Proteins 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 150000001241 acetals Chemical class 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 6
- 102000034287 fluorescent proteins Human genes 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 5
- 241000180579 Arca Species 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- FZWGECJQACGGTI-UHFFFAOYSA-N N7-methylguanine Natural products NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000010874 in vitro model Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 101900341982 Escherichia coli Uracil-DNA glycosylase Proteins 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000009615 deamination Effects 0.000 description 4
- 238000006481 deamination reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 102000048646 human APOBEC3A Human genes 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108010054624 red fluorescent protein Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000013607 AAV vector Substances 0.000 description 3
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 description 3
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- 238000010442 DNA editing Methods 0.000 description 3
- 241000701533 Escherichia virus T4 Species 0.000 description 3
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 description 3
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 101710172430 Uracil-DNA glycosylase inhibitor Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 108010021843 fluorescent protein 583 Proteins 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910052594 sapphire Inorganic materials 0.000 description 3
- 239000010980 sapphire Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BBGNINPPDHJETF-UHFFFAOYSA-N 5-heptadecylresorcinol Chemical compound CCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 BBGNINPPDHJETF-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 108091005941 EBFP Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 description 2
- 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 2
- 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 2
- 102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000002488 Nucleoplasmin Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 2
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102100021012 Ubiquitin-fold modifier 1 Human genes 0.000 description 2
- 101710082264 Ubiquitin-fold modifier 1 Proteins 0.000 description 2
- 101710082247 Ubiquitin-like protein 5 Proteins 0.000 description 2
- 102100030580 Ubiquitin-like protein 5 Human genes 0.000 description 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 2
- 102100031319 Ubiquitin-related modifier 1 Human genes 0.000 description 2
- 101710144315 Ubiquitin-related modifier 1 Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- HVVJCLFLKMGEIY-USYZEHPZSA-N [(2R)-2,3-dioctadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-USYZEHPZSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000010441 alabaster Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LKPJRFVEJFVTFQ-UHFFFAOYSA-N hentriacontane-15,16,17-triol Chemical compound CCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCC LKPJRFVEJFVTFQ-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 108060005597 nucleoplasmin Proteins 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010381 tandem affinity purification Methods 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- QEHCYTDFERPPPU-KDXMTYKHSA-N (2s)-2,3-dioctadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OCCCCCCCCCCCCCCCCCC QEHCYTDFERPPPU-KDXMTYKHSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- MGAXHFMCFLLMNG-UHFFFAOYSA-N 1h-pyrimidine-6-thione Chemical compound SC1=CC=NC=N1 MGAXHFMCFLLMNG-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical compound N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- ZAOGIVYOCDXEAK-UHFFFAOYSA-N 6-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=NC2=C1NC=N2 ZAOGIVYOCDXEAK-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229930188104 Alkylresorcinol Natural products 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 241000702199 Bacillus phage PBS2 Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101100135890 Caenorhabditis elegans pdi-6 gene Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 108091005943 CyPet Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108091005947 EBFP2 Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 101100176848 Escherichia phage N15 gene 15 gene Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710105047 Lipoprotein B Proteins 0.000 description 1
- 101000986081 Macaca mulatta Mamu class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100031911 NEDD8 Human genes 0.000 description 1
- 108700004934 NEDD8 Proteins 0.000 description 1
- 101150107958 NEDD8 gene Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 1
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108010012974 RNA triphosphatase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 102100029462 Sodium-dependent lysophosphatidylcholine symporter 1 Human genes 0.000 description 1
- 101710185583 Sodium-dependent lysophosphatidylcholine symporter 1 Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710087750 Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 244000042295 Vigna mungo Species 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- AGWRKMKSPDCRHI-UHFFFAOYSA-K [[5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound COC1C(OP([O-])(=O)OCC2OC(C(O)C2O)N2C=NC3=C2N=C(N)NC3=O)C(COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OCC2OC(C(O)C2O)N2C=[N+](C)C3=C2N=C(N)NC3=O)OC1N1C=NC2=C1N=CN=C2N AGWRKMKSPDCRHI-UHFFFAOYSA-K 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012012 beta Karyopherins Human genes 0.000 description 1
- 108010075890 beta Karyopherins Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 102000006783 calponin Human genes 0.000 description 1
- 108010086826 calponin Proteins 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 108700015457 human APOBEC3 Proteins 0.000 description 1
- 102000052632 human APOBEC3 Human genes 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ANALPBDHFRPGER-UHFFFAOYSA-N nonyl 8-[7,7-dioctoxyheptyl(2-hydroxyethyl)amino]octanoate Chemical compound C(CCCCCCC)OC(CCCCCCN(CCCCCCCC(=O)OCCCCCCCCC)CCO)OCCCCCCCC ANALPBDHFRPGER-UHFFFAOYSA-N 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000028499 poly(A) binding Human genes 0.000 description 1
- 108091023021 poly(A) binding Proteins 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002946 poly[2-(methacryloxy)ethyl phosphorylcholine] polymer Polymers 0.000 description 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- AJAMRCUNWLZBDF-UHFFFAOYSA-N propyl octadeca-9,12-dienoate Chemical compound CCCCCC=CCC=CCCCCCCCC(=O)OCCC AJAMRCUNWLZBDF-UHFFFAOYSA-N 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 101150024074 rub1 gene Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108091005946 superfolder green fluorescent proteins Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
本發明提供用於基因編輯之組合物及方法。在一些實施例中，提供一種編碼經RNA引導之DNA結合劑，諸如奈瑟氏腦膜炎菌(
N. meningitidis) Cas9之多核苷酸，其可提供改良之編輯效率、降低之免疫原性或其他益處中之一或多者。
Description
本發明係關於用於基因體編輯的多核苷酸、組合物及方法，該基因體編輯涉及經RNA引導之DNA結合劑，諸如CRISPR-Cas系統及其次單位。
經RNA引導之DNA結合劑，諸如CRISPR-Cas系統可用於進行靶向基因體編輯，包括在真核細胞中及活體內。已顯示此類編輯能夠不活化某些有害等位基因或校正某些有害點突變。舉例而言，奈瑟氏腦膜炎菌(
Neisseria meningitidis) Cas9 (NmeCas9)具有有利的低脫靶裂解速率。經RNA引導之DNA結合劑可藉由使細胞與多核苷酸，諸如mRNA或表現構築體接觸而原位產生。然而，現有方法，例如在某些細胞類型或生物體(諸如哺乳動物)中，可提供不如所需的穩健表達，或可具有不希望的免疫原性，例如可引起細胞介素水平之非所需升高。
因此，需要用於表現多肽，諸如NmeCas9之多核苷酸、組合物及方法。本發明旨在提供用於多肽表現之組合物及方法，其提供一或多種益處，諸如以下中之至少一者：改良表現量、增加經編碼多肽之活性或降低免疫原性(例如投與後降低細胞介素之升高降低)，或至少為公眾提供適用選擇。在一些實施例中，提供一種編碼經RNA引導之DNA結合劑(例如NmeCas9)的多核苷酸，其中其編碼序列、密碼子使用、非編碼序列(例如UTR)或異源結構域(例如NLS)中之一或多者以本文所揭示之方式不同於現有多核苷酸。已發現此類特徵可提供諸如上文所述之益處。在一些實施例中，經改良之編輯效率出現在哺乳動物之器官或細胞型，諸如肝臟或肝細胞中或對其具有特異性。
本發明提供以下實施例。
在一些實施例中，提供一種多核苷酸，該多核苷酸包含開放閱讀框架(ORF)，該ORF包含：編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、或301-303及317-321中之任一者至少90%一致，其中Nme Cas9為Nme2 Cas9、Nme1 Cas9或Nme3 Cas9；及編碼第一核定位信號(NLS)之核苷酸序列。
在一些實施例中，ORF進一步包含編碼第二NLS之核苷酸序列。在一些實施例中，第一及第二NLS獨立地選自SEQ ID NO: 388及410-422。在一些實施例中，多核苷酸進一步包含poly-A序列或聚腺苷酸化信號序列。
在一些實施例中，ORF進一步包含編碼第一NLS與第二NLS之間的連接子序列之核苷酸序列。在一些實施例中，ORF進一步包含編碼Nme Cas9編碼序列與接近Nme Cas9編碼序列之NLS之間的連接子間隔序列之核苷酸序列。在一些實施例中，ORF Nme Cas9具有雙股核酸內切酶活性。在一些實施例中，ORF Nme Cas9具有切口酶活性。在一些實施例中，ORF Nme Cas9包含dCas9 DNA結合域。
以下經編號實施例提供對本文中之實施例之額外支援及描述。
實施例1為包含開放閱讀框架(ORF)之多核苷酸，該ORF包含：編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致，其中Nme Cas9為Nme2 Cas9、Nme1 Cas9或Nme3 Cas9；及編碼第一核定位信號(NLS)之核苷酸序列。
實施例2為如實施例1之多核苷酸，其中ORF進一步包含編碼第二NLS之核苷酸序列。
實施例3為如實施例1之多核苷酸，其中第一及第二NLS獨立地選自SEQ ID NO: 388及410-422。
實施例4為如實施例1-3中任一項之多核苷酸，其中該多核苷酸進一步包含poly-A序列或聚腺苷酸化信號序列。
實施例5為如實施例4之多核苷酸，其中該poly-A序列包含非腺嘌呤核苷酸。
實施例6為如實施例4-5中任一項之多核苷酸，其中該poly-A序列包含100-400個核苷酸。
實施例7為如實施例4-6中任一項之多核苷酸，其中poly-A序列包含SEQ ID NO: 409之序列。
實施例8為如實施例1-7中任一項之多核苷酸，其中該ORF進一步包含編碼第一NLS與第二NLS之間的連接子序列之核苷酸序列。
實施例9為如實施例1-8中任一項之多核苷酸，其中該ORF進一步包含編碼Nme Cas9編碼序列與接近Nme Cas9編碼序列之NLS之間的連接子間隔序列的核苷酸序列。
實施例10為如實施例8-9中任一項之多核苷酸，其中該連接子包含至少1個、至少2個、至少3個、至少4個、至少5個、至少6個、至少7個、至少8個、至少9個或至少10個胺基酸。
實施例11為如實施例8-10中任一項之多核苷酸，其中該連接子序列包含GGG或GGGS，視情況其中該GGG或GGGS序列位於該間隔序列之N末端處。
實施例12為如實施例8-11中任一項之多核苷酸，其中該連接子序列包含SEQ ID NO: 61-122中之任一者之序列。
實施例13為如實施例1-12中任一項之多核苷酸，其中該ORF進一步包含一或多個額外異源功能域。
實施例14為如實施例1-13中任一項之多核苷酸，其中該Nme Cas9具有雙股核酸內切酶活性。
實施例15為如實施例1-14中任一項之多核苷酸，其中該Nme Cas9具有切口酶活性。
實施例16為如實施例1-14中任一項之多核苷酸，其中該Nme Cas9包含dCas9 DNA結合域。
實施例17為如實施例1-16中任一項之多核苷酸，其中NmeCas9包含與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315中之任一者具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%之胺基酸序列。
實施例18為如實施例1-17中任一項之多核苷酸，其中NmeCas9包含SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315之胺基酸序列。
實施例19為如實施例1-18中任一項之多核苷酸，其中編碼NmeCas9之序列包含與SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者之核苷酸序列具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%一致性之核苷酸序列。
實施例20為如實施例1-19中任一項之多核苷酸，其中編碼NmeCas9之序列包含SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者之核苷酸序列。
實施例21為包含編碼多肽之開放閱讀框架(ORF)之多核苷酸，該多肽包含：胞苷脫胺酶，其視情況為APOBEC3A脫胺酶；編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9切口酶多肽之核苷酸序列，其與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297中之任一者至少90%一致，其中Nme Cas9切口酶為Nme2 Cas9切口酶、Nme1 Cas9切口酶或Nme3 Cas9切口酶；及編碼第一核定位信號(NLS)之核苷酸序列；其中多肽不包含尿嘧啶醣苷酶抑制劑(UGI)。
實施例22為如實施例21之多核苷酸，其中ORF進一步包含編碼第二NLS之核苷酸序列。
實施例23為如實施例21-22中任一項之多核苷酸，其中該脫胺酶位於該多肽中之NLS的N末端。
實施例24為如實施例21-23中任一項之多核苷酸，其中胞苷脫胺酶位於多肽中之第一NLS及第二NLS之N末端。
實施例25為如實施例21-22中任一項之多核苷酸，其中胞苷脫胺酶位於該多肽中之NLS的C末端。
實施例26為如實施例23-25中任一項之多核苷酸，其中胞苷脫胺酶位於多肽中之第一NLS及第二NLS之C末端。
實施例27為如實施例21-26中任一項之多核苷酸，其中ORF不包含位於編碼Nme Cas9之ORF之C末端的NLS之編碼序列。
實施例28為如實施例21-26中任一項之多核苷酸，其中ORF不包含位於編碼Nme Cas9之ORF之C末端的編碼序列。
實施例29為如實施例1-28中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 151具有至少87%一致性之胺基酸序列。
實施例30為如實施例1-28中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 152-216具有至少80%一致性之胺基酸序列。
實施例31為如實施例1-28中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 14具有至少80%一致性之胺基酸序列。
實施例32為如實施例1-31中任一項之多核苷酸，ORF包含與SEQ ID NO: 42具有至少80%一致性之核苷酸序列。
實施例33為如實施例1-32中任一項之多核苷酸，其中多核苷酸包含與SEQ ID NO: 391-398中之任一者具有至少90%一致性之5' UTR。
實施例34為如實施例1-33中任一項之多核苷酸，其中多核苷酸含有包含SEQ ID NO: 391-398中之任一者的5' UTR。
實施例35為如實施例1-34中任一項之多核苷酸，其中多核苷酸包含與SEQ ID NO: 399-406中之任一者具有至少90%一致性之3' UTR。
實施例36為如實施例1-35中任一項之多核苷酸，其中多核苷酸含有包含SEQ ID NO: 399-306中之任一者的3' UTR。
實施例37為如實施例1-36中任一項之多核苷酸，其中多核苷酸包含來自相同來源之5' UTR及3' UTR。
實施例38為如實施例1-37中任一項之多核苷酸，其中多核苷酸包含5'帽，視情況其中5'帽為Cap0、Cap1或Cap2。
實施例39為如實施例1-38中任一項之多核苷酸，其中ORF之至少75%、80%、85%、90%、95%、98%、99%或100%的密碼子為最小腺嘌呤密碼子或最小尿苷密碼子。
實施例40為如實施例1-39中任一項之多核苷酸，其中ORF包含增加哺乳動物中mRNA之轉譯的密碼子或由其組成。
實施例41為如實施例1-40中任一項之多核苷酸，其中ORF包含增加人類中mRNA之轉譯的密碼子或由其組成。
實施例42為如實施例1-41中任一項之多核苷酸，其中多核苷酸為mRNA。
實施例43為如實施例42之多核苷酸，其中ORF包含與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者具有至少90%、95%、98%或100%一致性之序列。
實施例44為如實施例42-43中任一項之多核苷酸，其中mRNA中至少10%之尿苷經經修飾之尿苷取代。
實施例45為如實施例42-43中任一項之多核苷酸，其中mRNA中小於10%之尿苷經經修飾之尿苷取代。
實施例46為如實施例45之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷、假尿苷、5-甲氧基尿苷或5-碘尿苷中之一或多者。
實施例47為如實施例45之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷或5-甲氧基尿苷中之一或兩者。
實施例48為如實施例45-47中任一項之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷。
實施例49為如實施例45-47中任一項之多核苷酸，其中經修飾之尿苷為5-甲氧基尿苷。
實施例50為如實施例44及46-49中任一項之多核苷酸，其中15%至45%之尿苷經經修飾之尿苷取代。
實施例51為如實施例50之多核苷酸，其中至少20%或至少30%之尿苷經經修飾之尿苷取代。
實施例52為如實施例51之多核苷酸，其中至少80%或至少90%之尿苷經經修飾之尿苷取代。
實施例53為如實施例52之多核苷酸，其中100%之尿苷經經修飾之尿苷取代。
實施例54為如實施例42之多核苷酸，其中mRNA中小於10%之核苷酸經經修飾之核苷酸取代。
實施例55為一種組合物，其包含如實施例1-54中任一項之多核苷酸及至少一種引導RNA (gRNA)。
實施例56為一種組合物，其包含第一多核苷酸，該第一多核苷酸包含編碼包含胞苷脫胺酶，視情況APOBEC3A脫胺酶，及NmeCas9切口酶之多肽的第一開放閱讀框架(ORF)，及第二多核苷酸，該第二多核苷酸包含編碼尿嘧啶醣苷酶抑制劑(UGI)之第二開放閱讀框架，其中第二多核苷酸不同於第一多核苷酸，且視情況進一步包含引導RNA (gRNA)。
實施例57為如實施例55或56之組合物，其中gRNA為單引導RNA。
實施例58為如實施例55或56之組合物，其中gRNA為雙引導RNA。
實施例59為一種組合物，其包含如實施例1-57中任一項之多核苷酸，進一步包含單引導RNA，其中單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-48及53-64中之一或多者經缺失，且視情況核苷酸37-64中之一或多者經取代；及
(ii)核苷酸36藉由至少2個核苷酸連接至核苷酸65；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-86及91-95中之一或多者經缺失，且視情況位置82-96中之一或多者經取代；及
(ii)核苷酸81藉由至少4個核苷酸連接至核苷酸96；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-121及126-134中之一或多者經缺失，且視情況核苷酸113-134中之一或多者經取代；及
(ii)核苷酸112藉由至少4個核苷酸連接至核苷酸135；
其中核苷酸144-145中之一或兩者相對於SEQ ID NO: 500視情況經缺失；
其中至少10個核苷酸為經修飾之核苷酸。
實施例60為一種組合物，其包含如實施例1-57中任一項之多核苷酸，進一步包含單引導RNA，其中單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-64中之一或多者經缺失且視情況經取代；且
(ii)核苷酸36藉由以下各者連接至核苷酸65：(i)單獨或與核苷酸組合取代4個核苷酸之第一內部連接子，或(ii)至少4個核苷酸；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-95中之一或多者經缺失且視情況經取代；且
(ii)核苷酸81藉由以下各者連接至核苷酸96：(i)單獨或與核苷酸組合取代4個核苷酸之第二內部連接子，或(ii)至少4個核苷酸；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-134中之一或多者經缺失且視情況經取代；且
(ii)核苷酸112藉由以下各者連接至核苷酸135：(i)單獨或與核苷酸組合取代4個核苷酸之第三內部連接子，或(ii)至少4個核苷酸；
其中核苷酸144-145中之一者或兩者相比於SEQ ID NO: 500視情況經缺失；
其中該gRNA包含該第一內部連接子、該第二內部連接子及該第三內部連接子中之至少一者。
實施例61為由如實施例1-60中任一項之多核苷酸編碼的多肽。
實施例62係一種載體，其包含如實施例1-60中任一項之多核苷酸。
實施例63為一種表現構築體，其包含可操作地連接於編碼如實施例1-60中任一項之多核苷酸之序列的啟動子。
實施例64為如實施例63之表現構築體，其中啟動子為RNA聚合酶啟動子，視情況為細菌RNA聚合酶啟動子。
實施例65為如實施例63或64之表現構築體，其進一步包含poly-A尾序列或聚腺苷酸化信號序列。
實施例66為如實施例65之表現構築體，其中poly-A尾序列為經編碼poly-A尾序列。
實施例67為包含如實施例63-66中任一項之表現構築體的質體。
實施例68為一種宿主細胞，其包含如實施例62之載體、如實施例63-66中任一項之表現構築體或如實施例67之質體。
實施例69為一種醫藥組合物，其包含如實施例1-61中任一項之多核苷酸、組合物或多肽及醫藥學上可接受之載劑。
實施例70為一種套組，其包含如實施例1-61中任一項之多核苷酸、組合物或多肽。
實施例71為如實施例1-61中任一項之多核苷酸、組合物或多肽之用途，其用於修飾細胞中之目標基因。
實施例72為如實施例1-61中任一項之多核苷酸、組合物或多肽之用途，其用於製造供修飾細胞中之目標基因用之藥劑。
實施例73為如實施例1-60中任一項之多核苷酸或組合物，其中該多核苷酸或組合物調配為脂質核酸組裝組合物，視情況調配為脂質奈米粒子。
實施例74為一種修飾目標基因之方法，其包含向細胞遞送如實施例1-61中任一項之多核苷酸、多肽或組合物。
實施例75為一種修飾目標基因之方法，其包含向細胞遞送一或多種包含如實施例1-60中任一項之多核苷酸及一或多種引導RNA之脂質核酸組裝組合物，視情況脂質奈米粒子。
實施例76為如實施例74-75中任一項之方法，其中至少一種脂質核酸組裝組合物包含脂質奈米粒子(LNP)，視情況其中所有脂質核酸組裝組合物包含LNP。
實施例77為如實施例74-75中任一項之方法，其中至少一種脂質核酸組裝組合物為脂複合體組合物。
實施例78為如實施例75-77中任一項之組合物或方法，其中脂質核酸組裝組合物包含可離子化脂質。
實施例79為產生如實施例1-54中任一項之多核苷酸之方法，其包含使如實施例63-66之表現構築體與RNA聚合酶及包含至少一個經修飾之核苷酸的NTP接觸。
實施例80為實施例79之方法，其中NTP包含一個經修飾之核苷酸。
實施例81為如實施例79或80之方法，其中經修飾之核苷酸包含經修飾之尿苷。
實施例82為如實施例81之方法，其中至少80%或至少90%或100%之尿苷位置為經修飾之尿苷。
實施例83為如實施例81或82之方法，其中該經修飾之尿苷包含或為經取代之尿苷、假尿苷或經取代之假尿苷，視情況N1-甲基-假尿苷。
實施例84為如實施例79-83中任一項之方法，其中表現構築體包含經編碼poly-A尾序列。
本申請案主張2021年11月3日申請之美國臨時申請案第63/275,425號及2022年6月14日申請之美國臨時申請案第63/352,158號之優先權，該等申請案之內容均以全文引用之方式併入。
所揭示序列之簡要說明
轉錄本序列一般包括GGG作為供與ARCA一起使用的前三個核苷酸，或包括AGG作為供與CleanCap
TM一起使用的前三個核苷酸。因此，可對前三個核苷酸進行修飾以供與其他加帽方法，諸如牛痘(Vaccinia)加帽酶一起使用。啟動子及poly-A序列不包括於轉錄本序列中。諸如U6啟動子(SEQ ID NO: 389)之啟動子或CMV啟動子(SEQ ID NO: 390)及諸如SEQ ID NO: 409之poly-A序列可分別在5'端及3'端處附接至所揭示之轉錄本序列。大多數核苷酸序列以DNA形式提供，但可藉由將T變成U而容易轉化成RNA。
| SEQ ID NO | 描述 |
| 1 | Nme2Cas9之例示性胺基酸序列 |
| 2 | SpyCas9鹼基編輯劑之例示性胺基酸序列 |
| 3 | UGI之例示性胺基酸序列 |
| 4-8 | Nme2Cas9之例示性胺基酸序列 |
| 9 | 具有HiBiT標籤之Nme2Cas9之例示性胺基酸序列 |
| 10 | Nme2Cas9之例示性胺基酸序列 |
| 11 | Nme2Cas9之例示性胺基酸序列 |
| 12 | 具有HiBiT標籤之Nme2Cas9之例示性胺基酸序列 |
| 13 | Nme2Cas9之例示性胺基酸序列 |
| 14 | Nme2Cas9鹼基編輯劑之例示性胺基酸序列 |
| 15 | 編碼Nme2Cas9之例示性mRNA |
| 16 | 編碼SpyCas9鹼基編輯劑之例示性mRNA |
| 17 | 編碼UGI之例示性mRNA |
| 18-22 | 編碼Nme2Cas9之例示性mRNA |
| 23 | 具有HiBiT標籤之例示性編碼Nme2Cas9 |
| 24 | 編碼Nme2Cas9之例示性mRNA |
| 25 | 編碼Nme2Cas9之例示性mRNA |
| 26 | 具有HiBiT標籤之例示性編碼Nme2Cas9 |
| 27 | 編碼Nme2Cas9之例示性mRNA |
| 28 | 編碼Nme2Cas9鹼基編輯劑之例示性mRNA |
| 29 | Nme2Cas9之開放閱讀框架 |
| 30 | SpyCas9鹼基編輯劑之開放閱讀框架 |
| 31 | UGI之開放閱讀框架 |
| 32-36 | Nme2Cas9之開放閱讀框架 |
| 37 | 具有HiBiT標籤之Nme2Cas9之開放閱讀框架 |
| 38 | Nme2Cas9之開放閱讀框架序列 |
| 39 | Nme2Cas9之開放閱讀框架序列 |
| 40 | 具有HiBiT標籤之Nme2Cas9之開放閱讀框架 |
| 41 | Nme2Cas9之開放閱讀框架序列 |
| 42 | Nme2Cas9鹼基編輯劑之開放閱讀框架 |
| 43-47 | 編碼Sp. Cas9之ORF |
| 48 | Sp. Cas9之胺基酸序列 |
| 49 | 具有HiBiT標籤之Cas9之開放閱讀框架 |
| 50 | 具有HiBiT標籤之Cas9之胺基酸序列 |
| 51-57 | 未使用 |
| 58-122 | 肽連接子之例示性胺基酸序列 |
| 123-129 | 未使用 |
| 130-150 | 例示性引導RNA序列 |
| 151-216 | 胞苷脫胺酶之例示性胺基酸序列 |
| 217-219 | 未使用 |
| 220 | Nme1Cas9裂解酶之例示性胺基酸序列 |
| 221-223 | 編碼Nme1Cas9裂解酶之例示性編碼序列 |
| 224-226 | Nme1Cas9裂解酶之例示性開放閱讀框架 |
| 227 | Nme1Cas9 dCas9之例示性胺基酸序列 |
| 228-230 | 編碼Nme1Cas9 dCas9之例示性編碼序列 |
| 231-233 | Nme1Cas9 dCas9之例示性開放閱讀框架 |
| 234 | Nme1Cas9 RuvC切口酶之例示性胺基酸序列 |
| 235-237 | 編碼Nme1Cas9 RuvC切口酶之例示性編碼序列 |
| 238-240 | Nme1Cas9 RuvC切口酶之例示性開放閱讀框架 |
| 241 | Nme1Cas9 HNH切口酶之例示性胺基酸序列 |
| 242-244 | 編碼Nme1Cas9 HNH切口酶之例示性編碼序列 |
| 245-247 | Nme1Cas9 HNH切口酶之例示性開放閱讀框架 |
| 248 | Nme2Cas9裂解酶之例示性胺基酸序列 |
| 249-251 | 編碼Nme2Cas9裂解酶之例示性編碼序列 |
| 252-254 | Nme2Cas9裂解酶之例示性開放閱讀框架 |
| 255 | Nme2Cas9 dCas9之例示性胺基酸序列 |
| 256-258 | 編碼Nme2Cas9 dCas9之例示性編碼序列 |
| 259-261 | Nme2Cas9 dCas9之例示性開放閱讀框架 |
| 262 | Nme2Cas9 RuvC切口酶之例示性胺基酸序列 |
| 263-265 | 編碼Nme2Cas9 RuvC切口酶之例示性編碼序列 |
| 266-268 | Nme2Cas9 RuvC切口酶之例示性開放閱讀框架 |
| 269 | Nme2Cas9 HNH切口酶之例示性胺基酸序列 |
| 270-272 | 編碼Nme2Cas9 HNH切口酶之例示性編碼序列 |
| 273-275 | Nme2Cas9 HNH切口酶之例示性開放閱讀框架 |
| 276 | Nme3Cas9裂解酶之例示性胺基酸序列 |
| 277-279 | 編碼Nme3Cas9裂解酶之例示性編碼序列 |
| 280-282 | Nme3Cas9裂解酶之例示性開放閱讀框架 |
| 283 | Nme3Cas9 dCas9之例示性胺基酸序列 |
| 284-286 | 編碼Nme3Cas9 dCas9之例示性編碼序列 |
| 287-289 | Nme3Cas9 dCas9之例示性開放閱讀框架 |
| 290 | Nme3Cas9 RuvC切口酶之例示性胺基酸序列 |
| 291-293 | 編碼Nme3Cas9 RuvC切口酶之例示性編碼序列 |
| 294-296 | Nme3Cas9 RuvC切口酶之例示性開放閱讀框架 |
| 297 | Nme3Cas9 HNH切口酶之例示性胺基酸序列 |
| 298-300 | 編碼Nme3Cas9 HNH切口酶之例示性編碼序列 |
| 301-303 | Nme3Cas9 HNH切口酶之例示性開放閱讀框架 |
| 304 | 編碼Nme2Cas9 (mRNA AA)之例示性編碼序列 |
| 305 | 編碼Nme1Cas9 (mRNA AB)之例示性編碼序列 |
| 306 | 編碼具有HiBiT標籤之Nme2Cas9 (mRNA V)之例示性編碼序列 |
| 307 | 編碼具有HiBiT標籤之Nme1Cas9 (mRNA X)之例示性編碼序列 |
| 308 | 編碼具有HiBiT標籤之Nme1Cas9 (mRNA Y)之例示性編碼序列 |
| 309 | 編碼具有HiBiT標籤之Nme3Cas9 (mRNA Z)之例示性編碼序列 |
| 310 | Nme2Cas9 (mRNA AA胺基酸)之例示性胺基酸序列 |
| 311 | Nme1Cas9 (mRNA AB胺基酸)之例示性胺基酸序列 |
| 312 | 具有HiBiT標籤之Nme2Cas9 (mRNA V胺基酸)之例示性胺基酸序列 |
| 313 | 具有HiBiT標籤之Nme1Cas9 (mRNA X胺基酸)之例示性胺基酸序列 |
| 314 | 具有HiBiT標籤之Nme1Cas9 (mRNA Y胺基酸)之例示性胺基酸序列 |
| 315 | 具有HiBiT標籤之Nme3Cas9 (mRNA Z胺基酸)之例示性胺基酸序列 |
| 316 | Nme2Cas9之例示性開放閱讀框架(mRNA AA ORF) |
| 317 | Nme1Cas9之例示性開放閱讀框架(mRNA AB ORF) |
| 318 | 具有HiBiT標籤之Nme2Cas9之例示性開放閱讀框架(mRNA V ORF) |
| 319 | 具有HiBiT標籤之Nme1Cas9之例示性開放閱讀框架(mRNA X ORF) |
| 320 | 具有HiBiT標籤之Nme1Cas9之例示性開放閱讀框架(mRNA Y ORF) |
| 321 | 具有HiBiT標籤之Nme3Cas9之例示性開放閱讀框架(mRNA Z ORF) |
| 322-350 | 未使用 |
| 351-366 | 例示性引導RNA序列 |
| 367-382 | 未使用 |
| 383 | SV40 NLS |
| 384 | SV40 NLS |
| 385 | 雙聯NLS |
| 386 | c-myc樣NLS |
| 387 | SV40 NLS之核酸序列 |
| 388 | 用於SV40 NLS之胺基酸序列 |
| 389 | U6啟動子 |
| 390 | CMV啟動子 |
| 391 | 例示性5' UTR |
| 392 | 例示性5' UTR |
| 393 | 例示性5' UTR |
| 394 | 例示性5' UTR |
| 395 | 例示性5' UTR |
| 396 | 例示性5' UTR |
| 397 | 例示性5' UTR |
| 398 | 例示性5' UTR |
| 399 | 例示性3' UTR |
| 400 | 例示性3' UTR |
| 401 | 例示性3' UTR |
| 402 | 例示性3' UTR |
| 403 | 例示性3' UTR |
| 404 | 例示性3' UTR |
| 405 | 例示性3' UTR |
| 406 | 例示性3' UTR |
| 407 | 例示性Kozak序列 |
| 408 | 例示性Kozak序列 |
| 409 | 例示性poly-A序列 |
| 410 | 例示性NLS 1 |
| 411 | 例示性NLS 2 |
| 412 | 例示性NLS 3 |
| 413 | 例示性NLS 4 |
| 414 | 例示性NLS 5 |
| 415 | 例示性NLS 6 |
| 416 | 例示性NLS 7 |
| 417 | 例示性NLS 8 |
| 418 | 例示性NLS 9 |
| 419 | 例示性NLS 10 |
| 420 | 例示性NLS 11 |
| 421 | 替代SV40 NLS |
| 422 | 核質蛋白NLS |
| 423 | 用於SV40 NLS之例示性編碼序列 |
| 424 | 用於NLS1之例示性編碼序列 |
| 425 | 用於NLS2之例示性編碼序列 |
| 426 | 用於NLS3之例示性編碼序列 |
| 427 | 用於NLS4之例示性編碼序列 |
| 428 | 用於NLS5之例示性編碼序列 |
| 429 | 用於NLS6之例示性編碼序列 |
| 430 | 用於NLS7之例示性編碼序列 |
| 431 | 用於NLS8之例示性編碼序列 |
| 432 | 用於NLS9之例示性編碼序列 |
| 433 | 用於NLS10之例示性編碼序列 |
| 434 | 用於NLS11之例示性編碼序列 |
| 435 | 用於替代SV40 NLS之例示性編碼序列 |
| 436-458 | 例示性NmeCas9引導RNA序列 |
| 459-499 | 未使用 |
| 500 | 野生型NmeCas9引導RNA |
| 501 | 縮短/未經修飾之NmeCas9引導RNA |
| 502 | 縮短/未經修飾之NmeCas9引導RNA |
| 503 | 縮短/未經修飾之NmeCas9引導RNA |
| 504 | 僅Mod-N77保守部分 |
| 505 | 僅Mod-N78保守部分 |
| 506 | 包含內部連接子之縮短/未經修飾之NmeCas9引導RNA |
| 507 | 包含內部連接子之縮短/經修飾NmeCas9引導RNA |
| 508 | 縮短/經修飾之NmeCas9引導RNA |
現將詳細參考本發明之某些實施例，其實例在附圖中加以說明。儘管本發明將結合所說明之實施例描述，但應理解其並不意欲將本發明限於彼等實施例。相反，本發明意欲涵蓋所有替代方案、修改及等效物，其可如所附申請專利範圍所定義包括在本發明內。
在詳細描述本教示內容之前，應瞭解，本發明不限於特定組合物或方法步驟，因而可加以改變。應注意，除非上下文另外明確規定，否則如本說明書及所附申請專利範圍中所用，單數形式「一(a/an)」及「該(the)」包括複數個參考物。因此，舉例而言，提及「結合物(a conjugate)」包括複數個結合物且提及「細胞(a cell)」包括複數個細胞及其類似物。
數值範圍包括界定該範圍之數字。考慮到有效數位及與量測有關之誤差，所量測及可量測值應理解為大致的。因此，除非有相反指示，否則本說明書及所附申請專利範圍中所闡述之數值參數為可視設法獲得之所需特性而變化的近似值。至少，且不試圖將均等論之應用限於申請專利範圍之範疇，各數值參數至少應根據所報導之有效數位之個數且藉由應用一般捨入技術來解釋。
術語「約」在本文中用於意謂在此項技術中的許可差的典型範圍內。舉例而言，「約」可理解為與平均值差約2個標準差。在某些實施例中，約意謂+10%。在某些實施例中，約意謂+5%、+2%或+1%。當約存在於一系列數或範圍之前時，應理解，「約」可修飾系列中之數或範圍中之每一者。至少，且不試圖將均等論之應用限於申請專利範圍之範疇，各數值參數至少應根據所報導之有效數位之個數且藉由應用一般捨入技術來解釋。
「包含(comprise/comprises/comprising)」、「含有(contain/contains/containing)」及「包括(include/includes/including)」之使用並不意欲具有限制性。應理解，前述一般描述與詳細描述僅為例示性及解釋性的且並不限制教示內容。
一個數或一系列數前的術語「至少」應理解為包括與術語「至少」相鄰的數及可邏輯地包括在內的所有後續數或整數，如上下文所明示。舉例而言，核酸分子中之核苷酸數目必須為整數。舉例而言，「20個核苷酸之核酸分子之至少17個核苷酸」意謂17、18、19或20個核苷酸具有指定特性。當至少存在於一系列數或範圍之前時，應理解，「至少」可修飾該系列或範圍中之數中之每一者。
如本文所用，「不超過」或「小於」應理解為與片語相鄰的值，及上下文邏輯所示的邏輯較低值或整數至零。舉例而言，「不超過2個核苷酸鹼基對」之雙螺旋區具有2、1或0個核苷酸鹼基對。當「不超過」或「小於」存在於一系列數或範圍之前時，應理解，該系列或範圍中之數中之各者經修飾。
如本文所用，範圍包括上限及下限兩者。
如本文所用，應理解當值之最大量由100% (例如，100%抑制)表示時，該值係根據偵測方法解釋的。舉例而言，100%抑制及其類似者應理解為低於分析偵測水平之水平的抑制。
除非說明書中具體指出，否則本說明書中敍述「包含」各種組分之實施例亦設想為「由所敍述組分組成」或「基本上由所敍述組分組成」；本說明書中敍述「由各種組分組成」之實施例亦設想為「包含」所敍述組分或「基本上由所敍述組分組成」；且本說明書中敍述「基本上由各種組分組成」之實施例亦設想為「由所敍述組分組成」或「包含」所敍述組分(此互換性並不適用於此等術語在申請專利範圍中之使用)。
本文所用之章節標題僅出於組織目的而不應解釋為以任何方式限制所需主題。在以引用之方式併入之任何文獻與本說明書之表述內容(包括但不限於定義)相矛盾之情況下，以本說明書之表述內容為準。儘管本發明之教示係與各種實施例結合描述，但並不意欲使本發明之教示限制於此類實施例。相反，如熟習此項技術者將瞭解，本教示內容涵蓋各種替代方案、修改及等效物。
I. 定義
除非另外說明，否則如本文所用之以下術語及片語意欲具有以下含義：
如本文所用，術語「或其組合」係指在該術語前面所列項之所有排列及組合。舉例而言，「A、B、C或其組合」意欲包括以下中之至少一者：A、B、C、AB、AC、BC或ABC，且若在特定情況下順序為重要的，則亦包括BA、CA、CB、ACB、CBA、BCA、BAC或CAB。繼續此實例，明確地包括含有一或多個項或術語之重複的組合，諸如BB、AAA、AAB、BBC、AAABC、CBBA、BABB等等。本領域中熟習此項技術者應理解，除非另外自上下文顯而易知，否則通常不存在對任何組合中之項目或項之數目的限制。
如本文所用，術語「套組」係指相關組分，諸如一或多種多核苷酸或組合物及一或多種相關材料，諸如遞送裝置(例如注射器)、溶劑、溶液、緩衝劑、說明書或乾燥劑之封裝組。
除非本文另有規定，否則「或」係依包括性意義使用，亦即，等效於「及/或」。
「多核苷酸(polynucleotide)」及「核酸(nucleic acid)」在本文中用以指包含含氮雜環鹼基或鹼基類似物沿主鏈連接在一起之核苷或核苷類似物的多聚化合物，其包括習知RNA、DNA、混合RNA-DNA及為其類似物之聚合物。核酸「主鏈(backbone)」可由多個鍵聯組成，其包括糖-磷酸二酯鍵聯、肽-核酸鍵聯(「肽核酸」或PNA；PCT第WO 95/32305號)、硫代磷酸酯鍵聯、甲基膦酸酯鍵聯或其組合中之一或多者。核酸之糖部分可為核糖、去氧核糖，或具有取代(例如2'甲氧基或2'鹵基取代)之類似化合物。含氮鹼基可為習知鹼基(A、G、C、T、U)、其類似物(例如經修飾之尿苷，諸如5-甲氧基尿苷、假尿苷或N1-甲基假尿苷或其他經修飾之尿苷)、肌核苷、嘌呤或嘧啶之衍生物(例如N
4-甲基去氧鳥苷、去氮嘌呤或氮雜嘌呤、去氮嘧啶或氮雜嘧啶、在5位或6位處具有取代基之嘧啶鹼基(例如5-甲基胞嘧啶)、在2位、6位或8位處具有取代基之嘌呤鹼基、2-胺基-6-甲胺基嘌呤、O
6-甲基鳥嘌呤、4-硫基-嘧啶、4-胺基-嘧啶、4-二甲基肼-嘧啶及O
4-烷基-嘧啶；美國專利第5,378,825號及PCT第WO 93/13121號)。對於一般論述，參見The Biochemistry of the Nucleic Acids 5-36, Adams等人編, 第11版, 1992)。核酸可包括一或多個「無鹼基」殘基，其中主鏈不包括針對聚合物位置之含氮鹼基(美國專利第5,585,481號)。核酸可僅包含習知RNA或DNA糖、鹼基及鍵聯，或可包括習知組分與取代(例如具有2'甲氧基鍵聯之習知鹼基，或含有習知鹼基與一或多個鹼基類似物的聚合物)。核酸包括「鎖定核酸」(LNA)、含有一或多種LNA核苷酸單體之類似物，該等單體具有模擬糖構形之鎖定於RNA中的雙環呋喃醣單元，其會增強對互補RNA及DNA序列之雜合親和性)Vester及Wengel, 2004, Biochemistry 43(42):13233-41)。RNA及DNA具有不同糖部分且不同之處可為在RNA中存在尿嘧啶或其類似物及在DNA中存在胸腺嘧啶或其類似物。
如本文所用，「多肽」係指包含可採用三維構形之胺基酸殘基之多聚化合物。多肽包括但不限於酶、酶前驅蛋白、調節蛋白、結構蛋白、受體、核酸結合蛋白、抗體等。多肽可未必包含轉譯後修飾、非天然胺基酸、輔基及類似物。
如本文所用，「胞苷脫胺酶」意謂能夠具有胞苷脫胺酶活性之多肽或多肽複合物，其催化胞苷或去氧胞苷之水解脫胺作用，通常產生尿苷或去氧尿苷。胞苷脫胺酶涵蓋胞苷脫胺酶超家族中之酶，且特定言之APOBEC家族之酶(酶之APOBEC1、APOBEC2、APOBEC4及APOBEC3子群)、活性誘導之胞苷脫胺酶(AID或AICDA)及CMP脫胺酶(參見例如Conticello等人，Mol. Biol. Evol. 22:367-77, 2005；Conticello，Genome Biol. 9:229, 2008；Muramatsu等人，J. Biol. Chem. 274: 18470-6, 1999；Carrington等人，Cells 9:1690 (2020))。在一些實施例中，涵蓋任何已知胞苷脫胺酶或APOBEC蛋白之變異體。變異體包括具有與野生型蛋白質相差一個或若干個突變(即，取代、缺失、插入)之序列之蛋白質，該一個或若干個突變諸如一個或若干個單點取代。舉例而言，縮短序列可例如藉由使N末端、C末端或內部胺基酸缺失，較佳缺失序列C末端處之一至四個胺基酸來使用。如本文所用，術語「變異體」係指與參考序列同源之等位基因變異體、剪接變異體及天然或人工突變。變異體為「功能性的」，因為其展示DNA編輯之催化活性。
如本文所用，術語「APOBEC3A」係指胞苷脫胺酶，諸如由人類A3A基因表現之蛋白質。APOBEC3A可具有催化DNA編輯活性。已描述APOBEC3A之胺基酸序列(UniPROT寄存ID: p31941)且作為SEQ ID NO: 151包括在本文中。在一些實施例中，APOBEC3蛋白質為人類APOBEC3蛋白質或野生型蛋白質。變異體包括具有與野生型APOBEC3A蛋白質相差一個或若干個突變(即，取代、缺失、插入)之序列之蛋白質，該一個或若干個突變諸如一個或若干個單點取代。舉例而言，可使用縮短之APOBEC3A序列，例如藉由使N末端、C末端或內部胺基酸缺失，較佳地使序列之C末端處之一至四個胺基酸缺失。如本文所用，術語「變異體」係指與APOBEC3A參考序列同源之對偶基因變異體、剪接變異體及天然或人工突變。變異體為「功能性的」，因為其展示DNA編輯之催化活性。在一些實施例中，APOBEC3A (諸如人類APOBEC3A)具有野生型胺基酸位置57 (如野生型序列中所編號)。在一些實施例中，APOBEC3A (諸如人類APOBEC3A)在胺基酸位置57 (如野生型序列中所編號)處具有天冬醯胺。
若干Cas9直系同源物已獲自奈瑟氏腦膜炎菌(Esvelt等人, NAT. METHODS, 第10卷, 2013, 1116 - 1121；Hou等人, PNAS, 第110卷, 2013, 第15644 - 15649頁) (Nme1Cas9、Nme2Cas9及Nme3Cas9)。Nme2Cas9直系同源物在哺乳動物細胞中有效地起作用，識別N4CC PAM，且可用於活體內編輯(Ran等人，NATURE，第520卷，2015，第186至191頁；Kim等人，NAT. COMMUN.，第8卷，2017，第14500頁)。Nme2Cas9已展示為對脫靶編輯具有天然抗性(Lee等人，MOL. THER.，第24卷，2016，第645至654頁；Kim等人，2017)。亦參見例如，WO/2020081568 (例如，第28頁及42頁)，其描繪Nme2Cas9 D16A切口酶，該案之內容以全文引用的方式併入本文中。另外，NmeCas9變異體為此項技術中已知的，參見例如Huang等人, Nature Biotech. 2022, doi.org/10.1038/s41587-022-01410-2，其描述靶向單核苷酸-嘧啶PAM之Cas9變異體。在全文中，「NmeCas9」或「Nme Cas9」為通用的且涵蓋任何類型之NmeCas9，包括Nme1Cas9、Nme2Cas9及Nme3Cas9。
如本文所用，術語「融合蛋白質」係指包含來自至少兩種不同蛋白質或源之多肽之混合多肽。一個多肽可位於融合蛋白之胺基末端(N末端)部分處或羧基末端(C末端)蛋白處，因此分別形成「胺基末端融合蛋白」或「羧基末端融合蛋白」。本文所提供之任一蛋白可藉由此項技術中已知之任何方法產生。舉例而言，本文所提供之蛋白可經由重組蛋白表現及純化來產生，其尤其適合於包含肽連接子之融合蛋白。重組蛋白表現及純化之方法為熟知的，且包括由Green及Sambrook, Molecular Cloning: A Laboratory Manual (第4版, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012))描述之彼等方法，其全部內容以引用之方式併入本文中。
如本文所用，術語「尿嘧啶醣苷酶抑制劑」、「尿嘧啶DNA醣苷酶抑制劑」或「UGI」係指能夠抑制尿嘧啶-DNA醣苷酶(UDG)鹼基-切除修復酶(例如UniProt ID：P14739；SEQ ID NO: 3)之蛋白質。
如本文所用之術語「連接子」係指連接兩個相鄰分子或部分之化學基團或分子。通常，連接子位於兩個基團、分子或其他部分之間或由兩個基團、分子或其他部分側接，且經由共價鍵彼此連接。在一些實施例中，連接子為胺基酸或複數個胺基酸(例如肽或蛋白質)。例示性肽連接子揭示於本文他處。
「經修飾之尿苷」在本文中用於指代除胸苷外的與尿苷具有相同氫鍵受體且與尿苷存在一或多種結構差異的核苷。在一些實施例中，經修飾之尿苷為經取代之尿苷，亦即其中一或多個非質子取代基(例如烷氧基，諸如甲氧基)替代質子之尿苷。在一些實施例中，經修飾之尿苷為假尿苷。在一些實施例中，經修飾之尿苷為經取代之假尿苷，亦即其中一或多個非質子取代基(例如烷基，諸如甲基)替代質子之假尿苷。在一些實施例中，經修飾之尿苷為經取代之尿苷、假尿苷或經取代之假尿苷中之任一者，例如N1-甲基-假尿苷。
如本文所用，「尿苷位置」係指多核苷酸中由尿苷或經修飾之尿苷佔據之位置。因此，舉例而言，其中「100%之尿苷位置為經修飾之尿苷」之多核苷酸在將為相同序列之習知RNA (其中所有鹼基均為標準A、U、C或G鹼基)中之尿苷的每個位置處均含有經修飾之尿苷。除非另外指明，否則本發明中或附隨本發明的序列表(sequence table/sequence listing)之多核苷酸序列中之U可為尿苷或經修飾之尿苷。
如本文所用，若第一序列與第二序列之比對顯示整個第二序列之X%或更多位置與第一序列匹配，則第一序列被視為「包含與第二序列具有至少X%一致的序列」。舉例而言，序列AAGA包含與序列AAG具有100%一致性之序列，此係因為第二序列之全部三個位置均存在匹配，因此比對將得到100%一致性。RNA與DNA之間的差異(通常而言，尿苷更換為胸苷或反之亦然)及核苷類似物(諸如經修飾之尿苷)的存在不會造成多核苷酸之間一致性或互補性的差異，只要相關核苷酸(諸如胸苷、尿苷或經修飾之尿苷)具有相同互補序列(例如針對胸苷、尿苷或經修飾之尿苷均為腺苷；另一實例為胞嘧啶及5-甲基胞嘧啶，這兩者均以鳥苷作為互補序列)即可。因此，舉例而言，序列5'-AXG (其中X為任何經修飾之尿苷，諸如假尿苷、N1-甲基假尿苷或5-甲氧基尿苷)被視為與AUG 100%一致，因為兩者與同一序列(5'-CAU)完全互補。例示性比對演算法為所屬領域中熟知的史密斯-沃特曼(Smith-Waterman)及尼德曼-翁施(Needleman-Wunsch)演算法。熟習此項技術者應理解何種演算法選擇及參數設置適合於待對準之給定序列對；對於具有一般類似長度及針對胺基酸之＞50%預期一致性或針對核苷酸之＞75%預期一致性的序列而言，由EBI於www.ebi.ac.uk網站伺服器提供的尼德曼-翁施演算法介面之具有默認設置的尼德曼-翁施演算法通常為適合的。
「mRNA」在本文中用於指一種多核苷酸，其為RNA或經修飾之RNA且包含可轉譯成多肽之開放閱讀框架(亦即，可充當受質供核糖體及胺基醯基化tRNA轉譯)。mRNA可包含磷酸酯-糖主鏈，其包括核糖殘基或其類似物，例如2'-甲氧基核糖殘基。在一些實施例中，mRNA磷酸酯-糖主鏈之糖基本上由核糖殘基、2'-甲氧基核糖殘基或其組合組成。通常而言，mRNA不含大量胸苷殘基(例如0個殘基或小於30、20、10、5、4、3或2個胸苷殘基；或小於10%、9%、8%、7%、6%、5%、4%、4%、3%、2%、1%、0.5%、0.2%或0.1%的胸苷含量)。mRNA可在其一些或全部尿苷位置處含有經修飾之尿苷。
如本文所用，「經RNA引導之DNA結合劑」意謂具有RNA及DNA結合活性之多肽或多肽複合物，或此類複合物之DNA結合次單位，其中DNA結合活性具有序列特異性且依賴於RNA序列。例示性經RNA引導之DNA結合劑包括Cas裂解酶/切口酶及其不活化形式(「dCas DNA結合劑」)。如本文所用，「Cas核酸酶」亦稱作「Cas蛋白質」，其涵蓋Cas裂解酶、Cas切口酶及dCas DNA結合劑。dCas DNA結合劑可為包含非功能性核酸酶域(RuvC或HNH域)之死核酸酶。在一些實施例中，Cas裂解酶或Cas切口酶涵蓋經修飾以允許例如經由與FokI域融合而進行DNA裂解之dCas DNA結合劑。Cas9分子之例示性核苷酸及多肽序列提供於下文中。用於鑑定編碼Cas9多肽序列之替代核苷酸序列(包括替代天然存在之變體)的方法為此項技術中已知的。亦涵蓋與編碼本文所提供之胺基酸序列之Cas9核酸序列、胺基酸序列或核酸序列中之任一者具有至少75%、80%、85%，較佳90%、95%、96%、97%、98%或99%一致性的序列。Cas9之例示性開放閱讀框架提供於表39A中。
如本文中所用，給定胺基酸之「最小尿苷密碼子」為具有最少尿苷之密碼子(通常0個或1個，除了苯丙胺酸之密碼子以外，其中最小尿苷密碼子具有2個尿苷)。出於評估尿苷含量之目的，經修飾之尿苷殘基視為等效於尿苷。
如本文中所用，「尿苷二核苷酸(UU)含量」可以絕對術語表示為ORF中之UU二核苷酸之計數或基於比率，表示為尿苷二核苷酸之尿苷所佔據的位置之百分比(例如，AUUAU之尿苷二核苷酸含量將為40%，因為尿苷二核苷酸之尿苷佔據了5個位置中之2個)。出於評估尿苷二核苷酸含量之目的，經修飾之尿苷殘基視為等效於尿苷。
如本文中所用，給定胺基酸之「最小腺嘌呤密碼子」為具有最少腺嘌呤之密碼子(通常為0或1個，除了離胺酸及天冬醯胺之密碼子以外，其中最小腺嘌呤密碼子具有2個腺嘌呤)。出於評估腺嘌呤含量之目的，經修飾之腺嘌呤殘基視為等效於腺嘌呤。
如本文中所用，ORF之「腺嘌呤二核苷酸含量」可以絕對術語表現為ORF中之AA二核苷酸計數或基於比率，表現為腺嘌呤二核苷酸之腺嘌呤所佔據之位置的百分比(例如，UAAUA之腺嘌呤二核苷酸含量將為40%，因為腺嘌呤二核苷酸之腺嘌呤佔據5個位置中之2個)。出於評估腺嘌呤二核苷酸含量之目的，經修飾之腺嘌呤殘基視為等效於腺嘌呤。
如本文所用，給定開放閱讀框架(ORF)之「最小重複含量」為編碼與給定ORF相同之胺基酸序列的ORF中AA、CC、GG及TT (或TU、UT或UU)二核苷酸出現之最小可能總和。重複含量可以絕對值表示為ORF中AA、CC、GG及TT (或TU、UT或UU)二核苷酸之枚舉，或基於比率表示為ORF中之AA、CC、GG及TT(或 TU、UT 或 UU)二核苷酸除以ORF之核苷酸長度(例如，UAAUA將具有20%之重複含量，因為一個重複出現在5個核苷酸之序列中)。為了評估最小重複含量，經修飾之腺嘌呤、鳥嘌呤、胞嘧啶、胸腺嘧啶及尿嘧啶殘基被認為等效於腺嘌呤、鳥嘌呤、胞嘧啶、胸腺嘧啶及尿嘧啶殘基。
「引導RNA」、「gRNA」及「引導物」在本文中互換使用以指crRNA (亦稱為CRISPR RNA)，或crRNA與trRNA (亦稱為tracrRNA)之組合。crRNA及trRNA可以單一RNA分子(單引導RNA，sgRNA)或以兩個獨立RNA分子(雙引導RNA，dgRNA)形式締合。「引導RNA」或「gRNA」係指各類型。trRNA可為天然存在之序列或與天然存在之序列相比具有修飾或變異之trRNA序列。引導RNA可包括如本文所述之經修飾RNA。除非上下文另外明確指示，否則本文所述之引導RNA適用於與Nme Cas9，例如Nme1、Nme2或Nme3 Cas9一起使用。舉例而言，圖15顯示呈可能的二級結構之Nme2 sgRNA之例示性示意圖。
如本文中所用，「導引序列」或「導引區」或「間隔件」或「間隔件序列」及其類似物係指引導RNA內與目標序列互補且用於藉由NmeCas9將引導RNA導向至目標序列以用於結合或修飾(例如，裂解)之序列。引導序列之長度可為20-25個核苷酸，例如在Nme Cas9及相關Cas9同源物/直系同源物之情況下。亦可使用更短或更長的序列作為引導物，例如20、21、22、23、24或25個核苷酸之長度。在Nme Cas9之情況下，引導序列之長度可為至少22、23、24或25個核苷酸。在Nme Cas9之情況下，引導序列可與其目標序列形成22、23、24或25個連續鹼基對之雙螺旋，例如24個連續鹼基對之雙螺旋。
針對Cas蛋白質之目標序列包括基因體DNA之正鏈及負鏈兩者(亦即給定序列及該序列之反向互補序列)，因為Cas蛋白質之核酸受質為雙股核酸。因此，在稱引導序列「與目標序列互補」之情況下，應理解，引導序列可導引引導RNA結合至目標序列之反向補體。因此，在一些實施例中，在引導序列結合目標序列之反向互補序列之情況下，引導序列與目標序列(例如不包括PAM之目標序列)之某些核苷酸具有一致性，不同之處在於在引導序列中U取代T。
如本文所用，「插入/缺失」係指由多種核苷酸組成之插入/缺失突變，該等核苷酸在核酸中之雙鏈斷裂(DSB)位點處進行插入或缺失。
如本文所用，「阻斷基因表現(knockdown)」係指特定基因產物(例如蛋白質、mRNA或兩者)之表現降低。可藉由偵測由組織或細胞群(例如在血清或細胞培養基中)分泌之蛋白質或藉由偵測來自相關組織或細胞群的蛋白質之總細胞量來量測蛋白質之抑制基因表現。用於量測將mRNA阻斷基因表現的方法為已知的，且包括對自所關注之組織或細胞群體分離之mRNA進行定序。在一些實施例中，「抑制基因表現」可指一些特定基因產物之表現損失，例如經轉錄之mRNA的量下降或由細胞群(包括活體內細胞群，諸如組織中所發現的彼等者)表現或分泌的蛋白質之量下降。
如本文所用，「基因剔除」係指細胞中之特定蛋白質之表現缺失。基因剔除可藉由偵測由組織或細胞群(例如血清或細胞培養基中)分泌之蛋白質之量或藉由偵測組織或細胞群之蛋白質之總細胞量來量測。在一些實施例中，本發明之方法在一或多種細胞(例如在細胞群，包括活體內細胞群，諸如彼等出現在組織中者)「基因剔除」目標蛋白。在一些實施例中，基因剔除並非例如藉由indel導致形成突變靶蛋白，而是細胞中完全喪失靶蛋白之表現。
如本文所用，「核糖核蛋白」(RNP)或「RNP複合物」係指引導RNA以及經RNA引導之DNA結合劑，諸如Cas裂解酶、切口酶或dCas DNA結合劑(例如Cas9)。在一些實施例中，引導RNA將經RNA引導之DNA結合劑，諸如Cas9導引至目標序列，且該引導RNA與目標序列雜交且該結合劑結合於目標序列；在結合劑為裂解酶或切口酶之情況下，結合之後進行裂解或切口。
如本文所用，「目標序列」係指目標基因中與gRNA之引導序列互補的核酸序列。目標序列與引導序列之相互作用導引經RNA引導之DNA結合劑結合，且在目標序列中潛在地鏈裂或裂解(視試劑活性而定)。
在一些實施例中，目標序列可鄰近於PAM。在一些實施例中，PAM可鄰近於或在目標序列之3'端之1、2、3或4個核苷酸內。PAM之長度及序列可視所用Cas蛋白而定。舉例而言，PAM可選自特定Nme Cas9蛋白或Nme Cas9直系同源物之共有或特定PAM序列(Edraki等人, 2019)。在一些實施例中，PAM可包含2、3、4、5、6、7、8、9或10個核苷酸長度。非限制性例示性PAM序列包括NCC、N4GAYW、N4GYTT、N4GTCT、NNNNCC(a)、NNNNCAAA (其中N定義為任何核苷酸，W定義為A或T，且R定義為A或G；且(a)為較佳的，但並非必需的，A在第二C)之後)。在一些實施例中，PAM序列可為NCC。
如本文所用，「治療(treatment)」係指投與或施加用於個體之疾病或病症的治療劑，且包括減緩或遏制疾病發展或進展、減輕疾病之一或多種病徵或症狀、治癒疾病或預防疾病之一或多種症狀復發。
如本文所用，術語「脂質奈米粒子」(LNP)係指包含複數個(亦即，超過一個)藉由分子間力以物理方式彼此締合之脂質分子的粒子。LNP可例如為微球體(包括單層及多層囊泡，例如「脂質體」-在一些實施例中為大體上球形之層狀相脂質雙層-且在更特定實施例中可包含水性核心，例如包含大部分RNA分子)、乳液中之分散相、膠束或懸浮液中之內相。乳液、微胞及懸浮液可為用於局部或體表遞送之適合組合物。亦參見例如WO2017173054A1，其內容特此以全文引用之方式併入。熟習此項技術者已知的任何能夠向個體遞送核苷酸之LNP可與本文所述之引導RNA及編碼經RNA引導之DNA結合劑的核酸一起使用。
如本文中所用，術語「核定位信號」(NLS)或「核定域序列」係指誘導包含此類序列或連接至此類序列之分子輸送至真核細胞之細胞核的胺基酸序列。核定位信號可形成待輸送之分子之一部分。在一些實施例中，NLS可藉由共價鍵、氫鍵或離子相互作用連接至分子之其餘部分。
如本文中所用，「遞送」及「投與」可互換地使用，且包括活體外及活體內應用。
如本文中所用，共同投與意謂複數種物質在時間上足夠接近地一起投與，以使得與藥劑一起作用。共同投與涵蓋在單個調配物中一起投與物質及在單獨調配物中在時間上足夠接近地投與物質以使得藥劑一起作用。
如本文中所用，片語「醫藥學上可接受」意謂在製備藥物組合物時有用的，該藥物組合物通常無毒且在生物學上並非不合需要且在其他方面對於醫藥用途並非不可接受的。醫藥學上可接受之物質通常係指非熱解物質。醫藥學上可接受可指無菌物質，尤其對於注射或輸注用之醫藥物質。
II. 例示性多核苷酸及組合物
在一些實施例中，提供一種多核苷酸，該多核苷酸包含開放閱讀框架(ORF)，該ORF包含：
編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致；及
編碼第一核定位信號(NLS)之核苷酸序列；及
在一些實施例中，Nme Cas9為Nme2 Cas9。在一些實施例中，Nme Cas9為Nme1 Cas9。在一些實施例中，Nme Cas9為Nme3 Cas9。在一些實施例中，ORF進一步包含編碼第二NLS之核苷酸序列。
在一些實施例中，多核苷酸為mRNA。
在一些實施例中，ORF包含與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者之序列具有至少90%、95%、98%或100%一致性之序列。在一些實施例中，ORF包含與SEQ ID NO: 29或32-41中之任一者之序列具有至少90%、95%、98%或100%一致性之序列。在一些實施例中，ORF包含與SEQ ID NO: 32之序列具有至少90%、95%、98%或100%一致性之序列。在一些實施例中，ORF包含與SEQ ID NO: 33之序列具有至少90%、95%、98%或100%一致性之序列。在一些實施例中，ORF包含與SEQ ID NO: 34之序列具有至少90%、95%、98%或100%一致性之序列。在一些實施例中，ORF包含與SEQ ID NO: 35之序列具有至少90%、95%、98%或100%一致性之序列 在一些實施例中，ORF包含與SEQ ID NO: 36之序列具有至少90%、95%、98%或100%一致性之序列 在一些實施例中，ORF包含與SEQ ID NO: 38之序列具有至少90%、95%、98%或100%一致性之序列 在一些實施例中，ORF包含與SEQ ID NO: 39之序列具有至少90%、95%、98%或100%一致性之序列 在一些實施例中，ORF包含與SEQ ID NO: 41之序列具有至少90%、95%、98%或100%一致性之序列。
在一些實施例中，ORF包含與SEQ ID NO: 38或41之序列具有至少90%、95%、98%或100%一致性之序列。
在一些實施例中，提供一種多核苷酸，該多核苷酸包括本文所揭示之ORF。在一些實施例中，提供一種多核苷酸，該多核苷酸編碼與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致之Nme Cas9多肽，其中Nme Cas9為Nme2 Cas9、Nme3 Cas9或Nme1 Cas9；第一核定位信號(NLS)；及第二NLS，其中經編碼第一NLS及第二NLS位於NmeCas9多肽之N末端。
在一些實施例中，提供一種多肽，該多肽包含與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297或310-315中之任一者具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%之胺基酸序列中之任一者至少90%一致的Nme Cas9多肽，其中Nme Cas9為Nme2 Cas9、Nme3 Cas9或Nme1 Cas9；第一核定位信號(NLS)；及第二NLS，其中經編碼第一NLS及第二NLS位於NmeCas9多肽之N末端。
在一些實施例中，提供一種修飾目標基因之方法，其包含投與本文所描述之組合物。在一些實施例中，方法包含向細胞遞送包含開放閱讀框架(ORF)之多核苷酸，該ORF包含：編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致，其中Nme Cas9為Nme2 Cas9或Nme1 Cas9或Nme3 Cas9；編碼第一核定位信號(NLS)之核苷酸序列；及視情況，編碼第二NLS之核苷酸序列。在一些實施例中，多核苷酸活體外遞送至細胞。在一些實施例中，多核苷酸活體內遞送至細胞。
在一些實施例中，本文中所描述之組合物進一步包含至少一種gRNA。在一些實施例中，提供一種組合物，其包含本文所述之mRNA及至少一種gRNA。在一些實施例中，gRNA為單導引gRNA (sgRNA)。在一些實施例中，gRNA為雙導引gRNA (dgRNA)。
在一些實施例中，組合物在向個體投與後能夠實現基因體編輯。在一些實施例中，個體為人類。
A. 經RNA引導之DNA結合劑；NmeCas9
本文所述之經RNA引導之DNA結合劑涵蓋奈瑟氏腦膜炎菌Cas9 (NmeCas9)及其經修飾及變異體。在一些實施例中，NmeCas9為Nme2 Cas9。在一些實施例中，NmeCas9為Nme1 Cas9。在一些實施例中，NmeCas9為Nme3 Cas9。
具有一個非活性催化域(RuvC或HNH)之經修飾形式稱為「切口酶」。切口酶僅切割目標DNA上之一個股，從而產生單股斷裂。單鏈斷裂亦可稱為「鏈裂」。在一些實施例中，組合物及方法包含切口酶。在一些實施例中，組合物及方法包含切口酶RNA引導之DNA結合劑，諸如切口酶Cas，例如切口酶Cas9，其誘導目標DNA出現切口，而非雙股斷裂。
在一些實施例中，NmeCas9核酸酶可經修飾以僅含有一個功能性核酸酶域。舉例而言，經RNA引導之DNA結合劑可經修飾以使得核酸酶域之一發生突變或完全或部分缺失以降低其核酸裂解活性。
在一些實施例中，使用具有活性降低之RuvC域之NmeCas9切口酶。在一些實施例中，使用具有非活性RuvC域之NmeCas9切口酶。在一些實施例中，使用具有活性降低之HNH域之NmeCas9切口酶。在一些實施例中，使用具有非活性HNH域之NmeCas9切口酶。
在一些實施例中，NmeCas9核酸酶域內之保守胺基酸經取代以降低或改變核酸酶活性。野生型Cas9具有兩個核酸酶域：RuvC及HNH。RuvC域裂解非目標DNA股，且HNH域裂解目標DNA股。在一些實施例中，Cas9核酸酶包含多於一個RuvC域或多於一個HNH域。在一些實施例中，Cas9核酸酶為野生型Cas9。在一些實施例中，Cas9能夠誘導目標DNA中之雙股斷裂。在某些實施例中，Cas核酸酶可裂解dsDNA，其可裂解dsDNA之一個股，或其可不具有DNA裂解酶或切口酶活性。在一些實施例中，NmeCas9可包含RuvC或RuvC樣核酸酶域中之胺基酸取代。RuvC或RuvC樣核酸酶域中之例示性胺基酸取代包括H588A(基於奈瑟氏腦膜炎菌Cas9蛋白)。在一些實施例中，Cas蛋白可包含HNH或HNH樣核酸酶域中之胺基酸取代。HNH或HNH樣核酸酶域中之例示性胺基酸取代包括D16A (基於NmeCas9蛋白)。
在一些實施例中，使用嵌合Cas蛋白質，其中蛋白質之一個結構域或區域經不同蛋白質之一部分置換。在一些實施例中，NmeCas9核酸酶域可經來自不同核酸酶(諸如Fok1)之域置換。在一些實施例中，NmeCas9蛋白可為經修飾之NmeCas9核酸酶。
在一些實施例中，核酸酶可經修飾以誘導點突變或鹼基變化，例如脫胺作用。
在一些實施例中，Cas蛋白包含融合蛋白，其包含連接至異源功能域之Cas核酸酶(例如NmeCas9)，該Cas核酸酶為切口酶或為無催化活性的。在一些實施例中，Cas蛋白包含融合蛋白，其包含連接至異源功能域之無催化活性Cas核酸酶(例如NmeCas9)(參見例如WO2014152432)。在一些實施例中，無催化活性Cas9來自奈瑟氏腦膜炎菌Cas9。在一些實施例中，無催化活性Cas包含使Cas不活化之突變。
在一些實施例中，異源功能域為調節基因表現、組蛋白或DNA的結構域。在一些實施例中，異源功能域為轉錄活化域或轉錄抑制域。在一些實施例中，核酸酶為無催化活性Cas核酸酶，諸如dCas9。
在一些實施例中，異源功能域為脫胺酶，諸如胞苷脫胺酶或腺嘌呤脫胺酶。在某些實施例中，異源功能域為C至T鹼基轉換器(胞苷脫胺酶)，諸如脂蛋白元B mRNA編輯酶(APOBEC)脫胺酶。諸如脫胺酶之異源功能域可為含有下文進一步論述之具有切口酶活性之Cas核酸酶或無催化活性之Cas核酸酶的融合蛋白的一部分。
在一些實施例中，Nme Cas9具有雙股核酸內切酶活性。
在一些實施例中，Nme Cas9具有切口酶活性。
在一些實施例中，Nme Cas9包含dCas9 DNA結合域。
在一些實施例中，Nme Cas9包含與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297或310-315中之任一者至少91%、92%、93%、94%、95%、96%、97%、98%或99%之胺基酸序列(如表39A中所示)。在一些實施例中，Nme Cas9包含SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297或310-315中之任一者之胺基酸序列(如表39A中所示)。
在一些實施例中，編碼NmeCas9之序列包含與SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者至少91%、92%、93%、94%、95%、96%、97%、98%或99%一致之核苷酸序列(如表39A中所示)。在一些實施例中，編碼NmeCas9之序列包含SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者的核苷酸序列(如表39A中所示)。
在一些實施例中，前述一致性水平中之任一者為至少95%、至少98%、至少99%或100%。
B. 例示性編碼序列
在本文所闡述之實施例中之任一者中，多核苷酸為包含編碼上文所揭示之經RNA引導之DNA結合劑之ORF的mRNA。在本文所闡述之實施例中之任一者中，多核苷酸為包含編碼NmeCas9之ORF的mRNA。在本文所闡述之實施例中之任一者中，多核苷酸可為包含可操作地連接於編碼經RNA引導之DNA結合劑(例如NmeCas9)之ORF之啟動子的表現構築體。
就每個mRNA分子產生之多肽分子而言，某些ORF在活體內比其他ORF更有效地轉譯。此類經有效轉譯之ORF的密碼子對使用可有助於轉譯效率。ORF編碼序列、密碼子對使用、密碼子重複含量之改良之進一步描述揭示於WO 2019/0067910及WO 2020/198641中，其各自之內容特此以全文引用之方式併入。
舉例而言，在一些實施例中，ORF之至少75%、80%、85%、90%、95%、98%、99%或100%之密碼子為最小腺嘌呤密碼子或最小尿苷密碼子。在一些實施例中，ORF包含增加哺乳動物中mRNA之轉譯的密碼子或由其組成。在一些實施例中，ORF包含增加人類中mRNA之轉譯的密碼子或由其組成。哺乳動物、細胞型、哺乳動物之器官、人類、人類之器官等中之轉譯的增加可相對於ORF之轉譯野生型序列的程度或相對於具有匹配衍生ORF之生物體或含有處於胺基酸水準之最相似ORF的生物體之密碼子分佈的密碼子分佈之ORF來測定。
在一些實施例中，ORF之GC含量大於或等於56%。在一些實施例中，ORF之GC含量大於或等於56.5%。在一些實施例中，ORF之GC含量大於或等於57%。在一些實施例中，ORF之GC含量大於或等於57.5%。在一些實施例中，ORF之GC含量大於或等於58%。在一些實施例中，ORF之GC含量大於或等於58.5%。在一些實施例中，ORF之GC含量大於或等於59%。在一些實施例中，ORF之GC含量小於或等於63%。在一些實施例中，ORF之GC含量小於或等於62.6%。在一些實施例中，ORF之GC含量小於或等於62.1%。在一些實施例中，ORF之GC含量小於或等於61.6%。在一些實施例中，ORF之GC含量小於或等於61.1%。在一些實施例中，ORF之GC含量小於或等於60.6%。在一些實施例中，ORF之GC含量小於或等於60.1%。
在一些實施例中，ORF由一組密碼子組成，其中至少約75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表1中所列之密碼子。
表 1.
1. 具有低尿苷含量之ORF
| 胺基酸 | 低A/U |
| Gly | GGC |
| Glu | GAG |
| Asp | GAC |
| Val | GTG |
| Ala | GCC |
| Arg | CGG |
| Ser | AGC |
| Lys | AAG |
| Asn | AAC |
| Met | ATG |
| Ile | ATC |
| Thr | ACC |
| Trp | TGG |
| Cys | TGC |
| Tyr | TAC |
| Leu | CTG |
| Phe | TTC |
| Gln | CAG |
| His | CAC |
在一些實施例中，編碼多肽之ORF之尿苷含量在其最小尿苷含量至其最小尿苷含量之約150%範圍內。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%。在一些實施例中，ORF之尿苷含量等於其最小尿苷含量。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約150%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約145%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約140%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約135%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約130%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約125%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約120%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約115%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約110%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約105%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約104%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約103%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約102%。在一些實施例中，ORF之尿苷含量小於或等於其最小尿苷含量之約101%。
在一些實施例中，ORF之尿苷二核苷酸含量在其最小尿苷二核苷酸含量至其最小尿苷二核苷酸含量之200%範圍內。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約195%、190%、185%、180%、175%、170%、165%、160%、155%、150%、145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%。在一些實施例中，ORF之尿苷二核苷酸含量等於其最小尿苷二核苷酸含量。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約200%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約195%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約190%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約185%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約180%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約175%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約170%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約165%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約160%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約155%。在一些實施例中，ORF之尿苷二核苷酸含量等於其最小尿苷二核苷酸含量。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約150%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約145%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約140%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約135%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約130%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約125%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約120%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約115%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約110%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約105%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約104%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約103%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約102%。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於其最小尿苷二核苷酸含量之約101%。
在一些實施例中，ORF之尿苷二核苷酸含量在其最小尿苷二核苷酸含量至編碼與相關mRNA相同之蛋白質之參考序列之最大尿苷二核苷酸含量之90%或更低的尿苷二核苷酸含量範圍內。在一些實施例中，ORF之尿苷二核苷酸含量小於或等於編碼與相關mRNA相同之蛋白質的參考序列之最大尿苷二核苷酸含量之約85%、80%、75%、70%、65%、60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%。
在一些實施例中，ORF之尿苷三核苷酸含量在0個尿苷三核苷酸至1、2、3、4、5、6、7、8、9、10、20、30、40或50個尿苷三核苷酸範圍內(其中更長串之尿苷計數為其內獨特三尿苷區段之數目，例如尿苷四核苷酸含有兩個尿苷三核苷酸，尿苷五核苷酸含有三個尿苷三核苷酸等)。在一些實施例中，ORF之尿苷三核苷酸含量的範圍為0%尿苷三核苷酸至0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、1.5%或2%尿苷三核苷酸，其中尿苷三核苷酸百分比含量係以形成尿苷三核苷酸(或更長串尿苷)之一部分之尿苷所佔之序列中之位置百分比計算，使得序列UUUAAA及UUUUAAAA將各自具有50%之尿苷三核苷酸含量。舉例而言，在一些實施例中，ORF之尿苷三核苷酸含量小於或等於2%。舉例而言，在一些實施例中，ORF之尿苷三核苷酸含量小於或等於1.5%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於1%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.9%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.8%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.7%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.6%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.5%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.4%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.3%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.2%。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於0.1%。在一些實施例中，ORF不具有尿苷三核苷酸。
在一些實施例中，ORF之尿苷三核苷酸含量在其最小尿苷三核苷酸含量至編碼與相關多核苷酸相同之蛋白質之參考序列之最大尿苷三核苷酸含量之90%或更低的尿苷三核苷酸含量範圍內。在一些實施例中，ORF之尿苷三核苷酸含量小於或等於編碼與相關多核苷酸相同之蛋白質之參考序列之最大尿苷三核苷酸含量的約85%、80%、75%、70%、65%、60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%。
在一些實施例中，ORF具有最少核苷酸均聚物，例如相同核苷酸之重複串。舉例而言，在一些實施例中，當自表2中所列之密碼子選擇最小尿苷密碼子時，藉由選擇降低核苷酸均聚物之數量及長度的最小尿苷密碼子(例如，對於丙胺酸，選擇GCA代替GCC；或對於甘胺酸，選擇GGA代替GGG；或對於離胺酸，選擇AAG代替AAA)來構築多核苷酸。
可例如藉由在ORF之足夠多的一部分中使用最小尿苷密碼子來降低給定ORF之尿苷含量或尿苷二核苷酸含量或尿苷三核苷酸含量。舉例而言，可藉由將胺基酸轉化成密碼子而將由本文所述之ORF編碼之多肽的胺基酸序列轉譯回ORF序列，其中ORF中之一些或全部使用以下所示之例示性最小尿苷密碼子。在一些實施例中，ORF中至少約50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表2中所列之密碼子。
表 2. 例示性最小尿苷密碼子
| 胺基酸 | 最小尿苷密碼子 | |
| A | 丙胺酸 | GCA或GCC或GCG |
| G | 甘胺酸 | GGA或GGC或GGG |
| V | 纈胺酸 | GUC或GUA或GUG |
| D | 天冬胺酸 | GAC |
| E | 麩胺酸 | GAA或GAG |
| I | 異白胺酸 | AUC或AUA |
| T | 蘇胺酸 | ACA或ACC或ACG |
| N | 天冬醯胺 | AAC |
| K | 離胺酸 | AAG或AAA |
| S | 絲胺酸 | AGC |
| R | 精胺酸 | AGA或AGG |
| L | 白胺酸 | CUG或CUA或CUC |
| P | 脯胺酸 | CCG或CCA或CCC |
| H | 組胺酸 | CAC |
| Q | 麩醯胺酸 | CAG或CAA |
| F | 苯丙胺酸 | UUC |
| Y | 酪胺酸 | UAC |
| C | 半胱胺酸 | UGC |
| W | 色胺酸 | UGG |
| M | 甲硫胺酸 | AUG |
在一些實施例中，ORF由一組密碼子組成，其中至少約75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表2中所列之密碼子。
2. 具有低腺嘌呤含量之ORF
在一些實施例中，ORF之腺嘌呤含量在其最小腺嘌呤含量至其最小腺嘌呤含量之約150%範圍內。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%。在一些實施例中，ORF之腺嘌呤含量等於其最小腺嘌呤含量。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約150%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約145%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約140%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約135%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約130%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約125%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約120%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約115%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約110%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約105%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約104%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約103%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約102%。在一些實施例中，ORF之腺嘌呤含量小於或等於其最小腺嘌呤含量之約101%。
在一些實施例中，ORF之腺嘌呤二核苷酸含量在其最小腺嘌呤二核苷酸含量至其最小腺嘌呤二核苷酸含量之200%範圍內。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約195%、190%、185%、180%、175%、170%、165%、160%、155%、150%、145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%。在一些實施例中，ORF之腺嘌呤二核苷酸含量等於其最小腺嘌呤二核苷酸含量。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約200%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約195%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約190%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約185%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約180%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約175%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約170%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約165%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約160%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約155%。在一些實施例中，ORF之腺嘌呤二核苷酸含量等於其最小腺嘌呤二核苷酸含量。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約150%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約145%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約140%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約135%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約130%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約125%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約120%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約115%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約110%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約105%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約104%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約103%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約102%。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於其最小腺嘌呤二核苷酸含量之約101%。
在一些實施例中，ORF之腺嘌呤二核苷酸在其最小腺嘌呤二核苷酸含量至編碼與相關多核苷酸相同之蛋白質之參考序列之最大腺嘌呤二核苷酸含量之90%或更低的腺嘌呤二核苷酸含量範圍內。在一些實施例中，ORF之腺嘌呤二核苷酸含量小於或等於編碼與相關多核苷酸相同之蛋白質的參考序列之最大腺嘌呤二核苷酸含量約85%、80%、75%、70%、65%、60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%。
在一些實施例中，ORF之腺嘌呤三核苷酸含量的範圍為0個腺嘌呤三核苷酸至1、2、3、4、5、6、7、8、9、10、20、30、40或50個腺嘌呤三核苷酸(其中更長串腺嘌呤以其內之獨特三腺嘌呤區段之數目計數，例如腺嘌呤四核苷酸含有兩個腺嘌呤三核苷酸，腺嘌呤五核苷酸含有三個腺嘌呤三核苷酸等)。在一些實施例中，ORF之腺嘌呤三核苷酸含量的範圍為0%腺嘌呤三核苷酸至0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、1.5%或2%腺嘌呤三核苷酸，其中腺嘌呤三核苷酸百分比含量係以形成腺嘌呤三核苷酸(或更長串腺嘌呤)之一部分之腺嘌呤所佔之序列中之位置百分比計算，使得序列UUUAAA及UUUUAAAA各自具有50%之腺嘌呤三核苷酸含量。舉例而言，在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於2%。舉例而言，在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於1.5%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於1%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.9%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.8%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.7%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.6%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.5%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.4%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.3%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.2%。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於0.1%。在一些實施例中，ORF不具有腺嘌呤三核苷酸。
在一些實施例中，ORF之腺嘌呤三核苷酸在其最小腺嘌呤三核苷酸含量至編碼與相關多核苷酸相同之蛋白質之參考序列之最大腺嘌呤三核苷酸含量之90%或更低的腺嘌呤三核苷酸含量範圍內。在一些實施例中，ORF之腺嘌呤三核苷酸含量小於或等於編碼與相關mRNA相同之蛋白質的參考序列之最大腺嘌呤三核苷酸含量之約85%、80%、75%、70%、65%、60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%。在一些實施例中，ORF具有最少核苷酸均聚物，例如相同核苷酸之重複串。舉例而言，在一些實施例中，當自表3中所列之密碼子選擇最小腺嘌呤密碼子時，藉由選擇降低核苷酸均聚物之數量及長度的最小腺嘌呤密碼子(例如，對於丙胺酸，選擇GCA代替GCC；或對於甘胺酸，選擇GGA代替GGG；或對於離胺酸，選擇AAG代替AAA)來構築多核苷酸。可以降低所指定ORF中之腺嘌呤含量或腺嘌呤二核苷酸含量或腺嘌呤三核苷酸含量，例如藉由在大部分ORF中使用最少腺嘌呤密碼子。舉例而言，可藉由將胺基酸轉化成密碼子而將由本文所述之ORF編碼之多肽的胺基酸序列轉譯回ORF序列，其中ORF中之一些或全部使用以下所示之例示性最小腺嘌呤密碼子。在一些實施例中，ORF中至少約50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表3中所列之密碼子。
表 3. 例示性最小腺嘌呤密碼子
| 胺基酸 | 最小腺嘌呤密碼子 | |
| A | 丙胺酸 | GCU或GCC或GCG |
| G | 甘胺酸 | GGU或GGC或GGG |
| V | 纈胺酸 | GUC或GUU或GUG |
| D | 天冬胺酸 | GAC或GAU |
| E | 麩胺酸 | GAG |
| I | 異白胺酸 | AUC或AUU |
| T | 蘇胺酸 | ACU或ACC或ACG |
| N | 天冬醯胺 | AAC或AAU |
| K | 離胺酸 | AAG |
| S | 絲胺酸 | UCU或UCC或UCG |
| R | 精胺酸 | CGU或CGC或CGG |
| L | 白胺酸 | CUG或CUC或CUU |
| P | 脯胺酸 | CCG或CCU或CCC |
| H | 組胺酸 | CAC或CAU |
| Q | 麩醯胺酸 | CAG |
| F | 苯丙胺酸 | UUC或UUU |
| Y | 酪胺酸 | UAC或UAU |
| C | 半胱胺酸 | UGC或UGU |
| W | 色胺酸 | UGG |
| M | 甲硫胺酸 | AUG |
在一些實施例中，ORF由一組密碼子組成，其中至少約75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表3中所列之密碼子。
3. 具有低腺嘌呤及低尿苷含量之ORF
就可行性而言，上文關於低腺嘌呤含量所描述之特徵中之任一者可與上文關於低尿苷含量所描述之特徵中之任一者組合。舉例而言，ORF之尿苷含量介於其最小尿苷含量至約其最小尿苷含量之150%範圍內(例如ORF之尿苷含量小於或等於其最小尿苷含量之約145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%)且腺嘌呤含量介於其最小腺嘌呤含量至其最小腺嘌呤含量之150%約範圍內(例如小於或等於其最小腺嘌呤含量之約145%、140%、135%、130%、125%、120%、115%、110%、105%、104%、103%、102%或101%)。對於尿苷及腺嘌呤二核苷酸亦如此。同樣，ORF中之尿苷核苷酸及腺嘌呤二核苷酸之含量可如上文所闡述。類似地，ORF中之尿苷二核苷酸及腺嘌呤核苷酸之含量可如上文所闡述。
可例如藉由在ORF之足夠多的一部分中使用最小尿苷及腺嘌呤密碼子來降低給定ORF之尿苷及腺嘌呤核苷酸或二核苷酸含量。舉例而言，可藉由將胺基酸轉化成密碼子而將由本文所述之ORF編碼之多肽的胺基酸序列轉譯回ORF序列，其中ORF中之一些或全部使用以下所示之例示性最小尿苷及腺嘌呤密碼子。在一些實施例中，ORF中至少約50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表4中所列之密碼子。
表4. 例示性最小尿苷及腺嘌呤密碼子
| 胺基酸 | 最小尿苷密碼子 | |
| A | 丙胺酸 | GCC或GCG |
| G | 甘胺酸 | GGC或GGG |
| V | 纈胺酸 | GUC或GUG |
| D | 天冬胺酸 | GAC |
| E | 麩胺酸 | GAG |
| I | 異白胺酸 | AUC |
| T | 蘇胺酸 | ACC或ACG |
| N | 天冬醯胺 | AAC |
| K | 離胺酸 | AAG |
| S | 絲胺酸 | AGC或UCC或UCG |
| R | 精胺酸 | CGC或CGG |
| L | 白胺酸 | CUG或CUC |
| P | 脯胺酸 | CCG或CCC |
| H | 組胺酸 | CAC |
| Q | 麩醯胺酸 | CAG |
| F | 苯丙胺酸 | UUC |
| Y | 酪胺酸 | UAC |
| C | 半胱胺酸 | UGC |
| W | 色胺酸 | UGG |
| M | 甲硫胺酸 | AUG |
在一些實施例中，ORF由一組密碼子組成，其中至少約75%、80%、85%、90%、95%、98%、99%或100%之密碼子為表4中所列之密碼子。如表4中可見，三個所列出絲胺酸密碼子中之各者含有一個A或一個U。在一些實施例中，對於絲胺酸，藉由使用AGC密碼子來優先化進行尿苷最小化。在一些實施例中，對於絲胺酸，藉由使用UCC或UCG密碼子優先化進行腺嘌呤最小化。
4. 提高轉譯或對應於高度表現之tRNA的密碼子；例示性密碼子組
在一些實施例中，ORF具有增加哺乳動物(諸如人類)中之轉譯的密碼子。在其他實施例中，ORF具有增加哺乳動物，例如人類之器官，諸如肝臟中之轉譯的密碼子。在其他實施例中，ORF具有增加哺乳動物(例如，人類)之細胞類型，諸如肝臟細胞中之轉譯的密碼子。哺乳動物、細胞型、哺乳動物之器官、人類、人類之器官等中之轉譯的增加可相對於ORF之轉譯野生型序列的程度或相對於具有匹配衍生ORF之生物體或含有處於胺基酸水準之最相似ORF的生物體之密碼子分佈的密碼子分佈之ORF來測定。
在一些實施例中，由ORF編碼之多肽為衍生自下文描述之原核生物的Cas9核酸酶，且哺乳動物、細胞類型、哺乳動物器官、人類器官等中之轉譯的增加可相對於ORF之轉譯野生型序列的程度或相對於所關注ORF (諸如編碼用於在人類細胞中表現之人類蛋白質或轉殖基因的ORF)確定。例如，ORF可為具有如下密碼子分佈之ORF：該密碼子分佈與衍生ORF之生物體或在胺基酸水平上含有最相似ORF之生物體，諸如奈瑟氏腦膜炎菌，或相對於SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中包含之Cas9 ORF的翻譯，所有其他條件相同，包括任何適用的點突變、異源域及其類似者。適用於提高人類，包括人類肝臟及人類肝細胞中之表現的密碼子可為對應於人類肝臟/肝細胞中高度表現之tRNA的密碼子，其論述於Dittmar KA,
PLOS Genetics2(12): e221 (2006)中。在一些實施例中，ORF中至少約75%、80%、85%、90%、95%、96%、97%、98%、99%或100%之密碼子為對應於哺乳動物，諸如人類中的高度表現之tRNA (例如針對各胺基酸之表現最高之tRNA)的密碼子。在一些實施例中，ORF中至少75%、80%、85%、90%、95%、96%、97%、98%、99%或100%之密碼子為對應於哺乳動物器官，諸如人類器官中的高度表現之tRNA (例如針對各胺基酸之表現最高之tRNA)的密碼子。在一些實施例中，ORF中至少75%、80%、85%、90%、95%、96%、97%、98%、99%或100%之密碼子為對應於哺乳動物肝臟，諸如人類肝臟中的高度表現之tRNA (例如針對各胺基酸之表現最高之tRNA)的密碼子。在一些實施例中，ORF中至少75%、80%、85%、90%、95%、96%、97%、98%、99%或100%之密碼子為對應於哺乳動物肝細胞，諸如人類肝細胞中的高度表現之tRNA (例如針對各胺基酸之表現最高之tRNA)的密碼子。
或者，通常可使用對應於生物體(例如，人類)中之高度表現之tRNA的密碼子。
前述密碼子選擇方法中之任一者可與選擇有助於降低重複含量之密碼子組合；或使用如上文所示之表1之密碼子組；使用上文，例如表2、3或4中所示之最小尿苷或腺嘌呤密碼子，且接著當超過一個選項可用時，使用對應於一般生物體(例如人類)中，或所關注器官或細胞類型，諸如肝臟或肝細胞(例如人類肝臟或人類肝細胞)中之更高度表現之tRNA的密碼子。
C. 核定位信號(NLS)
本文中所揭示之核定位信號(NLS)可促進經RNA引導之DNA結合劑轉運至細胞核中。本文所揭示之第一NLS及(若存在)第二NLS可在N末端處連接至經RNA引導之DNA結合劑序列，亦即，經RNA引導之DNA結合劑為經編碼多肽中之C末端域。本文所揭示之第一NLS及(若存在)第二NLS可在N末端處連接至NmeCas9編碼序列。額外NLS可在NmeCas9編碼序列之N末端處連接。在一些實施例中，經編碼多肽包含位於NmeCas9編碼序列之N末端的三個NLS。在一些實施例中，至少一個NLS提供於經RNA引導之DNA結合劑序列之C末端處(例如在NLS與前一域之間具有或不具有中間間隔子)。在一些實施例中，第一NLS及第二NLS提供於經RNA引導之DNA結合劑序列之C末端處(例如在NLS與前一域之間具有或不具有中間間隔子)。
因此，在一些實施例中，編碼本文所揭示之多肽的ORF包含第一NLS之編碼序列及第二NLS之編碼序列，使得經編碼之第一NLS及第二NLS位於NmeCas9多肽之N末端。在一些實施例中，ORF進一步包含位於編碼Nme Cas9之ORF之C末端的第三NLS之編碼序列。
在一些實施例中，NLS可為單聯(monopartite)序列，諸如SV40 NLS、PKKKRKV (SEQ ID NO: 388)或PKKKRRV (SEQ ID NO: 421)。在一些實施例中，NLS可為雙聯序列，諸如核質蛋白之NLS、KRPAATKKAGQAKKKK (SEQ ID NO: 422)。在一些實施例中，NLS序列可包含LAAKRSRTT (SEQ ID NO: 410)、QAAKRSRTT (SEQ ID NO: 411)、PAPAKRERTT (SEQ ID NO: 412)、QAAKRPRTT (SEQ ID NO: 413)、RAAKRPRTT (SEQ ID NO: 414)、AAAKRSWSMAA (SEQ ID NO: 415)、AAAKRVWSMAF (SEQ ID NO: 416)、AAAKRSWSMAF (SEQ ID NO: 417)、AAAKRKYFAA (SEQ ID NO: 418)、RAAKRKAFAA (SEQ ID NO: 419)、或RAAKRKYFAV (SEQ ID NO: 420)。NLS可為核內小核糖核蛋白輸入蛋白(snurportin)-1內輸協助因子(importin)-β (IBB域，例如SPN1-impβ序列。參見Huber等人, 2002, J. Cell Bio., 156, 467-479。在一特定實施例中，單一PKKKRKV (SEQ ID NO: 388)。在一些實施例中，第一及第二NLS獨立地選自SV40 NLS、核質蛋白NLS、雙聯NLS、c-myc樣NLS及包含序列KTRAD之NLS。在某些實施例中，第一及第二NLS可相同(例如兩個SV40 NLS)。在某些實施例中，第一及第二NLS可不同。
在一些實施例中，第一NLS為SV40NLS且第二NLS為核質蛋白NLS。
在一些實施例中，SV40 NLS包含PKKKRKVE (SEQ ID NO: 383)或KKKRKVE (SEQ ID NO: 384)之序列。在一些實施例中，核質蛋白NLS包含KRPAATKKAGQAKKKK (SEQ ID NO: 422)之序列。在一些實施例中，雙聯NLS包含KRTADGSEFESPKKKRKVE (SEQ ID NO: 385)之序列。在一些實施例中，c-myc樣NLS包含PAAKKKKLD (SEQ ID NO: 386)之序列。
在一些實施例中，根據前述實施例中任一者之一或多個NLS與一或多個額外異源功能域，諸如下文所述的異源功能域中之任一者組合存在於經RNA引導之DNA結合劑中。
D. 其他異源功能域
在一些實施例中，由本文所述之ORF編碼之多肽(例如經RNA引導之DNA結合劑)包含一或多個額外異源功能域(例如為或包含融合多肽)。在一些實施例中，ORF進一步包含編碼一或多個額外異源功能域之核苷酸序列。
在一些實施例中，異源功能域可能夠修改經RNA引導之DNA結合劑的細胞內半衰期。在一些實施例中，經RNA引導之DNA結合劑之半衰期可得以提高。在一些實施例中，經RNA引導之DNA結合劑之半衰期可得以降低。在一些實施例中，異源功能域可能能夠增加經RNA引導之DNA結合劑的穩定性。在一些實施例中，異源功能域可能能夠降低經RNA引導之DNA結合劑的穩定性。在一些實施例中，異源功能域可充當蛋白質降解之信號肽。在一些實施例中，蛋白質降解可由蛋白水解酶介導，諸如蛋白酶體、溶酶體蛋白酶或鈣蛋白酶(calpain proteases)。在一些實施例中，異源功能域可包含PEST序列。在一些實施例中，經RNA引導之DNA結合劑可藉由添加泛素或多泛素鏈來修飾。在一些實施例中，泛素可為泛素樣蛋白(UBL)。泛素樣蛋白質之非限制性實例包括小泛素樣修飾因子(SUMO)、泛素交叉反應蛋白(UCRP，亦被稱作干擾素刺激基因-15 (ISG15))、泛素相關修飾因子-1 (URM1)、神經元-前驅細胞-細胞表現之發育下調蛋白-8 (NEDD8，在釀酒酵母中被稱作Rub1)、人類白血球抗原F相關(FAT10)、自噬-8 (ATG8)及自噬-12 (ATG12)、Fau泛素樣蛋白(FUB1)、膜錨定UBL (MUB)、泛素摺疊修飾因子-1 (UFM1)及泛素樣蛋白-5 (UBL5)。
在一些實施例中，異源功能域可為標記域。標記域之非限制性實例包括螢光蛋白、純化標籤、抗原決定基標籤及報導基因序列。在一些實施例中，標記域可為螢光蛋白。適合螢光蛋白之非限制實例包括綠色螢光蛋白(例如，GFP、GFP-2、tagGFP、turboGFP、sfGFP、EGFP、翡翠色(Emerald)、Azami綠(Azami Green)、單Azami綠(Monomeric Azami Green)、CopGFP、AceGFP、ZsGreen1)、黃色螢光蛋白(例如，YFP、EYFP、Citrine、Venus、YPet、PhiYFP、ZsYellow1)、藍色螢光蛋白(例如，EBFP、EBFP2、Azurite、mKalamal、GFPuv、藍寶石色(Sapphire)、T-藍寶石色(T-sapphire))、強化型藍螢光蛋白(例如，ECFP、Cerulean、CyPet、AmCyan1、Midoriishi強化型藍(Midoriishi-Cyan))、紅色螢光蛋白(mKate、mKate2、mPlum、DsRed單色、mCherry、mRFP1、DsRed-Express、DsRed2、DsRed單色、HcRed串色、HcRed1、AsRed2、eqFP611、mRasberry、mStrawberry、Jred)及橙色螢光蛋白(mOrange、mKO、Kusabira橙色(Kusabira-Orange)、單Kusabira橙色(Monomeric Kusabira-Orange)、mTangerine、tdTomato)或任何其他適合之螢光蛋白。在其他實施例中，標記域可為純化標籤或抗原決定基標籤。非限制性之例示性標籤包括麩胱甘肽-S-轉移酶(GST)、殼質結合蛋白(CBP)、麥芽糖結合蛋白(MBP)、硫氧還蛋白(TRX)、聚(NANP)、串聯親和純化(TAP)標籤、myc、AcV5、AU1、AU5、E、ECS、E2、FLAG、HA、nus、Softag 1、Softag 3、Strep、SBP、Glu-Glu、HSV、KT3、S、S1、T7、V5、VSV-G、6×His、8×His、生物素羧基載體蛋白質(BCCP)、聚His、調鈣蛋白及HiBiT。非限制性之例示性報導基因包括麩胱甘肽-S-轉移酶(GST)、辣根過氧化酶(HRP)、氯黴素乙醯基轉移酶(CAT)、β-半乳糖苷酶、β-葡糖醛酸酶、螢光素酶或螢光蛋白。
在其他實施例中，異源功能域可將經RNA引導之DNA結合劑靶向至特定細胞器、細胞型、組織或器官。
在其他實施例中，異源功能域可為效應域。當經RNA引導之DNA結合劑導引至其目標序列時，例如當Cas核酸酶藉由gRNA導引至目標序列時，效應子域可修飾或影響目標序列。在一些實施例中，效應子域可選自核酸結合域、核酸酶域(例如非Cas核酸酶域)、表觀遺傳修飾域、轉錄活化域或轉錄抑制子域。在一些實施例中，異源功能域為核酸酶，諸如FokI核酸酶。參見例如美國專利第9,023,649號。在一些實施例中，異源功能域為轉錄活化子或抑制子。參見例如Qi等人, 「Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression」, Cell 152:1173-83 (2013)；Perez-Pinera等人, 「RNA-guided gene activation by CRISPR-Cas9-based transcription factors」, Nat. Methods 10:973-6 (2013)；Mali等人, 「CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering」, Nat. Biotechnol. 31:833-8 (2013)；Gilbert等人, 「CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes」, Cell 154:442-51 (2013)。因此，經RNA引導之DNA結合劑基本上變成可使用引導RNA引導以結合所需目標序列之轉錄因子。在某些實施例中，DNA修飾域為甲基化域，諸如去甲基化或甲基轉移酶域。在某些實施例中，效應子域為DNA修飾域，諸如鹼基編輯域。在特定實施例中，DNA修飾域為將特異性修飾引入DNA中之核酸編輯域，諸如脫胺酶域，其在下文進一步論述。
在一些實施例中，ORF進一步包含編碼第一NLS與第二NLS之間的連接子序列之核苷酸序列。
在一些實施例中，ORF進一步包含編碼Nme Cas9編碼序列與接近Nme Cas9編碼序列之NLS之間的連接子序列之核苷酸序列。
在一些實施例中，間隔子包含至少1、2、3、4、5、6、7、8、9、10、15、16、17、18、19、20、25、30、40、50或更多個胺基酸。在一些實施例中，間隔子包含至少1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20個胺基酸。
在一些實施例中，肽連接子為16個殘基之「XTEN」連接子或其變異體(參見例如實例；及Schellenberger等人，A recombinant polypeptide extends the
in vivohalf-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186-1190 (2009))。在一些實施例中，XTEN連接子包含序列SGSETPGTSESATPES (SEQ ID NO: 58)、SGSETPGTSESA (SEQ ID NO:59)或SGSETPGTSESATPEGGSGGS (SEQ ID NO:60)。
在一些實施例中，肽連接子包含(GGGGS)
n(SEQ ID NO: 62)、(G)
n、(EAAAK)
n(SEQ ID NO: 63)、(GGS)
n(SEQ ID NO: 61)或SGSETPGTSESATPES (SEQ ID NO: 58)模體(參見例如Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification.
Nat. Biotechnol.2014; 32(6): 577-82；全部內容以引用之方式併入本文中)，或(XP)
n模體，或此等中之任一者之組合，其中n獨立地為1與30之間的整數。參見WO2015089406，例如第[0012]段，其全部內容以引用之方式併入本文中。
在一些實施例中，肽連接子包含選自SEQ ID NO: 61-122之一或多個序列。
E. UTR；Kozak序列
在一些實施例中，多核苷酸包含至少一個來自羥基類固醇17-β脫氫酶4 (HSD17B4或HSD)之UTR，例如來自HSD之5' UTR。在一些實施例中，多核苷酸包含至少一個來自血球蛋白mRNA，例如人類α血球蛋白(HBA) mRNA、人類β血球蛋白(HBB) mRNA或有爪蟾蜍β血球蛋白(XBG) mRNA之UTR。在一些實施例中，多核苷酸包含來自血球蛋白mRNA，諸如HBA、HBB或XBG之5' UTR、3' UTR或5'及3' UTR。在一些實施例中，多核苷酸包含來自牛生長激素、細胞巨大病毒(CMV)、小鼠Hba-a1、HSD、白蛋白基因、HBA、HBB或XBG之5' UTR。在一些實施例中，多核苷酸包含來自牛生長激素、細胞巨大病毒(CMV)、小鼠Hba-a1、HSD、白蛋白基因、HBA、HBB或XBG之3' UTR。在一些實施例中，多核苷酸包含來自牛生長激素、細胞巨大病毒、小鼠Hba-a1、HSD、白蛋白基因、HBA、HBB、XBG、熱休克蛋白90 (Hsp90)、甘油醛3-磷酸脫氫酶(GAPDH)、β-肌動蛋白、α-微管蛋白、腫瘤蛋白質(p53)或表皮生長因子受體(EGFR)之5'及3' UTR。
在一些實施例中，多核苷酸包含來自同一來源，例如組成性表現之mRNA，諸如肌動蛋白、白蛋白或血球蛋白(HBA、HBB或XBG)之5'及3' UTR。
在一些實施例中，本文所揭示之多核苷酸包含與SEQ ID NO: 391-398中之任一者具有至少90%一致性的5' UTR。在一些實施例中，本文所揭示之多核苷酸包含與SEQ ID NO: 399-406中之任一者具有至少90%一致性的3' UTR。在一些實施例中，前述一致性水平中之任一者為至少95%、至少98%、至少99%或100%。在一些實施例中，本文揭示之mRNA包含具有SEQ ID NO: 391-398中之任一者之序列的5' UTR。在一些實施例中，本文所揭示之多核苷酸包含具有SEQ ID NO: 399-406中之任一者之序列的3' UTR。
在一些實施例中，多核苷酸不包含5' UTR，例如在5'帽與起始密碼子之間不存在額外核苷酸。在一些實施例中，mRNA在5'帽與起始密碼子之間包含Kozak序列(下文所描述)，但不具有任何額外5' UTR。在一些實施例中，mRNA不包含3' UTR，例如在終止密碼子與poly-A尾之間不存在額外核苷酸。
在一些實施例中，mRNA包含科紮克序列。Kozak序列可影響轉譯起始及由mRNA轉譯之多肽的總產率。Kozak序列包括可充當起始密碼子之甲硫胺酸密碼子。最小Kozak序列為NNNRUGN，其中以下中之至少一者成立：第一個N為A或G且第二個N為G。在核苷酸序列之情形下，R意謂嘌呤(A或G)。在一些實施例中，Kozak序列為RNNRUGN、NNNRUGG、RNNRUGG、RNNAUGN、NNNAUGG或RNNAUGG。在一些實施例中，Kozak序列為具有零錯配或在呈小寫字母形式之位置具有至多一或兩個錯配之rccRUGg。在一些實施例中，Kozak序列為具有零錯配或在呈小寫字母形式之位置具有至多一或兩個錯配之rccAUGg。在一些實施例中，Kozak序列為具有零錯配或呈小寫字母形式之位置有至多一個、兩個或三個錯配之gccRccAUGG (SEQ ID NO: 408之核苷酸4-13；SEQ ID NO: 407)。在一些實施例中，Kozak序列為具有零錯配或在呈小寫字母形式之位置具有至多一個、二個、三個或四個錯配之gccAccAUG。在一些實施例中，Kozak序列為GCCACCAUG。在一些實施例中，Kozak序列為具有零錯配或呈小寫字母形式之位置有至多一個、二個、三個或四個錯配之gccgccRccAUGG (SEQ ID NO: 408)。
5'帽
在一些實施例中，本文揭示之多核苷酸(例如mRNA)包含5'帽，諸如Cap0、Cap1或Cap2。
5'帽通常為經由5'-三磷酸連接至核酸之5'至3'鏈之第一核苷酸之5'位的7-甲基鳥嘌呤核糖核苷酸(其可進一步修飾，如下文例如相對於ARCA所論述)，亦即第一帽近端核苷酸。在Cap0中，mRNA之第一與第二帽近端核苷酸之核糖均包含2'-羥基。在Cap1中，mRNA之第一及第二轉錄核苷酸之核糖分別包含2'-甲氧基及2'-羥基。在Cap2中，mRNA之第一與第二帽近端核苷酸之核糖包含2'-甲氧基。參見例如Katibah等人 (2014)
Proc Natl Acad Sci USA111(33):12025-30；Abbas等人 (2017)
Proc Natl Acad Sci USA114(11):E2106-E2115。包括哺乳動物核酸(諸如人類核酸)之大多數內源性高等真核核酸包含Cap1或Cap2。歸因於藉由先天免疫系統之組分，諸如IFIT-1及IFIT-5識別為「非自體(non-self)」，Cap0以及與Cap1及Cap2不同的其他帽結構在哺乳動物，諸如人類中可呈免疫原性，其可導致細胞介素，包括I型干擾素含量升高。先天免疫系統之組分，諸如IFIT-1及IFIT-5亦可與eIF4E競爭結合具有除Cap1或Cap2外之帽的核酸，從而潛在地抑制核酸轉譯。
帽可以共轉錄方式包括。舉例而言，ARCA (抗反向帽類似物；Thermo Fisher Scientific目錄號AM8045)為包含連接至鳥嘌呤核糖核苷酸之5'位的7-甲基鳥嘌呤3'-甲氧基-5'-三磷酸的帽類似物，其可在起始時活體外併入轉錄物中。ARCA產生Cap0帽或類Cap0帽，其中第一個帽近端核苷酸之2'位為羥基。參見例如Stepinski等人, (2001) 「Synthesis and properties of mRNAs containing the novel 『anti-reverse』 cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl(3'deoxy)GpppG」,
RNA7: 1486-1495。下文示出ARCA結構。
CleanCap
TMAG (m7G(5')ppp(5')(2'OMeA)pG；TriLink Biotechnologies目錄號N-7113)或CleanCap
TMGG (m7G(5')ppp(5')(2'OMeG)pG；TriLink Biotechnologies目錄號N-7133) 可用於以共轉錄方式提供Cap1結構。CleanCap
TMAG及CleanCap
TMGG之3'-O-甲基化形式亦可分別以目錄號N-7413及N-7433購自TriLink Biotechnologies。CleanCap
TMAG結構展示如下。CleanCap
TM結構在本文中有時會使用上文所列的目錄號之最後三個數位來指代(例如對於TriLink Biotechnologies目錄號N-7113，使用「CleanCap
TM113」指代)。
替代地，可以轉錄後方式將帽添加至RNA。舉例而言，牛痘加帽酶可在市面上購得(New England Biolabs目錄號M2080S)，且具有由其D1次單位提供之RNA三磷酸酶及鳥苷酸轉移酶活性，及由其D12次單位提供之鳥嘌呤甲基轉移酶。因此，在S-腺苷甲硫胺酸及GTP存在下，可將7-甲基鳥嘌呤添加至RNA，以產生Cap0。參見例如Guo, P.及Moss, B. (1990)
Proc. Natl. Acad. Sci.
USA87, 4023-4027；Mao, X.及Shuman, S. (1994)
J. Biol. Chem. 269, 24472-24479。關於帽及加帽方法之額外論述，參見例如WO2017/053297及Ishikawa等人,
Nucl. Acids. Symp. Ser.(2009) 第53期, 129-130。
F. Poly-A尾
在一些實施例中，多核苷酸為編碼包含ORF之本文所揭示之多肽之mRNA，且mRNA進一步包含聚腺苷酸化(poly-A)尾。
在一些實施例中，本文所揭示之多核苷酸進一步包含poly-A尾序列或聚腺苷酸化信號序列。在一些實施例中，poly-A尾序列包含100-400個核苷酸。
在一些實施例中，poly-A序列包含非腺嘌呤核苷酸。在一些情況下，poly-A尾在poly-A尾中之一或多個位置處經一或多個非腺嘌呤核苷酸「錨」「中斷」。poly-A尾可包含至少8個連續腺嘌呤核苷酸，但亦包含一或多個非腺嘌呤核苷酸。如本文所使用，「非腺嘌呤核苷酸」指不包含腺嘌呤之任何天然或非天然核苷酸。鳥嘌呤、胸腺嘧啶及胞嘧啶核苷酸為例示性非腺嘌呤核苷酸。因此，本文所述之mRNA上之poly-A尾可包含位於編碼本文所揭示之多肽之核苷酸之3'的連續腺嘌呤核苷酸。在一些情況下，mRNA上的poly-A尾包含位於編碼經RNA引導之DNA結合劑或相關序列之核苷酸之3'的非連續腺嘌呤核苷酸，其中非腺嘌呤核苷酸以規則或不規則間隔中斷腺嘌呤核苷酸。
在一些實施例中，poly-A尾編碼於用於活體外轉錄mRNA之質體中且變成轉錄物之一部分。編碼於質體中之poly-A序列，亦即poly-A序列中之連續腺嘌呤核苷酸之數目可能並不精確，例如質體中之100 poly-A序列可能不會在經轉錄之mRNA中產生恰好100 poly-A序列。在一些實施例中，poly-A尾未在質體中編碼，且藉由PCR加尾或酶加尾，例如使用大腸桿菌poly(A)聚合酶來添加。
在一些實施例中，一或多個非腺嘌呤核苷酸定位成中斷連續腺嘌呤核苷酸，以使得poly(A)結合蛋白可結合至一段連續腺嘌呤核苷酸。在一些實施例中，一或多個非腺嘌呤核苷酸位於至少8、9、10、11或12個連續腺嘌呤核苷酸之後。在一些實施例中，一或多個非腺嘌呤核苷酸位於至少8至50個連續腺嘌呤核苷酸之後。在一些實施例中，一或多個非腺嘌呤核苷酸位於至少8至100個連續腺嘌呤核苷酸之後。在一些實施例中，非腺嘌呤核苷酸在一個、兩個、三個、四個、五個、六個或七個腺嘌呤核苷酸之後且之後為至少8個連續腺嘌呤核苷酸。
本發明之poly-A尾可包含一個以下順序：連續腺嘌呤核苷酸，繼之以一或多個非腺嘌呤核苷酸，視情況繼之以額外腺嘌呤核苷酸。
在一些實施例中，poly-A尾包含或含有一個非腺嘌呤核苷酸或2至10個非腺嘌呤核苷酸之一個連續段。在一些實施例中，非腺嘌呤核苷酸位於至少8、9、10、11或12個連續腺嘌呤核苷酸之後。在一些情況下，一或多個非腺嘌呤核苷酸位於至少8至50個連續腺嘌呤核苷酸之後。在一些實施例中，一或多個非腺嘌呤核苷酸位於至少8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49或50個連續腺嘌呤核苷酸之後。
在一些實施例中，非腺嘌呤核苷酸為鳥嘌呤、胞嘧啶或胸腺嘧啶。在一些情況下，非腺嘌呤核苷酸為鳥嘌呤核苷酸。在一些實施例中，非腺嘌呤核苷酸為胞嘧啶核苷酸。在一些實施例中，非腺嘌呤核苷酸為胸腺嘧啶核苷酸。在其中存在多於一個非腺嘌呤核苷酸之一些情況下，非腺嘌呤核苷酸可選自：a)鳥嘌呤及胸腺嘧啶核苷酸；b)鳥嘌呤及胞嘧啶核苷酸；c)胸腺嘧啶及胞嘧啶核苷酸；或d)鳥嘌呤、胸腺嘧啶及胞嘧啶核苷酸。包含非腺嘌呤核苷酸之例示性poly-A尾提供為SEQ ID NO: 409。
在一些實施例中，poly-A尾序列包含SEQ ID NO: 409之序列。
G. 經修飾核苷酸
在一些實施例中，包含編碼本文所揭示之多肽之ORF的核酸在一些或所有尿苷位置包含經修飾之尿苷。
在一些實施例中，經修飾之尿苷為在5位處，例如用鹵素或C1-C3烷氧基修飾之尿苷。在一些實施例中，經修飾之尿苷為在1位處，例如用C1-C3烷基修飾之假尿苷。經修飾之尿苷可為例如假尿苷、N1-甲基假尿苷、5-甲氧基尿苷、5-碘尿苷或其組合。在一些實施例中，經修飾之尿苷為5-甲氧基尿苷。在一些實施例中，經修飾之尿苷為5-碘尿苷。在一些實施例中，經修飾之尿苷為假尿苷。在一些實施例中，經修飾之尿苷為N1-甲基-假尿苷。在一些實施例中，經修飾之尿苷為假尿苷及N1-甲基假尿苷之組合。在一些實施例中，經修飾之尿苷為假尿苷及5-甲氧基尿苷之組合。在一些實施例中，經修飾之尿苷為N1-甲基假尿苷與5-甲氧基尿苷之組合。在一些實施例中，經修飾之尿苷為5-碘尿苷及N1-甲基假尿苷之組合。在一些實施例中，經修飾之尿苷為假尿苷與5-碘尿苷之組合。在一些實施例中，經修飾之尿苷為5-碘尿苷與5-甲氧基尿苷之組合。
在一些實施例中，根據本發明之多核苷酸中至少10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、98%、99%或100%之尿苷位置為經修飾之尿苷。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的至少10%尿苷經經修飾之尿苷取代。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的至少20%尿苷經經修飾之尿苷取代。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的至少30%尿苷經經修飾之尿苷取代。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的至少80%尿苷經經修飾之尿苷取代。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的至少90%尿苷經經修飾之尿苷取代。
在一些實施例中，根據本發明之多核苷酸中10%-25%、15-25%、25-35%、35-45%、45-55%、55-65%、65-75%、75-85%、85-95%或90-100%之尿苷位置為經修飾之尿苷。在一些實施例中，根據本發明之多核苷酸中之尿苷位置的15%至45%尿苷經經修飾之尿苷取代。
在一些實施例中，根據本發明之多核苷酸中之尿苷位置的100%尿苷經經修飾之尿苷取代。
在一些實施例中，經修飾之尿苷為N1-甲基-假尿苷、假尿苷、5-甲氧基尿苷或5-碘尿苷，或其組合中之一或多者。在一些實施例中，經修飾之尿苷為N1-甲基-假尿苷或5-甲氧基尿苷中之一或兩者。在一些實施例中，經修飾之尿苷為N1-甲基-假尿苷。在一些實施例中，經修飾之尿苷為5-甲氧基尿苷。
在一些實施例中，根據本發明之多核苷酸中10%-25%、15-25%、25-35%、35-45%、45-55%、55-65%、65-75%、75-85%、85-95%或90-100%之尿苷位置為5-甲氧基尿苷。在一些實施例中，根據本發明之多核苷酸中10%至25%、15至25%、25至35%、35至45%、45至55%、55至65%、65至75%、75至85%、85至95%或90至100%之尿苷位置為假尿苷。在一些實施例中，根據本發明之多核苷酸中10%至25%、15至25%、25至35%、35至45%、45至55%、55至65%、65至75%、75至85%、85至95%或90至100%之尿苷位置為N1-甲基假尿苷。在一些實施例中，根據本發明之多核苷酸中10%至25%、15至25%、25至35%、35至45%、45至55%、55至65%、65至75%、75至85%、85至95%或90至100%之尿苷位置為5-碘尿苷。在一些實施例中，根據本發明之多核苷酸中10%至25%、15%至25%、25%至35%、35%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置為5-甲氧基尿苷，且剩餘部分為N1-甲基假尿苷。在一些實施例中，根據本發明之多核苷酸中10%至25%、15%至25%、25%至35%、35%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置為5-碘尿苷，且剩餘部分為N1-甲基假尿苷。在一些實施例中，根據本發明之多核苷酸中15%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置經經修飾之尿苷取代，視情況其中經修飾之尿苷為N1-甲基-假尿苷。在一些實施例中，根據本發明之多核苷酸中15%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置經N1-甲基-假尿苷取代。在一些實施例中，根據本發明之多核苷酸中85%、90%、95%或100%之尿苷位置經N1-甲基-假尿苷取代。在一些實施例中，100%之尿苷經N1-甲基-假尿苷取代。在一些實施例中，根據本發明之多核苷酸中15%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置經經修飾之尿苷取代，視情況其中經修飾之尿苷為假尿苷。在一些實施例中，根據本發明之多核苷酸中15%至45%、45%至55%、55%至65%、65%至75%、75%至85%、85%至95%或90%至100%之尿苷位置經假尿苷取代。在一些實施例中，根據本發明之多核苷酸中85%、90%、95%或100%之尿苷位置經假尿苷取代。在一些實施例中，100%之尿苷經假尿苷取代。
II. 包含脫胺酶及RNA引導之切口酶的例示性多核苷酸及組合物
本文所揭示之經RNA引導之DNA結合劑可進一步包含鹼基編輯域，其將特定修飾引入目標核酸，諸如脫胺酶域。
在一些實施例中，提供一種核酸，該核酸包含編碼多肽之開放閱讀框架，該多肽包含胞苷脫胺酶(例如A3A)及C末端NmeCas9切口酶，及第一核定位信號(NLS)，其中多肽不包含尿嘧啶醣苷酶抑制劑(UGI)。
在一些實施例中，第二NLS位於Nme Cas9切口酶之N末端。在一些實施例中，脫胺酶位於NLS (亦即，第一NLS或第二NLS)之N末端。在一些實施例中，脫胺酶位於多肽中之所有NLS之N末端。在一些實施例中，且其中多肽不包含尿嘧啶醣苷酶抑制劑(UGI)。
在一些實施例中，多核苷酸為DNA或RNA。在一些實施例中，多核苷酸為mRNA。在一些實施例中，提供一種由mRNA編碼之多肽。
在一些實施例中，多肽自N末端至C末端包含視情況存在之NLS、胞苷脫胺酶(例如APOBEC3A)、視情況存在之連接子、D16A NmeCas9切口酶。在一些實施例中，多肽自N末端至C末端包含視情況存在之NLS、胞苷脫胺酶(例如APOBEC3A)、視情況存在之連接子、D16A Nme2Cas9切口酶。在一些實施例中，多肽自N末端至C末端包含第一及第二NLS、胞苷脫胺酶(例如APOBEC3A)、視情況存在之連接子、D16A NmeCas9切口酶。在一些實施例中，多肽自N末端至C末端包含第一及第二NLS、胞苷脫胺酶(例如APOBEC3A)、視情況存在之連接子、D16A Nme2Cas9切口酶。在一些實施例中，多肽自N末端至C末端包含第一NLS、胞苷脫胺酶(例如APOBEC3A)、第二NLS、視情況存在之連接子、D16A NmeCas9切口酶。在一些實施例中，多肽自N末端至C末端包含第一NLS、胞苷脫胺酶(例如APOBEC3A)、第二NLS、視情況存在之連接子、D16A Nme2Cas9切口酶。
在一些實施例中，多肽包含A3A且RNA引導之切口酶不包含尿嘧啶醣苷酶抑制劑(UGI)。
在一些實施例中，提供一種組合物，其包含第一多肽或編碼第一多肽之mRNA，其包含胞苷脫胺酶，視情況APOBEC3A脫胺酶(A3A)；C末端NmeCas9切口酶；第一核定位信號(NLS)；及視情況，第二NLS；其中第一NLS及(當存在時)第二NLS位於編碼NmeCas9切口酶之序列的N末端，其中第一多肽不包含尿嘧啶醣苷酶抑制劑(UGI)；及第二多肽，或編碼第二多肽之mRNA，其包含尿嘧啶醣苷酶抑制劑(UGI)，其中第二多肽不同於第一多肽。
在一些實施例中，提供一種修飾目標基因之方法，其包含投與本文所描述之組合物。在一些實施例中，方法包含向細胞遞送第一核酸，其包含編碼第一多肽之第一開放閱讀框架，該第一多肽包含胞苷脫胺酶，視情況APOBEC3A脫胺酶(A3A)；C末端NmeCas9切口酶；第一核定位信號(NLS)；及視情況，第二NLS；其中第一NLS及(當存在時)第二NLS位於編碼NmeCas9切口酶之序列的N末端，其中第一多肽不包含尿嘧啶醣苷酶抑制劑(UGI)，及第二核酸，其包含編碼尿嘧啶醣苷酶抑制劑(UGI)之第二開放閱讀框架，其中第二核酸不同於第一核酸。
在一些實施例中，方法包含向細胞遞送多肽，該多肽包含脫胺酶，視情況APOBEC3A脫胺酶(A3A)；C末端NmeCas9切口酶；第一核定位信號(NLS)；及第二NLS；其中第一NLS及第二NLS位於編碼NmeCas9切口酶之序列的N末端，其中第一多肽不包含尿嘧啶醣苷酶抑制劑(UGI)，或編碼多肽之核酸，及向細胞遞送尿嘧啶醣苷酶抑制劑(UGI)，或編碼UGI之核酸。
在一些實施例中，編碼UGI之mRNA與編碼APOBEC3A脫胺酶(例如A3A)及RNA引導之切口酶之mRNA的莫耳比為約1:35至約30:1。在一些實施例中，莫耳比為約1:25至約25:1。在一些實施例中，莫耳比為約1:20至約25:1。在一些實施例中，莫耳比為約1:10至約22:1。在一些實施例中，莫耳比為約1:5至約25:1。在一些實施例中，莫耳比為約1:1至約30:1。在一些實施例中，莫耳比為約2:1至約10:1。在一些實施例中，莫耳比為約5:1至約20:1。在一些實施例中，莫耳比為約1:1至約25:1。在一些實施例中，莫耳比可為約1:35、1:34、1:33、1:32、1:31、1:30、1:32、1:31、1:30、1:29、1:28、1:27、1:26、1:25、1:24、1:23、1:22、1:21、1:20、1:19、1:18、1:17、1:16、1:15、1:14、1:13、1:12、1:11、1:10、1:9、1:8、1:7、1:6、1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1、5:1、6:1、7:1、8:1、9:1、10:1、11:1、12:1、13:1、14:1、15:1、16:1、17:1、18:1、19:1、20:1、21:1、22:1、23:1、24:1、25:1、26:1、27:1、28:1、29:1或30:1。在一些實施例中，莫耳比等於或大於約1:1。在一些實施例中，莫耳比為約1:1。在一些實施例中，莫耳比為約2:1。在一些實施例中，莫耳比為約3:1。在一些實施例中，莫耳比為約4:1。在一些實施例中，莫耳比為約5:1。在一些實施例中，莫耳比為約6:1。在一些實施例中，莫耳比為約7:1。在一些實施例中，莫耳比為約8:1。在一些實施例中，莫耳比為約9:1。在一些實施例中，莫耳比為約10:1。在一些實施例中，莫耳比為約11:1。在一些實施例中，莫耳比為約12:1。在一些實施例中，莫耳比為約13:1。在一些實施例中，莫耳比為約14:1。在一些實施例中，莫耳比為約15:1。在一些實施例中，莫耳比為約16:1。在一些實施例中，莫耳比為約17:1。在一些實施例中，莫耳比為約18:1。在一些實施例中，莫耳比為約19:1。在一些實施例中，莫耳比為約20:1。在一些實施例中，莫耳比為約21:1。在一些實施例中，莫耳比為約22:1。在一些實施例中，莫耳比為約23:1。在一些實施例中，莫耳比為約24:1。在一些實施例中，莫耳比為約25:1。
類似地，在一些實施例中，若遞送蛋白質，則上文關於編碼UGI蛋白質之mRNA與編碼APOBEC3A脫胺酶(A3A)及RNA引導之切口酶之mRNA所論述之莫耳比類似。
在一些實施例中，本文中所描述之組合物進一步包含至少一種gRNA。在一些實施例中，提供一種組合物，其包含本文所述之mRNA及至少一種gRNA。在一些實施例中，gRNA為單導引gRNA (sgRNA)。在一些實施例中，gRNA為雙導引gRNA (dgRNA)。
在一些實施例中，組合物在投與個體之後能夠實現基因體編輯。
A. 胞苷脫胺酶；APOBEC3A脫胺酶
胞苷脫胺酶涵蓋胞苷脫胺酶超家族中之酶，且特定言之APOBEC家族之酶(酶之APOBEC1、APOBEC2、APOBEC4及APOBEC3子群)、活性誘導之胞苷脫胺酶(AID或AICDA)及CMP脫胺酶(參見例如Conticello等人，Mol. Biol. Evol. 22:367-77, 2005；Conticello，Genome Biol. 9:229, 2008；Muramatsu等人，J. Biol. Chem. 274: 18470-6, 1999；及Carrington等人，Cells 9:1690 (2020))。
在一些實施例中，本文揭示之胞苷脫胺酶係APOBEC家族之酶。在一些實施例中，本文所揭示之胞苷脫胺酶為APOBEC1、APOBEC2、APOBEC4及APOBEC3子群之酶。在一些實施例中，本文揭示之胞苷脫胺酶為APOBEC3子群之酶。在一些實施例中，本文揭示之胞苷脫胺酶為APOBEC3A脫胺酶(A3A)。在一些實施例中，脫胺酶包含APOBEC3A脫胺酶。
在一些實施例中，本文中所揭示之APOBEC3A脫胺酶(A3A)為人類A3A。在一些實施例中，本文中所揭示之APOBEC3A脫胺酶(A3A)為人類A3A。在一些實施例中，A3A為野生型A3A。
在一些實施例中，A3A為A3A變異體。A3A變異體與野生型A3A或其片段共有同源性。在一些實施例中，A3A變異體與野生型A3A具有至少約80%一致性、至少約85%一致性、至少約90%一致性、至少約95%一致性、至少約96%一致性、至少約97%一致性、至少約98%一致性、至少約99%一致性、至少約99.5%一致性或至少約99.9%一致性。在一些實施例中，與野生型A3A相比較，A3A變異體可具有1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、21、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50個或更多個胺基酸改變。在一些實施例中，A3A變異體包含A3A之片段，使得該片段與野生型A3A之對應片段具有至少約80%一致性、至少約90%一致性、至少約95%一致性、至少約96%一致性、至少約97%一致性、至少約98%一致性、至少約99%一致性、至少約99.5%一致性或至少約99.9%一致性。
在一些實施例中，A3A變異體為具有與野生型A3A蛋白質相差一個或若干個突變之序列之蛋白質，該一個或若干個突變諸如取代、缺失、插入、一個或若干個單點取代。在一些實施例中，縮短A3A序列可例如，藉由使N末端、C末端或內部胺基酸確實來使用。在一些實施例中，使用縮短的A3A序列，其中序列之C末端處之一至四個胺基酸缺失。在一些實施例中，APOBEC3A (諸如人類APOBEC3A)具有野生型胺基酸位置57 (如野生型序列中所編號)。在一些實施例中，APOBEC3A (諸如人類APOBEC3A)在胺基酸位置57 (如野生型序列中所編號)處具有天冬醯胺。
在一些實施例中，野生型A3A為人類A3A (UniProt寄存ID：p319411，SEQ ID NO: 151)。
在一些實施例中，本文中所揭示之A3A包含與SEQ ID NO: 151具有至少80%一致性之胺基酸序列。在一些實施例中，一致性水平為至少85%、至少87%、至少90%、至少95%、至少98%、至少99%或100%。在一些實施例中，A3A包含與SEQ ID NO: 151具有至少87%一致性之胺基酸序列。在一些實施例中，A3A包含與SEQ ID NO: 151具有至少90%一致性之胺基酸序列。在一些實施例中，A3A包含與SEQ ID NO: 151具有至少95%一致性之胺基酸序列。在一些實施例中，A3A包含與SEQ ID NO: 151具有至少98%一致性之胺基酸序列。在一些實施例中，A3A包含與A3A ID NO: 151具有至少99%一致性之胺基酸序列。在一些實施例中，A3A包含SEQ ID NO: 151之胺基酸序列。
在一些實施例中，本文所揭示之胞苷脫胺酶包含與SEQ ID NO: 151-216中之任一者具有至少80%一致性之胺基酸序列。在一些實施例中，一致性水平為至少85%、至少87%、至少90%、至少95%、至少98%、至少99%或100%。在一些實施例中，胞苷脫胺酶包含SEQ ID NO: 151-216中之任一者之胺基酸序列。
B. UGI
在不受任何理論束縛之情況下，提供UGI以及包含脫胺酶之多肽可藉由抑制細胞DNA修復機構(例如UDG及下游修復效應子)而有助於本文所描述之方法，該等機構將識別DNA中之尿嘧啶作為DNA損傷形式或以其他方式將切除或修飾尿嘧啶或周圍核苷酸。應理解，UGI之用途可提高能夠對C殘基進行去胺之酶之編輯效率。
適合之UGI蛋白質及核苷酸序列提供於本文中且額外適合之UGI序列為熟習此項技術者所知，且包括例如以下各者中公佈之彼等：Wang Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264: 1163-1171(1989)；Lundquist等人, Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419(1997)；Ravishankar等人, X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887(1998)；及Putnam等人, Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346(1999)，其各自之全部內容以引用之方式併入本文中。應瞭解，能夠抑制尿嘧啶-DNA醣苷酶鹼基-切除修復酶之任何蛋白質均在本發明之範疇內。另外，阻斷或抑制鹼基切除修復之任何蛋白質亦在本發明之範疇內。在一些實施例中，尿嘧啶醣苷酶抑制劑為結合尿嘧啶之蛋白質。在一些實施例中，尿嘧啶醣苷酶抑制劑為結合DNA中之尿嘧啶之蛋白質。在一些實施例中，尿嘧啶醣苷酶抑制劑為單股結合蛋白。在一些實施例中，尿嘧啶醣苷酶抑制劑為無催化活性尿嘧啶DNA-醣苷酶蛋白質。在一些實施例中，尿嘧啶醣苷酶抑制劑為不自DNA切除尿嘧啶之無催化活性尿嘧啶DNA-醣苷酶蛋白質。在一些實施例中，尿嘧啶醣苷酶抑制劑為無催化活性UDG。
在一些實施例中，本文中所揭示之尿嘧啶醣苷酶抑制劑(UGI)包含與SEQ ID NO: 3具有至少80%之胺基酸序列。在一些實施例中，前述一致性水平中之任一者為至少90%、至少95%、至少98%、至少99%或100%。在一些實施例中，UGI包含與SEQ ID NO: 3具有至少90%一致性之胺基酸序列。在一些實施例中，UGI包含與SEQ ID NO: 3具有至少95%一致性之胺基酸序列。在一些實施例中，UGI包含與SEQ ID NO: 3具有至少98%一致性之胺基酸序列。在一些實施例中，UGI包含與SEQ ID NO: 3具有至少99%一致性之胺基酸序列。在一些實施例中，UGI包含SEQ ID NO: 3之胺基酸序列。
C. 連接子
在一些實施例中，包含本文所述之之脫胺酶及RNA引導之切口酶的多肽進一步包含連接脫胺酶與RNA引導之切口酶之連接子。在一些實施例中，連接子為肽連接子。在一些實施例中，編碼包含脫胺酶及RNA引導之切口酶之多肽的核酸進一步包含編碼肽連接子之序列。在一些實施例中，提供編碼脫胺酶-連接子-RNA引導之切口酶融合蛋白的mRNA。
在一些實施例中，肽連接子為具有至少1個、至少2個、至少3個、至少4個、至少5個、至少6個、至少7個、至少8個、至少9個、至少10個、至少15個、至少20個、至少25個、至少30個、至少40個、至少50個或更多個胺基酸之任何胺基酸伸長段。
在一些實施例中，肽連接子為16個殘基之「XTEN」連接子或其變異體(參見例如實例；及Schellenberger等人，A recombinant polypeptide extends the
in vivohalf-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186-1190 (2009))。在一些實施例中，XTEN連接子包含序列SGSETPGTSESATPES (SEQ ID NO: 58)、SGSETPGTSESA (SEQ ID NO:59)或SGSETPGTSESATPEGGSGGS (SEQ ID NO:60)。
在一些實施例中，肽連接子包含(GGGGS)
n(SEQ ID NO: 62)、(G)
n、(EAAAK)
n(SEQ ID NO: 63)、(GGS)
n(SEQ ID NO: 61)或SGSETPGTSESATPES (SEQ ID NO: 58)模體(參見例如Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification.
Nat. Biotechnol.2014; 32(6): 577-82；全部內容以引用之方式併入本文中)，或(XP)
n模體，或此等中之任一者之組合，其中n獨立地為1與30之間的整數。參見WO2015089406，例如第[0012]段，其全部內容以引用之方式併入本文中。
在一些實施例中，肽連接子包含選自SEQ ID NO: 58-122之一或多個序列。在一些實施例中，肽連接子包含選自SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 118、SEQ ID NO: 119、SEQ ID NO: 120、SEQ ID NO: 121及SEQ ID NO: 122之一或多個序列。
D. 包含APOBEC3A脫胺酶及RNA引導之切口酶的組合物
在一些實施例中，提供一種編碼包含胞苷脫胺酶(例如A3A)及RNA引導之切口酶之多肽的mRNA。在一些實施例中，多肽包含人類脫胺酶(例如A3A)及C末端RNA引導之切口酶；及編碼第一NLS及視情況存在之第二NLS之核苷酸序列。在某些實施例中，脫胺酶位於NLS之N末端。在某些實施例中，脫胺酶位於所有NLS之N末端。
在一些實施例中，多肽包含野生型脫胺酶(例如A3A)及C末端RNA引導之切口酶。在一些實施例中，多肽包含A3A變異體及RNA引導之切口酶。在一些實施例中，多肽包含脫胺酶(例如A3A)及Cas9切口酶。在一些實施例中，多肽包含脫胺酶(例如A3A)及D16A NmeCas9切口酶。在一些實施例中，多肽包含人類脫胺酶(例如A3A)及D16A NmeCas9切口酶。在一些實施例中，多肽包含A3A變異體及D16A NmeCas9切口酶。在一些實施例中，多肽缺少UGI。在一些實施例中，脫胺酶(例如A3A)及RNA引導之切口酶經由連接子連接。在一些實施例中，多肽進一步包含一或多個額外異源功能域。在一些實施例中，多肽進一步包含核定位序列(NLS) (本文所述)。
在一些實施例中，多肽包含人類脫胺酶(例如A3A)及C末端D16A NmeCas9切口酶，其中人類脫胺酶(例如A3A)及D16A NmeCas9經由連接子融合。在一些實施例中，多肽包含人類A3A及C末端D16A NmeCas9切口酶以及位於融合多肽之N末端處的NLS。在一些實施例中，多肽包含人類A3A及C末端D16A NmeCas9切口酶，其中人類A3A及D16A NmeCas9經由連接子融合，且NLS視情況經由連接子融合至人類A3A之N末端。
多肽可以多種方式組織以形成單鏈。第一NLS及(當存在時)第二NLS位於編碼Cas9切口酶之序列的N末端。額外NLS可位於Cas9切口酶之N末端。相比於NLS，A3A可為N末端或C末端。在一些實施例中，多肽自N末端至C末端包含第一NLS、視情況存在之第二NLS、脫胺酶、視情況存在之連接子、RNA引導之切口酶及視情況存在之NLS。在一些實施例中，連接子獨立地存在於第一與第二NLS及NLS與脫胺酶之間。在一些實施例中，多肽自N末端至C末端包含脫胺酶、第一NLS、視情況存在之第二NLS、C末端RNA引導之切口酶。在一些實施例中，連接子獨立地存在於脫胺酶與第一NLS之間、第一NLS與第二NLS之間及NLS與C末端切口酶之間。
在前述實施例中之任一者中，多肽可包含與SEQ ID NO: 14具有至少80%一致性之胺基酸序列。在一些實施例中，前述一致性水平中之任一者為至少85%、90%、95%、98%、或99%、或100%一致。在一些實施例中，本文揭示之多肽可包含與SEQ ID NO: 14具有至少90%一致性之胺基酸序列。在一些實施例中，本文揭示之多肽可包含與SEQ ID NO: 3或6具有至少95%一致性之胺基酸序列。在一些實施例中，本文揭示之多肽可包含與SEQ ID NO: 14具有至少98%一致性之胺基酸序列。在一些實施例中，本文揭示之多肽可包含與SEQ ID NO: 14具有至少99%一致性之胺基酸序列。在一些實施例中，本文揭示之多肽可包含SEQ ID NO: 14之胺基酸序列。
在前述實施例中之任一者中，包含編碼本文揭示之多肽之開放閱讀框架的核酸序列可包含與SEQ ID NO: 42具有至少80%一致性之核酸序列。在一些實施例中，前述一致性水平中之任一者為至少85%、90%、95%、98%、或99%、或100%一致。
在前述實施例中之任一者中，編碼本文揭示之多肽的mRNA序列可包含與SEQ ID NO: 28具有至少80%一致性之核酸序列。在一些實施例中，前述一致性水平中之任一者為至少85%、90%、95%、98%、或99%、或100%一致。
在前述實施例中之任一者中，A3A可包含與SEQ ID NO: 151具有至少80%一致性之胺基酸序列。在一些實施例中，一致性水平為至少85%、87%、90%、95%、98%、或99%、或100%一致。在一些實施例中，A3A包含SEQ ID NO: 151之胺基酸序列。
在前述實施例中之任一者中，NmeCas9切口酶可包含與SEQ ID NO: 220、248或276中之任一者具有至少80%、90%、95%、98%、或99%一致性之胺基酸序列。在一些實施例中，一致性水平為至少85%、87%、90%、95%、98%、或99%、或100%一致。在一些實施例中，RNA引導之切口酶包含SEQ ID NO: 220、248或276之胺基酸序列。在一些實施例中，RNA引導之切口酶包含SEQ ID NO: 220、248或276之胺基酸序列。在一些實施例中，RNA引導之切口酶包含SEQ ID NO: 220、248或276之胺基酸序列。
III. 引導RNA
在一些實施例中，與本文揭示之多核苷酸，諸如編碼經RNA引導之DNA結合劑之多核苷酸組合提供至少一種引導RNA。在一些實施例中，引導RNA提供為與多核苷酸分離之分子。在一些實施例中，引導RNA提供為本文所揭示之多核苷酸之一部分，諸如UTR之一部分。
在一些實施例中，包含本文揭示之多核苷酸之組合物進一步包含至少一個引導RNA (或「gRNA」)。
在一些實施例中，gRNA為單引導gRNA (或「sgRNA」)。
在一些實施例中，gRNA為雙引導RNA。
在一些實施例中，引導RNA包含經修飾之sgRNA。sgRNA可經修飾以改良其活體內穩定性。
在一些實施例中，本文中所描述之gRNA為奈瑟氏腦膜炎菌Cas9 (NmeCas9) gRNA，其包含含有重複/反重複區、髮夾1區及髮夾2區之保守部分，其中重複/反重複區、髮夾1區及髮夾2區中之一或多者經縮短。例示性野生型NmeCas9引導RNA包含(N)
20-25GUUGUAGCUCCCUUUCUCAUUUCGGAAACGAAAUGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCCUUAAAGCUUCUGCUUUAAGGGGCAUCGUUUA (SEQ ID NO: 500)之序列。如本文所使用之(N)
20-25表示20至25，亦即20、21、22、23、24或25鄰接N。A、C、G及U分別表示具有腺嘌呤、胞嘧啶、鳥嘌呤及尿嘧啶鹼基之核苷酸。在一些實施例中，(N)
20-25長度為24個核苷酸。N為任何天然或非天然核苷酸，且其中N之總體包含導引序列。
在一些實施例中，單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-48及53-64中之一或多者經缺失，且視情況核苷酸37-64中之一或多者經取代；及
(ii)核苷酸36藉由至少2個核苷酸連接至核苷酸65；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-86及91-95中之一或多者經缺失，且視情況位置82-96中之一或多者經取代；且
(ii)核苷酸81藉由至少4個核苷酸連接至核苷酸96；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-121及126-134中之一或多者經缺失，且視情況核苷酸113-134中之一或多者經取代；且
(ii)核苷酸112藉由至少4個核苷酸連接至核苷酸135；
其中相對於SEQ ID NO: 500，一個或兩個核苷酸144-145視情況經缺失；且其中至少10個核苷酸為經修飾之核苷酸。
在一些實施例中，gRNA之經縮短之重複/反重複區缺少18個核苷酸。在一些實施例中，gRNA之經縮短之重複/反重複區缺少22個核苷酸。
在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由6個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區域中，核苷酸36藉由7個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由8個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由9個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由10個核苷酸連接至核苷酸65。
在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸38-48及53-63相對於SEQ ID NO: 500經缺失。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸38、41-48、53-60及63相對於SEQ ID NO: 500經缺失。
在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由6個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸38-48及53-63相對於SEQ ID NO: 500經缺失，且核苷酸36藉由核苷酸37、49-52及64連接至核苷酸65。
在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸36藉由10個核苷酸連接至核苷酸65。在一些實施例中，在gRNA之經縮短之重複/反重複區中，核苷酸38、41-48、53-60及63相對於SEQ ID NO: 500經缺失，且核苷酸36藉由核苷酸37、39、40、49-52、61、62及64連接至核苷酸65。
在一些實施例中，經縮短之重複/反重複區之上莖的所有核苷酸38-48及核苷酸53-63均相對於SEQ ID NO: 500經缺失。
在一些實施例中，經縮短之重複/反重複區之上莖的所有核苷酸39-48及核苷酸53-62均相對於SEQ ID NO: 500經缺失，且核苷酸38及63經取代。
在一些實施例中，經縮短之重複/反重複區具有14個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有15個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有16個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有17個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有18個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有19個經修飾核苷酸。在一些實施例中，經縮短之重複/反重複區具有20個經修飾核苷酸。
在一些實施例中，經縮短之髮夾1區缺少2個核苷酸。在一些實施例中，經縮短之髮夾1區缺少21個核苷酸。在一些實施例中，經縮短之髮夾1區缺少2個核苷酸，且核苷酸86及91相對於SEQ ID NO: 500經缺失。在一些實施例中，經縮短之髮夾1區缺少2個核苷酸，且核苷酸85及92相對於SEQ ID NO: 500經缺失。在一些實施例中，在經縮短之髮夾1區中，核苷酸81藉由12個核苷酸連接至核苷酸96。在一些實施例中，在經縮短之髮夾1區中，核苷酸81藉由12個核苷酸連接至核苷酸96。在一些實施例中，在經縮短之髮夾1區中，核苷酸86及91相對於SEQ ID NO: 500經缺失，且核苷酸81藉由核苷酸82-85、87-90及92-95連接至核苷酸96。在一些實施例中，在經縮短之髮夾1區中，核苷酸85及92相對於SEQ ID NO: 500經缺失，且核苷酸81藉由核苷酸82-84、86-91及93-95連接至核苷酸96。
在一些實施例中，經縮短之髮夾1區具有長度為7個鹼基配對核苷酸之雙螺旋部分。在一些實施例中，經縮短之髮夾1區具有長度為8個鹼基配對核苷酸之雙螺旋部分。
在經縮短之髮夾1區之莖中，長度為七個鹼基配對核苷酸。在一些實施例中，經縮短之髮夾1區之核苷酸85-86及核苷酸91-92經缺失。
在一些實施例中，經縮短之髮夾1區具有13個經修飾之核苷酸。
在一些實施例中，經縮短之髮夾2缺少18個核苷酸。在一些實施例中，經縮短之髮夾2具有24個核苷酸。在一些實施例中，在經縮短之髮夾2中，核苷酸113-121及126-134相對於SEQ ID NO: 500經缺失。在一些實施例中，經縮短之髮夾2缺少18個核苷酸，且核苷酸113-121及126-134相對於SEQ ID NO: 500經缺失。在一些實施例中，在經縮短之髮夾2區中，核苷酸112藉由4個核苷酸連接至核苷酸135。在一些實施例中，在經縮短之髮夾2區中，核苷酸113-121及126-134相對於SEQ ID NO: 500經缺失且核苷酸112藉由核苷酸122-125連接至核苷酸135。
在一些實施例中，經縮短之重複/反重複區具有28個核苷酸之長度。在一些實施例中，經縮短之重複/反重複區具有32個核苷酸之長度。
在一些實施例中，經縮短之重複/反重複區之上莖包含不超過一個鹼基對。在一些實施例中，經縮短之重複/反重複區之上莖包含不超過三個鹼基對。
在一些實施例中，經縮短之髮夾2區具有8個經修飾之核苷酸。
在一些實施例中，引導RNA (gRNA)包含引導區及保守區，該保守區包含：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區相對於SEQ ID NO: 500缺少18-22個核苷酸，其中
(i)核苷酸38-48及53-63經缺失；且
(ii)核苷酸36藉由6-10個核苷酸連接至核苷酸65；
(b)經縮短之髮夾1區，其中經縮短之髮夾1缺少2個核苷酸，其中相對於SEQ ID NO: 500，核苷酸86及91經缺失或核苷酸85及92經缺失；及
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少18個核苷酸，其中核苷酸113-121及126-134相對於SEQ ID NO: 500經缺失；且其中核苷酸144-145相對於SEQ ID NO: 500經缺失；其中至少10個核苷酸為經修飾之核苷酸。
在一些實施例中，引導RNA (gRNA)包含引導區及保守區，該保守區包含：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區相對於SEQ ID NO: 500缺少18-22個核苷酸，其中
(i)核苷酸38、41-48、53-60及63經缺失；且
(ii)核苷酸36藉由6-10個核苷酸連接至核苷酸65；
(b)經縮短之髮夾1區，其中經縮短之髮夾1缺少2個核苷酸，其中相對於SEQ ID NO: 500，核苷酸86及91經缺失或核苷酸85及92經缺失；
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少18個核苷酸，其中相對於SEQ ID NO: 500，核苷酸113-121及126-134經缺失；且
其中相對於SEQ ID NO: 500，核苷酸144-145經缺失；
其中至少10個核苷酸為經修飾之核苷酸。
在一些實施例中，提供一種引導RNA (gRNA)，該gRNA包含引導區及保守區，該保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區相對於SEQ ID NO: 500缺少18-22個核苷酸，其中
(i)核苷酸37-48及53-64經缺失；且
(ii)核苷酸36藉由6-10個核苷酸連接至核苷酸65；或
(b)經縮短之髮夾1區，其中經縮短之髮夾1缺少2個核苷酸，其中相對於SEQ ID NO: 500，核苷酸86及91經缺失或核苷酸85及92經缺失；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少18個核苷酸，其中相對於SEQ ID NO: 500，核苷酸113-121及126-134經缺失；且
其中相對於SEQ ID NO: 500，核苷酸144-145經缺失；
其中至少10個核苷酸為經修飾之核苷酸。
在其他實施例中，經縮短之重複/反重複區，其中該經縮短之重複/反重複區相對於SEQ ID NO: 500缺少22個核苷酸。在其他實施例中，核苷酸36藉由包含核苷酸序列UGAAAC之序列連接至核苷酸65。在其他實施例中，核苷酸36藉由10個核苷酸連接至核苷酸65。在其他實施例中，核苷酸36藉由包含核苷酸序列UUCGAAAGAC之序列連接至核苷酸65。
在一些實施例中，前述實施例之引導RNA (gRNA)包含引導區及保守區，該保守區包含：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少18-22個核苷酸，其中
(i)核苷酸37-48及53-64相對於SEQ ID NO: 500經缺失；且
(ii)核苷酸36藉由6-10個核苷酸連接至核苷酸65；
(b)經縮短之髮夾1區，其中經縮短之髮夾1相對於SEQ ID NO: 500缺少2個核苷酸，其中核苷酸86及91經缺失或核苷酸85及92經缺失；
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少18個核苷酸，其中相對於SEQ ID NO: 500，核苷酸113-121及126-134經缺失；且
(d)其中相對於SEQ ID NO: 500，核苷酸144-145經缺失；
其中至少10個核苷酸為經修飾之核苷酸。
在其他實施例中，經縮短之重複/反重複區，其中該經縮短之重複/反重複區相對於SEQ ID NO: 500缺少22個核苷酸。在其他實施例中，核苷酸36藉由包含核苷酸序列UGAAAC之序列連接至核苷酸65。在其他實施例中，核苷酸36藉由10個核苷酸連接至核苷酸65。在其他實施例中，核苷酸36藉由包含核苷酸序列UUCGAAAGAC之序列連接至核苷酸65。
圖33-35顯示呈可能的二級結構之例示性sgRNA。
在一些實施例中，NmeCas9短sgRNA包含呈5'至3'定向之以下序列中之一者：(N)
20-25GUUGUAGC UCCCUGAAACCGUU GCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU (SEQ ID NO: 501)；
(N)
20-25GUUGUAGCUCCCU GAAACCGUUGC UACAAUAAGGC CGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUUAUU (SEQ ID NO: 502)；
(N)
20-25GUUGUA GCUCCCUGGAAACCCGU UGCUACAAU AAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUUAUU (SEQ ID NO: 503)；
(N)
20-25GUUGUA GCUCCCUUCGAAA GACCGUU GCUACAA UAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU (SEQ ID NO: 514)，
其中N為編碼引導序列之核苷酸。在一些實施例中，N等於24。在一些實施例中，N等於25。N表示具有任何鹼基(例如A、C、G或U)之核苷酸。(N)20-25表示20-25個，亦即20、21、22、23、24或25個連續N。
在一些實施例中，NmeCas9短sgRNA之保守部分之至少10個核苷酸為經修飾之核苷酸。
在一些實施例中，NmeCas9 短sgRNA包含含有呈5'至3'定向之以下序列中之一者的保守區：
mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU (SEQ ID NO: 504)；
mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 505)；或
mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 515 )。NmeCas9短gRNA (例如SEQ ID NO: 512-530)之額外實例提供於表39B中。
在一些實施例中，NmeCas9短gRNA包含5'至3'位向之以下序列中之一者：
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 512)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 525)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU(SEQ ID NO: 526)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 527)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 516)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 520)；
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 521)；或
mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 522)；
(N)
20-25mGUUGm UmAmGmCU CCCmUmGm AmAmAmCmCG UUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmCmUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU (SEQ ID NO: 523)；或
(N)
20-25mGUUGmUmAmGmCUCCCmUmUmC mGmAmAmAmGm AmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 524)，
其中N表示具有任何鹼基(例如A、C、G或U)之核苷酸。(mN*)
3表示三個連續核苷酸，其各自分別具有與下一核苷酸之任何鹼基、2'-OMe及3'PS鍵聯。核苷酸修飾表示為m為2'-OMe修飾且*為PS鍵聯。在經修飾之核苷酸序列之情況下，在某些實施例中，N、A、C、G及U為未經修飾之RNA核苷酸，亦即2'-OH及與3'核苷酸之磷酸二酯酶鍵聯。
經縮短之NmeCas9 gRNA可包含本文揭示之內部連接子。
如本文所使用之「內部連接子」描述接合引導RNA內之兩個核苷酸的非核苷酸片段。若gRNA含有間隔區，則內部連接子位於間隔區外部(例如，gRNA之骨架或保守區中)。對於V型引導物，應理解，最後一個髮夾為結構中之唯一髮夾，亦即重複反重複區。在一些實施例中，內部連接子包含本文揭示之PEG-連接子。在一些實施例中，內部連接子包含本文揭示之PEG-連接子。
在一些實施例中，單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-64中之一或多者經缺失且視情況經取代；且
(ii)核苷酸36藉由以下各者連接至核苷酸65：(i)單獨或與核苷酸組合取代4個核苷酸之第一內部連接子，或(ii)至少4個核苷酸；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-95中之一或多者經缺失且視情況經取代；且
(ii)核苷酸81藉由以下各者連接至核苷酸96：(i)單獨或與核苷酸組合取代4個核苷酸之第二內部連接子，或(ii)至少4個核苷酸；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-134中之一或多者經缺失且視情況經取代；且
(ii)核苷酸112藉由以下各者連接至核苷酸135：(i)單獨或與核苷酸組合取代4個核苷酸之第三內部連接子，或(ii)至少4個核苷酸；
其中核苷酸144-145中之一者或兩者相比於SEQ ID NO: 500視情況經缺失；
其中該gRNA包含該第一內部連接子、該第二內部連接子及該第三內部連接子中之至少一者。
連接子之例示性位置如以下所示：
(N)
20-25GUUGUAGCUCCCUUC
(L1)G ACCGUUGCUACAAUAAG GCCGUC
(L1)GAUGUGCCGCAACGCUCUGCC
(L1)GGCAUCGUU (SEQ ID NO: 506)。如本文所使用，(L1)係指具有約15至21個原子之橋連長度的內部連接子。
在一些實施例中，包含內部連接子之經縮短之NmeCas9引導RNA可經化學修飾。例示性修飾包括以下序列之修飾模式：mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmC(L1)mGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU (SEQ ID NO: 507)。
在一些實施例中，sgRNA包含SEQ ID NO: 141及143-150 (Nme PEG引導物)中所示之修飾模式，其中N為任何天然或非天然核苷酸，且其中全部N均包含引導序列。
IV. 遞送
在一些實施例中，本文中所揭示之多核苷酸或組合物調配於脂質奈米粒子中或經由脂質奈米粒子投與；參見例如WO2017173054，其內容特此以全文引用之方式併入。
脂質
本文揭示使用包含本文中所描述之核酸或組合物之脂質核酸組裝組合物的各種實施例。在一些實施例中，脂質核酸組裝組合物包含核酸(例如mRNA)，其包含編碼包含開放閱讀框架(ORF)之多核苷酸的開放閱讀框架，該ORF包含編碼本文所揭示之C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列及編碼第一核定位信號(NLS)之核苷酸序列。在一些實施例中，NmeCas9為Nme2Cas9、Nme1Cas9或Nme3Cas9。
如本文所用，「脂質核酸組裝組合物」係指基於脂質之遞送組合物，包括脂質奈米粒子(LNP)及脂質複合體。LNP係指＜100nM之脂質奈米粒子。LNP係藉由將脂質組分(例如於乙醇中)與水性核酸組分精確混合而形成，且LNP之大小均一。脂複合體為藉由使脂質及核酸組分大量混合而形成之粒子且大小在約100 nm與1微米之間。在某些實施例中，脂質核酸組裝體為LNP。如本文所用，「脂質核酸組裝體」包含複數個(亦即，超過一個)藉由分子間力以物理方式彼此締合之脂質分子。脂質核酸組裝體可包含pKa值為＜7.5或＜7之生物可用脂質。脂質核酸組裝體係藉由混合含核酸水溶液與基於有機溶劑之脂質溶液(例如100%乙醇)形成。適合溶液或溶劑包括或可含有：水、PBS、Tris緩衝液、NaCl、檸檬酸鹽緩衝液、乙醇、氯仿、二乙醚、環己烷、四氫呋喃、甲醇、異丙醇。醫藥學上可接受之緩衝液可視情況包含於包含脂質核酸組裝體之醫藥調配物中，例如用於離體療法。在一些實施例中，水溶液包含RNA，諸如mRNA或gRNA。在一些實施例中，水溶液包含編碼RNA引導之DNA結合劑(諸如Cas9)的mRNA。
如本文所使用，脂質奈米粒子(LNP)係指包含複數個(亦即，超過一個)藉由分子間力以物理方式彼此締合之脂質分子的粒子。LNP可例如為微球體(包括單層及多層囊泡，例如「脂質體」-在一些實施例中為大體上球形之層狀相脂質雙層-且在更特定實施例中可包含水性核心，例如包含大部分RNA分子)、乳液中之分散相、膠束或懸浮液中之內相。乳液、微胞及懸浮液可為用於局部及/或體表遞送之適合組合物。亦參見例如WO2017173054A1，其內容特此以全文引用之方式併入。熟習此項技術者已知能夠將核苷酸遞送至個體之任何LNP可與引導RNA及編碼本文所描述之NmeCas9及NLS的核酸一起使用。
在一些實施例中，水溶液包含編碼包含A3A及RNA引導之切口酶之多肽的核酸。包含脂質核酸組裝組合物之醫藥調配物可視情況包含醫藥學上可接受之緩衝液。
在一些實施例中，脂質核酸組裝組合物包括「胺脂質」(在本文中或其他地方有時描述為「可離子化脂質」或「可生物降解脂質」)，以及視情況存在之「輔助脂質」、「中性脂質」及隱形脂質，諸如PEG脂質。在一些實施例中，取決於pH，胺脂質或可離子化脂質為陽離子型的。
1. 胺脂質
在一些實施例中，脂質核酸組裝組合物包含「胺脂質」，其為例如可離子化脂質，諸如脂質A或其等效物，包括脂質A之縮醛類似物。
在一些實施例中，胺脂質為脂質A，其為十八-9,12-二烯酸(9Z,12Z)-3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙酯，亦稱為(9Z,12Z)-十八-9,12-二烯酸3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙酯。脂質A可描繪為：
。
可根據WO2015/095340 (例如第84-86頁)合成脂質A。在一些實施例中，胺脂質為脂質A之等效物。
在一些實施例中，胺脂質為脂質A之類似物。在一些實施例中，脂質A類似物為脂質A之縮醛類似物。在特定脂質核酸組裝組合物中，縮醛類似物為C4-C12縮醛類似物。在一些實施例中，縮醛類似物為C5-C12縮醛類似物。在額外實施例中，縮醛類似物為C5-C10縮醛類似物。在其他實施例中，縮醛類似物係選自C4、C5、C6、C7、C9、C10、C11及C12縮醛類似物。
適用於本文所描述之脂質核酸組裝體的胺脂質及其他「可生物降解脂質」為活體內或離體可生物降解的。胺脂質具有低毒性(例如，以大於或等於10 mg/kg之量在動物模型中得到耐受而不具有不良作用)。在一些實施例中，包含胺脂質之脂質核酸組裝體包括其中在8、10、12、24或48小時或3、4、5、6、7或10天內自血漿或工程化細胞清除至少75%之胺脂質的脂質核酸組裝體。在一些實施例中，包含胺脂質之脂質核酸組裝體包括其中在8、10、12、24或48小時或3、4、5、6、7或10天內自血漿清除至少50%核酸，例如mRNA或gRNA的脂質核酸組裝體。在一些實施例中，包含胺脂質之脂質核酸組裝體包括其中在8、10、12、24或48小時或3、4、5、6、7或10天內自血漿清除至少50%之脂質核酸組裝體之彼等，例如藉由量測脂質(例如，胺脂質)、核酸(例如，RNA/mRNA)或其他組分。在一些實施例中，量測脂質核酸組裝體之經脂質囊封相對於游離脂質、RNA或核酸組分。
可生物降解脂質包括例如WO/2020/219876、WO/2020/118041、WO/2020/072605、WO/2019/067992、WO/2017/173054、WO2015/095340及WO2014/136086之可生物降解脂質，且LNP包括其中所描述之LNP組合物，其脂質及組合物特此以引用之方式併入。
脂質清除率可如文獻中所述量測。參見Maier, M.A.等人 Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics.
Mol. Ther.2013, 21(8), 1570-78 (「
Maier」)。舉例而言，在
Maier中，以0.3 mg/kg藉由靜脈內彈丸注射(bolus injection)經由側尾靜脈向六至八週齡雄性C57BL/6小鼠投與含有靶向螢光素酶之siRNA的LNP-siRNA系統。在給藥後0.083、0.25、0.5、1、2、4、8、24、48、96及168小時收集血液、肝臟及脾臟樣品。在收集組織之前向小鼠灌注生理鹽水且處理血液樣品以獲得血漿。處理且藉由LC-MS分析所有樣品。此外，
Maier描述一種用於評估投與LNP-siRNA調配物之後的毒性之程序。舉例而言，以0、1、3、5及10 mg/kg (5隻動物/組)經由單一靜脈內彈丸注射以5 mL/kg之劑量體積向雄性史泊格-多利大鼠(Sprague-Dawley rat)投與靶向螢光素酶之siRNA。24小時之後，自有意識動物之頸靜脈獲得約1 mL血液且分離血清。在給藥後72小時，將所有動物安樂死用於屍體剖檢。進行臨床症狀、體重、血清化學、器官重量及組織病理學之評定。儘管
Maier描述用於評定siRNA-LNP調配物之方法，但此等方法可適用於評定本發明之脂質核酸組裝組合物之投藥的清除率、藥物動力學及毒性。
此項技術中已知之用於核酸之LNP遞送的可離子化及生物可用脂質為適合的。脂質可視所處之介質之pH而離子化。舉例而言，在弱酸性介質中，脂質，諸如胺脂質，可質子化且因此帶有正電荷。相反地，在弱鹼性介質中，諸如pH大約7.35之血液中，脂質，諸如胺脂質，可不質子化且因此不帶電荷。
脂質帶有電荷之能力與其固有pKa有關。在一些實施例中，本發明之胺脂質可各自獨立地具有在約5.1至約7.4範圍內之pKa。在一些實施例中，本發明之生物可用脂質可各自獨立地具有在約5.1至約7.4，諸如約5.5至約6.6、約5.6至約6.4、約5.8至約6.2，或約5.8至約6.5範圍內之pKa。舉例而言，本發明之胺脂質可各自獨立地具有在約5.8至約6.5範圍內之pKa。pKa在約5.1至約7.4範圍內之脂質有效用於活體內遞送負荷，例如遞送至肝臟。此外，已發現，pKa在約5.3至約6.4範圍內之脂質於活體內遞送至例如腫瘤為有效的。參見例如WO2014/136086。
2. 額外脂質
適用於本發明之脂質核酸組裝組合物中的「中性脂質」包括例如多種中性、不帶電荷或兩性離子型脂質。適用於本發明之中性磷脂之實例包括但不限於：5-十七基苯-1,3-二醇(間苯二酚)、二軟脂醯基磷脂醯膽鹼(DPPC)、二硬脂醯基磷脂醯膽鹼例如1,2-二硬脂醯-sn-甘油-3-磷酸膽鹼(DSPC)、磷酸膽鹼(DOPC)、二肉豆蔻醯基磷脂醯膽鹼(DMPC)、磷脂醯膽鹼(PLPC)、1,2-二硬脂醯基-sn-甘油-3-磷酸膽鹼(DAPC)、磷脂醯乙醇胺(PE)、卵磷脂醯膽鹼(EPC)、二月桂醯基磷脂醯膽鹼(DLPC)、二肉豆蔻醯基磷脂醯膽鹼(DMPC)、1-肉豆蔻醯基-2-軟脂醯基磷脂醯膽鹼(MPPC)、1-軟脂醯基-2-肉豆蔻醯基磷脂醯膽鹼(PMPC)、1-軟脂醯基-2-硬脂醯基磷脂醯膽鹼(PSPC)、1,2-二花生醯基-sn-甘油-3-磷酸膽鹼(DBPC)、1-硬脂醯基-2-軟脂醯基磷脂醯膽鹼(SPPC)、1,2-二十碳烯醯基-sn-甘油-3-磷酸膽鹼(DEPC)、軟脂醯油醯基磷脂醯膽鹼(POPC)、溶血磷脂醯基膽鹼、二油醯基磷脂醯乙醇胺(DOPE)、二亞油醯基磷脂醯膽鹼二硬脂醯基磷脂醯乙醇胺(DSPE)、二肉豆蔻醯基磷脂醯乙醇胺(DMPE)、二軟脂醯基磷脂醯乙醇胺(DPPE)、軟脂醯油醯基磷脂醯乙醇胺(POPE)、溶血磷脂醯乙醇胺及其組合。在一個實施例中，中性磷脂可選自由以下組成之群：二硬脂醯基磷脂醯膽鹼(DSPC)及二肉豆蔻醯基磷脂醯乙醇胺(DMPE)。在另一實施例中，中性磷脂可為二硬脂醯基磷脂醯膽鹼(DSPC)。
「輔助脂質」包括類固醇、固醇及烷基間苯二酚。適用於本發明中之輔助脂質包括但不限於膽固醇、5-十七基間苯二酚及膽固醇半丁二酸酯。在一個實施例中，輔助脂質可為膽固醇。在一個實施例中，輔助脂質可為膽固醇半丁二酸酯。
「隱形脂質」為改變奈米粒子可在活體內(例如血液中)存在之時長的脂質。隱形脂質可藉由例如減少粒子聚集且控制粒度來輔助調配過程。本文使所用之隱形脂質可調節脂質核酸組裝體之藥物動力學特性或有助於奈米粒子離體穩定性。適用於本發明之脂質核酸組裝組合物之隱形脂質包括但不限於具有連接至脂質部分之親水性頭基的隱形脂質。適用於本發明之脂質核酸組裝組合物之隱形脂質及關於此類脂質之生物化學的資訊可見於Romberg等人, Pharmaceutical Research, 第25卷, 第1期, 2008, 第55至71頁及Hoekstra等人, Biochimica et Biophysica Acta 1660 (2004) 41-52中。額外適合PEG脂質揭示於例如WO 2006/007712中。
在一個實施例中，隱形脂質之親水性頭基包含選自基於PEG之聚合物的聚合物部分。隱形脂質可包含脂質部分。在一些實施例中，隱形脂質為PEG脂質。
在一個實施例中，隱形脂質包含選自基於以下之聚合物的聚合物部分：PEG (有時稱作聚(環氧乙烷))、聚(㗁唑啉)、聚(乙烯醇)、聚(甘油)、聚(N-乙烯基吡咯啶酮)、聚胺基酸及聚[N-(2-羥丙基)甲基丙烯醯胺]。
在一個實施例中，PEG脂質包含基於PEG (有時稱作聚(環氧乙烷))之聚合物部分。
PEG脂質進一步包含脂質部分。在一些實施例中，脂質部分可源自二醯基甘油或二醯基甘油醯胺、包括包含具有獨立地包含約約C4至約C40飽和或不飽和碳原子之烷基鏈長度的二烷基甘油或二烷基甘油醯胺基之彼等者，其中該鏈可包含一或多個官能基，諸如醯胺或酯。在一些實施例中，烷基鏈長度包含約C10至C20。二烷基甘油或二烷基甘油醯胺基可進一步包含一或多個經取代之烷基。鏈長可為對稱或不對稱的。
除非另外指示，否則如本文所使用，術語「PEG」意謂任何聚乙二醇或其他聚伸烷醚聚合物。在一個實施例中，PEG為乙二醇或環氧乙烷的視情況經取代之直鏈或分支鏈聚合物。在一個實施例中，PEG為未經取代的。在一個實施例中，PEG經例如一或多個烷基、烷氧基、醯基、羥基、或芳基取代。在一個實施例中，該術語包括PEG共聚物，諸如PEG-聚胺基甲酸酯或PEG-聚丙烯(參見例如J. Milton Harris, Poly(ethylene glycol) chemistry: biotechnical and biomedical applications (1992))；在另一實施例中，該術語不包括PEG共聚物。在一個實施例中，PEG之分子量為約130至約50,000，在子實施例中，約150至約30,000，在子實施例中，約150至約20,000，在子實施例中，約150至約15,000，在子實施例中，約150至約10,000，在子實施例中，約150至約6,000，在子實施例中，約150至約5,000，在子實施例中，約150至約4,000，在子實施例中，約150至約3,000，在子實施例中，約300至約3,000，在子實施例中，約1,000至約3,000，及在子實施例中，約1,500至約2,500。
在一些實施例中，PEG (例如與脂質部分或脂質，諸如隱形脂質結合)為「PEG-2K」，亦稱為「PEG 2000」，其平均分子量為約2,000道爾頓。PEG-2K在本文中由下式(I)表示，其中n為45，意謂經數目平均化之聚合度包含約45個次單位
。然而，可使用此項技術中已知之其他PEG實施例，包括例如其中數目平均化聚合度包含約23個次單位(n=23)及/或68個次單位(n=68)之彼等。在一些實施例中，n可在約30至約60範圍內。在一些實施例中，n可在約35至約55範圍內。在一些實施例中，n可在約40至約50範圍內。在一些實施例中，n可在約42至約48範圍內。在一些實施例中，n可為45。在一些實施例中，R可選自H、經取代之烷基及未經取代之烷基。在一些實施例中，R可為未經取代之烷基。在一些實施例中，R可為甲基。
在本文所述之實施例中之任一者中，PEG脂質可選自PEG-二月桂醯甘油、PEG-二肉豆蔻醯甘油(例如1,2-二肉豆蔻醯基-rac-甘油基-3-甲基聚氧基乙烯二醇2000 (PEG2k-DMG)或PEG-DMG (目錄號GM-020，來自NOF, Tokyo, Japan)、PEG-二棕櫚醯甘油、PEG-二硬脂醯甘油(PEG-DSPE) (目錄號DSPE-020CN，NOF, Tokyo, Japan)、PEG-二月桂基甘油醯胺、PEG-二肉豆蔻基甘油醯胺、PEG-二棕櫚醯甘油醯胺及PEG-二硬脂醯甘油醯胺、PEG-膽固醇(1-[8'-(膽甾-5-烯-3[β]-氧基)甲醯胺基-3',6'-二氧雜辛基]胺甲醯基-[ω]-甲基-聚(乙二醇)、PEG-DMB (3,4-二-十四氧基苯甲基-[ω]-甲基-聚(乙二醇)醚)、1,2-二肉豆蔻醯基-sn-甘油基-3-磷酸乙醇胺-N-[甲氧基(聚乙二醇)-2000] (PEG2k-DMG) (目錄號880150P，來自Avanti Polar Lipids, Alabaster, Alabama, USA)、1,2-二硬脂醯基-sn-甘油基-3-磷酸乙醇胺-N-[甲氧基(聚乙二醇)-2000] (PEG2k-DSPE) (目錄號880120C，來自Avanti Polar Lipids, Alabaster, Alabama, USA)、1,2-二硬脂醯基-sn-甘油、甲氧基聚乙二醇(PEG2k-DSG；GS-020，NOF Tokyo, Japan)、聚(乙二醇)-2000-二甲基丙烯酸酯(PEG2k-DMA)及1,2-二硬脂醯氧基丙基-3-胺-N-[甲氧基(聚乙二醇)-2000] (PEG2k-DSA)。在一個實施例中，PEG脂質可為1,2-二肉豆蔻醯基-rac-甘油-3-甲基聚氧乙二醇2000 (PEG2k-DMG)。在一個實施例中，PEG脂質可為PEG2k-DMG。在一個實施例中，PEG脂質可為PEG2k-DMG。在一些實施例中，PEG脂質可為PEG2k-DSG。在一個實施例中，PEG脂質可為PEG2k-DSPE。在一個實施例中，PEG脂質可為PEG2k-DMA。在一個實施例中，PEG脂質可為PEG2k-C-DMA。在一個實施例中，PEG脂質可為化合物S027，其揭示於WO2016/010840 (第[00240]至[00244]段)中。在一個實施例中，PEG脂質可為PEG2k-DSA。在一個實施例中，PEG脂質可為PEG2k-C11。在一些實施例中，PEG脂質可為PEG2k-C14。在一些實施例中，PEG脂質可為PEG2k-C16。在一些實施例中，PEG脂質可為PEG2k-C18。
在較佳實施例中，PEG脂質包括甘油基。在較佳實施例中，PEG脂質包括二肉豆蔻醯基甘油(DMG)基。在較佳實施例中，PEG脂質包含PEG-2k。在較佳實施例中，PEG脂質為PEG-DMG。在較佳實施例中，PEG脂質為PEG-2k-DMG。在較佳實施例中，PEG脂質為1,2-二肉豆蔻醯基-rac-甘油基-3-甲氧基聚乙二醇2000。在較佳實施例中，PEG-2k-DMG為1,2-二肉豆蔻醯基-rac-甘油基-3-甲氧基聚乙二醇-2000。
LNP
脂質奈米粒子(LNP)為遞送核苷酸及蛋白質負荷之熟知方式，且可用於遞送本文所揭示之多核苷酸、組合物或醫藥調配物。在一些實施例中，LNP遞送核酸、蛋白質、或核酸連同蛋白質一起。
如本文所使用，脂質奈米粒子(LNP)係指包含複數個(亦即，超過一個)藉由分子間力以物理方式彼此締合之脂質分子的粒子。LNP可為例如微球(包括單層及多層囊泡，例如「脂質體」-層狀相脂質雙層，其在一些實施例中為大體上球體，且在更特定實施例中可包含水性核心，例如包含相當大部分之RNA分子)、乳液中之分散相、膠束或懸浮液中之內相(參見例如WO2017173054，其內容特此以全文引用之方式併入)。可利用熟習此項技術者已知能夠向個體遞送核苷酸之任何LNP。
在一些實施例中，LNP包含陽離子脂質。在一些實施例中，LNP包含(9Z,12Z)-3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙基十八-9,12-二烯酸酯，亦稱作3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙基(9Z,12Z)-十八-9,12-二烯酸酯)，在本文中稱為脂質A。在一些實施例中，LNP包含約4.5之陽離子脂質胺與RNA磷酸酯之莫耳比(N:P)。在一些實施例中，LNP包含8-((7,7-雙(辛氧基)庚基)(2-羥乙基)胺基)辛酸壬酯。在一些實施例中，LNP包含約4.5-6.5之陽離子脂質胺與RNA磷酸酯之莫耳比(N:P)。在一些實施例中，LNP包含約4.5之陽離子脂質胺與RNA磷酸酯之莫耳比(N:P)。在一些實施例中，LNP包含約6.0之陽離子脂質胺與RNA磷酸酯之莫耳比(N:P)。
在一些實施例中，本發明包含一種用於向個體遞送本文所揭示之多核苷酸或組合物之方法，其中多核苷酸與LNP締合。在一些實施例中，本發明包含一種用於向個體遞送第一多核苷酸及第二多核苷酸之方法，或用於向個體遞送第一多核苷酸及第二多核苷酸之組合物，其中第一多核苷酸及第二多核苷酸與相同LNP締合，例如與相同LNP共調配。在一些實施例中，本發明包含一種用於向個體遞送第一多核苷酸及第二多核苷酸之方法，或用於向個體遞送第一多核苷酸及第二多核苷酸之組合物，其中第一多核苷酸及第二多核苷酸各自與獨立LNP締合，例如各多核苷酸與用於向個體投與或一起使用之獨立LNP締合，例如用於共投與。在一些實施例中，第一多核苷酸及第二多核苷酸編碼NmeCas9切口酶及UGI。在一些實施例中，組合物進一步包含一或多個引導RNA。在一些實施例中，該方法進一步包含遞送一或多個引導RNA。
在一些實施例中，本文提供一種將本文所述之多核苷酸或組合物中之任一者遞送至細胞或細胞群體或個體，包括活體內遞送至個體之細胞或細胞群體的方法，其中該等組分中之任何一或多者與LNP締合。在一些實施例中，組合物進一步包含一或多個引導RNA。在一些實施例中，該方法進一步包含遞送一或多個引導RNA。
在一些實施例中，本發明提供一種組合物，其包含單獨或與LNP組合的本文所述之多核苷酸或組合物或本文所揭示之供體構築體中之任一者。在一些實施例中，組合物進一步包含一或多個引導RNA。在一些實施例中，該方法進一步包含遞送一或多個引導RNA。
在一些實施例中，與本文所揭示之多核苷酸或組合物締合之LNP用於製備供治療疾病或病症用之藥物。
在一些實施例中，提供一種修飾目標基因之方法，該方法包含將一或多種包含本文所揭示之多核苷酸及一或多種引導RNA之脂質核酸組裝組合物，視情況脂質奈米粒子遞送至細胞。
在一些實施例中，至少一種脂質核酸組裝組合物包含脂質奈米粒子(LNP)，視情況其中所有脂質核酸組裝組合物包含LNP。在一些實施例中，至少一種脂質核酸組裝組合物為脂質複合物組合物。在一些實施例中，脂質核酸組合物包含可離子化脂質。
電穿孔為遞送負荷之熟知方法，且任何電穿孔方法可用於遞送本文所揭示之多核苷酸或組合物。在一些實施例中，電穿孔可用於遞送本文所揭示之多核苷酸或組合物中之任一者。
在一些實施例中，本發明包含一種將本文所揭示之多核苷酸、多肽或組合物遞送至離體細胞之方法，其中多核苷酸或組合物與LNP締合或不與LNP締合。在一些實施例中，LNP亦與一或多個引導RNA締合。參見例如以引用方式併入本文中之PCT/US2021/029446。
在一些實施例中，提供一種套組，其包含本文所揭示之多核苷酸、多肽或組合物。
在一些實施例中，提供一種醫藥調配物，其包含本文所揭示之多核苷酸、多肽或組合物。醫藥調配物可進一步包含醫藥學上可接受之載劑，例如水或緩衝液。醫藥調配物可進一步包含一或多種醫藥學上可接受之賦形劑，諸如穩定劑、防腐劑、膨化劑或其類似者。醫藥調配物可進一步包含一或多種醫藥學上可接受之鹽，諸如氯化鈉。在一些實施例中，醫藥調配物經調配以用於靜脈內投與。在一些實施例中，醫藥調配物為非熱原的。在一些實施例中，醫藥調配物為無菌的，尤其用於注射或輸注用醫藥調配物。
V. 例示性用途、方法及治療
在一些實施例中，本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物用於例如目標基因之基因療法中。
在一些實施例中，提供本文所揭示之多核苷酸、組合物或多肽的用途，其用於修飾細胞中之目標基因。
在一些實施例中，提供本文所揭示之多核苷酸、組合物或多肽至用途，其用於製造供修飾細胞中之目標基因用之藥劑。
在一些實施例中，多核苷酸或組合物調配為脂質核酸組合物，視情況脂質奈米粒子。
在一些實施例中，提供一種修飾目標基因之方法，該方法包含向細胞遞送本文所揭示之多核苷酸、多肽或組合物。
在一些實施例中，多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物供用於基因體編輯，例如編輯其中多核苷酸編碼經RNA引導之DNA結合劑(例如NmeCas9)的目標基因。
在一些實施例中，編碼本文所揭示之多肽的本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物用於在異源細胞，例如人類細胞或小鼠細胞中表現多肽。
在一些實施例中，多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物用於修飾目標基因，例如改變其序列或表觀遺傳狀態，其中多核苷酸編碼經RNA引導之DNA結合劑(例如NmeCas9)。
在一些實施例中，多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物用於在目標基因內誘導雙股斷裂(DSB)。在一些實施例中，多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物用於在目標基因中誘導插入/缺失。在一些實施例中，提供本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物之用途，其用於製備供基因體編輯，例如編輯其中多核苷酸編碼經RNA引導之DNA結合劑(例如NmeCas9)的目標基因用之藥劑。在一些實施例中，提供編碼本文所揭示之多肽的本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物之用途，其用於製備供在異源細胞(例如人類細胞或小鼠細胞)中表現多肽或增加多肽之表現用之藥劑。在一些實施例中，提供本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物之用途，其用於製備供修飾目標基因，例如改變其序列或表觀遺傳狀態用之藥劑。在一些實施例中，提供本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物之用途，其用於製備供在目標基因內誘導雙股斷裂(DSB)用之藥劑。在一些實施例中，提供本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物之用途，其用於製備供在目標基因中誘發插入/缺失之藥劑。
在一些實施例中，目標基因為轉殖基因。在一些實施例中，目標基因為內源基因。目標基因可在個體，諸如哺乳動物，諸如人類中。在一些實施例中，目標基因處於器官，諸如肝臟，諸如哺乳動物肝臟，諸如人類肝臟中。在一些實施例中，目標基因處於肝臟細胞，諸如哺乳動物肝臟細胞，諸如人類肝臟細胞中。在一些實施例中，目標基因處於肝細胞，諸如哺乳動物肝細胞，諸如人類肝細胞中。在一些實施例中，肝臟細胞或肝細胞處於原位。在一些實施例中，肝臟細胞或肝細胞分離於例如培養物中，諸如原代培養物中。在一些實施例中，目標細胞為周邊血液單核細胞(PBMC)，諸如哺乳動物PBMC，諸如人類PBMC。在一些實施例中，PBMC為免疫細胞，例如T細胞、B細胞、NK細胞。在一些實施例中，細胞為多能細胞，諸如哺乳動物多能細胞，諸如人類多能細胞。在一些實施例中，目標細胞為幹細胞，諸如哺乳動物幹細胞，諸如人類幹細胞。在一些實施例中，幹細胞存在於骨髓中。在一些實施例中，幹細胞為誘導多能幹細胞(iPCS)。在一些實施例中，細胞為分離的，例如在離體培養物中。
亦提供對應於本文所揭示之用途的方法，其包含向個體投與本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物或使細胞(諸如上文所述之細胞)與本文所揭示之多核苷酸、LNP或醫藥組合物接觸，例如以表現本文所揭示之多肽或增加本文所揭示之多肽在例如異源細胞，諸如人類細胞或小鼠細胞中之表現。
在涉及個體之前述實施例中之任一者中，個體可為哺乳動物。在涉及個體之前述實施例中之任一者中，個體可為人類。
在一些實施例中，本文所揭示之多核苷酸、表現構築體、組合物、脂質奈米粒子(LNP)或醫藥組合物經靜脈內投與或用於靜脈內投與。
在一些實施例中，單次投與本文所揭示之多核苷酸、LNP或醫藥組合物足以使靶基因產物之表現發生基因減弱。在一些實施例中，單次投與本文所揭示之多核苷酸、LNP或醫藥組合物足以使靶基因產物之表現發生基因剔除。在其他實施例中，不止一次投與本文所揭示之多核苷酸、LNP或醫藥組合物對於使編輯、修飾、indel形成、DSB形成或其類似者經由累積效應達至最大可為有益的。
VI. 例示性DNA分子、載體、表現構築體、宿主細胞及產生方法
在某些實施例中，本發明提供包含編碼本文所揭示之多肽之ORF序列的DNA分子。在一些實施例中，除ORF序列以外，DNA分子進一步包含不編碼本文所揭示之多肽的核酸。不編碼多肽之核酸包括但不限於啟動子、強化子、調節序列及編碼引導RNA之核酸。
在一些實施例中，DNA分子進一步包含編碼crRNA、trRNA或crRNA及trRNA之核苷酸序列。在一些實施例中，編碼crRNA、trRNA或crRNA及trRNA之核苷酸序列包含或由以下組成：由來自天然存在之CRISPR/Cas系統的重複序列之全部或一部分側接的引導序列。包含或由crRNA、trRNA或crRNA及trRNA組成之核酸可進一步構成載體序列，其中該載體序列包含或由以下組成：不會與crRNA、trRNA或crRNA及trRNA一起經天然發現的核酸。在一些實施例中，crRNA及trRNA由一個載體內之非連續核酸編碼。在其他實施例中，crRNA及trRNA可由連續核酸編碼。在一些實施例中，crRNA及trRNA由單一核酸之相對股編碼。在其他實施例中，crRNA及trRNA由單一核酸之相同股編碼。
在一些實施例中，DNA分子進一步包含可操作地連接於編碼ORF中之任一者的序列之啟動子，該等ORF編碼本文所揭示之多肽。在一些實施例中，DNA分子為適用於在哺乳動物細胞，例如人類細胞或小鼠細胞，諸如人類肝細胞或嚙齒動物(例如，小鼠)肝細胞中表現之表現構築體。在一些實施例中，DNA分子為適用於在哺乳動物器官，例如人類肝臟或嚙齒動物(例如，小鼠)肝臟之細胞中表現之表現構築體。在一些實施例中，DNA分子為質體或游離基因體。在一些實施例中，DNA分子包含於宿主細胞，諸如細菌或經培養之真核細胞中。例示性細菌包括變形菌門，諸如大腸桿菌。例示性經培養之真核細胞包括原代肝細胞，包括嚙齒動物(例如，小鼠)或人源之肝細胞；肝細胞細胞株，包括嚙齒動物(例如，小鼠)或人源之肝細胞；人類細胞株；嚙齒動物(例如，小鼠)細胞株；CHO細胞；微生物真菌，諸如裂殖或出芽酵母，例如酵母菌，諸如釀酒酵母；及昆蟲細胞。
在一些實施例中，提供一種製造本文所揭示之mRNA的方法。在一些實施例中，此類方法包含使本文所描述之DNA分子與RNA聚合酶在容許轉錄之條件下接觸。在一些實施例中，活體外，例如在無細胞系統中進行接觸。在一些實施例中，RNA聚合酶為噬菌體源之RNA聚合酶，諸如T7 RNA聚合酶。在一些實施例中，提供包括至少一種如上文所論述之經修飾之核苷酸的NTP。在一些實施例中，NTP包括至少一種如上文所論述之經修飾之核苷酸且不包含UTP。
在一些實施例中，提供一種產生本文所揭示之多核苷酸的方法。在一些實施例中，此類方法包括使本文所揭示之表現構築體與RNA聚合酶及包括至少一個經修飾之核苷酸的NTP接觸。在一些實施例中，經修飾之核苷酸包含經修飾之尿苷。在其他實施例中，至少80%之尿苷位置為經修飾之尿苷。在其他實施例中，至少90%之尿苷位置為經修飾之尿苷。在其他實施例中，100%之尿苷位置為經修飾之尿苷。在其他實施例中，經修飾之尿苷包含或為經取代之尿苷、假尿苷或經取代之假尿苷。在其他實施例中，經修飾之尿苷包含或為N1-甲基-假尿苷。在一些實施例中，表現構築體包含經編碼poly-A尾序列。
在一些實施例中，本文所揭示之多核苷酸可包含在一或多個載體之載體系統內或藉由其遞送。在一些實施例中，載體中之一或多者或所有載體可為DNA載體。在一些實施例中，載體中之一或多者或所有載體可為RNA載體。在一些實施例中，載體中之一或多者或所有載體可為環狀的。在其他實施例中，載體中之一或多者或所有載體可為線性的。在一些實施例中，載體中之一或多者或所有載體可包封於脂質奈米粒子、脂質體、非脂質奈米粒子或病毒衣殼中。非限制性例示性載體包括質體、噬菌粒、黏質體、人工染色體、袖珍染色體、轉位子、病毒載體及表現載體。
非限制性例示性病毒載體包括腺相關病毒(AAV)載體、慢病毒載體、腺病毒載體、輔助依賴型腺病毒載體(HDAd)、單純疱疹病毒(HSV-1)載體、噬菌體T4、桿狀病毒載體及反轉錄病毒載體。在一些實施例中，病毒載體可為AAV載體。在其他實施例中，病毒載體可為慢病毒載體。在一些實施例中，慢病毒可為非整合的。在一些實施例中，病毒載體可為腺病毒載體。在一些具體實例中，腺病毒可為高選殖容量或「無腸」腺病毒，其中除5'及3'反轉末端重複序列(ITR)及封裝信號(『I』)之外之所有病毒編碼區係從病毒中刪除以增加其封裝容量。在其他實施例中，病毒載體可為HSV-1載體。在一些實施例中，基於HSV-1之載體為輔助依賴型的，且在其他實施例中，其為非輔助依賴型的。舉例而言，僅保留封裝序列之擴增子載體需要具有結構性組分之輔助病毒用於封裝，而移除非必需病毒功能的缺失30kb之HSV-1載體不需要輔助病毒。在其他實施例中，病毒載體可為噬菌體T4。在一些實施例中，當清空病毒頭時，噬菌體T4可能夠封裝任何線性或環狀DNA或RNA分子。在其他實施例中，病毒載體可為桿狀病毒載體。在又其他實施例中，病毒載體可為反轉錄病毒載體。在使用具有較小選殖容量之AAV或慢病毒載體之實施例中，可能需要使用多於一個載體以遞送如本文揭示之載體系統的全部組分。舉例而言，一個AAV載體可含有編碼Cas蛋白之序列，而第二AAV載體可含有一或多個導引序列。
在一些實施例中，載體可能夠驅動細胞中一或多個編碼序列，諸如本文揭示之mRNA之編碼序列的表現。在一些實施例中，細胞可為原核細胞，諸如細菌細胞。在一些實施例中，細胞可為諸如酵母、植物、昆蟲或哺乳動物細胞之真核細胞。在一些實施例中，真核細胞可為哺乳動物細胞。在一些實施例中，真核細胞可為嚙齒動物細胞。在一些實施例中，真核細胞可為人類細胞。驅動不同類型細胞中之表現的適合啟動子為所屬領域中已知的。在一些實施例中，啟動子可為野生型的。在其他實施例中，啟動子可經修飾以供更高效或更有效地表現。在又其他實施例中，啟動子可經截短但仍保留其功能。舉例而言，啟動子可具有正常大小或適用於將載體適當封裝於病毒中的減小之大小。
在一些實施例中，載體系統可包含一個包含編碼本文所揭示之多肽之ORF的核苷酸序列之複本。在其他實施例中，載體系統可包含編碼本文揭示之多肽的核苷酸序列之多於一個複本。在一些實施例中，編碼本文揭示之多肽的核苷酸序列可操作地連接於至少一個轉錄或轉譯控制序列。在一些實施例中，編碼核酸酶之核苷酸序列可與至少一個啟動子可操作地連接。
在一些實施例中，啟動子可為組成性、誘導性或組織特異性的。在一些實施例中，啟動子可為組成性啟動子。非限制性例示性的組成性啟動子包括細胞巨大病毒即刻早期啟動子(CMV)、猴病毒(SV40)啟動子、腺病毒主要晚期啟動子(MLP)、勞斯肉瘤病毒(RSV)啟動子、小鼠乳腺腫瘤病毒(MMTV)啟動子、磷酸甘油酸激酶(PGK)啟動子、延長因子-α(EF1a)啟動子、泛蛋白啟動子、肌動蛋白啟動子、微管蛋白啟動子、免疫球蛋白啟動子、其功能性片段或前述中之任一者之組合。在一些實施例中，啟動子可為CMV啟動子。在一些實施例中，啟動子可為經截短之CMV啟動子。在其他實施例中，啟動子可為EF1a啟動子。在一些實施例中，啟動子可為誘導性啟動子。非限制性例示性的誘導性啟動子包括可藉由熱衝擊、光、化學物質、肽、金屬、類固醇、抗生素或醇誘導之誘導性啟動子。在一些具體實例中，可誘導啟動子可為具有低基礎(非誘導)表現量之可誘導啟動子，諸如Tet-On
®啟動子(Clontech)。
在一些實施例中，啟動子可為組織特異性啟動子，例如對肝臟中之表現具有特異性之啟動子。
載體可進一步包含編碼至少一個引導RNA之核苷酸序列。在一些實施例中，載體包含引導RNA之一個複本。在其他實施例中，載體包含引導RNA之多於一個複本。在具有多於一個引導RNA之實施例中，引導RNA可不同以使得其靶向不同目標序列，或可相同以便其靶向相同目標序列。在其中載體包含多於一個引導RNA之一些實施例中，各引導RNA可具有其他不同特性，諸如在與經RNA引導之DNA結合劑(例如NmeCas9)之核糖核蛋白複合物中的活性或穩定性。在一些具體實例中，編碼引導RNA之核苷酸序列可與諸如啟動子、3' UTR或5' UTR之至少一個轉錄或轉譯控制序列可操作地連接。在一個實施例中，啟動子可為tRNA啟動子，例如tRNALys3或tRNA嵌合體。參見Mefferd等人,
RNA.2015 21:1683-9；Scherer等人,
Nucleic Acids Res.2007 35: 2620-2628。在一些實施例中，啟動子可藉由RNA聚合酶III (Pol III)識別。Pol III啟動子之非限制性實例包括U6及H1啟動子。在一些實施例中，編碼引導RNA之核苷酸序列可與小鼠或人類U6啟動子可操作地連接。在其他實施例中，編碼引導RNA之核苷酸序列可與小鼠或人類H1啟動子可操作地連接。在具有多於一個引導RNA之實施例中，用於驅動表現之啟動子可相同或不同。在一些實施例中，編碼引導RNA之crRNA的核苷酸及編碼引導RNA之trRNA的核苷酸可提供於相同載體上。在一些實施例中，編碼crRNA之核苷酸及編碼trRNA之核苷酸可藉由同一啟動子驅動。在一些實施例中，crRNA及trRNA可轉錄為單一轉錄物。舉例而言，crRNA及trRNA可由單一轉錄物進行處理以形成雙分子引導RNA。或者，crRNA及trRNA可轉錄為單分子引導RNA。在其他實施例中，crRNA及trRNA可藉由其處於相同載體上之對應啟動子來驅動。在又其他實施例中，crRNA及trRNA可藉由不同載體編碼。
在一些實施例中，組合物包含載體系統，其中該系統包含多於一個載體。在一些實施例中，載體系統可包含一個單一載體。在其他實施例中，載體系統可包含兩個載體。在其他實施例中，載體系統可包含三個載體。當將不同多核苷酸用於多工(multiplexing)時或當使用多核苷酸之多個複本時，載體系統可包含多於三個載體。
在一些實施例中，提供一種宿主細胞，該宿主細胞包含本文所揭示之載體、表現構築體或質體。
在一些實施例中，載體系統可包含誘導性啟動子以僅在其遞送至目標細胞之後開始表現。非限制性例示性的誘導性啟動子包括可藉由熱衝擊、光、化學物質、肽、金屬、類固醇、抗生素或醇誘導之誘導性啟動子。在一些具體實例中，可誘導啟動子可為具有低基礎(非誘導)表現量之可誘導啟動子，諸如Tet-On
®啟動子(Clontech)。
在額外實施例中，載體系統可包含組織特異性啟動子以僅在其遞送至特定組織中之後開始表現。
VII. ORF功效之測定
當多肽與目標功能或系統之其他組分一起表現時，可確定包含編碼本文所揭示之多肽之ORF的多核苷酸之功效，例如，使用此項技術中公認之彼等中之任一者來偵測特定多肽之存在、表現量或活性，例如藉由酶聯免疫吸附分析(ELISA)、其他免疫學方法、西方墨點)、液相層析-質譜法(LC-MS)、FACS分析、HiBiT肽分析(Promega)，或本文所述之其他分析；或確定生物樣品(例如細胞、細胞溶解物或提取物、條件培養基、全血、血清、血漿、尿液或組織)中酶活性水平之方法，例如活體外活性分析。本文所述之各種編碼多肽，例如RNA引導之DNA結合劑之活性的例示性分析包括關於插入/缺失形成、脫胺作用或mRNA或蛋白質表現之分析。在一些實施例中，基於活體外模型確定包含編碼本文所揭示之多肽之ORF的多核苷酸之功效。
1. 確定編碼經RNA引導之DNA結合劑之ORF的功效
在一些實施例中，當與RNP之其他組分，例如至少一個gRNA，諸如靶向TTR之gRNA一起表現時，測定mRNA之功效。
具有裂解酶活性的經RNA引導之DNA結合劑(例如NmeCas9)可導致DNA中之雙股斷裂。非同源末端連接(NHEJ)為一種以下方法，藉由該方法，DNA中之雙鏈斷裂(DSB)經由重新連接斷裂末端而得到修補，其可能會產生呈插入/缺失(indel)突變形式之錯誤。在重新連接末端之前，DSB之DNA末端常常會經歷酶處理，其引起在一或兩個股處添加或移除核苷酸。重新連接之前的此等添加或移除引起DNA序列中NHEJ修復位點處存在插入或缺失(indel)突變。歸因於插入/缺失之多種突變會改變閱讀框架或過早地引入終止密碼子，且因此產生非功能性蛋白質。
在一些實施例中，基於活體外模型而測定編碼核酸酶之mRNA的功效。在一些實施例中，活體外模型為HEK293細胞。在一些實施例中，活體外模型為HUH7人類肝癌細胞。在一些實施例中，活體外模型為初級肝細胞，諸如初級人類或小鼠肝細胞。
在一些實施例中，偵測基因編輯事件，諸如利用經標記引子之線性擴增形成插入/缺失(「插入/缺失(indel)」)突變及分離經標記擴增產物(下文稱為「LAM-PCR」或「線性擴增(LA)」方法，如WO2018/067447或Schmidt等人, Nature Methods 4:1051-1057 (2007)中所述，或如下所述之次世代定序(「NGS」；例如使用Illumina NGS平台)，或此項技術中已知用於偵測插入/缺失突變之其他方法。
舉例而言，為了定量地測定基因體中目標位置處之編輯效率，在NGS方法中，分離基因體DNA且利用深度定序鑑定由基因編輯引入之插入及缺失之存在。在目標位點(例如TTR)周圍設計PCR引子，且擴增所關注之基因體區域。根據製造商之方案(Illumina)進行額外PCR以添加定序所需之化學性質。在Illumina MiSeq儀器上對擴增子定序。在消除具有低品質評分之讀段之後，將讀段與參考基因體(例如mm10)比對。將含有讀段之所得檔案映射至參考基因體(BAM檔案)，其中選擇與所關注之目標區域重疊之讀段且計算野生型讀段之數目相對於含有插入、取代或缺失之讀段的數目。編輯百分比(例如「編輯效率」或「編輯%」)定義為具有插入或缺失之序列讀段之總數目相對於包括野生型之序列讀段之總數目。
實例
提供以下實例以說明某些所揭示實施例且不應視為以任何方式限制本發明之範疇。
實例 1. 材料及方法 核酸酶 mRNA 之活體外轉錄 ( 「 IVT 」 )
含有N1-甲基假U之經封端且聚腺苷酸化之mRNA係使用常規方法藉由活體外轉錄產生。舉例而言，根據製造商之方案用XbaI使含有T7啟動子、用於轉錄之序列及聚腺苷酸化區之質體DNA線性化。藉由加熱使XbaI不活化。由酶及緩衝鹽純化經線性化質體。用於產生經修飾mRNA之IVT反應係藉由在37℃下培育以下各者來進行：50 ng/µL線性化質體；各2-5 mM之GTP、ATP、CTP及N1-甲基假-UTP (Trilink)；10-25 mM ARCA (Trilink)；5 U/µL T7 RNA聚合酶；1 U/µL鼠類RNase抑制劑(NEB)；0.004 U/µL無機大腸桿菌焦磷酸酶(NEB)；及1×反應緩衝液。將TURBO DNA酶(Thermo Fisher)添加至0.01 U/µL之最終濃度，且將反應物在37℃下培育以移除DNA模板。
根據製造商之方案使用MegaClear Transcription Clean-up套組(Thermo Fisher)或RNeasy Maxi套組(Qiagen)純化mRNA。或者，經由沈澱方案，在一些情況下接著基於HPLC之純化，來純化mRNA。簡言之，在DNase消化之後，使用LiCl沈澱、乙酸銨沈澱及乙酸鈉沈澱來純化mRNA。對於經HPLC純化之mRNA，在LiCl沈澱及復原之後，藉由RP-IP HPLC純化mRNA (參見例如Kariko等人, Nucleic Acids Research, 2011, 第39卷, 第21期el42)。合併選擇用於彙集之溶離份且藉由如上文所描述之乙酸鈉/乙醇沈澱來去鹽。在另一替代方法中，mRNA用LiCl沈澱法純化，隨後藉由切向流過濾進一步純化。藉由量測260 nm處之吸光度(Nanodrop)測定RNA濃度，且藉由毛細電泳法用Bioanalyzer (Agilent)來分析轉錄物。
當本段中引用的序列在下文中針對RNA提及時，應理解，T應替換為U (其可為如上文所述之經修飾之核苷)。用於實例中之信使RNA包括5'帽及3'聚腺苷酸化序列，例如至多100 nt。由商業供應商或使用標準活體外合成技術用經修飾之核苷酸化學合成引導RNA。
根據SEQ ID No: 43-47及49 (參見表39A中之序列)，自編碼開放閱讀框架之質體DNA生成釀膿鏈球菌(「Spy」) Cas9 mRNA。
肝細胞製備
如下製備原代小鼠肝細胞(PMH)、原代大鼠肝細胞(PRH)、原代人類肝細胞(PHH)及原代食蟹獼猴肝細胞(PCH)。將PMH (Gibco，MCM837，除非另外規定)、PRH (Gibco，Rs977，除非另外規定)、PCH (In Vitro ADMET Laboratories，10136011，除非另外規定)、PHH (Gibco，Hu8284，除非另外規定)解凍且再懸浮於50 mL冷凍保存肝細胞回收培養基(CHRM) (Invitrogen，CM7000)中，接著離心。細胞藉由以下接種補充劑再懸浮於肝細胞培養基中：具有FBS含量之威廉姆斯氏E培養基平板補充劑(Gibco，目錄號A13450)。細胞藉由離心粒化，再懸浮於培養基中，且以20,000個細胞/孔(對於PMH)及30,000個細胞/孔(對於PHH)之密度接種於經Bio-coat膠原蛋白I塗佈之96孔盤(Corning # 354407)上。使接種之細胞在37℃及5% CO
2氛圍下在組織培養恆溫箱中靜置且黏附4-6小時。在培育之後，檢查細胞之單層形成且洗滌一次，且用100 µL肝細胞維持培養基接種：威廉姆斯氏E培養基(Gibco，目錄號A12176-01)加上補充劑包(Gibco，目錄號CM3000)。
HEK 細胞製備
將HEK-293細胞(ATCC，CRL-1573，除非另外規定)解凍且再懸浮於具有10% FBS含量(Gibco #A31605-02)及1%青黴素-鏈黴素(Gibco #15070063)之無血清達爾伯克氏改良伊格爾培養基(Dulbecco's Modified Eagle Medium)(Corning #10-013-CV)中。細胞經計數且接種於96孔組織培養盤(Falcon，#353072)上具有10% FBS含量(Gibco #A31605-02)之達爾伯克氏改良伊格爾培養基(Corning #10-013-CV)中。使接種之細胞在37℃及5% CO
2氛圍下在組織培養恆溫箱中靜置且黏附18小時。
製備含有 sgRNA 及 Cas9 mRNA 之 LNP 調配物
一般而言，以各種莫耳比將脂質奈米粒子組分溶解於100%乙醇中。將RNA負荷(例如Cas9 mRNA及gRNA)溶解於25 mM檸檬酸鹽、100 mM NaCl (pH 5.0)中，產生大致0.45 mg/mL之RNA負荷濃度。所用LNP含有之可離子化脂質(十八碳-9,12-二烯酸(9Z,12Z)-3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙酯，亦稱為(9Z,12Z)-十八碳-9,12-二烯酸3-((4,4-雙(辛氧基)丁醯基)氧基)-2-((((3-(二乙胺基)丙氧基)羰基)氧基)甲基)丙酯) (本文中亦稱為脂質A)、膽固醇、二硬脂醯基磷脂醯膽鹼(DSPC)及1,2-二肉豆蔻醯基-rac-甘油-3-甲基聚氧乙二醇2000 (PEG2k-DMG)呈50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。所使用之LNP包含單一RNA物種，諸如Cas9 mRNA或sgRNA。用Cas9 mRNA及引導RNA之混合物類似地製備LNP。
使用交叉流技術，利用含脂質之乙醇與兩個體積之RNA溶液及一個體積之水的衝擊射流混合來製備LNP。首先，經由混合十字管使乙醇中之脂質與兩個體積之RNA溶液混合。接著，經由線內T形件將第四物料流與十字管之輸出流混合(參見WO2016010840，圖2)。將LNP在室溫下保持1小時且進一步用水稀釋(大致1:1 v/v)。將稀釋之LNP緩衝液交換至50 mM Tris、45 mM NaCl、5% (w/v)蔗糖，pH 7.5 (TSS)中，且按需要藉由此項技術中已知之方法濃縮。接著使用0.2 μm無菌過濾器過濾所得混合物。最終LNP經表徵以確定囊封效率、多分散性指數及平均粒度。將最終LNP儲存於4℃或-80℃下直至進一步使用。
sgRNA 及 Cas9 mRNA 脂質體轉染
使用預混合脂質調配物進行Cas9 mRNA及gRNA之脂質體轉染。脂質體轉染試劑含有可離子化脂質A、膽固醇、DSPC及PEG2k-DMG，莫耳比為50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG。將此混合物在100%乙醇中復原，接著以約6.0之脂質胺與RNA磷酸酯之莫耳比(N:P)與RNA (例如Cas9 mRNA及gRNA)混合。
次世代定序 ( 「 NGS 」 ) 及編輯效率分析
使用商業套組根據製造商之方案，例如QuickExtract™ DNA提取溶液(Lucigen，目錄號QE09050)提取基因體DNA。為了定量地測定基因體中之目標位置處之編輯效率，使用深度定序來鑑定藉由基因編輯引入之插入及缺失的存在。圍繞所關注基因(例如TRAC)內之目標位點設計PCR引子，且擴增所關注基因體區域。按本領域中之標準進行引子序列設計。
根據製造商之方案(Illumina)進行額外PCR以添加用於定序之化學物質。擴增子在Illumina MiSeq儀器上定序。在消除具有低品質評分之讀數之後，將讀數與人類參考基因體(例如，hg38)比對。將與所關注靶區重疊之讀段與局部基因體序列重新比對以改良該比對。接著計算野生型讀段之數目相對於含有C至T突變、C至A/G突變或插入/缺失之讀段之數目。在以所預測之Cas9裂解位點為中心的20 bp區中對插入及缺失進行評分。插入/缺失百分比定義為在20 bp評分區內插入或缺失一或多個鹼基之定序讀數之總數目除以定序讀數(包括野生型)之總數目。在包括20 bp sgRNA目標序列之上游10 bp及下游10 bp之40 bp區中對C至T突變或C至A/G突變進行評分。C至T編輯百分比定義為在40 bp區域內具有一或多個C至T突變之定序讀段之總數目除以定序讀段(包括野生型)之總數目。類似地計算C至A/G突變之百分比。
實例 2. 在原代小鼠肝細胞 (PMH) 中使用所選引導物進行活體外編輯
進行經修飾之sgRNA篩選以評估靶向小鼠TTR基因內之不同位點之95種不同sgRNA的編輯效率。基於該研究，選擇兩個sgRNA (G021320及G021256)用於劑量反應分析中之評估。將此兩個測試引導物與具有20個核苷酸引導序列之小鼠TTR SpyCas9引導物(G000502)進行比較。靶向小鼠TTR基因之所測試NmeCas9 sgRNA包括如下之24個核苷酸的引導序列(如由N表示)及引導骨架：mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU (SEQ ID NO: 508)，其中除非另外規定，否則A、C、G、U及N分別為腺嘌呤、胞嘧啶、鳥嘌呤、尿嘧啶及任何核糖核苷酸。m指示2'O-甲基修飾，且*指示核苷酸之間的硫代磷酸酯鍵聯。引導物之未經修飾及經修飾之型式提供於表39B中。
如下所述，將引導物及Cas9 mRNA脂質體轉染至原代小鼠肝細胞(PMH)中。如實例1中所述來製備PMH (In Vitro ADMET Laboratories MCM114)。如實例1中所述地進行脂質體轉染，具有sgRNA及mRNA之劑量反應。簡言之，將細胞在37℃、5% CO
2下培育24小時，之後用脂複合體處理。將脂複合體在37℃下在含有10%胎牛血清(FBS)之維持培養基中培育10分鐘。培育後，在以300 ng Cas9 mRNA及50 nM sgRNA之最大劑量開始之8點、3倍劑量反應分析中將脂複合體添加至小鼠肝細胞中。在各條件下，信使RNA劑量與gRNA劑量成比例，儘管表5中僅列出gRNA劑量。細胞在處理後72小時溶解，且如實例1中所述地進行NGS分析。
在一式三份樣品中進行編輯效率對引導物濃度之劑量反應。表5展示在各引導物濃度及所計算EC
50值下之平均編輯百分比及標準差(SD)。平均值及標準差(SD)繪示於圖1中。
表5 - 原代小鼠肝細胞中之平均編輯百分比
實例 3. 使用 LNP 之相對於 sgRNA 或 pgRNA 之 sgRNA:mRNA 比率
| 樣品 | EC 50(nM) | SgRNA (nM) | 平均編輯% | SD |
| SpyCas9 mRNA + G000502 | 22.0 | 50 | 95.7 | 0.3 |
| 16.7 | 40.9 | 14.8 | ||
| 5.6 | 6.4 | 3.3 | ||
| 1.9 | 0.8 | 0.3 | ||
| 0.6 | 0.2 | 0.08 | ||
| 0.2 | 0.1 | 0 | ||
| 0.1 | 0.1 | 0 | ||
| 0 | 0.1 | 0 | ||
| Nme2 Cas9 mRNA Q SEQ ID NO: 27+ G021320 | 18.7 | 50 | 86.5 | 0.9 |
| 16.7 | 41.8 | 2.1 | ||
| 5.6 | 5.8 | 1.4 | ||
| 1.9 | 1.2 | 0.3 | ||
| 0.6 | 0.4 | 0.2 | ||
| 0.2 | 0.1 | 0.1 | ||
| 0.1 | 0.1 | 0 | ||
| 0 | 0.1 | 0 | ||
| Nme2 Cas9 mRNA Q SEQ ID NO: 27 + G021256 | 20.9 | 50 | 92.3 | 0.5 |
| 16.7 | 35.1 | 2 | ||
| 5.6 | 2.6 | 0.5 | ||
| 1.9 | 0.6 | 0.4 | ||
| 0.6 | 0.1 | 0 | ||
| 0.2 | 0.1 | 0 | ||
| 0.1 | 0.1 | 0 | ||
| 0 | 0.1 | 0 |
進行研究以評估含有PEG連接子之sgRNA設計(pgRNA)之編輯效率。該研究比較兩種具有相同引導序列的靶向TTR之gRNA，其中一種在引導物之恆定區中包括三個PEG連接子(pgRNA，G021846)，且一種不包括(G021845)，如表39B中所示。引導物及mRNA調配於單獨的LNP中且混合至所要比率，以經由脂質奈米粒子(LNP)遞送至原代小鼠肝細胞(PMH)。
除非另外指出，否則如實例1中所述地製備、處理及分析PMH細胞。來自In Vitro ADMET Laboratories之PMH細胞(批號MCM114)以15,000個細胞/孔之密度接種。如下文所描述用LNP處理細胞。LNP一般如實例1所述來製備。LNP以50/9/38/3之脂質組成製備，分別表示為可離子化脂質A/膽固醇/DSPC/PEG之莫耳比。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。LNP囊封單一RNA物種，gRNA G021845、gRNA G021846或mRNA (mRNA M)，如實例1中所述。
用不同量的按RNA負荷之重量計1:4、1:2、1:1、2:1、4:1或8:1之gRNA與mRNA比率的LNP來處理PMH細胞。各分析中包括重複樣品。以1 ng/μL總RNA濃度起始之8點3倍劑量反應曲線分析引導物，如表6中所示。平均編輯百分比結果展示於表6中。圖2A展示sgRNA G021845之平均編輯百分比，且圖2B展示sgRNA G021846之平均編輯百分比。表中之「ND」表示由於實驗失敗而無法偵測到的值。
表 6. PMH 中之平均編輯百分比
實例 3.1 使用 LNP 在 PMH 中經修飾之聚乙二醇化引導物 (pgRNA) 之活體外編輯
| 負荷比(gRNA:mRNA) | LNP 劑量(ng/µL) | sgRNA (G021845) | pgRNA (G021846) | ||
| 平均編輯% | SD | 平均編輯% | SD | ||
| 1:4 | 1 | 88.1 | 1.7 | 不分散 | 不分散 |
| 0.3 | 68.7 | 5.7 | 78 | 0.3 | |
| 0.1 | 28.1 | 4.1 | 39.8 | 8.2 | |
| 0.03 | 8.7 | 2 | 5.1 | 0 | |
| 0.01 | 1.5 | 0.4 | 4 | 1.2 | |
| 0.004 | 0.6 | 0.5 | 0.2 | 0 | |
| 0.001 | 0.3 | 0.2 | 0.6 | 0.3 | |
| 1:2 | 1 | 90.6 | 0 | 91.2 | 2.9 |
| 0.3 | 78 | 2.4 | 85.6 | 1.4 | |
| 0.1 | 41.5 | 5.8 | 56.6 | 4.4 | |
| 0.03 | 23 | 5.4 | 17.5 | 0 | |
| 0.01 | 6.1 | 4.3 | 18.6 | 0.5 | |
| 0.004 | 0.1 | 0.1 | 3.4 | 1.7 | |
| 0.001 | 0.1 | 0 | 2.4 | 0.7 | |
| 1:1 | 1 | 90.9 | 1.4 | 94.7 | 0.6 |
| 0.3 | 71.8 | 4.2 | 84.7 | 0.9 | |
| 0.1 | 45.7 | 3.2 | 64.3 | 5.3 | |
| 0.03 | 27.4 | 1 | 44.8 | 11.5 | |
| 0.01 | 4.7 | 2.5 | 10.2 | 4.3 | |
| 0.004 | 0.2 | 0 | 1.7 | 0.7 | |
| 0.001 | 0.1 | 0 | 0.7 | 0.5 | |
| 2:1 | 1 | 92.4 | 1.6 | 94.5 | 0.8 |
| 0.3 | 80 | 1.3 | 85.7 | 0.2 | |
| 0.1 | 45.4 | 0 | 68 | 7.9 | |
| 0.03 | 47.2 | 3 | 49.3 | 0 | |
| 0.01 | 18.1 | 1.8 | 28.8 | 4.1 | |
| 0.004 | 0.8 | 0.7 | 3.8 | 2.4 | |
| 0.001 | 0.2 | 0.1 | 0.8 | 0.3 | |
| 4:1 | 1 | 87.9 | 1.9 | 90.1 | 0 |
| 0.3 | 80.2 | 2.2 | 84 | 0.1 | |
| 0.1 | 43.4 | 0 | 60.4 | 0.1 | |
| 0.03 | 46.2 | 0.5 | 46.1 | 0 | |
| 0.01 | 11.3 | 2.3 | 26.7 | 4.9 | |
| 0.004 | 0.4 | 0.2 | 1.5 | 0.4 | |
| 0.001 | 0.4 | 0.1 | 0.5 | 0.3 | |
| 8:1 | 1 | 89.2 | 0 | 87.5 | 0 |
| 0.3 | 76.7 | 3.9 | 78.6 | 3.1 | |
| 0.1 | 59.5 | 9.4 | 59.4 | 1.1 | |
| 0.03 | 36.4 | 7 | 45.3 | 0.5 | |
| 0.01 | 8.2 | 1.2 | 18.7 | 2.9 | |
| 0.004 | 0.6 | 0.6 | 2.6 | 0.3 | |
| 0.001 | 0.1 | 0 | 0.6 | 0.2 |
分析具有小鼠TTR基因中之相同靶向位點的經修飾pgRNA以評估PMH細胞中之編輯效率。
除非另外指出，否則如實例1中所述地製備、處理及分析PMH細胞。來自In Vitro ADMET Laboratories之PMH細胞(批號MC148)以15,000個細胞/孔之密度接種。LNP調配物如實例1中所述地製備。LNP以50/9/38/3之脂質組成製備，分別表示為可離子化脂質A/膽固醇/DSPC/PEG之莫耳比。以約6之脂質胺與RNA磷酸酯(N:P)莫耳比且用表7中所指示之gRNA或用mRNA來調配LNP。
用按重量計30 ng總mRNA (mRNA P)之LNP及表7中所指示之量的gRNA之LNP來處理100 µl培養基中之PMH。一式兩份地操作樣品。PMH之平均編輯結果展示於表7及圖3中。
表 7. PMH 中之平均編輯百分比
實例 4. Nme2-mRNA 研究 實例 4.1 - 原代小鼠肝細胞中之活體外編輯
| 引導物ID | LNP sgRNA (ng/ µL) | 平均編輯% | SD | 引導物ID | LNP sgRNA (ng/ µL) | 平均編輯% | SD |
| G021844 | 0.7 | 96.6 | 0.5 | G023416 | 0.7 | 91.5 | 1.8 |
| 0.23 | 95.0 | 0.5 | 0.23 | 84.8 | 0.1 | ||
| 0.08 | 80.0 | 5.9 | 0.08 | 56.4 | 2.7 | ||
| 0.03 | 51.9 | 1.9 | 0.03 | 28.2 | 3.6 | ||
| 0.009 | 13.9 | 0.4 | 0.009 | 10.0 | 1.7 | ||
| 0.003 | 4.6 | 0.9 | 0.003 | 3.2 | 0.0 | ||
| 0.001 | 0.8 | 0.1 | 0.001 | 0.8 | 0.3 | ||
| 0.0003 | 0.2 | 0.1 | 0.0003 | 0.2 | 0.0 | ||
| 0.0001 | 0.1 | 0.0 | 0.0001 | 0.1 | 0.0 | ||
| 0.00004 | 0.2 | 0.1 | 0.00004 | 0.1 | 0.0 | ||
| 0.00001 | 0.1 | 0.0 | 0.00001 | 0.1 | 0.0 | ||
| 0 | 0.1 | 0.0 | 0 | 0.1 | 0.0 | ||
| G023413 | 0.7 | 96.4 | 0.4 | G023417 | 0.7 | 90.5 | 1.8 |
| 0.23 | 92.5 | 0.7 | 0.23 | 71.6 | 0.2 | ||
| 0.08 | 73.9 | 0.9 | 0.08 | 30.9 | 6.7 | ||
| 0.03 | 36.4 | 2.6 | 0.03 | 12.8 | 1.3 | ||
| 0.009 | 10.3 | 1.5 | 0.009 | 4.8 | 1.5 | ||
| 0.003 | 2.4 | 0.7 | 0.003 | 0.4 | 0.4 | ||
| 0.001 | 0.6 | 0.1 | 0.001 | 0.2 | 0.1 | ||
| 0.0003 | 0.3 | 0.0 | 0.0003 | 0.1 | 0.0 | ||
| 0.0001 | 0.1 | 0.0 | 0.0001 | 0.1 | 0.1 | ||
| 0.00004 | 0.1 | 0.0 | 0.00004 | 0.1 | 0.0 | ||
| 0.00001 | 0.1 | 0.0 | 0.00001 | 0.1 | 0.0 | ||
| 0 | 0.1 | 0.0 | 0 | 0.1 | 0.0 | ||
| G023414 | 0.7 | 96.5 | 0.2 | G023418 | 0.7 | 96.8 | 0.3 |
| 0.23 | 92.7 | 0.4 | 0.23 | 90.8 | 1.7 | ||
| 0.08 | 74.1 | 2.7 | 0.08 | 63.3 | 1.8 | ||
| 0.03 | 45.7 | 1.5 | 0.03 | 27.7 | 2.4 | ||
| 0.009 | 13.7 | 0.7 | 0.009 | 8.8 | 0.5 | ||
| 0.003 | 4.3 | 1.3 | 0.003 | 1.9 | 0.6 | ||
| 0.001 | 0.7 | 0.1 | 0.001 | 0.7 | 0.2 | ||
| 0.0003 | 0.2 | 0.0 | 0.0003 | 0.2 | 0.1 | ||
| 0.0001 | 0.2 | 0.1 | 0.0001 | 0.1 | 0.0 | ||
| 0.00004 | 0.2 | 0.1 | 0.00004 | 0.1 | 0.0 | ||
| 0.00001 | 0.1 | 0.0 | 0.00001 | 0.1 | 0.0 | ||
| 0 | 0.1 | 0.0 | 0 | 0.2 | 0.1 | ||
| G023415 | 0.7 | 96.5 | 0.5 | G023419 | 0.7 | 96.6 | 0.6 |
| 0.23 | 92.6 | 0.7 | 0.23 | 93.4 | 1.3 | ||
| 0.08 | 73.1 | 0.2 | 0.08 | 71.1 | 3.3 | ||
| 0.03 | 34.4 | 0.8 | 0.03 | 29.0 | 4.6 | ||
| 0.009 | 14.2 | 0.2 | 0.009 | 9.7 | 4.1 | ||
| 0.003 | 3.9 | 0.4 | 0.003 | 2.3 | 0.5 | ||
| 0.001 | 0.5 | 0.2 | 0.001 | 0.4 | 0.0 | ||
| 0.0003 | 0.2 | 0.0 | 0.0003 | 0.1 | 0.0 | ||
| 0.0001 | 0.2 | 0.0 | 0.0001 | 0.2 | 0.0 | ||
| 0.00004 | 0.1 | 0.0 | 0.00004 | 0.2 | 0.0 | ||
| 0.00001 | 0.1 | 0.0 | 0.00001 | 0.1 | 0.0 | ||
| 0 | 0.1 | 0.0 | 0 | 0.1 | 0.0 |
分析具有不同NLS置放的編碼Nme2Cas9 ORF之信使mRNA在原代小鼠肝細胞(PMH)中之編輯效率。
如實例1中所述地製備PMH。根據製造商之方案使用Lipofectamine MessengerMAX轉染試劑(Invitrogen LMRNA001)進行脂質體轉染，以用靶向小鼠PCSK9之100 nM sgRNA G020361及表8中所列濃度之mRNA轉化細胞。分析中包括一式三份樣品。在37℃下在維持培養基中培育72小時之後，收集細胞且如實例1中所述地進行NGS分析。具有標準差(SD)之平均編輯結果顯示於表8及圖4中。
表 8. PMH 中 PCSK9 基因座處之平均編輯百分比
實例 4.2 - Nme2 ORF 變異體及具有化學修飾變異之引導物的劑量反應
| 構築體 | mRNA 濃度(ng/uL) | 平均編輯% | SD |
| mRNA H | 2.00 | 0.07 | 0.05 |
| 0.66 | 0.07 | 0.05 | |
| 0.22 | 0.03 | 0.05 | |
| 0.07 | 0.03 | 0.05 | |
| 0.03 | 0.03 | 0.05 | |
| 0.008 | 0.00 | 0.00 | |
| 0.003 | 0.00 | 0.00 | |
| 0.00 | 0.05 | 0.05 | |
| mRNA I | 2.00 | 22.53 | 1.59 |
| 0.66 | 10.37 | 2.25 | |
| 0.22 | 0.80 | 0.22 | |
| 0.07 | 0.07 | 0.05 | |
| 0.03 | 0.07 | 0.05 | |
| 0.008 | 0.03 | 0.05 | |
| 0.003 | 0.03 | 0.05 | |
| 0.00 | 0.20 | 0.28 | |
| mRNA J | 2.00 | 26.30 | 0.86 |
| 0.66 | 10.07 | 1.27 | |
| 0.22 | 0.93 | 0.33 | |
| 0.07 | 0.03 | 0.05 | |
| 0.03 | 0.03 | 0.05 | |
| 0.008 | 0.03 | 0.05 | |
| 0.003 | 0.03 | 0.05 | |
| 0.00 | 0.05 | 0.05 | |
| mRNA K | 2.00 | 14.20 | 1.84 |
| 0.66 | 6.70 | 1.16 | |
| 0.22 | 0.53 | 0.17 | |
| 0.07 | 0.07 | 0.09 | |
| 0.03 | 0.03 | 0.05 | |
| 0.008 | 0.00 | 0.00 | |
| 0.003 | 0.00 | 0.00 | |
| 0.00 | 0.05 | 0.05 | |
| mRNA L | 2.00 | 23.30 | 0.80 |
| 0.66 | 10.57 | 1.54 | |
| 0.22 | 0.70 | 0.42 | |
| 0.7 | 0.07 | 0.05 | |
| 0.03 | 0.07 | 0.05 | |
| 0.008 | 0.07 | 0.05 | |
| 0.003 | 0.03 | 0.05 | |
| 0.00 | 0.05 | 0.05 | |
| mRNA N | 2.00 | 22.63 | 2.25 |
| 0.66 | 11.00 | 0.00 | |
| 0.22 | 0.97 | 0.19 | |
| 0.07 | 0.17 | 0.09 | |
| 0.03 | 0.03 | 0.05 | |
| 0.008 | 0.03 | 0.05 | |
| 0.003 | 0.00 | 0.00 | |
| 0.00 | 0.05 | 0.05 | |
| mRNA C | 2.00 | 19.90 | 0.16 |
| 0.66 | 8.40 | 2.20 | |
| 0.22 | 0.70 | 0.22 | |
| 0.07 | 0.03 | 0.05 | |
| 0.03 | 0.00 | 0.00 | |
| 0.008 | 0.03 | 0.05 | |
| 0.003 | 0.00 | 0.00 | |
| 0.00 | 0.00 | 0.00 |
對編碼具有不同NLS配置之Nme2Cas9 ORF的信使mRNA在原代人類肝細胞(PHH)及HEK-293細胞中之編輯效率進行了分析。使用具有靶向VEGFA基因座TS47之相同引導序列的gRNA進行分析，且gRNA具有不同長度及化學修飾模式。如實例1中所述地製備PHH細胞。將HEK293細胞解凍且以30,000個細胞/孔之密度接種於96孔盤中具有10% FBS之DMEM (Corning，10-013-CV)中，且培育24小時。使用Lipofectamine MessengerMAX轉染試劑(Invitrogen LMRNA001)根據製造商之方案進行脂質體轉染。以100 nM gRNA及1 ng/μL mRNA之最高劑量開始之劑量反應1:3稀釋系列用於用表9-10中所列濃度之gRNA轉化細胞。分析中包括重複樣品。在37℃下培育72小時之後，收集細胞且如實例1中所述地進行NGS分析。具有標準差(SD)之平均編輯結果展示於表9及圖5A-圖5C (對於HEK細胞)以及表10及圖5D-圖5F (對於PHH)中。
表 9. HEK 細胞中之平均編輯百分比
表 10 - PHH 細胞中之平均編輯百分比
實例 4.3 - 在 PMH 中使用 LNP 之 Nme2 NLS 變異體之劑量反應
| mRNA | gRNA [nM] | G020055 | G020073 | ||||
| 平均值 | SD | N | 平均值 | SD | N | ||
| mRNA C SEQ ID NO: 15 | 100 | 76.05 | 5.18 | 4 | 90.50 | 4.15 | 4 |
| 33.33 | 61.68 | 14.86 | 4 | 75.55 | 8.65 | 4 | |
| 11.11 | 32.93 | 8.59 | 4 | 63.53 | 11.92 | 4 | |
| 3.70 | 14.63 | 4.08 | 4 | 39.88 | 2.40 | 4 | |
| 1.23 | 5.95 | 1.42 | 4 | 13.00 | 5.36 | 4 | |
| 0.41 | 3.35 | 0.60 | 4 | 6.03 | 1.05 | 4 | |
| 0.14 | 2.05 | 0.50 | 4 | 3.65 | 0.47 | 4 | |
| 0.00 | 1.50 | 0.22 | 4 | 1.30 | 0.22 | 4 | |
| mRNA I SEQ ID NO:19 | 100 | 85.55 | 7.06 | 4 | 88.08 | 4.90 | 4 |
| 33.33 | 65.33 | 17.06 | 4 | 77.13 | 4.78 | 4 | |
| 11.11 | 34.98 | 12.93 | 4 | 48.63 | 4.83 | 4 | |
| 3.70 | 21.25 | 13.09 | 4 | 22.43 | 6.49 | 4 | |
| 1.23 | 8.03 | 8.06 | 4 | 9.80 | 2.12 | 4 | |
| 0.41 | 2.83 | 1.94 | 4 | 5.55 | 0.94 | 4 | |
| 0.14 | 2.15 | 0.83 | 4 | 2.45 | 0.60 | 4 | |
| mRNA J SEQ ID NO: 20 | 100 | 87.03 | 3.79 | 4 | 90.93 | 1.14 | 4 |
| 33.33 | 72.25 | 4.18 | 4 | 72.08 | 3.88 | 4 | |
| 11.11 | 40.05 | 5.01 | 4 | 42.83 | 9.02 | 4 | |
| 3.70 | 11.65 | 5.34 | 4 | 16.63 | 6.64 | 4 | |
| 1.23 | 5.78 | 0.86 | 4 | 7.00 | 1.47 | 4 | |
| 0.41 | 2.60 | 0.42 | 4 | 4.50 | 2.76 | 4 | |
| 0.14 | 1.53 | 0.50 | 4 | 1.78 | 0.24 | 4 | |
| 0.00 | 1.33 | 0.13 | 4 | 1.53 | 0.25 | 4 |
| mRNA | gRNA [nM] | G020055 | G020073 | ||||
| 平均值 | SD | N | 平均值 | SD | N | ||
| mRNA C | 100 | 27.70 | 4.29 | 3 | 31.43 | 3.63 | 3 |
| 33.33 | 32.98 | 5.10 | 4 | 31.58 | 2.49 | 4 | |
| 11.11 | 25.55 | 2.53 | 4 | 33.58 | 1.06 | 4 | |
| 3.70 | 13.80 | 3.68 | 4 | 19.38 | 3.86 | 4 | |
| 1.23 | 6.20 | 0.68 | 4 | 12.83 | 3.60 | 4 | |
| 0.41 | 2.70 | 0.81 | 4 | 6.35 | 1.41 | 4 | |
| 0.14 | 2.25 | 0.66 | 4 | 3.18 | 1.05 | 4 | |
| 0.00 | 1.65 | 0.24 | 4 | 1.50 | 0.18 | 4 | |
| mRNA I | 100 | 25.00 | 2.73 | 4 | 29.88 | 1.67 | 4 |
| 33.33 | 25.73 | 3.69 | 4 | 26.60 | 4.95 | 4 | |
| 11.11 | 26.08 | 3.23 | 4 | 22.98 | 3.09 | 4 | |
| 3.70 | 14.55 | 3.74 | 4 | 19.03 | 3.55 | 4 | |
| 1.23 | 7.65 | 0.70 | 4 | 7.28 | 3.41 | 4 | |
| 0.41 | 4.18 | 0.97 | 4 | 4.15 | 0.62 | 4 | |
| 0.14 | 2.18 | 0.15 | 4 | 2.83 | 0.93 | 4 | |
| 0.00 | 1.40 | 0.12 | 4 | 1.35 | 0.17 | 4 | |
| mRNA J | 100 | 27.90 | 1.57 | 4 | 36.38 | 5.06 | 4 |
| 33.33 | 26.50 | 3.59 | 4 | 32.95 | 2.27 | 4 | |
| 11.11 | 21.23 | 3.98 | 4 | 29.88 | 3.59 | 4 | |
| 3.70 | 14.85 | 2.37 | 4 | 14.88 | 2.81 | 4 | |
| 1.23 | 6.78 | 2.29 | 4 | 6.43 | 0.74 | 4 | |
| 0.41 | 2.73 | 1.35 | 4 | 3.13 | 0.49 | 4 | |
| 0.14 | 2.63 | 1.69 | 4 | 2.45 | 0.73 | 4 | |
| 0.00 | 1.40 | 0.12 | 4 | 1.50 | 0.16 | 4 |
分析具有不同NLS置放的編碼Nme2Cas9 ORF之信使mRNA在原代小鼠肝細胞(PMH)中之編輯效率。該分析測試靶向小鼠TTR基因座之引導物，且包括sgRNA及pgRNA兩種設計。
如同實例1製備PMH。LNP一般如實例1中所描述用單一RNA物種作為負荷製備，如表11中所指示。LNP以50/9/38/3之脂質組成製備，分別表示為可離子化脂質A/膽固醇/DSPC/PEG之莫耳比。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。
用按RNA重量計60 ng/100 μl含有gRNA之LNP及含有如表11中所指示之mRNA之LNP來處理細胞。將細胞在含有維持補充劑及10%胎牛血清之威廉姆斯氏E培養基(Gibco，A1217601)中在37℃下培育72小時。在37℃下培育72小時後，收集細胞且藉由NGS評估編輯，如實例1中所述。平均編輯百分比資料展示於表11及圖6中。
表 11. 原代小鼠肝細胞中小鼠 TTR 基因座處之平均編輯百分比。
實例 4.4 - 在 PMH 中使用 LNP 之 Nme2 NLS 變異體之劑量反應
| 樣品 | mRNA LNP (ng RNA) | 平均編輯% | SD | N |
| mRNA P (2xNLS) G021536 | 40.000 | 92.30 | 0.85 | 3 |
| 13.330 | 82.67 | 1.61 | 3 | |
| 4.440 | 62.27 | 2.96 | 3 | |
| 1.480 | 32.80 | 4.54 | 3 | |
| 0.490 | 11.23 | 1.37 | 3 | |
| 0.160 | 3.40 | 0.71 | 3 | |
| 0.050 | 0.80 | 0.22 | 3 | |
| 0.018 | 0.30 | 0.08 | 3 | |
| 0.006 | 0.20 | 0.08 | 3 | |
| 0.002 | 0.13 | 0.05 | 3 | |
| 0.001 | 0.13 | 0.05 | 3 | |
| 0.000 | 0.10 | 0.00 | 3 | |
| mRNA P (2xNLS) G021844 (pgRNA) | 40.000 | 96.17 | 0.12 | 3 |
| 13.330 | 91.83 | 0.34 | 3 | |
| 4.440 | 75.37 | 6.80 | 3 | |
| 1.480 | 44.53 | 13.11 | 3 | |
| 0.490 | 18.30 | 5.77 | 3 | |
| 0.160 | 5.50 | 1.43 | 3 | |
| 0.050 | 1.63 | 0.71 | 3 | |
| 0.018 | 0.33 | 0.05 | 3 | |
| 0.006 | 0.17 | 0.05 | 3 | |
| 0.002 | 0.07 | 0.05 | 3 | |
| 0.001 | 0.10 | 0.00 | 3 | |
| 0.000 | 0.07 | 0.05 | 3 | |
| mRNA M (1xNLS) G021536 | 40.000 | 84.27 | 1.23 | 3 |
| 13.330 | 66.23 | 5.39 | 3 | |
| 4.440 | 33.80 | 5.14 | 3 | |
| 1.480 | 10.17 | 5.51 | 3 | |
| 0.490 | 4.20 | 0.92 | 3 | |
| 0.160 | 1.10 | 0.45 | 3 | |
| 0.050 | 0.33 | 0.17 | 3 | |
| 0.018 | 0.23 | 0.09 | 3 | |
| 0.006 | 0.10 | 0.00 | 3 | |
| 0.002 | 0.10 | 0.00 | 3 | |
| 0.001 | 0.10 | 0.00 | 3 | |
| 0.000 | 0.07 | 0.05 | 3 | |
| mRNA M (1xNLS) G021844 (pgRNA) | 40.000 | 88.83 | 0.37 | 3 |
| 13.330 | 74.37 | 4.63 | 3 | |
| 4.440 | 39.00 | 3.72 | 3 | |
| 1.480 | 16.40 | 2.52 | 3 | |
| 0.490 | 4.03 | 0.77 | 3 | |
| 0.160 | 1.27 | 0.05 | 3 | |
| 0.050 | 0.23 | 0.05 | 3 | |
| 0.018 | 0.20 | 0.08 | 3 | |
| 0.006 | 0.10 | 0.00 | 3 | |
| 0.002 | 0.10 | 0.00 | 3 | |
| 0.001 | 0.10 | 0.00 | 3 | |
| 0.000 | 0.10 | 0.00 | 3 |
分析具有不同NLS置放的編碼Nme2Cas9 ORF之信使mRNA在原代小鼠肝細胞(PMH)中之編輯效率。
如實例1中所述地製備PMH (Gibco，MC148)。LNP一般如實例1中所描述用單一RNA物種作為負荷製備。LNP以50/9/38/3之脂質組成製備，分別表示為可離子化脂質A/膽固醇/DSPC/PEG之莫耳比。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。
用按RNA重量計30 ng/100 μl含有gRNA G021844之LNP及含有如表LS4中所指示之mRNA之LNP來處理細胞。將細胞在含有維持補充劑及10%胎牛血清之威廉姆斯氏E培養基(Gibco，A1217601)中培育24小時。培育72小時後，收集細胞且藉由NGS評估編輯，如實例1中所述。平均編輯百分比資料展示於表12及圖7中。
表 12. 用 LNP 處理之 PMH 中之平均編輯百分比。
實例5 - NmeCas9蛋白表現
實例5.1 原代人類肝細胞中之蛋白質表現
| mRNA | mRNA LNP (ng/uL) | 平均值 | SD | N | EC 50(ng/uL) |
| mRNA C SEQ ID NO: 15 | 0.30 | 86.30 | 4.46 | 3 | 0.0082 |
| 0.10 | 84.17 | 5.52 | |||
| 0.03 | 75.80 | 1.91 | |||
| 0.01 | 43.90 | 14.36 | |||
| 0.004 | 34.03 | 8.64 | |||
| 0.001 | 15.63 | 4.35 | |||
| 0.0004 | 6.17 | 2.41 | |||
| 0.0001 | 3.47 | 0.62 | |||
| 0.00005 | 2.37 | 0.34 | |||
| 0.00002 | 3.00 | 0.64 | |||
| 0.00001 | 2.60 | 0.57 | |||
| 0.00 | 2.70 | 0.16 | |||
| mRNA J SEQ ID NO: 20 | 0.30 | 91.30 | 2.92 | 3 | 0.0053 |
| 0.10 | 89.60 | 4.23 | |||
| 0.03 | 80.93 | 8.17 | |||
| 0.01 | 62.85 | 14.35 | |||
| 0.004 | 39.95 | 5.15 | |||
| 0.001 | 16.70 | 3.79 | |||
| 0.0004 | 7.73 | 2.98 | |||
| 0.0001 | 4.23 | 0.95 | |||
| 0.00005 | 2.80 | 0.70 | |||
| 0.00002 | 3.23 | 0.54 | |||
| 0.00001 | 2.67 | 0.48 | |||
| 0.00 | 3.60 | 0.57 | |||
| mRNA Q SEQ ID NO: 27 | 0.30 | 90.67 | 4.40 | 3 | 0.0065 |
| 0.10 | 86.77 | 5.43 | |||
| 0.03 | 80.27 | 6.65 | |||
| 0.01 | 56.90 | 5.48 | |||
| 0.004 | 35.45 | 1.35 | |||
| 0.001 | 12.63 | 3.16 | |||
| 0.0004 | 5.17 | 0.56 | |||
| 0.0001 | 2.73 | 0.17 | |||
| 0.00005 | 2.97 | 0.41 | |||
| 0.00002 | 2.73 | 0.21 | |||
| 0.00001 | 2.87 | 0.56 | |||
| 0.00 | 2.43 | 0.82 | |||
| mRNA N SEQ ID NO: 24 | 0.30 | 93.93 | 2.20 | 3 | 00045 |
| 0.10 | 90.97 | 1.77 | |||
| 0.03 | 82.80 | 8.24 | |||
| 0.01 | 68.67 | 10.18 | |||
| 0.004 | 42.07 | 2.25 | |||
| 0.001 | 24.13 | 4.21 | |||
| 0.0004 | 10.60 | 0.94 | |||
| 0.0001 | 4.67 | 0.66 | |||
| 0.00005 | 3.30 | 1.84 | |||
| 0.00002 | 3.37 | 0.69 | |||
| 0.00001 | 2.53 | 0.90 | |||
| 0.00 | 2.33 | 1.48 | |||
| mRNA P SEQ ID NO: 26 | 0.30 | 94.47 | 1.04 | 3 | 0.0036 |
| 0.10 | 95.03 | 0.96 | |||
| 0.03 | 91.27 | 2.36 | |||
| 0.01 | 74.77 | 6.91 | |||
| 0.004 | 50.57 | 4.89 | |||
| 0.001 | 22.67 | 0.25 | |||
| 0.0004 | 8.27 | 0.74 | |||
| 0.0001 | 4.93 | 0.70 | |||
| 0.00005 | 3.37 | 0.74 | |||
| 0.00002 | 2.93 | 0.68 | |||
| 0.00001 | 2.87 | 0.05 | |||
| 0.00 | 2.87 | 0.45 | |||
| mRNA M SEQ ID NO: 23 | 0.30 | 92.00 | 0.80 | 3 | 0.0093 |
| 0.10 | 91.40 | 1.90 | |||
| 0.03 | 79.70 | 0.70 | |||
| 0.01 | 53.10 | 6.80 | |||
| 0.004 | 22.47 | 14.28 | |||
| 0.001 | 8.20 | 4.20 | |||
| 0.0004 | 4.57 | 1.57 | |||
| 0.0001 | 2.73 | 0.31 | |||
| 0.00005 | 3.07 | 0.21 | |||
| 0.00002 | 2.93 | 0.09 | |||
| 0.00001 | 2.77 | 0.66 | |||
| 0.00 | 3.47 | 1.09 | |||
| mRNA O SEQ ID NO: 25 | 0.30 | 89.40 | 7.00 | 3 | 0.0042 |
| 0.10 | 86.83 | 12.52 | |||
| 0.03 | 78.17 | 15.41 | |||
| 0.01 | 64.83 | 12.48 | |||
| 0.004 | 47.33 | 9.03 | |||
| 0.001 | 20.67 | 7.12 | |||
| 0.0004 | 8.60 | 2.95 | |||
| 0.0001 | 2.47 | 1.33 | |||
| 0.00005 | 4.13 | 0.37 | |||
| 0.00002 | 2.80 | 0.62 | |||
| 0.00001 | 11.13 | 231. | |||
| 0.00 | 6.13 | 2.16 |
為了量化各mRNA構築體之表現，在LNP遞送編碼SpyCas9或NmeCas9之mRNA至原代人類肝細胞後量測mRNA及蛋白質表現量。
如實例1中所述地製備PHH細胞。LNP一般如實例1中所描述用單一RNA物種作為負荷製備。LNP以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。
給與細胞一種含有mRNA之LNP (僅mRNA)，或兩種含有mRNA或gRNA之LNP。各LNP以16.7 ng總RNA負荷/100 µl施加至細胞。用LNP處理後，將細胞在含有維持補充劑及10%胎牛血清之威廉姆斯氏E培養基(Gibco，A1217601)中培育24小時。在37℃下培育24小時後，收集細胞且經由Nano-Glo HiBiT溶解偵測系統(Promega，N3030)遵循製造商說明書來定量表現。使用HiBiT對照蛋白質(Promega，N3010)將原始發光標準化為標準曲線。將表13及圖8中所示之不同Cas9變異體之蛋白質表現標準化為僅用SpyCas9 mRNA遞送之對應肝細胞中量測之SpyCas9表現。與表13中顯示之資料一致，當用來自PHH細胞提取物之抗HiBiT抗體藉由西方墨點偵測或藉由PMH、PCH、PHH及PRH細胞中之HiBiT偵測量測時，來自此等相同構築體之蛋白質表現對於NmeCas9構築體高於SpyCas9構築體。
表13. 相比於僅用SpyCas9 mRNA遞送之對應肝細胞中之SpyCas9表現的Cas9變異體之平均表現倍數，如藉由HiBiT分析所量測
實例 5.2 ： T 細胞中之蛋白質表現
| mRNA | gRNA | 細胞類型 | 表現倍數 | |
| 平均值 | N | |||
| Spy Cas9 mRNA | 無 | PMH | 1 | 2 |
| PRH | 1 | 3 | ||
| PCH | 1 | 3 | ||
| PHH | 1 | 3 | ||
| G000502 | PMH | 0.8 | 2 | |
| PRH | 2.7 | 3 | ||
| PCH | 1.8 | 3 | ||
| PHH | 0.6 | 3 | ||
| Nme2 Cas9 mRNA M | 無 | PMH | 6.8 | 2 |
| PRH | 19.2 | 3 | ||
| PCH | 7.3 | 3 | ||
| PHH | 4.3 | 3 | ||
| G021536 | PMH | 5.1 | 2 | |
| PRH | 11.5 | 3 | ||
| PCH | 4.1 | 3 | ||
| PHH | 3.0 | 3 |
為了量化各mRNA構築體之表現，在LNP遞送編碼SpyCas9或Nme2Cas9之mRNA至T細胞後，量測蛋白質表現量。
健康人類供體血球分離術為商業獲得的(Hemacare，目錄號)。根據製造商說明書在MultiMACS Cell24 Separator Plus儀器上使用EasySep人類T細胞分離套組(Stem Cell Technology，目錄號17951)藉由負選擇分離來自兩個供體(W106及W864)之T細胞。將分離之T細胞冷凍保存於CS10冷凍培養基(Cryostor，目錄號07930)中以供將來使用。
解凍後，將T細胞在由補充有細胞介素(200 IU/ml IL2、5 ng/ml IL7及5 ng/mL IL15)及2.5%人類血清(Gemini，100-512)之CTS OpTmizer基礎培養基(CTS OpTmizer培養基(Gibco，A1048501)，含有1X GlutaMAX、10mM HEPES緩衝液、1%青黴素/鏈黴素))構成之完全T細胞生長培養基中培養。在37℃下隔夜靜置之後，將密度為1e6/mL之T細胞用T細胞TransAct試劑(1:100稀釋，Miltenyi)活化且在組織培養恆溫箱中培育48小時。
用遞送編碼具有HiBiT標籤之Nme2-mRNA或Spy mRNA之mRNA的LNP處理活化T細胞。LNP一般如同實例1來製備。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。囊封Nme2Cas9 mRNA之LNP使用脂質A、膽固醇、DSPC及PEG2k-DMG，莫耳比為50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG。囊封SpyCas9 mRNA之LNP使用脂質A、膽固醇、DSPC及PEG2k-DMG，莫耳比為50%脂質A、38.5%膽固醇、10% DSPC及1.5% PEG2k-DMG。
在即將對T細胞進行LNP處理之前，將LNP在37℃下以13.33 μg/ml總RNA之LNP濃度與10 μg/mL ApoE3 (Peprotech，目錄號350-02)一起在完全T細胞培養基中預培育5分鐘，該培養基補充有細胞介素(200 IU/ml IL2 (Peprotech，目錄號200-02)、5 ng/ml IL7 (Peprotech，目錄號200-07)及5 ng/ml IL15 (Peprotech，目錄號200-15)及2.5%人類血清(Gemini，100-512)。培育後，接著將LNP與T細胞在完全T細胞培養基中以1:1體積混合，細胞介素用於ApoE培育。在LNP處理後24小時、48小時及72小時收集T細胞用於蛋白質表現分析。藉由Nano-Glo® HiBiT Lytic Assay (Promega)溶解T細胞，且經由Nano-Glo® Nano-Glo HiBiT細胞外偵測系統(Promega，目錄號N2420)遵循製造商說明書定量Cas9蛋白水平。使用Biotek Neo2盤讀取器來量測發光。使用來自標準對照之蛋白質數目及發光讀數在GraphPad上繪製線性回歸，迫使線經過X = 0，Y = 0。使用Y= ax + 0方程式計算每個溶解物之蛋白質數目。
將樣品標準化為0.83 μg/ml LNP劑量之SpyCas9的平均值。表14A-14B及圖9A-圖9F顯示供體1或供體2在LNP處理後24、48及72小時時mRNA在活化細胞中之相對Cas9蛋白表現。Cas9以劑量依賴性方式在活化T細胞中表現。與活化T細胞中之SpyCas9樣品相比，Nme2Cas9樣品之蛋白質表現更高。
表 14A ： 供體 1 標準化為平均 SpyCas9 0.83 μ g/ml 樣品之蛋白質表現
表14B：供體2標準化為平均SpyCas9 0.83 μg/ml樣品之蛋白質表現
實例 6. 使用脂質奈米粒子 (LNP) 在小鼠肝臟中之活體內編輯
| 時間點 ( 小時 ) | LNP (ug/mL) | T 細胞供體 1 | |||||
| mRNA P SEQ ID NO: 26 | mRNA M SEQ ID NO: 23 | Spy Cas9 | |||||
| 平均值 | N | 平均值 | N | 平均值 | N | ||
| 24 h | 6.67 | 89.3 | 2 | 86.5 | 2 | 26.5 | 2 |
| 3.33 | 67.7 | 2 | 50.3 | 2 | 11.3 | 2 | |
| 1.67 | 32.4 | 2 | 13.5 | 2 | 4.4 | 2 | |
| 0.83 | 7.3 | 2 | 2.9 | 2 | 1.0 | 2 | |
| 0.42 | 1.6 | 2 | 0.8 | 2 | 0.2 | 2 | |
| 0.21 | 0.4 | 2 | 0.3 | 2 | 0.1 | 2 | |
| 0.10 | 0.2 | 2 | 0.1 | 2 | 0.0 | 2 | |
| 0.00 | 0.0 | 2 | 0.0 | 2 | 0.0 | 2 | |
| 48 h | 6.67 | 657.2 | 2 | 987.0 | 2 | 165.9 | 2 |
| 3.33 | 487.4 | 2 | 551.0 | 2 | 58.5 | 2 | |
| 1.67 | 271.0 | 2 | 165.1 | 2 | 21.4 | 2 | |
| 0.83 | 64.5 | 2 | 32.3 | 2 | 4.3 | 2 | |
| 0.42 | 11.8 | 2 | 7.8 | 2 | 1.0 | 2 | |
| 0.21 | 3.2 | 2 | 2.6 | 2 | 0.1 | 2 | |
| 0.10 | 1.1 | 2 | 0.7 | 2 | 0.1 | 2 | |
| 0.00 | 0.0 | 2 | 0.0 | 2 | 0.0 | 2 | |
| 72 h | 6.67 | 53.8 | 2 | 125.6 | 2 | 24.6 | 2 |
| 3.33 | 40.8 | 2 | 75.6 | 2 | 11.6 | 2 | |
| 1.67 | 23.1 | 2 | 25.0 | 2 | 3.5 | 2 | |
| 0.83 | 5.6 | 2 | 4.0 | 2 | 1.0 | 2 | |
| 0.42 | 1.0 | 2 | 1.3 | 2 | 0.2 | 2 | |
| 0.21 | 0.2 | 2 | 0.4 | 2 | 0.0 | 2 | |
| 0.10 | 0.2 | 2 | 0.0 | 2 | 0.1 | 2 | |
| 0.00 | 0.0 | 2 | 0.0 | 2 | 0.0 | 2 |
| 時間點 ( 小時 ) | LNP (ug/mL) | T 細胞供體 2 | |||||
| mRNA P | mRNA M | SpyCas9 | |||||
| 平均值 | SD | 平均值 | SD | 平均值 | SD | ||
| 24 h | 6.67 | 151.5 | 2 | 134.0 | 2 | 36.2 | 2 |
| 3.33 | 98.2 | 2 | 64.5 | 2 | 17.2 | 2 | |
| 1.67 | 37.6 | 2 | 19.4 | 2 | 4.9 | 2 | |
| 0.83 | 10.4 | 2 | 4.5 | 2 | 1.0 | 2 | |
| 0.42 | 2.4 | 2 | 1.0 | 2 | 0.2 | 2 | |
| 0.21 | 0.7 | 2 | 0.4 | 2 | 0.1 | 2 | |
| 0.10 | 0.3 | 2 | 0.2 | 2 | 0.0 | 2 | |
| 0.00 | 0.0 | 2 | 0.0 | 2 | 0.0 | 2 | |
| 48 h | 6.67 | 713.6 | 2 | 1067.3 | 2 | 119.0 | 2 |
| 3.33 | 507.5 | 2 | 587.1 | 2 | 54.9 | 2 | |
| 1.67 | 229.0 | 2 | 149.2 | 2 | 15.9 | 2 | |
| 0.83 | 59.1 | 2 | 33.8 | 2 | 3.6 | 2 | |
| 0.42 | 10.5 | 2 | 8.3 | 2 | 1.0 | 2 | |
| 0.21 | 3.1 | 2 | 2.8 | 2 | 0.3 | 2 | |
| 0.10 | 1.0 | 2 | 1.9 | 2 | 0.2 | 2 | |
| 0.00 | 0.0 | 2 | 0.2 | 2 | 0.0 | 2 | |
| 72 h | 6.67 | 53.8 | 2 | 108.2 | 2 | 17.1 | 2 |
| 3.33 | 40.7 | 2 | 60.5 | 2 | 8.3 | 2 | |
| 1.67 | 19.3 | 2 | 18.2 | 2 | 3.1 | 2 | |
| 0.83 | 4.7 | 2 | 3.8 | 2 | 1.0 | 2 | |
| 0.42 | 1.3 | 2 | 1.4 | 2 | 0.3 | 2 | |
| 0.21 | 0.4 | 2 | 0.4 | 2 | 0.1 | 2 | |
| 0.10 | 0.3 | 2 | 0.0 | 2 | 0.4 | 2 | |
| 0.00 | 0.0 | 2 | 0.1 | 2 | 0.0 | 2 |
如實例1中所述地調配用於所有活體內研究中之LNP。在各別實例中注意到與方案之偏差。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
小鼠模型中之活體內編輯
測試所選引導物設計之活體內編輯效率。涉及小鼠的各研究中使用6-10週齡範圍內的CD-1雌性小鼠。給藥前對動物進行稱重。LNP一般如實例1中所述地調配。LNP含有50%可離子化脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比。脂質核酸組裝體用約6之脂質胺與RNA磷酸酯(N:P)莫耳比調配。
以每隻動物0.2 mL之體積(每公斤體重約10 mL)，經由外側尾部靜脈給與LNP。在投與後二十四小時量測體重。LNP遞送後約6-7天，在給藥後異氟醚麻醉下藉由放血對動物實施安樂死。經由心臟穿刺將血液收集至血清分離管中。對於涉及活體內編輯之研究，肝組織收集自來自各動物之左內側葉以用於DNA提取及分析。
對於活體內研究，使用基於珠粒之提取套組，例如Zymo Quick-DNA 96套組(Zymo Research，目錄號D3010)根據製造商之方案自組織提取基因體DNA。如實例1中所述地進行NGS分析。
動物研究中所用的轉甲狀腺素蛋白 (TTR) ELISA 分析
收集血液且如上文所描述分離血清。使用小鼠前白蛋白(甲狀腺素轉運蛋白)ELISA套組(Aviva Systems Biology，目錄號OKIA00111)測定總TTR血清水準。根據製造商之方案製備套組試劑及標準品。藉由1×分析稀釋劑將小鼠血清稀釋至10,000倍之最終稀釋度。將標準曲線稀釋液(各100 μL)與稀釋之血清樣品均添加至預塗有捕捉抗體之ELISA盤之各孔中。培養盤在室溫下培育30分鐘，隨後洗滌。添加酶-抗體結合物(每孔100 μL)，培育20分鐘。移除非結合之抗體結合物且再次洗滌培養盤，隨後添加顯色受質溶液。將培養盤培育10分鐘，隨後添加100 μL終止溶液，例如硫酸(約0.3 M)。在Clariostar盤讀取器上以450 nm之吸光度讀取該盤。使用脫離標準曲線之四參數邏輯曲線擬合，藉由SoftMax Pro軟體版本6.4.2或Mars軟體版本3.31計算血清TTR含量。根據分析稀釋度調整最終血清值。相對於對照組，測定蛋白質阻斷百分比(KD%)值，除非另外指示，否則對照組通常為經媒劑(TSS)假治療之動物。藉由將各樣品TTR值除以TSS組之平均值，接著調整為百分比值來計算TSS百分比。
實例 6.1. 使用共調配 LNP 之活體內編輯
在小鼠模型中進一步評估實例4.2中測試之經修飾sgRNA的編輯效率。測試了具有靶向小鼠PCSK9之相同引導序列但具有不同長度之保守區的引導RNA設計，如實例1中所述地製備LNP。使用可離子化脂質A、膽固醇、DSPC及PEG2k-DMG以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。如表15中所指示之靶向PCSK9基因之gRNA及mRNA C在LNP中以gRNA與mRNA按重量計1:2共調配。以1 mg/kg如上文所述之總RNA的劑量向雌性CD-1小鼠(n=5)投與LNP。給藥後7天對小鼠實施安樂死。含有所指示gRNA之LNP之編輯效率展示於表15中且繪示於圖10中。
表 15. 小鼠肝臟中之平均編輯百分比。
實例 6.2. 使用 pgRNA 及 mRNA LNP 之活體內編輯
| 引導物 | 劑量(mg/kg) | 平均編輯% | SD |
| 媒劑 | - | 0.0 | 0.0 |
| G017564 | 1 | 2.5 | 0.9 |
| G017565 | 1 | 2.2 | 1.0 |
| G017566 | 1 | 2.2 | 1.2 |
在活體內評估經修飾pgRNA之編輯效率。除實例6.1之先前研究中指定之引導修飾以外，重複/反重複區、髮夾1及髮夾2之各環中之四個核苷酸亦經間隔子-18個PEG連接子取代。
LNP一般如實例1中所描述用單一RNA物種作為負荷製備。LNP含有脂質A、膽固醇、DSPC及PEG2k-DMG，莫耳比為50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。
含有表16中所指示之靶向TTR基因之gRNA的LNP如上文所描述以0.1 mg/kg或0.3 mg/kg總RNA之劑量向雌性CD-1小鼠(n=5)投與。含有mRNA (mRNA M；SEQ ID NO: 23)之LNP及含有pgRNA (G021846或G021844)之LNP分別以按RNA重量計1:2之比率同時遞送。給藥後7天將小鼠安樂死。
含有指定pgRNA之LNP之編輯效率、血清TTR減弱及%TSS展示於表16中且分別繪示於圖11A-圖11C中。
表 16. 肝臟編輯、血清 TTR 蛋白及 TTR 蛋白減弱
| 引導物 | 劑量(mg/kg) | 平均編輯% | SD | 平均血清TTR ( μg/ml) | SD | 平均%TSS | SD |
| TSS | NA | 0.1 | 0 | 733.1 | 131.2 | 100 | 17.9 |
| G021846 | 0.1 | 21.9 | 2.8 | 369.5 | 56.2 | 50.4 | 7.7 |
| 0.3 | 33.8 | 2.9 | 269.8 | 21.3 | 36.8 | 2.6 | |
| G021844 | 0.1 | 59.6 | 3.9 | 84.1 | 26.6 | 11.5 | 3.6 |
| 0.3 | 71.6 | 1.8 | 24.4 | 9.2 | 3.3 | 1.2 |
在不同劑量水平之替代mRNA的情況下，在小鼠中評估來自上文所述之研究的pgRNA (G021844)。LNP一般如實例1中所描述用單一RNA物種作為負荷製備。含有pgRNA (G21844)或mRNA (mRNA P或mRNA M)之LNP如實例1中所述地調配。用可離子化脂質A、膽固醇、DSPC及PEG2k-DMG以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。G000502及G021844均靶向小鼠TTR基因之外顯子3。含有pgRNA之LNP及含有mRNA之LNP基於組合RNA重量，分別以按RNA重量計2:1之引導物:mRNA比率同時給藥。額外LNP分別與按重量計1:2比率(較佳SpyCas9引導物:mRNA比率)之G000502及SpyCas9 mRNA共同調配。
表17中所指示之LNP以0.1 mg/kg或0.03 mg/kg總RNA之劑量向雌性CD-1小鼠(n=4)投與。含有指定gRNA之LNP之編輯效率展示於表17中且繪示於圖11D及圖11E中。
表 17. 肝臟編輯及血清 TTR 蛋白減弱
實例 6.3. 使用 sgRNA 及 mRNA LNP 之活體內編輯
| 引導物 | mRNA | 劑量(mg/kg) | 平均編輯% | SD | 平均血清TTR ( μg/ml) | SD |
| TSS | TSS | NA | 0.12 | 0.04 | 937.4 | 100.5 |
| G000502 | SpyCas9 | 0.1 | 44.50 | 6.9 | 370.7 | 80.1 |
| G021844 | mRNA P SEQ ID NO: 26 | 0.03 | 37.70 | 2.9 | 398.7 | 41.9 |
| 0.1 | 65.40 | 2.2 | 92.8 | 27.5 | ||
| mRNA M SEQ ID NO: 23 | 0.03 | 32.02 | 2.1 | 527.4 | 93.6 | |
| 0.1 | 62.50 | 17.4 | 268.6 | 236.8 |
LNP一般如實例1中所描述用單一RNA物種作為負荷製備。用脂質A、膽固醇、DSPC及PEG2k-DMG以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。sgRNA經設計以靶向pcsk9基因(G020361)或Rosa26基因(G020848)。
以1 mg/kg總RNA之劑量向雌性CD-1小鼠(n=5)投與含有sgRNA或mRNA之LNP。測試之mRNA(mRNA C、mRNA J、mRNA Q、mRNA N)被設計成具有不同數目及佈置之NLS。LNP基於RNA負荷之組合重量以按RNA重量計1:1之gRNA:mRNA比率同時給藥。平均編輯百分比展示於表18中且繪示於圖12中。
表 18. 小鼠肝臟中之平均編輯百分比。
實例 7. 使用 NmeCas9 及 sgRNA 或 pgRNA 之活體內編輯
| 引導物 | mRNA | 劑量(mg/kg) | 平均插入 / 缺失 % | SD |
| TSS | TSS | NA | 0.1 | 0.0 |
| G020361 | mRNA C | 1 | 3.7 | 1.5 |
| mRNA J | 1 | 2.1 | 0.8 | |
| mRNA Q | 1 | 4.5 | 1.8 | |
| mRNA N | 1 | 3.6 | 1.0 | |
| G020848 | mRNA C | 1 | 0.8 | 0.3 |
| mRNA J | 1 | 0.4 | 0.1 | |
| mRNA Q | 1 | 0.7 | 0.2 | |
| mRNA N | 1 | 0.9 | 0.5 |
在小鼠模型中測試用Nme2Cas9測試的經修飾pgRNA之編輯效率。所測試之所有Nme sgRNA均包含靶向mTTR之相同24nt引導序列。
LNP一般如實例1中所描述用單一RNA物種作為負荷製備。用脂質A、膽固醇、DSPC及PEG2k-DMG以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。LNP以按gRNA與mRNA負荷之重量計2:1之比率混合。劑量係基於gRNA及mRNA之組合RNA質量計算。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
將6-10週齡範圍內之CD-1雌性小鼠用於涉及小鼠之各研究中(n=5/組，除了TSS對照之n=4)。根據表19中所列之劑量，經由尾部靜脈注射靜脈內投與調配物。在給藥後至少24小時，定期觀測動物之不良反應。治療後六天，在異氟醚麻醉下藉由心臟穿刺將動物安樂死；收集肝臟組織用於下游分析。收集重量在5與15 mg之間的肝臟穿孔以分離基因體DNA及總RNA。用NGS定序分析基因體DNA樣品，如實例1中所描述。含有指定mRNA及gRNA之LNP之編輯效率展示於表19中且繪示於圖13中。
表 19. 小鼠肝臟中之平均編輯百分比
實例 8. 使用 Nme2Cas9 gRNA 之活體內鹼基編輯
| mRNA | gRNA | 劑量(mg/kg) | |||
| 平均編輯% | SD | N | |||
| TSS | TSS | - | 0.08 | 0.05 | 4 |
| mRNA P (2x N末端NLS，HiBiT) | G021536 (101-nt Nme sgRNA) | 0.03 | 21.68 | 6.87 | 5 |
| 0.1 | 63.22 | 3.28 | 5 | ||
| mRNA P (2x N末端NLS，HiBiT) | G021844 (93-nt Nme pgRNA) | 0.03 | 36.28 | 9.45 | 5 |
| 0.1 | 66.44 | 3.55 | 5 | ||
| mRNA O (2 x N末端NLS) | G021844 (93-nt Nme pgRNA) | 0.03 | 40.88 | 14.16 | 5 |
| 0.1 | 66.02 | 5.01 | 5 |
在小鼠模型中用Nme鹼基編輯劑構築體測試具有不同mRNA之經修飾gRNA的編輯效率。此實驗與實例7並行地進行且使用相同對照樣品。LNP一般如實例1中所描述用單一RNA物種作為負荷製備。用脂質A、膽固醇、DSPC及PEG2k-DMG以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比製備所使用LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。所使用之LNP如實例1中所描述調配，不同之處在於各組分、引導RNA或mRNA個別地調配於LNP中，且LNP在投與之前混合，如表20中所描述。對於Nme2Cas9及Nme2Cas9鹼基編輯器樣本，LNP以按gRNA與編輯劑mRNA負荷之重量計2:1之比率混合。對於SpyCas9鹼基編輯劑樣本，LNP以按gRNA與編輯劑mRNA負荷之重量計1:2之比率混合。如表20及圖14中所指示之劑量係基於gRNA與編輯劑mRNA之組合RNA重量計算。用額外0.03 mpk UGI mRNA處理鹼基編輯劑樣本。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
將6-10週齡範圍內之CD-1雌性小鼠用於涉及小鼠之各研究中(n=5/組，除了TSS對照之n=4)。根據表20中所列之劑量，經由尾部靜脈注射靜脈內投與調配物。在給藥後至少24小時，定期觀測動物之不良反應。治療後六天，在異氟醚麻醉下藉由心臟穿刺將動物安樂死；收集肝臟組織用於下游分析。收集重量在5與15 mg之間的肝臟穿孔以分離基因體DNA及總RNA。使用DNA分離套組(ZymoResearch，D3010)提取基因體DNA且用NGS定序分析樣品，如實例1中所描述。含有指定gRNA之LNP之編輯效率展示於表20中且繪示於圖14中。
表 20. 小鼠肝臟中之平均編輯百分比。
實例 9. 在 T 細胞中使用 Nme1Cas9 及 Nme3Cas9 mRNA 之引導物篩選
| 樣品 | 劑量 (mg/kg) | C 至 T % | C 至 A/G % | 插入 / 缺失 % | ||||||
| 平均值 | SD | n | 平均值 | SD | n | 平均值 | SD | n | ||
| TSS | 0 | 0.00 | 0.00 | 4 | 0.10 | 0.00 | 4 | 0.08 | 0.05 | 4 |
| mRNA O + G021844 (Nme2Cas9 + pgRNA) | 0.03 | 0.00 | 0.00 | 5 | 0.08 | 0.04 | 5 | 40.88 | 14.16 | 5 |
| 0.1 | 0.00 | 0.00 | 5 | 0.02 | 0.04 | 5 | 66.02 | 5.01 | 5 | |
| mRNA S + mRNA G + G021844 (Nme2鹼基編輯劑 + UGI + pgRNA) | 0.03 | 25.60 | 5.28 | 5 | 3.50 | 0.76 | 5 | 11.14 | 2.18 | 5 |
| 0.1 | 46.34 | 1.53 | 5 | 5.74 | 0.33 | 5 | 13.52 | 0.90 | 5 | |
| mRNA E + mRNA G + G000502 (SpyBC22n + UGI + sgRNA) | 0.03 | 9.28 | 2.82 | 5 | 0.94 | 0.54 | 5 | 7.34 | 1.61 | 5 |
| 0.1 | 30.72 | 8.51 | 5 | 2.86 | 0.23 | 5 | 15.60 | 2.58 | 5 |
在具有Nme1Cas9或Nme3Cas9 mRNA之T細胞中使用TRAC基因座中具有9個不同目標序列之引導物測試了一種經修飾gRNA支架之編輯效率。
健康人類供體血球分離術為商業上獲得的(Hemacare，供體3786)，且細胞經洗滌且再懸浮於CliniMACS® PBS/EDTA緩衝液(Miltenyi Biotec目錄號130-070-525)中且在MultiMACS™ Cell 24 Separator Plus裝置(Miltenyi Biotec)中進行處理。使用Straight from Leukopak® CD4/CD8 MicroBead套組，人類(Miltenyi Biotec目錄號130-122-352)經由陽性選擇分離T細胞。T細胞經等分且冷凍保存以在Cryostor® CS10 (StemCell Technologies目錄號07930)中使用。解凍後，將T細胞以1.0×10^
6個細胞/毫升之密度接種於由以下各者構成之T細胞生長培養基(TCGM)中：CTS OpTmizer T細胞擴增SFM及T細胞擴增補充物(Thermo Fisher目錄號A1048501)、5%人類AB血清(GeminiBio，目錄號100-512)、1×青黴素-鏈黴素、1× Glutamax、10 mM HEPES、200 U/mL重組人類介白素-2 (Peprotech，目錄號200-02)、5 ng/mL重組人類介白素-7 (Peprotech，目錄號200-07)及5 ng/mL重組人類介白素-15 (Peprotech，目錄號200-15)。T細胞在此培養基中靜置24小時，此時其經以1:100體積比添加之T Cell TransAct™人類試劑(Miltenyi，目錄號130-111-160)活化。
對於Nme1Cas9引導物篩選，在P3緩衝液中製備含有編碼Nme1Cas9之mRNA (mRNA AB)的溶液。將靶向TRAC基因座中之各種位點之引導RNA在95℃下變性2分鐘，且在室溫下培育5分鐘。活化後四十八小時，收集T細胞，離心，且以12.5×10^
6個T細胞/毫升之濃度再懸浮於P3電穿孔緩衝液(Lonza)中。對於待電穿孔之各孔，將1×10^
5個T細胞與600 ng Nme1Cas9 mRNA及5μM gRNA在最終體積為20 µL之P3電穿孔緩衝液中混合。將此混合物一式兩份地轉移至96孔Nucleofector™盤中且使用製造商之脈衝碼電穿孔。經電穿孔之T細胞緊接著在不含細胞介素之CTS OpTmizer T細胞生長培養基中靜置15分鐘，隨後轉移至含有額外補充有細胞介素之CTS OpTmizer T細胞生長培養基的新平底96孔盤中。將所得盤在37℃下培育3天。在電穿孔後第3天，細胞在2個U形底盤中以1:2分裂。
在第電穿孔後第7天，藉由流式細胞分析技術分析接種之T細胞以確定T細胞受體之表面表現。簡言之，將T細胞與針對CD3 (BioLegend，目錄號317336)、CD4 (BioLegend，目錄號317434)、CD8 (BioLegend，目錄號301046)及Viakrome (Beckman Coulter，目錄號C36628)之抗體一起培育。隨後洗滌細胞，再懸浮於細胞染色緩衝液中且在Cytoflex流式細胞儀(Beckman Coulter)上進行處理。使用FlowJo套裝軟體分析流動式細胞量測術資料。T細胞基於大小、形狀、活力以及CD8及CD3之表現進行閘控。一式兩份地操作樣品。
CD3為T細胞受體複合物之細胞表面組分，且其在細胞表面處之存在被用作TRAC蛋白表現之替代標記。指定gRNA中之各者之CD3陰性細胞群體及對應標準差(SD)展示於表21中且繪示於圖16中。
表 21. 用 Nme1Cas9 進行 TRAC 編輯之後的平均 CD3 陰性 T 細胞百分比
| 引導物ID | 平均值 | SD |
| G024103 | 0.95 | 0.02 |
| G024104 | 1.52 | 0.04 |
| G024108 | 52.82 | 0.40 |
| G024109 | 1.69 | 0.14 |
| G024110 | 2.24 | 0.39 |
| G024111 | 2.10 | 0.06 |
| G024112 | 1.81 | 0.14 |
| G024113 | 1.19 | 0.26 |
| G024114 | 0.97 | 0.05 |
對於用Nme3Cas9 mRNA篩選引導物，如此實例中所述地製備T細胞。在P3緩衝液中製備含有編碼Nme3Cas9之mRNA (mRNA Z)之溶液，以及Nme1Cas9 (mRNA AB)及Nme2Cas9 (mRNA O)之對照。如上文所述地進行NmeCas9 (例如Nme1Cas9、Nme2Cas9或Nme3Cas9) gRNA及mRNA之電穿孔。樣品一式三份地電穿孔。電穿孔後第3天，如上文所述地經由流式細胞分析技術分析細胞。
指定gRNA中之各者之CD3陰性細胞群體及對應標準差(SD)展示於表22中且繪示於圖17中。
表 22. 用 Nme3Cas9 進行 TRAC 編輯之後的平均 CD3 陰性 T 細胞百分比。
實例 10. 密碼子最佳化 NmeCas9 mRNA 之表現
| 引導物ID | 平均值 | SD |
| G028844 | 2.99 | 0.49 |
| G028845 | 2.97 | 0.30 |
| G028846 | 22.83 | 1.65 |
| G028847 | 8.71 | 1.16 |
| G028848 | 95.6 | 0.74 |
| G028849 | 6.24 | 0.02 |
| G028850 | 69.63 | 3.57 |
| G028851 | 1.49 | 0.53 |
| G028852 | 79.13 | 3.34 |
| G028853 (Nme1對照) | 97.43 | 0.20 |
| G021469 (Nme2對照) | 92.46 | 2.00 |
為了量化各mRNA構築體之表現，在將編碼Nme1Cas9、Nme2Cas9或Nme3Cas9之mRNA電穿孔至T細胞後量測蛋白質表現量。所有NmeCas9 mRNA構築體均具有相同的通式結構，具有在NmeCas9開放閱讀框之N末端的連續SV40及核質蛋白核定位信號編碼序列。構築體包括在NmeCas9開放閱讀框架之C末端的HiBiT標籤之編碼序列。該等組分由連接子連接且本文提供特異性序列。
健康人類供體血球分離術為商業上獲得的(Hemacare，供體3786)，且細胞經洗滌且再懸浮於CliniMACS® PBS/EDTA緩衝液(Miltenyi Biotec目錄號130-070-525)中且在MultiMACS™ Cell 24 Separator Plus裝置(Miltenyi Biotec)中進行處理。使用Straight from Leukopak® CD4/CD8 MicroBead套組，人類(Miltenyi Biotec目錄號130-122-352)經由陽性選擇分離T細胞。T細胞經等分且在Cryostor® CS10 (StemCell Technologies目錄號07930)中冷凍保存以供將來使用。解凍後，將T細胞以1.0×10^
6個細胞/毫升之密度接種於由以下各者構成之T細胞生長培養基(TCGM)中：CTS OpTmizer T細胞擴增SFM及T細胞擴增補充物(ThermoFisher目錄號A1048501)、5%人類AB血清(GeminiBio，目錄號100-512)、1×青黴素-鏈黴素、1× Glutamax、10 mM HEPES、200 U/mL重組人類介白素-2 (Peprotech，目錄號200-02)、5 ng/mL重組人類介白素-7 (Peprotech，目錄號200-07)及5 ng/mL重組人類介白素-15 (Peprotech，目錄號200-15)。T細胞在此培養基中靜置24小時，此時其經以1:100體積比添加之T Cell TransAct™人類試劑(Miltenyi，目錄號130-111-160)活化。
在P3緩衝液中製備含有編碼NmeCas9之mRNA的溶液。將靶向TRAC基因座之引導RNA自儲存中取出，且在95℃下變性2分鐘，且在室溫下培育5分鐘。活化後四十八小時，收集T細胞，離心，且以12.5×10^
6個T細胞/毫升之濃度再懸浮於P3電穿孔緩衝液(Lonza)中。待電穿孔之各孔含有1×10^
5個細胞、表23中指定之NmeCas9 mRNA及表23中指定之1 μM gRNA (對於Nme1Cas9為G028853；對於Nme2Cas9為G021469；對於Nme3Cas9為G028848)，最終體積為20 μL P3電穿孔緩衝液。使用自600 ng mRNA開始之三倍、五點連續稀釋來測試NmeCas9 mRNA。將適當gRNA及mRNA混合物一式三份轉移至96孔Nucleofector™盤中，且使用製造商之脈衝碼進行電穿孔。經電穿孔之T細胞緊接著在不含細胞介素之CTS OpTmizer T細胞生長培養基中靜置15分鐘，隨後轉移至含有額外補充有細胞介素之CTS OpTmizer T細胞生長培養基的新平底96孔盤中。將所得盤在37℃下培育24小時，隨後進行HiBiT發光分析，或培育96小時，隨後進行流式細胞分析技術。
在電穿孔後24小時收集T細胞用於蛋白表現分析。T細胞藉由Nano-Glo® HiBiT Lytic Assay (Promega)溶解。使用Biotek Neo2盤讀取器來量測發光。表23及圖18展示活化細胞中作為相對發光單位(RLU)之Cas9蛋白表現及對應標準差(SD)。
表 23. 作為 24 小時 T 細胞中之 Cas9 蛋白表現之相對量度的平均發光 (RLU) 。
| mRNA (ng) | 600 | 200 | 66.6 | 22.2 | 7.4 | |
| mRNA X (Nme1Cas9)G028853 | 平均值(RLU) | 6955.7 | 2941.0 | 1893.7 | 758.3 | 288.7 |
| SD | 800.5 | 232.0 | 268.3 | 256.0 | 21.4 | |
| mRNA Y (Nme1Cas9)G028853 | 平均值(RLU) | 10999.7 | 4967.6 | 2888.7 | 1423.0 | 479.3 |
| SD | 1621.8 | 444.6 | 451.5 | 213.3 | 42.0 | |
| mRNA V (Nme2Cas9)G021469 | 平均值(RLU) | 43026.7 | 15244.0 | 6522.3 | 2658.3 | 1067.3 |
| SD | 7729.3 | 1288.1 | 229.0 | 174.3 | 127.1 | |
| mRNA Z (Nme3Cas9)G028848 | 平均值(RLU) | 19217.3 | 6488.0 | 2386.0 | 1033.3 | 414.7 |
| SD | 1311.8 | 521.0 | 394.3 | 93.6 | 50.2 |
編輯後第4天，T細胞藉由流式細胞分析技術進行分析以確定表面蛋白質表現。簡言之，將T細胞與在細胞染色緩衝液(BioLegend，目錄號420201)中稀釋之抗體的混合物一起在4℃下培育30分鐘。以1:100稀釋針對CD3 (BioLegend，目錄號317336)、CD4 (BioLegend，目錄號317434)、CD8 (BioLegend，目錄號301046)及Viakrome (Beckman Coulter，目錄號C36628)之抗體。隨後洗滌細胞，再懸浮於100 µL細胞染色緩衝液中且在Cytoflex流式細胞儀(Beckman Coulter)上進行處理。使用FlowJo套裝軟體分析流式細胞分析技術資料。T細胞基於大小、形狀、活力、CD8及CD3進行閘控。樣品均一式三份地進行。指定gRNA中之各者之CD3陰性細胞群體及對應標準差(SD)展示於表24中且繪示於圖19中。
表 24. TRAC 編輯之後 T 細胞之 CD3 陰性細胞百分比。
實例 11. 在原代食蟹獼猴肝細胞 (PCH) 中使用所選引導物進行活體外編輯
| mRNA (ng) | 600 | 200 | 66.7 | 22.2 | 7.4 | |
| mRNA X (Nme1Cas9)G028853 | 平均值 | 95.2 | 94.6 | 90.3 | 79.9 | 58.7 |
| SD | 0.8 | 1.1 | 0.6 | 3.1 | 4.8 | |
| mRNA Y (Nme1Cas9)G028853 | 平均值 | 97.2 | 96.2 | 93.7 | 88.7 | 75.0 |
| SD | 0.8 | 1.1 | 0.9 | 1.4 | 1.3 | |
| mRNA V (Nme2Cas9)G021469 | 平均值 | 87.7 | 84.6 | 80.3 | 66.6 | 42.7 |
| SD | 3.3 | 3.9 | 2.4 | 1.6 | 0.1 | |
| mRNA Z (Nme3Cas9)G028848 | 平均值 | 96.6 | 93.4 | 85.5 | 73.6 | 36.0 |
| SD | 0.1 | 1.1 | 2.3 | 5.8 | 2.0 |
選擇三種NmeCas9 sgRNA (G024739、G024741及G024743)用於劑量反應分析中之評估。測試之靶向食蟹獼猴TTR基因之NmeCas9 sgRNA包括24個核苷酸之引導序列。
引導物之未經修飾及經修飾之型式提供於表25中。
表 25. 所選 gRNA 之 未經修飾及經修飾之型式。
| 引導物 ID | 未經修飾之序列 | 經修飾序列 |
| G024739 | AGGACCAGCCUCAGACACAAAUACGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU (SEQ ID NO: 509) | mA*mG*mG*mAmCCAmGmCCmUCmAGACAmCAAAmUACmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 456) |
| G024741 | CUGCCUCGGACGGCAUCUAGAACUGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU (SEQ ID NO: 510 | mC*mU*mG*mCmCUCmGmGAmCGmGCAUCmUAGAmACUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 457) |
| G024743 | AGGCAGAGGAGGAGCAGACGAUGAGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU (SEQ ID NO: 511) | mA*mG*mG*mCmAGAmGmGAmGGmAGCAGmACGAmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU (SEQ ID NO: 458) |
如下所述，將gRNA及Cas9 mRNA脂質體轉染至原代食蟹獼猴肝細胞(PCH)中。如實例1中所述來製備(In Vitro ADMET Laboratories 10136011)。以40,000個細胞/孔之密度接種PCH。LNP調配物如實例1中所述地製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比之脂質組成來製備LNP。以約6之脂質胺與RNA磷酸酯(N:P)莫耳比且用表25中所指示之gRNA來調配LNP。100 μL培養基中之PCH用含有sgRNA之LNP之8點、4倍稀釋系列(自70 ng開始)及按mRNA重量計固定30 ng劑量之囊封mRNA O之LNP處理。各孔中之sgRNA濃度指示於表26中。細胞在處理後72小時溶解，且如實例1中所述地進行NGS分析。在一式三份樣品中量測編輯效率對引導物濃度之劑量反應。表26及圖20顯示在各引導物濃度下之平均編輯百分比及標準差(SD)。
表 26. 在 PCH 中編輯後在 TTR 處之平均插入 / 缺失百分比。
實例 12. 在 PCH 中使用 mRNA 稀釋系列活體外編輯 LNP
| G024739 | G024741 | G024743 | ||||
| 引導物LNP (ng/μL) | 平均值 | SD | 平均值 | SD | 平均值 | SD |
| 0.7 | 79.0 | 1.7 | 63.5 | 3.7 | 42.6 | 1.1 |
| 0.2 | 56.8 | 2.4 | 17.4 | 1.2 | 25.4 | 2.3 |
| 0.04 | 27.2 | 3.6 | 2.3 | 0.5 | 9.8 | 0.5 |
| 0.01 | 9.5 | 1.8 | 0.6 | 0.1 | 3.6 | 0.5 |
| 0.003 | 3.5 | 0.9 | 0.3 | 0.1 | 0.7 | 0.3 |
| 0.0007 | 0.9 | 0.3 | 0.1 | 1.3 | 0.3 | 0.1 |
| 0.0002 | 0.4 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| 0.00004 | 0.2 | 0.0 | 0.1 | 1.3 | 0.0 | 0.0 |
分析在食蟹獼猴TTR基因中具有相同靶向位點之經修飾sgRNA以評估不同mRNA (mRNA O、mRNA AA)及調配物比率在PCH中之編輯效率。除非另有說明，否則此實例中PCH (In Vitro ADMET Laboratories，10136011)之製備、處理及分析均與實例1中所述相同。使用PCH且以50,000個細胞/孔之密度接種。LNP調配物如實例1中所述地製備。以具有50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比之脂質組成來製備LNP。以約6之脂質胺與RNA磷酸酯(N:P)莫耳比且用表27中所指示之gRNA來調配LNP。100 μL培養基中之PCH用8點、3倍連續稀釋之混合(單獨調配)或共調配的具有各種gRNA:mRNA比率之LNP處理。最高劑量為按重量計3 ng/μL總RNA，且稀釋系列之gRNA:mRNA比率如表43中所指示。樣品均一式三份地進行。平均編輯百分比、標準差(SD)及計算EC50展示於表27及圖21中。
表 27. 在 PCH 中編輯後在 TTR 基因座處之平均插入 / 缺失百分比。
實例 13. 使用 NmeCas9 gRNA 之活體內編輯
| LNP (ng/ μL) | EC50 (ng/ μL) | |||||||||
| 3 | 1 | 0.33 | 0.11 | 0.04 | 0.01 | 0.004 | 0.001 | |||
| G024739:mRNA O LNP 混合2:1 | 平均編輯% | 64 | 64.3 | 45.7 | 25.6 | 6.5 | 1.6 | 0.2 | 0.1 | 0.17 |
| SD | 6.9 | 12.8 | 5.1 | 8.5 | 2.0 | 0.9 | 0.0 | 1.3 | ||
| G024739:mRNA AA LNP 混合2:1 | 平均編輯% | 58.2 | 69.2 | 46.5 | 29.3 | 7.4 | 0.6 | 0.1 | 0.0 | 0.13 |
| SD | 4.5 | 12.2 | 13.8 | 7.6 | 3.3 | 0.3 | 0.0 | 0.0 | ||
| G024739:mRNA AA LNP 混合1:2 | 平均編輯% | 56.5 | 67.1 | 53.4 | 25.4 | 5.8 | 0.7 | 0.1 | 0.0 | 0.13 |
| SD | 4.7 | 10.9 | 16.0 | 11.7 | 2.4 | 0.5 | 0.0 | 0.0 | ||
| G024739:mRNA O 共調配2:1 | 平均編輯% | 61.3 | 59.2 | 47.0 | 27.2 | 7.2 | 0.4 | 0.1 | 0.1 | 0.14 |
| SD | 4.4 | 9.3 | 13.2 | 8.4 | 2.2 | 0.2 | 0.0 | 0.0 | ||
| G024739:mRNA AA 共調配2:1 | 平均編輯% | 58.2 | 69.6 | 56.4 | 35.3 | 7.2 | 1.2 | 0.2 | 0.1 | 0.10 |
| SD | 3.0 | 14.4 | 11.4 | 11.4 | 3.3 | 0.4 | 0.1 | 1.3 | ||
| G024739:mRNA AA 共調配1:2 | 平均編輯% | 47.0 | 62.8 | 56.1 | 38 | 12.3 | 1.3 | 0.1 | 0.1 | 0.07 |
| SD | 5.8 | 10.5 | 15.3 | 13.9 | 4.3 | 0.1 | 0.0 | 1.3 |
在小鼠中用Nme2Cas9構築體測試經修飾gRNA之編輯效率。測試之所有Nme sgRNA均包含靶向小鼠TTR基因(mTTR)之相同24 nt引導序列。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。劑量係基於gRNA及mRNA之組合RNA重量計算。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
在涉及小鼠之各研究中使用約6-8週齡之CD-1雌性小鼠。動物被定期餵食且進行標準維護。在劑量投與之前對動物進行稱重。經由尾部靜脈注射以0.03 mpk之劑量靜脈內投與TSS及LNP調配物。在給藥後至少24小時，定期觀測動物之不良反應。治療後十四天，在異氟醚麻醉下藉由心臟放血將動物安樂死；收集用於血清製備之血液及肝臟組織用於下游分析。
使用血清TTR ELISA-前白蛋白ELISA (Aviva Systems；目錄號OKIA00111)根據製造商之方案對所有實驗組產生表28及圖22中所示之血清TTR含量且相比於陰性對照(TSS)。
表 28 . 血清 TTR 含量 ( μ g/ml) 。
| 引導物ID | 血清TTR ( μg/ml) | SD | %TSS | N |
| TSS | 673.7 | 44.13 | 100 | 5 |
| G021536 | 378.2 | 83.0 | 56.1 | 7 |
| G029377 | 419.3 | 83.5 | 62.2 | 9 |
| G029384 | 270.1 | 63.90 | 40.1 | 4 |
| G029392 | 375.4 | 58.23 | 55.7 | 4 |
| G029391 | 509.1 | 115.3 | 75.6 | 4 |
| G029390 | 623.2 | 144.3 | 92.5 | 4 |
收集重量在5與15 mg之間的肝臟穿孔活檢以分離基因體DNA。使用DNA分離套組(ZymoResearch，D3012)提取基因體DNA且用NGS定序分析樣品，如實例1中所描述。含有指定gRNA之LNP之編輯效率展示於表29中且繪示於圖23中。
表 29. 小鼠肝臟樣品中 TTR 基因座處之平均插入 / 缺失百分比
實例 14. NmeCas9 gRNA 在具有 Nme2Cas9 之 PMH 中之 劑量反應曲線
| 引導物 | 平均編輯% | SD | N |
| TSS | 0.1 | 0 | 5 |
| G021536 | 27.2 | 4.58 | 7 |
| G029377 | 25.7 | 6.77 | 9 |
| G029384 | 34.9 | 4.05 | 4 |
| G029392 | 20.9 | 6.14 | 4 |
| G029391 | 5.4 | 2.60 | 4 |
| G029390 | 5.5 | 3.66 | 4 |
在原代小鼠肝細胞(PMH)中用Nme2Cas9構築體測試經修飾gRNA之編輯效率。測試之所有Nme sgRNA均包含靶向小鼠TTR基因(mTTR)之相同24nt引導序列。
將PMH (Gibco，批號MC931)解凍且再懸浮於肝細胞解凍培養基中，接著離心。丟棄上清液且將粒化細胞再懸浮於具有接種補充劑地塞米松+混合液補充劑(Gibco，目錄號A15563，批號2459010)及FBS內含物(Gibco，目錄號A13450，批號2486425)之肝細胞平板培養基(威廉姆斯氏E培養基(Gibco，目錄號A12176-01))中。對細胞進行計數且以15,000個細胞/孔之濃度接種於經Bio-coat膠原蛋白I塗佈之96孔盤(Corning，參考號356407，批號08722018)上。使接種之細胞在37℃及5% CO
2氛圍下在組織培養恆溫箱中靜置且黏附4-6小時。培育後，檢查細胞之單層形成且用具有平板培養基補充劑(Gibco，目錄號A15564，批號2459014)之肝細胞維持培養基(威廉姆斯氏E培養基)洗滌一次。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。如表30中所示，在最高劑量(300 ng mRNA O及46.5 nM gRNA (約150 ng gRNA))下使用自450 ng總負荷/100 µl孔開始之8點3倍連續稀釋將各LNP施加至細胞。用LNP處理後，將細胞在含有平板培養基補充劑(Gibco，目錄號A15564，批號2459014)及3%胎牛血清之威廉姆斯氏E培養基中在37℃下培育24小時。72小時後，收集細胞且藉由NGS進行分析，如實例1中所述。
含有指定gRNA之LNP之編輯效率及各自之對應EC50展示於表30中且繪示於圖24中。
表 30. 原代小鼠肝細胞中 TTR 基因座處之平均插入 / 缺失百分比。
實例 15. NmeCas9 gRNA 在具有 Nme2Cas9 之 PMH 中之劑量反應曲線
| 引導物 | 插入/ 缺失% | nM gRNA | EC50 (nM gRNA) | |||||||
| 46.5 | 15.5 | 5.1 | 1.7 | 0.5 | 0.19 | 0.064 | 0.02 | |||
| G021536 | 平均值 | 97.20 | 97.83 | 97.73 | 96.75 | 95.55 | 83.83 | 48.33 | 15.53 | 0.071 |
| SD | 0.63 | 0.25 | 0.45 | 1.70 | 0.50 | 2.17 | 4.99 | 0.90 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||
| G029377 | 平均值 | 96.65 | 96.68 | 96.90 | 96.73 | 93.63 | 83.65 | 46.88 | 16.73 | 0.075 |
| SD | 0.82 | 1.42 | 1.04 | 0.59 | 2.40 | 1.92 | 3.14 | 1.05 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||
| G029380 | 平均值 | 95.90 | 97.00 | 96.08 | 95.55 | 88.38 | 62.00 | 22.85 | 5.38 | 0.136 |
| SD | 2.27 | 0.99 | 1.23 | 1.28 | 2.04 | 0.84 | 1.47 | 1.05 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||
| G029379 | 平均值 | 97.13 | 96.75 | 96.43 | 95.20 | 90.65 | 62.20 | 22.00 | 5.33 | 0.139 |
| SD | 0.49 | 1.33 | 1.11 | 1.16 | 1.61 | 1.47 | 1.64 | 0.43 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||
| G029378 | 平均值 | 95.88 | 97.00 | 96.05 | 94.90 | 87.05 | 53.03 | 16.28 | 3.40 | 0.172 |
| SD | 1.54 | 0.94 | 1.15 | 1.56 | 2.00 | 2.00 | 1.37 | 0.86 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||
| G029381 | 平均值 | 97.08 | 96.05 | 96.65 | 95.50 | 87.90 | 52.28 | 16.83 | 3.40 | 0.175 |
| SD | 0.82 | 1.95 | 0.93 | 0.94 | 1.71 | 3.03 | 2.35 | 0.48 | ||
| N | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
在原代小鼠肝細胞(PMH)中用Nme2Cas9構築體測試經修飾gRNA之編輯效率。測試之所有Nme sgRNA均包含靶向小鼠TTR基因(mTTR)之相同24nt引導序列。
將PMH (Gibco，批號MC931)解凍且再懸浮於肝細胞解凍培養基中，接著離心。丟棄上清液且將粒化細胞再懸浮於具有接種補充劑地塞米松+混合液補充劑(Gibco，目錄號A15563，批號2459010)及FBS內含物(Gibco，目錄號A13450，批號2486425)之肝細胞平板培養基(威廉姆斯氏E培養基(Gibco，目錄號A12176-01))中。對細胞進行計數且以15,000個細胞/孔之濃度接種於經Bio-coat膠原蛋白I塗佈之96孔盤(Corning，參考號356407，批號08722018)上。使接種之細胞在37℃及5% CO
2氛圍下在組織培養恆溫箱中靜置且黏附4-6小時。培育後，檢查細胞之單層形成且用具有平板培養基補充劑(Gibco，目錄號A15564，批號2459014)之肝細胞維持培養基(威廉姆斯氏E培養基)洗滌一次。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。如表31中所示，在最高劑量(300 ng mRNA O及46.5 nM gRNA (亦即，150 ng gRNA))下使用自450 ng總負荷/100 µl孔開始之8點3倍連續稀釋將各LNP施加至細胞。用LNP處理後，將細胞在含有平板培養基補充劑(Gibco，目錄號A15564，批號2459014)及3%胎牛血清之威廉姆斯氏E培養基中在37℃下培育24小時。一式兩份地操作樣品。72小時後，收集細胞且藉由NGS進行分析，如實例1中所述。
含有指定gRNA之LNP之編輯效率及各自之對應EC50展示於表31中且繪示於圖25中。
表 31. 原代小鼠肝細胞中 TTR 基因座處之平均插入 / 缺失百分比。
實例 16. 使用稀釋曲線在原代小鼠肝細胞 (PMH) 中進行活體外編輯A. 實例16.1. 使用稀釋系列進行經修飾sgRNA評估
| 引導物 | 插入/ 缺失% | nM gRNA | EC50 | |||||||
| (nM gRNA) | ||||||||||
| 46.5 | 15.5 | 5.1 | 1.7 | 0.5 | 0.19 | 0.064 | 0.02 | |||
| G029384 | 平均值 | 96.70 | 97.30 | 96.57 | 95.37 | 92.70 | 78.67 | 43.77 | 13.87 | 0.077 |
| SD | 0.85 | 0.52 | 1.71 | 1.01 | 1.95 | 3.73 | 4.00 | 1.50 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G021536 | 平均值 | 97.13 | 96.91 | 96.58 | 95.77 | 90.42 | 73.29 | 36.63 | 10.49 | 0.092 |
| SD | 0.00 | 0.23 | 0.03 | 0.76 | 1.26 | 1.96 | 1.53 | 0.10 | ||
| N | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | ||
| G029383 | 平均值 | 96.93 | 96.83 | 96.13 | 94.37 | 90.50 | 73.20 | 34.77 | 9.07 | 0.094 |
| SD | 0.90 | 1.08 | 2.21 | 2.75 | 3.05 | 2.92 | 2.23 | 0.91 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029388 | 平均值 | 96.60 | 97.03 | 96.67 | 95.23 | 89.63 | 71.13 | 34.07 | 9.90 | 0.100 |
| SD | 0.95 | 0.98 | 2.05 | 2.80 | 0.76 | 2.75 | 3.74 | 3.12 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029392 | 平均值 | 96.57 | 95.87 | 96.60 | 95.23 | 90.30 | 72.50 | 31.13 | 6.87 | 0.101 |
| SD | 1.47 | 2.03 | 1.47 | 2.72 | 3.15 | 1.56 | 1.74 | 0.81 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029382 | 平均值 | 96.83 | 97.37 | 96.50 | 95.87 | 89.43 | 69.10 | 33.80 | 9.87 | 0.104 |
| SD | 0.67 | 0.47 | 1.30 | 1.12 | 3.41 | 4.92 | 4.06 | 0.61 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029386 | 平均值 | 97.17 | 97.20 | 96.23 | 95.80 | 91.70 | 71.53 | 32.57 | 9.43 | 0.105 |
| SD | 0.55 | 1.13 | 0.38 | 1.32 | 0.95 | 0.61 | 1.62 | 0.93 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029385 | 平均值 | 96.80 | 95.90 | 96.67 | 94.87 | 87.83 | 66.95 | 25.60 | 7.20 | 0.123 |
| SD | 0.80 | 0.14 | 1.23 | 1.53 | 3.11 | 2.47 | 2.52 | 0.87 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029387 | 平均值 | 94.07 | 95.65 | 95.23 | 94.00 | 81.90 | 56.83 | 22.67 | 5.97 | 0.149 |
| SD | 0.15 | 0.35 | 0.71 | 0.56 | 2.69 | 1.80 | 0.47 | 0.49 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029391 | 平均值 | 95.70 | 95.77 | 95.43 | 94.30 | 85.40 | 56.03 | 19.83 | 4.70 | 0.156 |
| SD | 1.40 | 2.49 | 2.98 | 2.96 | 3.03 | 2.62 | 2.40 | 0.69 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029389 | 平均值 | 96.80 | 96.40 | 95.87 | 94.60 | 85.53 | 54.23 | 17.63 | 3.40 | 0.164 |
| SD | 1.14 | 0.99 | 2.32 | 1.93 | 2.16 | 4.05 | 1.75 | 0.62 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||
| G029390 | 平均值 | 96.00 | 95.40 | 94.60 | 93.07 | 77.60 | 42.13 | 11.70 | 2.20 | 0.219 |
| SD | 1.49 | 3.49 | 3.97 | 2.97 | 2.29 | 4.10 | 2.49 | 0.70 | ||
| N | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
如表1-2中所示地設計具有各種骨架結構之經修飾sgRNA，其全部靶向小鼠pcsk9基因中先前公佈之位點(參見WO2019094791)，且使用原代小鼠肝細胞(PMH)測試編輯效率。使用PMH細胞(In Vitro ADMET Laboratories)如實例1中所述地製備細胞且以20,000個細胞/孔之密度接種。根據製造商之方案使用MessengerMax (Invitrogen)以1 ng/µl Nme2 Cas9 mRNA (mRNA U)及表32中所指示濃度之sgRNA轉染細胞。分析中包括重複樣品。在轉染後72小時收集細胞且藉由NGS進行分析，如實例1中所述。具有標準差之平均編輯百分比展示於表32及圖26中。
表 32. PMH 中之平均編輯百分比
B. 實例16.2. mRNA poly-A尾修飾及負荷比率之評估
| 引導物濃度(nM) | G017564 | G017565 | G017566 | |||
| 平均編輯% | SD | 平均編輯% | SD | 平均編輯% | SD | |
| 50.0 | 25.7 | 3.2 | 25.6 | 4.9 | 27.7 | 0.4 |
| 25.0 | 27.8 | 1.4 | 20.0 | 1.7 | 26.4 | 4.7 |
| 12.5 | 15.3 | 1.7 | 12.9 | 0.8 | 18.2 | 1.7 |
| 6.3 | 10.6 | 0.6 | 8.7 | 0.9 | 12.6 | 0.9 |
| 3.1 | 5.3 | 0.2 | 3.6 | 0.3 | 6.7 | 0.7 |
| 1.6 | 5.0 | 1.1 | 3.6 | 0.6 | 4.8 | 0.2 |
| 0.8 | 1.3 | 0.5 | 0.2 | 0.1 | 2.8 | 0.3 |
| 0.4 | 0.8 | 0.3 | 0.5 | 0.1 | 1.8 | 0.1 |
| 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.7 | 0.1 |
| 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 |
| 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.3 | 0.1 |
靶向小鼠psck9基因之sgRNA選自表32以評估由poly-A尾修飾及sgRNA:mRNA比率之特定組合產生的引導物編輯效率。除非另外指出，否則如實例1中所述地製備、處理及分析所用PMH細胞。以15,000個細胞/孔之密度接種PMH (Gibco)。
LNP一般如實例1所述來製備。LNP以50/9/38/3之脂質組成製備，分別表示為可離子化脂質A/膽固醇/DSPC/PEG之莫耳比。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。LNP囊封gRNA G017566或編碼相同Nme2Cas9開放閱讀框架(ORF)但具有不同經編碼poly-A尾之三種mRNA中之一者，如表33中所指示。保持sgRNA施用恆定且改變mRNA施用量之初步實驗表明，按重量計1:1之sgRNA:mRNA比率產生最高編輯百分比。在當前實例中，將增加劑量之mRNA LNP及gRNA LNP施加至如表33中所述之100 µl培養基中之細胞，維持按重量計1:1之sgRNA:mRNA比率。表33及圖27顯示平均編輯百分比及標準差(SD)。
表 33. PMH 中之平均編輯百分比
實例 17. NmeCas9 gRNA 在具有 Nme2Cas9 之 PMH 中之 劑量反應曲線
| 總RNA (ng) | mRNA CSEQ ID NO: 622 | mRNA B SEQ ID NO:621 | mRNA D SEQ ID NO: 623 | |||
| 平均編輯% | SD | 平均編輯% | SD | 平均編輯% | N | |
| 333. | 49.1 | 0.9 | 44.3 | 0.0 | 39.6 | 1 |
| 111. | 37.5 | 3.2 | 43.4 | 0.2 | 30.3 | 1 |
| 37. | 12.8 | 0.2 | 15.6 | 1.0 | 9.3 | 1 |
| 12.3 | 1.3 | 0.2 | 2.2 | 0.0 | 1.1 | 1 |
| 4.1 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 1 |
| 1.4 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 1 |
| 0.5 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 1 |
在原代小鼠肝細胞(PMH)中用Nme2Cas9構築體測試經修飾gRNA之編輯效率。測試之所有Nme sgRNA均包含靶向小鼠TTR基因(mTTR)之相同24nt引導序列。
將PMH (Gibco，批號MC931)解凍且再懸浮於含有接種補充劑(威廉姆斯氏E培養基(Gibco，目錄號A12176-01))與地塞米松+混合液補充劑(Gibco，目錄號A15563，批號2019842)及具有FBS內含物之接種補充劑(Gibco，目錄號A13450，批號1970698)之肝細胞解凍培養基中，接著離心。丟棄上清液，且將粒化細胞再懸浮於肝細胞平板培養基加補充劑包(Invitrogen，目錄號A1217601及Gibco，目錄號CM3000)中。對細胞進行計數且以15,000個細胞/孔之濃度接種於經Bio-coat膠原蛋白I塗佈之96孔盤(Thermo Fisher，目錄號877272)上。使接種之細胞在37℃及5% CO
2氛圍下在組織培養恆溫箱中靜置且黏附4-6小時。培育後，檢查細胞之單層形成，且用肝細胞維持培養基(Invitrogen, 目錄號A1217601及Gibco, 目錄號CM4000)洗滌一次。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。使用自300 ng總RNA/100 µl孔(約32.25 nM gRNA濃度/孔)開始之8點4倍連續稀釋將各LNP施加至細胞，如表32中所示。用LNP處理後，將細胞在含有維持補充劑及3%胎牛血清之威廉姆斯氏E培養基(Gibco，A1217601)中在37℃下培育24小時。樣品均一式三份地進行。72小時後，收集細胞且藉由NGS進行分析，如實例1中所述。
含有指定gRNA之LNP之編輯效率及各自之對應EC50展示於表34中且繪示於圖28中。
表 34. 原代小鼠肝細胞中 TTR 基因座處之平均插入 / 缺失百分比。
實例 18. 使用 NmeCas9 gRNA 之活體內編輯
| 引導物 | 插入/ 缺失% | ng RNA | EC50 (ng RNA) | |||||||
| 300 | 75 | 18.75 | 4.68 | 1.17 | 0.29 | 0.07 | 0 | |||
| G021536 | 平均值 | 97.7 | 96.4 | 90.9 | 43.1 | 13.9 | 1.3 | 0.3 | 0.0 | 5.23 |
| SD | 0.5 | 0.3 | 5.0 | 10.1 | 6.5 | 0.7 | 0.1 | 0.0 | ||
| G021844 | 平均值 | 96.7 | 96.9 | 93.8 | 60.6 | 27.2 | 4.0 | 0.5 | 0.3 | 2.86 |
| SD | 0.8 | 0.3 | 1.9 | 7.5 | 13.4 | 2.7 | 0.3 | 0.1 | ||
| G027492 | 平均值 | 97.1 | 96.5 | 95.2 | 64.3 | 30.2 | 6.2 | 0.5 | 0.0 | 2.49 |
| SD | 1.4 | 0.4 | 1.6 | 13.4 | 15.9 | 3.5 | 0.4 | 0.1 | ||
| G027493 | 平均值 | 96.5 | 94.9 | 82.7 | 32.4 | 8.6 | 0.9 | 0.0 | 0.0 | 6.95 |
| SD | 0.1 | 0.6 | 6.4 | 6.2 | 5.5 | 0.8 | 0.1 | 0.0 | ||
| G027494 | 平均值 | 96.0 | 91.7 | 78.3 | 19.6 | 6.7 | 0.7 | 0.0 | 0.0 | 9.06 |
| SD | 1.0 | 2.2 | 8.9 | 7.6 | 4.0 | 0.4 | 0.1 | 0.0 | ||
| G027495 | 平均值 | 96.0 | 94.6 | 83.8 | 22.0 | 11.6 | 1.8 | 0.2 | 0.1 | 8.31 |
| SD | 0.5 | 1.8 | 6.8 | 9.5 | 7.3 | 1.8 | 0.1 | 0.1 | ||
| G027496 | 平均值 | 96.2 | 93.2 | 77.8 | 13.2 | 5.4 | 0.4 | 0.1 | 0.0 | 10.22 |
| SD | 0.7 | 2.9 | 8.4 | 3.4 | 2.7 | 0.4 | 0.1 | 0.0 |
在小鼠中用Nme2Cas9構築體測試經修飾gRNA之編輯效率。測試之所有Nme sgRNA均包含靶向小鼠TTR基因(mTTR)之相同24 nt引導序列。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。劑量係基於gRNA及mRNA之組合RNA重量計算。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
在涉及小鼠之各研究中使用約6-8週齡之CD-1雌性小鼠(所有組之n=5)。動物被定期餵食且進行標準維護。在劑量投與之前對動物進行稱重。經由尾部靜脈注射以0.03 mpk之劑量靜脈內投與TSS及LNP調配物。在給藥後至少24小時，定期觀測動物之不良反應。治療後七天，在異氟醚麻醉下藉由心臟放血將動物安樂死；收集用於血清製備之血液及肝臟組織用於下游分析。
使用血清TTR ELISA-前白蛋白ELISA (Aviva Systems；目錄號OKIA00111)根據製造商之方案產生表35及圖29中所示之血清TTR含量。相比於陰性對照(TSS)，所有實驗組中之血清TTR含量顯著較低。
表 35. 血清 TTR 含量 ( μ g/ml) 。
| 引導物ID | 血清TTR ( μg/ml) | SD | %TSS |
| TSS | 704.9 | 98.3 | 100% |
| G021844 | 150.0 | 84.9 | 21% |
| G021536 | 371.1 | 95.6 | 53% |
| G027492 | 239.4 | 30.5 | 34% |
| G027493 | 423.4 | 170.0 | 60% |
| G027494 | 496.3 | 89.8 | 70% |
| G027495 | 263.6 | 68.9 | 37% |
| G027496 | 362.4 | 52.7 | 51% |
收集重量在5與15 mg之間的肝穿孔活檢以分離基因體DNA。使用DNA分離套組(ZymoResearch，D3012)提取基因體DNA且用NGS定序分析樣品(所有組之n=5)，如實例1中所描述。含有指定gRNA之LNP之編輯效率展示於表36中且繪示於圖30中。
表 36. 小鼠肝臟樣品中 TTR 基因座處之平均插入 / 缺失百分比。
實例 19. 使用 NmeCas9 gRNA 之活體內編輯
| 引導物 | 平均值 | SD |
| TSS | 0.12 | 0.22 |
| G021844 | 57.1 | 5.7 |
| G021536 | 31.5 | 4.9 |
| G027492 | 51.3 | 10.4 |
| G027493 | 27.0 | 14.0 |
| G027494 | 17.6 | 8.6 |
| G027495 | 43.2 | 7.2 |
| G027496 | 23.5 | 8.6 |
在小鼠中用Nme2Cas9 mRNA測試經修飾gRNA之編輯效率。所測試之所有Nme sgRNA均包含靶向mTTR之相同24nt引導序列。
LNP一般如實例1中所描述以按gRNA與mRNA O之重量計1:2之負荷來製備。以50%脂質A、38%膽固醇、9% DSPC及3% PEG2k-DMG之莫耳比來製備所使用之LNP。用約6之脂質胺與RNA磷酸酯(N:P)莫耳比來調配LNP。劑量係基於gRNA及mRNA之組合RNA重量計算。用於LNP製備之運輸及儲存溶液(TSS)在實驗中作為僅媒劑陰性對照給藥。
在涉及小鼠之各研究中使用約6週齡之CD-1雌性小鼠(所有組之n=5)。在劑量投與之前對動物稱重以用於劑量計算，且在投與後24小時對動物稱重以用於監測。經由尾部靜脈注射以0.01 mpk或0.03 mpk之劑量靜脈內投與TSS及LNP調配物。在給藥後至少24小時，定期觀測動物之不良反應。治療後七天，藉由在異氟醚麻醉下心臟放血使動物安樂死。藉由心臟穿刺收集血液用於血清TTR ELISA，且收集肝組織用於下游分析。
使用血清TTR ELISA-前白蛋白ELISA (Aviva Systems；目錄號OKIA00111)根據製造商之方案製備之血清TTR結果展示於圖31及表37中。
表 37. 治療之後的血清 TTR 量測結果。
| 引導物ID | 劑量(mpk) | 血清TTR ( μg/ml) | SD | N |
| 媒劑 | 663.5 | 61.5 | 5 | |
| G021844 | 0.01 | 585.5 | 166.1 | 5 |
| 0.03 | 205.8 | 99.2 | 5 | |
| G021536 | 0.01 | 749.2 | 425.3 | 5 |
| 0.03 | 252.6 | 50.2 | 4 | |
| G027492 | 0.01 | 527.4 | 163.1 | 4 |
| 0.03 | 266.0 | 92.4 | 5 | |
| G027495 | 0.01 | 626.9 | 157.7 | 5 |
| 0.03 | 310.0 | 118.1 | 5 |
收集重量為約5mg-15mg之肝臟穿孔活檢以分離基因體DNA及總RNA。使用DNA分離套組(ZymoResearch，D3012)提取基因體DNA且用NGS定序分析樣品(所有組之n=5)，如實例1中所描述。含有指定gRNA之LNP之編輯效率展示於表38中且繪示於圖32中。
表 38. 小鼠肝臟樣品中 TTR 基因座處之平均插入 / 缺失百分比。
實例 20. 額外實施例
| 引導物ID | 劑量 | 平均值 | SD | N |
| 媒劑 | 0.00 | 0.1 | 0.07 | 5 |
| G021844 | 0.01 | 19.7 | 2.9 | 5 |
| 0.03 | 49.6 | 7.9 | 5 | |
| G021536 | 0.01 | 10.7 | 4.7 | 5 |
| 0.03 | 34.4 | 4.1 | 4 | |
| G027492 | 0.01 | 21.1 | 9.2 | 4 |
| 0.03 | 44.6 | 9.4 | 5 | |
| G027495 | 0.01 | 9.3 | 2.6 | 4 |
| 0.03 | 30.2 | 10.9 | 5 |
以下編號條項提供對本文實施例之額外支持及描述。
第1項為包含開放閱讀框架(ORF)之多核苷酸，該ORF包含：編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致，其中Nme Cas9為Nme2 Cas9、Nme1 Cas9或Nme3 Cas9；及編碼第一核定位信號(NLS)之核苷酸序列。
第2項為如第1項之多核苷酸，其中ORF進一步包含編碼第二NLS之核苷酸序列。
第3項為如第1項之多核苷酸，其中第一及第二NLS獨立地選自SEQ ID NO: 388及410-422。
第4項為如前述項中任一項之多核苷酸，其中該多核苷酸進一步包含polyA序列或聚腺苷酸化信號序列。
第5項為如第4項之多核苷酸，其中polyA序列包含非腺嘌呤核苷酸。
第6項為如第4-5項中任一項之多核苷酸，其中polyA序列包含100-400個核苷酸。
第7項為如第4-6中任一項之多核苷酸，其中polyA序列包含SEQ ID NO: 409之序列。
第8項為如前述項中任一項之多核苷酸，其中ORF進一步包含編碼第一NLS與第二NLS之間的連接子序列之核苷酸序列。
第9項為如如前述項中任一項之多核苷酸，其中該ORF進一步包含編碼Nme Cas9編碼序列與接近Nme Cas9編碼序列之NLS之間的連接子間隔序列的核苷酸序列。
第10項為如第8-9項中任一項之多核苷酸，其中該連接子包含至少1個、至少2個、至少3個、至少4個、至少5個、至少6個、至少7個、至少8個、至少9個或至少10個胺基酸。
第11項為如第8-10項中任一項之多核苷酸，其中該連接子序列包含GGG或GGGS，視情況其中該GGG或GGGS序列位於該間隔序列之N末端處。
第12項為如第8-11項中任一項之多核苷酸，其中連接子序列包含SEQ ID NO: 61-122中之任一者之序列。
第13項為如前述項中任一項之多核苷酸，其中ORF進一步包含一或多個額外異源功能域。
第14項為如前述項中任一項之多核苷酸，其中Nme Cas9具有雙股核酸內切酶活性。
第15項為如第1-14項中任一項之多核苷酸，其中Nme Cas9具有切口酶活性。
第16項為如第1-14項中任一項之多核苷酸，其中該Nme Cas9包含dCas9 DNA結合域。
第17項為如前述項中任一項之多核苷酸，其中NmeCas9包含與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315中之任一者具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%之胺基酸序列。
第18項為如前述項中任一項之多核苷酸，其中NmeCas9包含SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315之胺基酸序列。
第19項為如前述項中任一項之多核苷酸，其中編碼NmeCas9之序列包含與SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者之核苷酸序列具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%一致性之核苷酸序列。
第20項為如前述項中任一項之多核苷酸，其中編碼NmeCas9之序列包含SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中之任一者之核苷酸序列。
第21項為包含編碼多肽之開放閱讀框架(ORF)之多核苷酸，該多肽包含：胞苷脫胺酶，其視情況為APOBEC3A脫胺酶；編碼C末端奈瑟氏腦膜炎菌(Nme) Cas9切口酶多肽之核苷酸序列，其與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297中之任一者至少90%一致，其中Nme Cas9切口酶為Nme2 Cas9切口酶、Nme1 Cas9切口酶或Nme3 Cas9切口酶；及編碼第一核定位信號(NLS)之核苷酸序列；其中多肽不包含尿嘧啶醣苷酶抑制劑(UGI)。
第22項為如第21項之多核苷酸，其中ORF進一步包含編碼第二NLS之核苷酸序列。
第23項為如第21-22項中任一項之多核苷酸，其中該脫胺酶位於該多肽中之NLS的N末端。
第24項為如第21-23項中任一項之多核苷酸，其中胞苷脫胺酶位於多肽中之第一NLS及第二NLS之N末端。
第25項為如第21-22項中任一項之多核苷酸，其中胞苷脫胺酶位於該多肽中之NLS的C末端。
第26項為如第23-25項中任一項之多核苷酸，其中胞苷脫胺酶位於多肽中之第一NLS及第二NLS之C末端。
第27項為如第21-26項中任一項之多核苷酸，其中ORF不包含位於編碼Nme Cas9之ORF之C末端的NLS之編碼序列。
第28項為如第21-26項中任一項之多核苷酸，其中ORF不包含位於編碼Nme Cas9之ORF之C末端的編碼序列。
第29項為如前述項中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 151具有至少87%一致性之胺基酸序列。
第30項為如前述項中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 152-216具有至少80%一致性之胺基酸序列。
第31項為如前述項中任一項之多核苷酸，其中胞苷脫胺酶包含與SEQ ID NO: 14具有至少80%一致性之胺基酸序列。
第32項為如前述項中任一項之多核苷酸，ORF包含與SEQ ID NO: 42具有至少80%一致性之核苷酸序列。
第33項為如前述項中任一項之多核苷酸，其中多核苷酸包含與SEQ ID NO: 391-398中之任一者具有至少90%一致性之5' UTR。
第34項為如前述項中任一項之多核苷酸，其中多核苷酸含有包含SEQ ID NO: 391-398中之任一者的5' UTR。
第35項為如前述項中任一項之多核苷酸，其中多核苷酸包含與SEQ ID NO: 399-406中之任一者具有至少90%一致性的3' UTR。
第36項為如前述項中任一項之多核苷酸，其中多核苷酸含有包含SEQ ID NO: 399-306中之任一者的3' UTR。
第37項為如前述項中任一項之多核苷酸，其中多核苷酸包含來自相同來源之5' UTR及3' UTR。
第38項為如前述項中任一項之多核苷酸，其中多核苷酸包含5'帽，視情況其中5'帽為Cap0、Cap1或Cap2。
第39項為如前述項中任一項之多核苷酸，其中ORF之至少75%、80%、85%、90%、95%、98%、99%或100%的密碼子為最小腺嘌呤密碼子或最小尿苷密碼子。
第40項為如前述項中任一項之多核苷酸，其中ORF包含增加哺乳動物中mRNA之轉譯的密碼子或由其組成。
第41項為如前述項中任一項之多核苷酸，其中ORF包含增加人類中mRNA之轉譯的密碼子或由其組成。
第42項為如前述項中任一項之多核苷酸，其中多核苷酸為mRNA。
第43項為如第42項之多核苷酸，其中ORF包含與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者具有至少90%、95%、98%或100%一致性之序列。
第44項為如第42-43項中任一項之多核苷酸，其中mRNA中至少10%之尿苷經經修飾之尿苷取代。
第45項為如第42-43項中任一項之多核苷酸，其中mRNA中小於10%之尿苷經經修飾之尿苷取代。
第46項為如第45項之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷、假尿苷、5-甲氧基尿苷或5-碘尿苷中之一或多者。
第47項為如第45項之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷或5-甲氧基尿苷中之一或兩者。
第48項為如第45-47項中任一項之多核苷酸，其中經修飾之尿苷為N1-甲基-假尿苷。
第49項為如第45-47項中任一項之多核苷酸，其中經修飾之尿苷為5-甲氧基尿苷。
第50項為如第44及36-49項中任一項之多核苷酸，其中15%至45%之尿苷經經修飾之尿苷取代。
第51項為如第50項之多核苷酸，其中至少20%或至少30%之尿苷經經修飾之尿苷取代。
第52項為如第51項之多核苷酸，其中至少80%或至少90%之尿苷經經修飾之尿苷取代。
第53項為如第52項之多核苷酸，其中100%之尿苷經經修飾之尿苷取代。
第54項為如第42項之多核苷酸，其中mRNA中小於10%之核苷酸經經修飾之核苷酸取代。
第55項為一種組合物，其包含如前述項中任一項之多核苷酸及至少一個引導RNA (gRNA)。
第56項為一種組合物，其包含第一多核苷酸，該第一多核苷酸包含編碼包含胞苷脫胺酶，視情況APOBEC3A脫胺酶，及NmeCas9切口酶之多肽的第一開放閱讀框架(ORF)，及第二多核苷酸，該第二多核苷酸包含編碼尿嘧啶醣苷酶抑制劑(UGI)之第二開放閱讀框架，其中第二多核苷酸不同於第一多核苷酸，且視情況進一步包含引導RNA (gRNA)。
第57項為如第55或56項之組合物，其中gRNA為單引導RNA。
第58項為如第55或56項之組合物，其中gRNA為雙引導RNA。
第59項為一種組合物，其包含如第1-57項中任一項之多核苷酸，進一步包含單引導RNA，其中單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-48及53-64中之一或多者缺失，且視情況核苷酸37-64中之一或多者經取代；及
(ii)核苷酸36藉由至少2個核苷酸連接至核苷酸65；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-86及91-95中之一或多者缺失，且視情況位置82-96中之一或多者經取代；且
(ii)核苷酸81藉由至少4個核苷酸連接至核苷酸96；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-121及126-134中之一或多者缺失，且視情況核苷酸113-134中之一或多者經取代；且
(ii)核苷酸112藉由至少4個核苷酸連接至核苷酸135；
其中相對於SEQ ID NO: 500，核苷酸144-145中之一或兩者視情況缺失；
其中至少10個核苷酸為經修飾之核苷酸。
第60項為一種組合物，其包含如第1-57項中任一項之多核苷酸，進一步包含單引導RNA，其中單引導RNA包含引導區及保守區，其中保守區包含以下中之一或多者：
(a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸37-64中之一或多者缺失且視情況經取代；且
(ii)核苷酸36藉由以下各者連接至核苷酸65：(i)單獨或與核苷酸組合取代4個核苷酸之第一內部連接子，或(ii)至少4個核苷酸；或
(b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸82-95中之一或多者缺失且視情況經取代；且
(ii)核苷酸81藉由以下各者連接至核苷酸96：(i)單獨或與核苷酸組合取代4個核苷酸之第二內部連接子，或(ii)至少4個核苷酸；或
(c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中
(i)相對於SEQ ID NO: 500，核苷酸113-134中之一或多者缺失且視情況經取代；且
(ii)核苷酸112藉由以下各者連接至核苷酸135：(i)單獨或與核苷酸組合取代4個核苷酸之第三內部連接子，或(ii)至少4個核苷酸；
其中相比於SEQ ID NO: 500，核苷酸144-145中之一者或兩者視情況缺失；
其中該gRNA包含該第一內部連接子、該第二內部連接子及該第三內部連接子中之至少一者。
第61項為由如第1-60項中任一項之多核苷酸編碼的多肽。
第62項係一種載體，其包含如第1-60項中任一項之多核苷酸。
第63項為一種表現構築體，其包含啟動子可操作地連接於編碼如第1-60項中任一項之多核苷酸之序列。
第64項為一種質體，其包含如第63項之表現構築體。
第65項為一種宿主細胞，其包含如第62項之載體、如第63項之表現構築體或如第64項之質體。
第66項為一種醫藥組合物，其包含如前述項中任一項之多核苷酸、組合物或多肽及醫藥學上可接受之載劑。
第67項為一種套組，其包含如前述項中任一項之多核苷酸、組合物或多肽。
第68項為如前述項中任一項之多核苷酸、組合物或多肽之用途，其用於修飾細胞中之目標基因。
第69項為如前述項中任一項之多核苷酸、組合物或多肽之用途，其用於製造修飾細胞中之目標基因之藥劑。
第70項為如前述項中任一項之多核苷酸或組合物，其中多核苷酸或組合物調配為脂質核酸組裝組合物，視情況脂質奈米粒子。
第71項為一種修飾目標基因之方法，其包含向細胞遞送如前述項中任一項之多核苷酸、多肽或組合物。
第72項為一種修飾目標基因之方法，其包含向細胞遞送一或多種包含如第1-60項中任一項之多核苷酸及一或多種引導RNA之脂質核酸組裝組合物，視情況脂質奈米粒子。
第73項為如第71-72項中任一項之方法，其中至少一種脂質核酸組裝組合物包含脂質奈米粒子(LNP)，視情況其中所有脂質核酸組裝組合物包含LNP。
第74項為如第71-72項中任一項之方法，其中至少一種脂質核酸組裝組合物為脂複合體(lipoplex)組合物。
第75項為如第72-74項中任一項之組合物或方法，其中脂質核酸組裝組合物包含可離子化脂質。
表 39A. 序列表
以下序列表提供本文揭示之序列的清單。應理解，若相對於RNA提及DNA序列(包含Ts)，則Ts應經Us (取決於上下文，其可經修飾或未經修飾)置換，且反之亦然。*=PS鍵聯；『m』=2'-O-Me核苷酸。對於ORF描述，BP=I-對耗盡；GP=E-對富集；BS=I-單一耗盡；GS=E-單一富集；GCU=經受最小化尿苷、最小化重複及最大化GC含量之步驟。E-對、I-對、E-單一及I-單一分別係指表1-4之密碼子對或密碼子。
表 39B. 額外序列
| 描述 | SEQ ID NO | 序列 |
| 由mRNA C編碼之Nme2Cas9之胺基酸序列 | 1 | MTGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE |
| 由mRNA E編碼之SpyCas9鹼基編輯劑之胺基酸序列 | 2 | MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGGGSPKKKRKV |
| 由mRNA G編碼之UGI之胺基酸序列 | 3 | MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSKRTADGSEFESPKKKRKVE |
| 由mRNA H編碼之Nme2Cas9之胺基酸序列 | 4 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKSGGGSPKKKRKVSGGSGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA I編碼之Nme2Cas9之胺基酸序列 | 5 | MVPKKKRKVAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRYPYDVPDYAAAPAAKKKKLD |
| 由mRNA J編碼之Nme2Cas9之胺基酸序列 | 6 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA K編碼之Nme2Cas9之胺基酸序列 | 7 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA L編碼之Nme2Cas9之胺基酸序列 | 8 | MDGSGGGSPKKKRKVGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA M編碼之具有HiBiT標籤之Nme2Cas9的胺基酸序列 | 9 | MDGSGGGSPKKKRKVGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS |
| 由mRNA N編碼之Nme2Cas9之胺基酸序列 | 10 | MDGSGGGSPKKKRKVGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSGGGSPAAKKKKLD |
| 由mRNA O編碼之Nme2Cas9之胺基酸序列 | 11 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA P編碼之具有HiBiT標籤之Nme2Cas9的胺基酸序列 | 12 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS |
| 由mRNA Q編碼之Nme2Cas9之胺基酸序列 | 13 | MDGSGGGSEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 由mRNA R編碼之Nme2Cas9鹼基編輯劑之胺基酸序列 | 14 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 編碼Nme2Cas9之mRNA C | 15 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCGGUGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCGACGGCUCCGAGUUCGAGUCCCCCAAGAAGAAGCGGAAGGUGGAGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAA |
| 編碼SpyCas9鹼基編輯劑之mRNA E | 16 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGAGGCCUCCCCCGCCUCCGGCCCCCGGCACCUGAUGGACCCCCACAUCUUCACCUCCAACUUCAACAACGGCAUCGGCCGGCACAAGACCUACCUGUGCUACGAGGUGGAGCGGCUGGACAACGGCACCUCCGUGAAGAUGGACCAGCACCGGGGCUUCCUGCACAACCAGGCCAAGAACCUGCUGUGCGGCUUCUACGGCCGGCACGCCGAGCUGCGGUUCCUGGACCUGGUGCCCUCCCUGCAGCUGGACCCCGCCCAGAUCUACCGGGUGACCUGGUUCAUCUCCUGGUCCCCCUGCUUCUCCUGGGGCUGCGCCGGCGAGGUGCGGGCCUUCCUGCAGGAGAACACCCACGUGCGGCUGCGGAUCUUCGCCGCCCGGAUCUACGACUACGACCCCCUGUACAAGGAGGCCCUGCAGAUGCUGCGGGACGCCGGCGCCCAGGUGUCCAUCAUGACCUACGACGAGUUCAAGCACUGCUGGGACACCUUCGUGGACCACCAGGGCUGCCCCUUCCAGCCCUGGGACGGCCUGGACGAGCACUCCCAGGCCCUGUCCGGCCGGCUGCGGGCCAUCCUGCAGAACCAGGGCAACUCCGGCUCCGAGACCCCCGGCACCUCCGAGUCCGCCACCCCCGAGUCCGACAAGAAGUACUCCAUCGGCCUGGCCAUCGGCACCAACUCCGUGGGCUGGGCCGUGAUCACCGACGAGUACAAGGUGCCCUCCAAGAAGUUCAAGGUGCUGGGCAACACCGACCGGCACUCCAUCAAGAAGAACCUGAUCGGCGCCCUGCUGUUCGACUCCGGCGAGACCGCCGAGGCCACCCGGCUGAAGCGGACCGCCCGGCGGCGGUACACCCGGCGGAAGAACCGGAUCUGCUACCUGCAGGAGAUCUUCUCCAACGAGAUGGCCAAGGUGGACGACUCCUUCUUCCACCGGCUGGAGGAGUCCUUCCUGGUGGAGGAGGACAAGAAGCACGAGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAGGUGGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAAGAAGCUGGUGGACUCCACCGACAAGGCCGACCUGCGGCUGAUCUACCUGGCCCUGGCCCACAUGAUCAAGUUCCGGGGCCACUUCCUGAUCGAGGGCGACCUGAACCCCGACAACUCCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCGAGGAGAACCCCAUCAACGCCUCCGGCGUGGACGCCAAGGCCAUCCUGUCCGCCCGGCUGUCCAAGUCCCGGCGGCUGGAGAACCUGAUCGCCCAGCUGCCCGGCGAGAAGAAGAACGGCCUGUUCGGCAACCUGAUCGCCCUGUCCCUGGGCCUGACCCCCAACUUCAAGUCCAACUUCGACCUGGCCGAGGACGCCAAGCUGCAGCUGUCCAAGGACACCUACGACGACGACCUGGACAACCUGCUGGCCCAGAUCGGCGACCAGUACGCCGACCUGUUCCUGGCCGCCAAGAACCUGUCCGACGCCAUCCUGCUGUCCGACAUCCUGCGGGUGAACACCGAGAUCACCAAGGCCCCCCUGUCCGCCUCCAUGAUCAAGCGGUACGACGAGCACCACCAGGACCUGACCCUGCUGAAGGCCCUGGUGCGGCAGCAGCUGCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGUCCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCGCCUCCCAGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACCGAGGAGCUGCUGGUGAAGCUGAACCGGGAGGACCUGCUGCGGAAGCAGCGGACCUUCGACAACGGCUCCAUCCCCCACCAGAUCCACCUGGGCGAGCUGCACGCCAUCCUGCGGCGGCAGGAGGACUUCUACCCCUUCCUGAAGGACAACCGGGAGAAGAUCGAGAAGAUCCUGACCUUCCGGAUCCCCUACUACGUGGGCCCCCUGGCCCGGGGCAACUCCCGGUUCGCCUGGAUGACCCGGAAGUCCGAGGAGACCAUCACCCCCUGGAACUUCGAGGAGGUGGUGGACAAGGGCGCCUCCGCCCAGUCCUUCAUCGAGCGGAUGACCAACUUCGACAAGAACCUGCCCAACGAGAAGGUGCUGCCCAAGCACUCCCUGCUGUACGAGUACUUCACCGUGUACAACGAGCUGACCAAGGUGAAGUACGUGACCGAGGGCAUGCGGAAGCCCGCCUUCCUGUCCGGCGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACCAACCGGAAGGUGACCGUGAAGCAGCUGAAGGAGGACUACUUCAAGAAGAUCGAGUGCUUCGACUCCGUGGAGAUCUCCGGCGUGGAGGACCGGUUCAACGCCUCCCUGGGCACCUACCACGACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGACCCUGACCCUGUUCGAGGACCGGGAGAUGAUCGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCAGCUGAAGCGGCGGCGGUACACCGGCUGGGGCCGGCUGUCCCGGAAGCUGAUCAACGGCAUCCGGGACAAGCAGUCCGGCAAGACCAUCCUGGACUUCCUGAAGUCCGACGGCUUCGCCAACCGGAACUUCAUGCAGCUGAUCCACGACGACUCCCUGACCUUCAAGGAGGACAUCCAGAAGGCCCAGGUGUCCGGCCAGGGCGACUCCCUGCACGAGCACAUCGCCAACCUGGCCGGCUCCCCCGCCAUCAAGAAGGGCAUCCUGCAGACCGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCCGAGAACAUCGUGAUCGAGAUGGCCCGGGAGAACCAGACCACCCAGAAGGGCCAGAAGAACUCCCGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGGGCUCCCAGAUCCUGAAGGAGCACCCCGUGGAGAACACCCAGCUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAACGGCCGGGACAUGUACGUGGACCAGGAGCUGGACAUCAACCGGCUGUCCGACUACGACGUGGACCACAUCGUGCCCCAGUCCUUCCUGAAGGACGACUCCAUCGACAACAAGGUGCUGACCCGGUCCGACAAGAACCGGGGCAAGUCCGACAACGUGCCCUCCGAGGAGGUGGUGAAGAAGAUGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACCCAGCGGAAGUUCGACAACCUGACCAAGGCCGAGCGGGGCGGCCUGUCCGAGCUGGACAAGGCCGGCUUCAUCAAGCGGCAGCUGGUGGAGACCCGGCAGAUCACCAAGCACGUGGCCCAGAUCCUGGACUCCCGGAUGAACACCAAGUACGACGAGAACGACAAGCUGAUCCGGGAGGUGAAGGUGAUCACCCUGAAGUCCAAGCUGGUGUCCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGCGGGAGAUCAACAACUACCACCACGCCCACGACGCCUACCUGAACGCCGUGGUGGGCACCGCCCUGAUCAAGAAGUACCCCAAGCUGGAGUCCGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUGCGGAAGAUGAUCGCCAAGUCCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACUCCAACAUCAUGAACUUCUUCAAGACCGAGAUCACCCUGGCCAACGGCGAGAUCCGGAAGCGGCCCCUGAUCGAGACCAACGGCGAGACCGGCGAGAUCGUGUGGGACAAGGGCCGGGACUUCGCCACCGUGCGGAAGGUGCUGUCCAUGCCCCAGGUGAACAUCGUGAAGAAGACCGAGGUGCAGACCGGCGGCUUCUCCAAGGAGUCCAUCCUGCCCAAGCGGAACUCCGACAAGCUGAUCGCCCGGAAGAAGGACUGGGACCCCAAGAAGUACGGCGGCUUCGACUCCCCCACCGUGGCCUACUCCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGCAAGUCCAAGAAGCUGAAGUCCGUGAAGGAGCUGCUGGGCAUCACCAUCAUGGAGCGGUCCUCCUUCGAGAAGAACCCCAUCGACUUCCUGGAGGCCAAGGGCUACAAGGAGGUGAAGAAGGACCUGAUCAUCAAGCUGCCCAAGUACUCCCUGUUCGAGCUGGAGAACGGCCGGAAGCGGAUGCUGGCCUCCGCCGGCGAGCUGCAGAAGGGCAACGAGCUGGCCCUGCCCUCCAAGUACGUGAACUUCCUGUACCUGGCCUCCCACUACGAGAAGCUGAAGGGCUCCCCCGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUCUCCGAGUUCUCCAAGCGGGUGAUCCUGGCCGACGCCAACCUGGACAAGGUGCUGUCCGCCUACAACAAGCACCGGGACAAGCCCAUCCGGGAGCAGGCCGAGAACAUCAUCCACCUGUUCACCCUGACCAACCUGGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCACCAUCGACCGGAAGCGGUACACCUCCACCAAGGAGGUGCUGGACGCCACCCUGAUCCACCAGUCCAUCACCGGCCUGUACGAGACCCGGAUCGACCUGUCCCAGCUGGGCGGCGACGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGUGACUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼UGI之mRNA G | 17 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCAACCUGUCCGACAUCAUCGAGAAGGAGACCGGCAAGCAGCUGGUGAUCCAGGAGUCCAUCCUGAUGCUGCCCGAGGAGGUGGAGGAGGUGAUCGGCAACAAGCCCGAGUCCGACAUCCUGGUGCACACCGCCUACGACGAGUCCACCGACGAGAACGUGAUGCUGCUGACCUCCGACGCCCCCGAGUACAAGCCCUGGGCCCUGGUGAUCCAGGACUCCAACGGCGAGAACAAGAUCAAGAUGCUGUCCGGCGGCUCCAAGCGGACCGCCGACGGCUCCGAGUUCGAGUCCCCCAAGAAGAAGCGGAAGGUGGAGUGAUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9之mRNA H | 18 | GGGaagctcagaataaacgctcaactttggccggatctgccacCATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGTCCGGCGGCTCCGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTAGCTAGCaccagcctcaagaacacccgaatggagtctctaagctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacattctCTCGAGAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATAAAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAAACTCAAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATGTAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAAGTTAAAAAAAAAAAACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT |
| 編碼Nme2Cas9之mRNA I | 19 | GGGaagctcagaataaacgctcaactttggccggatctgccacCATGGTGCCCAAGAAGAAGCGGAAGGTGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTACCCCTACGACGTGCCCGACTACGCCGCCGCCCCCGCCGCCAAGAAGAAGAAGCTGGACTAGCTAGCaccagcctcaagaacacccgaatggagtctctaagctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacattctCTCGAGAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATAAAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAAACTCAAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATGTAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAAGTTAAAAAAAAAAAACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT |
| 編碼Nme2Cas9之mRNA J | 20 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGUGCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGAUGGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGUACCCCUACGACGUGCCCGACUACGCCGGCUACCCCUACGACGUGCCCGACUACGCCGGCUCCUACCCCUACGACGUGCCCGACUACGCCGCCGCCCCCGCCGCCAAGAAGAAGAAGCUGGACUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9之mRNA K | 21 | GGGaagctcagaataaacgctcaactttggccggatctgccacCatggccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggTCCGGAAAGCGGACCGCCGACGGCTCCGGAGGAGGAAGCCCCAAGAAGAAGCGGAAGGTGtagctagcaccagcctcaagaacacccgaatggagtctctaagctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacattctctcgagAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATAAAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAACTCAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATGTAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAGTTAAAAAAAAAAAACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT |
| 編碼Nme2Cas9之mRNA L | 22 | GGGaagctcagaataaacgctcaactttggccggatctgccacCatgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtagctagcaccagcctcaagaacacccgaatggagtctctaagctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacattctctcgagAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATAAAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAAACTCAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATGTAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAGTTAAAAAAAAAAAACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT |
| 編碼具有HiBiT標籤之Nme2Cas9的mRNA M | 23 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9之mRNA N | 24 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCGACGGCUCCGGAGGAGGAAGCCCCGCCGCCAAGAAGAAGAAGCUGGACUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9之mRNA O | 25 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼具有HiBiT標籤之Nme2Cas9的mRNA P | 26 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9之mRNA Q | 27 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 編碼Nme2Cas9鹼基編輯劑之mRNA S | 28 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGAGGCCUCCCCCGCCUCCGGCCCCCGGCACCUGAUGGACCCCCACAUCUUCACCUCCAACUUCAACAACGGCAUCGGCCGGCACAAGACCUACCUGUGCUACGAGGUGGAGCGGCUGGACAACGGCACCUCCGUGAAGAUGGACCAGCACCGGGGCUUCCUGCACAACCAGGCCAAGAACCUGCUGUGCGGCUUCUACGGCCGGCACGCCGAGCUGCGGUUCCUGGACCUGGUGCCCUCCCUGCAGCUGGACCCCGCCCAGAUCUACCGGGUGACCUGGUUCAUCUCCUGGUCCCCCUGCUUCUCCUGGGGCUGCGCCGGCGAGGUGCGGGCCUUCCUGCAGGAGAACACCCACGUGCGGCUGCGGAUCUUCGCCGCCCGGAUCUACGACUACGACCCCCUGUACAAGGAGGCCCUGCAGAUGCUGCGGGACGCCGGCGCCCAGGUGUCCAUCAUGACCUACGACGAGUUCAAGCACUGCUGGGACACCUUCGUGGACCACCAGGGCUGCCCCUUCCAGCCCUGGGACGGCCUGGACGAGCACUCCCAGGCCCUGUCCGGCCGGCUGCGGGCCAUCCUGCAGAACCAGGGCAACUCCGGCUCCGAGACCCCCGGCACCUCCGAGUCCGCCACCCCCGAGUCCGCAGCGUUCAAACCAAAUCCCAUCAACUACAUCCUGGGCCUGGCCAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUAGUGACUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| 由mRNA C編碼之Nme2Cas9之開放閱讀框架 | 29 | atgaccggtgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtccggaaagcggaccgccgacggctccgagttcgagtcccccaagaagaagcggaaggtggagtag |
| 由mRNA E編碼之SpyCas9鹼基編輯劑之開放閱讀框架 | 30 | ATGgaggcctcccccgcctccggcccccggcacctgatggacccccacatcttcacctccAACTTCAACAACggcATCggccggCACAAGaccTACCTGTGCTACgaggtggagcggCTGGACAACggcacctccgtgAAGATGGACCAGCACcggggcTTCCTGCACAACCAGgccAAGAACCTGCTGTGCggcTTCTACggccggCACgccgagCTGcggTTCCTGGACCTGgtgccctccCTGCAGCTGGACcccgccCAGATCTACcgggtgaccTGGTTCATCtccTGGtcccccTGCTTCtccTGGggcTGCgccggcgaggtgcgggccTTCCTGCAGgagAACaccCACgtgcggCTGcggATCTTCgccgcccggATCTACGACTACGACcccCTGTACAAGgaggccCTGCAGATGCTGcggGACgccggcgccCAGgtgtccATCATGaccTACGACgagTTCAAGCACTGCTGGGACaccTTCgtgGACCACCAGggcTGCcccTTCCAGcccTGGGACggcCTGGACgagCACtccCAGgccCTGtccggccggCTGcgggccATCCTGCAGAACCAGggcAACtccggctccgagacccccggcacctccgagtccgccacccccgagtccgacaagaagtactccatcggcctggCcatcggcaccaactccgtgggctgggccgtgatcaccgacgagtacaaggtgccctccaagaagttcaaggtgctgggcaacaccgaccggcactccatcaagaagaacctgatcggcgccctgctgttcgactccggcgagaccgccgaggccacccggctgaagcggaccgcccggcggcggtacacccggcggaagaaccggatctgctacctgcaggagatcttctccaacgagatggccaaggtggacgactccttcttccaccggctggaggagtccttcctggtggaggaggacaagaagcacgagcggcaccccatcttcggcaacatcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacctgcggaagaagctggtggactccaccgacaaggccgacctgcggctgatctacctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaactccgacgtggacaagctgttcatccagctggtgcagacctacaaccagctgttcgaggagaaccccatcaacgcctccggcgtggacgccaaggccatcctgtccgcccggctgtccaagtcccggcggctggagaacctgatcgcccagctgcccggcgagaagaagaacggcctgttcggcaacctgatcgccctgtccctgggcctgacccccaacttcaagtccaacttcgacctggccgaggacgccaagctgcagctgtccaaggacacctacgacgacgacctggacaacctgctggcccagatcggcgaccagtacgccgacctgttcctggccgccaagaacctgtccgacgccatcctgctgtccgacatcctgcgggtgaacaccgagatcaccaaggcccccctgtccgcctccatgatcaagcggtacgacgagcaccaccaggacctgaccctgctgaaggccctggtgcggcagcagctgcccgagaagtacaaggagatcttcttcgaccagtccaagaacggctacgccggctacatcgacggcggcgcctcccaggaggagttctacaagttcatcaagcccatcctggagaagatggacggcaccgaggagctgctggtgaagctgaaccgggaggacctgctgcggaagcagcggaccttcgacaacggctccatcccccaccagatccacctgggcgagctgcacgccatcctgcggcggcaggaggacttctaccccttcctgaaggacaaccgggagaagatcgagaagatcctgaccttccggatcccctactacgtgggccccctggcccggggcaactcccggttcgcctggatgacccggaagtccgaggagaccatcaccccctggaacttcgaggaggtggtggacaagggcgcctccgcccagtccttcatcgagcggatgaccaacttcgacaagaacctgcccaacgagaaggtgctgcccaagcactccctgctgtacgagtacttcaccgtgtacaacgagctgaccaaggtgaagtacgtgaccgagggcatgcggaagcccgccttcctgtccggcgagcagaagaaggccatcgtggacctgctgttcaagaccaaccggaaggtgaccgtgaagcagctgaaggaggactacttcaagaagatcgagtgcttcgactccgtggagatctccggcgtggaggaccggttcaacgcctccctgggcacctaccacgacctgctgaagatcatcaaggacaaggacttcctggacaacgaggagaacgaggacatcctggaggacatcgtgctgaccctgaccctgttcgaggaccgggagatgatcgaggagcggctgaagacctacgcccacctgttcgacgacaaggtgatgaagcagctgaagcggcggcggtacaccggctggggccggctgtcccggaagctgatcaacggcatccgggacaagcagtccggcaagaccatcctggacttcctgaagtccgacggcttcgccaaccggaacttcatgcagctgatccacgacgactccctgaccttcaaggaggacatccagaaggcccaggtgtccggccagggcgactccctgcacgagcacatcgccaacctggccggctcccccgccatcaagaagggcatcctgcagaccgtgaaggtggtggacgagctggtgaaggtgatgggccggcacaagcccgagaacatcgtgatcgagatggcccgggagaaccagaccacccagaagggccagaagaactcccgggagcggatgaagcggatcgaggagggcatcaaggagctgggctcccagatcctgaaggagcaccccgtggagaacacccagctgcagaacgagaagctgtacctgtactacctgcagaacggccgggacatgtacgtggaccaggagctggacatcaaccggctgtccgactacgacgtggaccacatcgtgccccagtccttcctgaaggacgactccatcgacaacaaggtgctgacccggtccgacaagaaccggggcaagtccgacaacgtgccctccgaggaggtggtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgatcacccagcggaagttcgacaacctgaccaaggccgagcggggcggcctgtccgagctggacaaggccggcttcatcaagcggcagctggtggagacccggcagatcaccaagcacgtggcccagatcctggactcccggatgaacaccaagtacgacgagaacgacaagctgatccgggaggtgaaggtgatcaccctgaagtccaagctggtgtccgacttccggaaggacttccagttctacaaggtgcgggagatcaacaactaccaccacgcccacgacgcctacctgaacgccgtggtgggcaccgccctgatcaagaagtaccccaagctggagtccgagttcgtgtacggcgactacaaggtgtacgacgtgcggaagatgatcgccaagtccgagcaggagatcggcaaggccaccgccaagtacttcttctactccaacatcatgaacttcttcaagaccgagatcaccctggccaacggcgagatccggaagcggcccctgatcgagaccaacggcgagaccggcgagatcgtgtgggacaagggccgggacttcgccaccgtgcggaaggtgctgtccatgccccaggtgaacatcgtgaagaagaccgaggtgcagaccggcggcttctccaaggagtccatcctgcccaagcggaactccgacaagctgatcgcccggaagaaggactgggaccccaagaagtacggcggcttcgactcccccaccgtggcctactccgtgctggtggtggccaaggtggagaagggcaagtccaagaagctgaagtccgtgaaggagctgctgggcatcaccatcatggagcggtcctccttcgagaagaaccccatcgacttcctggaggccaagggctacaaggaggtgaagaaggacctgatcatcaagctgcccaagtactccctgttcgagctggagaacggccggaagcggatgctggcctccgccggcgagctgcagaagggcaacgagctggccctgccctccaagtacgtgaacttcctgtacctggcctcccactacgagaagctgaagggctcccccgaggacaacgagcagaagcagctgttcgtggagcagcacaagcactacctggacgagatcatcgagcagatctccgagttctccaagcgggtgatcctggccgacgccaacctggacaaggtgctgtccgcctacaacaagcaccgggacaagcccatccgggagcaggccgagaacatcatccacctgttcaccctgaccaacctgggcgcccccgccgccttcaagtacttcgacaccaccatcgaccggaagcggtacacctccaccaaggaggtgctggacgccaccctgatccaccagtccatcaccggcctgtacgagacccggatcgacctgtcccagctgggcggcgacggcggcggctcccccaagaagaagcggaaggtgTgA |
| 由mRNA G編碼之UGI之開放閱讀框架 | 31 | ATGACCAACCTGTCCGACATCATCGAGAAGGAGACCGGCAAGCAGCTGGTGATCCAGGAGTCCATCCTGATGCTGCCCGAGGAGGTGGAGGAGGTGATCGGCAACAAGCCCGAGTCCGACATCCTGGTGCACACCGCCTACGACGAGTCCACCGACGAGAACGTGATGCTGCTGACCTCCGACGCCCCCGAGTACAAGCCCTGGGCCCTGGTGATCCAGGACTCCAACGGCGAGAACAAGATCAAGATGCTGTCCGGCGGCTCCAAGCGGACCGCCGACGGCTCCGAGTTCGAGTCCCCCAAGAAGAAGCGGAAGGTGGAGTGATAG |
| 由mRNA H編碼之Nme2Cas9之開放閱讀框架 | 32 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGTCCGGCGGCTCCGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTAG |
| 由mRNA I編碼之Nme2Cas9之開放閱讀框架 | 33 | ATGGTGCCCAAGAAGAAGCGGAAGGTGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTACCCCTACGACGTGCCCGACTACGCCGCCGCCCCCGCCGCCAAGAAGAAGAAGCTGGACTAG |
| 由mRNA J編碼之Nme2Cas9之開放閱讀框架 | 34 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 由mRNA K編碼之Nme2Cas9之開放閱讀框架 | 35 | atggccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcgg |
| 由mRNA L編碼之Nme2Cas9之開放閱讀框架 | 36 | atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtag |
| 由mRNA M編碼之具有HiBiT標籤之Nme2Cas9之開放閱讀框架 | 37 | ATGGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTCCGAGTCCGCCACCCCCGAGTCCGTGTCCGGCTGGCGGCTGTTCAAGAAGATCTCCTAG |
| 由mRNA N編碼之Nme2Cas9之開放閱讀框架 | 38 | atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggTCCGGAAAGCGGACCGCCGACGGCTCCGGAGGAGGAAGCCCCGCCGCCAAGAAGAAGAAGCTGGACtag |
| 由mRNA O編碼之Nme2Cas9之開放閱讀框架 | 39 | atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtag |
| 由mRNA P編碼之具有HiBiT標籤之Nme2Cas9之開放閱讀框架 | 40 | atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTCCGAGTCCGCCACCCCCGAGTCCGTGTCCGGCTGGCGGCTGTTCAAGAAGATCTCCTAG |
| 由mRNA Q編碼之Nme2Cas9之開放閱讀框架 | 41 | atgGACGGCTCCGGCGGCGGCTCCGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtag |
| 由mRNA R編碼之Nme2Cas9鹼基編輯劑之開放閱讀框架 | 42 | ATGGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCGAGGCCTCCCCCGCCTCCGGCCCCCGGCACCTGATGGACCCCCACATCTTCACCTCCAACTTCAACAACGGCATCGGCCGGCACAAGACCTACCTGTGCTACGAGGTGGAGCGGCTGGACAACGGCACCTCCGTGAAGATGGACCAGCACCGGGGCTTCCTGCACAACCAGGCCAAGAACCTGCTGTGCGGCTTCTACGGCCGGCACGCCGAGCTGCGGTTCCTGGACCTGGTGCCCTCCCTGCAGCTGGACCCCGCCCAGATCTACCGGGTGACCTGGTTCATCTCCTGGTCCCCCTGCTTCTCCTGGGGCTGCGCCGGCGAGGTGCGGGCCTTCCTGCAGGAGAACACCCACGTGCGGCTGCGGATCTTCGCCGCCCGGATCTACGACTACGACCCCCTGTACAAGGAGGCCCTGCAGATGCTGCGGGACGCCGGCGCCCAGGTGTCCATCATGACCTACGACGAGTTCAAGCACTGCTGGGACACCTTCGTGGACCACCAGGGCTGCCCCTTCCAGCCCTGGGACGGCCTGGACGAGCACTCCCAGGCCCTGTCCGGCCGGCTGCGGGCCATCCTGCAGAACCAGGGCAACTCCGGCTCCGAGACCCCCGGCACCTCCGAGTCCGCCACCCCCGAGTCCGCAGCGTTCAAACCAAATcccatcaactacatcctgggcctggccatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagaccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtag |
| 編碼Sp. Cas9之ORF | 43 | ATGGACAAGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGTTCAAGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGCAACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTGGAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGACACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGAAAAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCGACAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACTGGCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCATCCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCCGATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGCAAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGATCGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTCGACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACATACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGACCAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGACGCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATCACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGACGAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGACAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAGAGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGCCAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAGATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATCCCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGAAGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAAAAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCGGACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAAGAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAATGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGCCGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGAACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCCGGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCTGCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTGACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAGCAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAGCAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACAGCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAATCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAACTGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCATCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAATCAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCTGCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACATCAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACCTGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAGGCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATCACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACAAAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACGCACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGATCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAGACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCGAACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACAGCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAAACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCAACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTCAAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAGCATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAAGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAAGGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGGGAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGAAAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGCAGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACTTCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACAAGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCAGCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCCTGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGGGAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACAGAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACACTGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCGACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGTCTAG |
| 編碼Sp. Cas9之ORF | 44 | ATGGACAAGAAGTACTCCATCGGCCTGGACATCGGCACCAACTCCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCTCCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGGCACTCCATCAAGAAGAACCTGATCGGCGCCCTGCTGTTCGACTCCGGCGAGACCGCCGAGGCCACCCGGCTGAAGCGGACCGCCCGGCGGCGGTACACCCGGCGGAAGAACCGGATCTGCTACCTGCAGGAGATCTTCTCCAACGAGATGGCCAAGGTGGACGACTCCTTCTTCCACCGGCTGGAGGAGTCCTTCCTGGTGGAGGAGGACAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGGAAGAAGCTGGTGGACTCCACCGACAAGGCCGACCTGCGGCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACTCCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAGAACCCCATCAACGCCTCCGGCGTGGACGCCAAGGCCATCCTGTCCGCCCGGCTGTCCAAGTCCCGGCGGCTGGAGAACCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCGCCCTGTCCCTGGGCCTGACCCCCAACTTCAAGTCCAACTTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGTCCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGTCCGACATCCTGCGGGTGAACACCGAGATCACCAAGGCCCCCCTGTCCGCCTCCATGATCAAGCGGTACGACGAGCACCACCAGGACCTGACCCTGCTGAAGGCCCTGGTGCGGCAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGTCCAAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCTCCCAGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAACCGGGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCTCCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGCGGCGGCAGGAGGACTTCTACCCCTTCCTGAAGGACAACCGGGAGAAGATCGAGAAGATCCTGACCTTCCGGATCCCCTACTACGTGGGCCCCCTGGCCCGGGGCAACTCCCGGTTCGCCTGGATGACCCGGAAGTCCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGGTGGACAAGGGCGCCTCCGCCCAGTCCTTCATCGAGCGGATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACTCCCTGCTGTACGAGTACTTCACCGTGTACAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGGAAGCCCGCCTTCCTGTCCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAGGTGACCGTGAAGCAGCTGAAGGAGGACTACTTCAAGAAGATCGAGTGCTTCGACTCCGTGGAGATCTCCGGCGTGGAGGACCGGTTCAACGCCTCCCTGGGCACCTACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAGAACGAGGACATCCTGGAGGACATCGTGCTGACCCTGACCCTGTTCGAGGACCGGGAGATGATCGAGGAGCGGCTGAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAAGCGGCGGCGGTACACCGGCTGGGGCCGGCTGTCCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACCATCCTGGACTTCCTGAAGTCCGACGGCTTCGCCAACCGGAACTTCATGCAGCTGATCCACGACGACTCCCTGACCTTCAAGGAGGACATCCAGAAGGCCCAGGTGTCCGGCCAGGGCGACTCCCTGCACGAGCACATCGCCAACCTGGCCGGCTCCCCCGCCATCAAGAAGGGCATCCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAGATGGCCCGGGAGAACCAGACCACCCAGAAGGGCCAGAAGAACTCCCGGGAGCGGATGAAGCGGATCGAGGAGGGCATCAAGGAGCTGGGCTCCCAGATCCTGAAGGAGCACCCCGTGGAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGGGACATGTACGTGGACCAGGAGCTGGACATCAACCGGCTGTCCGACTACGACGTGGACCACATCGTGCCCCAGTCCTTCCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCCGGTCCGACAAGAACCGGGGCAAGTCCGACAACGTGCCCTCCGAGGAGGTGGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATCACCCAGCGGAAGTTCGACAACCTGACCAAGGCCGAGCGGGGCGGCCTGTCCGAGCTGGACAAGGCCGGCTTCATCAAGCGGCAGCTGGTGGAGACCCGGCAGATCACCAAGCACGTGGCCCAGATCCTGGACTCCCGGATGAACACCAAGTACGACGAGAACGACAAGCTGATCCGGGAGGTGAAGGTGATCACCCTGAAGTCCAAGCTGGTGTCCGACTTCCGGAAGGACTTCCAGTTCTACAAGGTGCGGGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTGGTGGGCACCGCCCTGATCAAGAAGTACCCCAAGCTGGAGTCCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGTCCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACTCCAACATCATGAACTTCTTCAAGACCGAGATCACCCTGGCCAACGGCGAGATCCGGAAGCGGCCCCTGATCGAGACCAACGGCGAGACCGGCGAGATCGTGTGGGACAAGGGCCGGGACTTCGCCACCGTGCGGAAGGTGCTGTCCATGCCCCAGGTGAACATCGTGAAGAAGACCGAGGTGCAGACCGGCGGCTTCTCCAAGGAGTCCATCCTGCCCAAGCGGAACTCCGACAAGCTGATCGCCCGGAAGAAGGACTGGGACCCCAAGAAGTACGGCGGCTTCGACTCCCCCACCGTGGCCTACTCCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGTCCAAGAAGCTGAAGTCCGTGAAGGAGCTGCTGGGCATCACCATCATGGAGCGGTCCTCCTTCGAGAAGAACCCCATCGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTGAAGAAGGACCTGATCATCAAGCTGCCCAAGTACTCCCTGTTCGAGCTGGAGAACGGCCGGAAGCGGATGCTGGCCTCCGCCGGCGAGCTGCAGAAGGGCAACGAGCTGGCCCTGCCCTCCAAGTACGTGAACTTCCTGTACCTGGCCTCCCACTACGAGAAGCTGAAGGGCTCCCCCGAGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCTCCGAGTTCTCCAAGCGGGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGTCCGCCTACAACAAGCACCGGGACAAGCCCATCCGGGAGCAGGCCGAGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCCCGCCGCCTTCAAGTACTTCGACACCACCATCGACCGGAAGCGGTACACCTCCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAGTCCATCACCGGCCTGTACGAGACCCGGATCGACCTGTCCCAGCTGGGCGGCGACGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGTGA |
| 編碼Sp. Cas9之ORF | 45 | AUGGACAAGAAGUACAGCAUCGGCCUGGACAUCGGCACGAACAGCGUUGGCUGGGCUGUGAUCACGGACGAGUACAAGGUUCCCUCAAAGAAGUUCAAGGUGCUGGGCAACACGGACCGGCACAGCAUCAAGAAGAAUCUCAUCGGUGCACUGCUGUUCGACAGCGGUGAGACGGCCGAAGCCACGCGGCUGAAGCGGACGGCCCGCCGGCGGUACACGCGGCGGAAGAACCGGAUCUGCUACCUGCAGGAGAUCUUCAGCAACGAGAUGGCCAAGGUGGACGACAGCUUCUUCCACCGGCUGGAGGAGAGCUUCCUGGUGGAGGAGGACAAGAAGCACGAGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAAGUCGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAAGAAGCUGGUGGACUCGACUGACAAGGCCGACCUGCGGCUGAUCUACCUGGCACUGGCCCACAUGAUAAAGUUCCGGGGCCACUUCCUGAUCGAGGGCGACCUGAACCCUGACAACAGCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCGAGGAGAACCCCAUCAACGCCAGCGGCGUGGACGCCAAGGCCAUCCUCAGCGCCCGCCUCAGCAAGAGCCGGCGGCUGGAGAAUCUCAUCGCCCAGCUUCCAGGUGAGAAGAAGAAUGGGCUGUUCGGCAAUCUCAUCGCACUCAGCCUGGGCCUGACUCCCAACUUCAAGAGCAACUUCGACCUGGCCGAGGACGCCAAGCUGCAGCUCAGCAAGGACACCUACGACGACGACCUGGACAAUCUCCUGGCCCAGAUCGGCGACCAGUACGCCGACCUGUUCCUGGCUGCCAAGAAUCUCAGCGACGCCAUCCUGCUCAGCGACAUCCUGCGGGUGAACACAGAGAUCACGAAGGCCCCCCUCAGCGCCAGCAUGAUAAAGCGGUACGACGAGCACCACCAGGACCUGACGCUGCUGAAGGCACUGGUGCGGCAGCAGCUUCCAGAGAAGUACAAGGAGAUCUUCUUCGACCAGAGCAAGAAUGGGUACGCCGGGUACAUCGACGGUGGUGCCAGCCAGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACAGAGGAGCUGCUGGUGAAGCUGAACAGGGAGGACCUGCUGCGGAAGCAGCGGACGUUCGACAAUGGGAGCAUCCCCCACCAGAUCCACCUGGGUGAGCUGCACGCCAUCCUGCGGCGGCAGGAGGACUUCUACCCCUUCCUGAAGGACAACAGGGAGAAGAUCGAGAAGAUCCUGACGUUCCGGAUCCCCUACUACGUUGGCCCCCUGGCCCGCGGCAACAGCCGGUUCGCCUGGAUGACGCGGAAGAGCGAGGAGACGAUCACUCCCUGGAACUUCGAGGAAGUCGUGGACAAGGGUGCCAGCGCCCAGAGCUUCAUCGAGCGGAUGACGAACUUCGACAAGAAUCUUCCAAACGAGAAGGUGCUUCCAAAGCACAGCCUGCUGUACGAGUACUUCACGGUGUACAACGAGCUGACGAAGGUGAAGUACGUGACAGAGGGCAUGCGGAAGCCCGCCUUCCUCAGCGGUGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACGAACCGGAAGGUGACGGUGAAGCAGCUGAAGGAGGACUACUUCAAGAAGAUCGAGUGCUUCGACAGCGUGGAGAUCAGCGGCGUGGAGGACCGGUUCAACGCCAGCCUGGGCACCUACCACGACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGACGCUGACGCUGUUCGAGGACAGGGAGAUGAUAGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCAGCUGAAGCGGCGGCGGUACACGGGCUGGGGCCGGCUCAGCCGGAAGCUGAUCAAUGGGAUCCGAGACAAGCAGAGCGGCAAGACGAUCCUGGACUUCCUGAAGAGCGACGGCUUCGCCAACCGGAACUUCAUGCAGCUGAUCCACGACGACAGCCUGACGUUCAAGGAGGACAUCCAGAAGGCCCAGGUCAGCGGCCAGGGCGACAGCCUGCACGAGCACAUCGCCAAUCUCGCCGGGAGCCCCGCCAUCAAGAAGGGGAUCCUGCAGACGGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCAGAGAACAUCGUGAUCGAGAUGGCCAGGGAGAACCAGACGACUCAAAAGGGGCAGAAGAACAGCAGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGGGCAGCCAGAUCCUGAAGGAGCACCCCGUGGAGAACACUCAACUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAAUGGGCGAGACAUGUACGUGGACCAGGAGCUGGACAUCAACCGGCUCAGCGACUACGACGUGGACCACAUCGUUCCCCAGAGCUUCCUGAAGGACGACAGCAUCGACAACAAGGUGCUGACGCGGAGCGACAAGAACCGGGGCAAGAGCGACAACGUUCCCUCAGAGGAAGUCGUGAAGAAGAUGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACUCAACGGAAGUUCGACAAUCUCACGAAGGCCGAGCGGGGUGGCCUCAGCGAGCUGGACAAGGCCGGGUUCAUCAAGCGGCAGCUGGUGGAGACGCGGCAGAUCACGAAGCACGUGGCCCAGAUCCUGGACAGCCGGAUGAACACGAAGUACGACGAGAACGACAAGCUGAUCAGGGAAGUCAAGGUGAUCACGCUGAAGAGCAAGCUGGUCAGCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGAGGGAGAUCAACAACUACCACCACGCCCACGACGCCUACCUGAACGCUGUGGUUGGCACGGCACUGAUCAAGAAGUACCCCAAGCUGGAGAGCGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUGCGGAAGAUGAUAGCCAAGAGCGAGCAGGAGAUCGGCAAGGCCACGGCCAAGUACUUCUUCUACAGCAACAUCAUGAACUUCUUCAAGACAGAGAUCACGCUGGCCAAUGGUGAGAUCCGGAAGCGGCCCCUGAUCGAGACGAAUGGUGAGACGGGUGAGAUCGUGUGGGACAAGGGGCGAGACUUCGCCACGGUGCGGAAGGUGCUCAGCAUGCCCCAGGUGAACAUCGUGAAGAAGACAGAAGUCCAGACGGGUGGCUUCAGCAAGGAGAGCAUCCUUCCAAAGCGGAACAGCGACAAGCUGAUCGCCCGCAAGAAGGACUGGGACCCCAAGAAGUACGGUGGCUUCGACAGCCCCACCGUGGCCUACAGCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGGAAGAGCAAGAAGCUGAAGAGCGUGAAGGAGCUGCUGGGCAUCACGAUCAUGGAGCGGAGCAGCUUCGAGAAGAACCCCAUCGACUUCCUGGAAGCCAAGGGGUACAAGGAAGUCAAGAAGGACCUGAUCAUCAAGCUUCCAAAGUACAGCCUGUUCGAGCUGGAGAAUGGGCGGAAGCGGAUGCUGGCCAGCGCCGGUGAGCUGCAGAAGGGGAACGAGCUGGCACUUCCCUCAAAGUACGUGAACUUCCUGUACCUGGCCAGCCACUACGAGAAGCUGAAGGGGAGCCCAGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUCAGCGAGUUCAGCAAGCGGGUGAUCCUGGCCGACGCCAAUCUCGACAAGGUGCUCAGCGCCUACAACAAGCACCGAGACAAGCCCAUCAGGGAGCAGGCCGAGAACAUCAUCCACCUGUUCACGCUGACGAAUCUCGGUGCCCCCGCUGCCUUCAAGUACUUCGACACGACGAUCGACCGGAAGCGGUACACGUCGACUAAGGAAGUCCUGGACGCCACGCUGAUCCACCAGAGCAUCACGGGCCUGUACGAGACGCGGAUCGACCUCAGCCAGCUGGGUGGCGACGGUGGUGGCAGCCCCAAGAAGAAGCGGAAGGUGUAG |
| 編碼Sp. Cas9之ORF | 46 | AUGGACAAGAAGUACAGCAUCGGCCUCGACAUCGGCACCAACAGCGUCGGCUGGGCCGUCAUCACCGACGAGUACAAGGUCCCCAGCAAGAAGUUCAAGGUCCUCGGCAACACCGACCGCCACAGCAUCAAGAAGAACCUCAUCGGCGCCCUCCUCUUCGACAGCGGCGAGACCGCCGAGGCCACCCGCCUCAAGCGCACCGCCCGCCGCCGCUACACCCGCCGCAAGAACCGCAUCUGCUACCUCCAGGAGAUCUUCAGCAACGAGAUGGCCAAGGUCGACGACAGCUUCUUCCACCGCCUCGAGGAGAGCUUCCUCGUCGAGGAGGACAAGAAGCACGAGCGCCACCCCAUCUUCGGCAACAUCGUCGACGAGGUCGCCUACCACGAGAAGUACCCCACCAUCUACCACCUCCGCAAGAAGCUCGUCGACAGCACCGACAAGGCCGACCUCCGCCUCAUCUACCUCGCCCUCGCCCACAUGAUCAAGUUCCGCGGCCACUUCCUCAUCGAGGGCGACCUCAACCCCGACAACAGCGACGUCGACAAGCUCUUCAUCCAGCUCGUCCAGACCUACAACCAGCUCUUCGAGGAGAACCCCAUCAACGCCAGCGGCGUCGACGCCAAGGCCAUCCUCAGCGCCCGCCUCAGCAAGAGCCGCCGCCUCGAGAACCUCAUCGCCCAGCUCCCCGGCGAGAAGAAGAACGGCCUCUUCGGCAACCUCAUCGCCCUCAGCCUCGGCCUCACCCCCAACUUCAAGAGCAACUUCGACCUCGCCGAGGACGCCAAGCUCCAGCUCAGCAAGGACACCUACGACGACGACCUCGACAACCUCCUCGCCCAGAUCGGCGACCAGUACGCCGACCUCUUCCUCGCCGCCAAGAACCUCAGCGACGCCAUCCUCCUCAGCGACAUCCUCCGCGUCAACACCGAGAUCACCAAGGCCCCCCUCAGCGCCAGCAUGAUCAAGCGCUACGACGAGCACCACCAGGACCUCACCCUCCUCAAGGCCCUCGUCCGCCAGCAGCUCCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGAGCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCGCCAGCCAGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUCGAGAAGAUGGACGGCACCGAGGAGCUCCUCGUCAAGCUCAACCGCGAGGACCUCCUCCGCAAGCAGCGCACCUUCGACAACGGCAGCAUCCCCCACCAGAUCCACCUCGGCGAGCUCCACGCCAUCCUCCGCCGCCAGGAGGACUUCUACCCCUUCCUCAAGGACAACCGCGAGAAGAUCGAGAAGAUCCUCACCUUCCGCAUCCCCUACUACGUCGGCCCCCUCGCCCGCGGCAACAGCCGCUUCGCCUGGAUGACCCGCAAGAGCGAGGAGACCAUCACCCCCUGGAACUUCGAGGAGGUCGUCGACAAGGGCGCCAGCGCCCAGAGCUUCAUCGAGCGCAUGACCAACUUCGACAAGAACCUCCCCAACGAGAAGGUCCUCCCCAAGCACAGCCUCCUCUACGAGUACUUCACCGUCUACAACGAGCUCACCAAGGUCAAGUACGUCACCGAGGGCAUGCGCAAGCCCGCCUUCCUCAGCGGCGAGCAGAAGAAGGCCAUCGUCGACCUCCUCUUCAAGACCAACCGCAAGGUCACCGUCAAGCAGCUCAAGGAGGACUACUUCAAGAAGAUCGAGUGCUUCGACAGCGUCGAGAUCAGCGGCGUCGAGGACCGCUUCAACGCCAGCCUCGGCACCUACCACGACCUCCUCAAGAUCAUCAAGGACAAGGACUUCCUCGACAACGAGGAGAACGAGGACAUCCUCGAGGACAUCGUCCUCACCCUCACCCUCUUCGAGGACCGCGAGAUGAUCGAGGAGCGCCUCAAGACCUACGCCCACCUCUUCGACGACAAGGUCAUGAAGCAGCUCAAGCGCCGCCGCUACACCGGCUGGGGCCGCCUCAGCCGCAAGCUCAUCAACGGCAUCCGCGACAAGCAGAGCGGCAAGACCAUCCUCGACUUCCUCAAGAGCGACGGCUUCGCCAACCGCAACUUCAUGCAGCUCAUCCACGACGACAGCCUCACCUUCAAGGAGGACAUCCAGAAGGCCCAGGUCAGCGGCCAGGGCGACAGCCUCCACGAGCACAUCGCCAACCUCGCCGGCAGCCCCGCCAUCAAGAAGGGCAUCCUCCAGACCGUCAAGGUCGUCGACGAGCUCGUCAAGGUCAUGGGCCGCCACAAGCCCGAGAACAUCGUCAUCGAGAUGGCCCGCGAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGCGAGCGCAUGAAGCGCAUCGAGGAGGGCAUCAAGGAGCUCGGCAGCCAGAUCCUCAAGGAGCACCCCGUCGAGAACACCCAGCUCCAGAACGAGAAGCUCUACCUCUACUACCUCCAGAACGGCCGCGACAUGUACGUCGACCAGGAGCUCGACAUCAACCGCCUCAGCGACUACGACGUCGACCACAUCGUCCCCCAGAGCUUCCUCAAGGACGACAGCAUCGACAACAAGGUCCUCACCCGCAGCGACAAGAACCGCGGCAAGAGCGACAACGUCCCCAGCGAGGAGGUCGUCAAGAAGAUGAAGAACUACUGGCGCCAGCUCCUCAACGCCAAGCUCAUCACCCAGCGCAAGUUCGACAACCUCACCAAGGCCGAGCGCGGCGGCCUCAGCGAGCUCGACAAGGCCGGCUUCAUCAAGCGCCAGCUCGUCGAGACCCGCCAGAUCACCAAGCACGUCGCCCAGAUCCUCGACAGCCGCAUGAACACCAAGUACGACGAGAACGACAAGCUCAUCCGCGAGGUCAAGGUCAUCACCCUCAAGAGCAAGCUCGUCAGCGACUUCCGCAAGGACUUCCAGUUCUACAAGGUCCGCGAGAUCAACAACUACCACCACGCCCACGACGCCUACCUCAACGCCGUCGUCGGCACCGCCCUCAUCAAGAAGUACCCCAAGCUCGAGAGCGAGUUCGUCUACGGCGACUACAAGGUCUACGACGUCCGCAAGAUGAUCGCCAAGAGCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACAGCAACAUCAUGAACUUCUUCAAGACCGAGAUCACCCUCGCCAACGGCGAGAUCCGCAAGCGCCCCCUCAUCGAGACCAACGGCGAGACCGGCGAGAUCGUCUGGGACAAGGGCCGCGACUUCGCCACCGUCCGCAAGGUCCUCAGCAUGCCCCAGGUCAACAUCGUCAAGAAGACCGAGGUCCAGACCGGCGGCUUCAGCAAGGAGAGCAUCCUCCCCAAGCGCAACAGCGACAAGCUCAUCGCCCGCAAGAAGGACUGGGACCCCAAGAAGUACGGCGGCUUCGACAGCCCCACCGUCGCCUACAGCGUCCUCGUCGUCGCCAAGGUCGAGAAGGGCAAGAGCAAGAAGCUCAAGAGCGUCAAGGAGCUCCUCGGCAUCACCAUCAUGGAGCGCAGCAGCUUCGAGAAGAACCCCAUCGACUUCCUCGAGGCCAAGGGCUACAAGGAGGUCAAGAAGGACCUCAUCAUCAAGCUCCCCAAGUACAGCCUCUUCGAGCUCGAGAACGGCCGCAAGCGCAUGCUCGCCAGCGCCGGCGAGCUCCAGAAGGGCAACGAGCUCGCCCUCCCCAGCAAGUACGUCAACUUCCUCUACCUCGCCAGCCACUACGAGAAGCUCAAGGGCAGCCCCGAGGACAACGAGCAGAAGCAGCUCUUCGUCGAGCAGCACAAGCACUACCUCGACGAGAUCAUCGAGCAGAUCAGCGAGUUCAGCAAGCGCGUCAUCCUCGCCGACGCCAACCUCGACAAGGUCCUCAGCGCCUACAACAAGCACCGCGACAAGCCCAUCCGCGAGCAGGCCGAGAACAUCAUCCACCUCUUCACCCUCACCAACCUCGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCACCAUCGACCGCAAGCGCUACACCAGCACCAAGGAGGUCCUCGACGCCACCCUCAUCCACCAGAGCAUCACCGGCCUCUACGAGACCCGCAUCGACCUCAGCCAGCUCGGCGGCGACGGCGGCGGCAGCCCCAAGAAGAAGCGCAAGGUCUAG |
| 編碼Sp. Cas9之ORF | 47 | ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACAGCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGCGCCCTGCTGTTCGACAGCGGCGAGACCGCCGAGGCCACCCGGCTGAAGCGGACCGCCCGGCGGCGGTACACCCGGCGGAAGAACCGGATCTGCTACCTGCAGGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACCGGCTGGAGGAGAGCTTCCTGGTGGAGGAGGACAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGGAAGAAGCTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAGAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGAGCGCCCGGCTGAGCAAGAGCCGGCGGCTGGAGAACCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGAGCGACGCCATCCTGCTGAGCGACATCCTGCGGGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCAGCATGATCAAGCGGTACGACGAGCACCACCAGGACCTGACCCTGCTGAAGGCCCTGGTGCGGCAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCAGCCAGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAACCGGGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGCGGCGGCAGGAGGACTTCTACCCCTTCCTGAAGGACAACCGGGAGAAGATCGAGAAGATCCTGACCTTCCGGATCCCCTACTACGTGGGCCCCCTGGCCCGGGGCAACAGCCGGTTCGCCTGGATGACCCGGAAGAGCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGGTGGACAAGGGCGCCAGCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTACAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGGAAGCCCGCCTTCCTGAGCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAGGTGACCGTGAAGCAGCTGAAGGAGGACTACTTCAAGAAGATCGAGTGCTTCGACAGCGTGGAGATCAGCGGCGTGGAGGACCGGTTCAACGCCAGCCTGGGCACCTACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAGAACGAGGACATCCTGGAGGACATCGTGCTGACCCTGACCCTGTTCGAGGACCGGGAGATGATCGAGGAGCGGCTGAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAAGCGGCGGCGGTACACCGGCTGGGGCCGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGAGCGGCAAGACCATCCTGGACTTCCTGAAGAGCGACGGCTTCGCCAACCGGAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTCAAGGAGGACATCCAGAAGGCCCAGGTGAGCGGCCAGGGCGACAGCCTGCACGAGCACATCGCCAACCTGGCCGGCAGCCCCGCCATCAAGAAGGGCATCCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAGATGGCCCGGGAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGGGAGCGGATGAAGCGGATCGAGGAGGGCATCAAGGAGCTGGGCAGCCAGATCCTGAAGGAGCACCCCGTGGAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGGGACATGTACGTGGACCAGGAGCTGGACATCAACCGGCTGAGCGACTACGACGTGGACCACATCGTGCCCCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTGCTGACCCGGAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCAGCGAGGAGGTGGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATCACCCAGCGGAAGTTCGACAACCTGACCAAGGCCGAGCGGGGCGGCCTGAGCGAGCTGGACAAGGCCGGCTTCATCAAGCGGCAGCTGGTGGAGACCCGGCAGATCACCAAGCACGTGGCCCAGATCCTGGACAGCCGGATGAACACCAAGTACGACGAGAACGACAAGCTGATCCGGGAGGTGAAGGTGATCACCCTGAAGAGCAAGCTGGTGAGCGACTTCCGGAAGGACTTCCAGTTCTACAAGGTGCGGGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTGGTGGGCACCGCCCTGATCAAGAAGTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTCTTCAAGACCGAGATCACCCTGGCCAACGGCGAGATCCGGAAGCGGCCCCTGATCGAGACCAACGGCGAGACCGGCGAGATCGTGTGGGACAAGGGCCGGGACTTCGCCACCGTGCGGAAGGTGCTGAGCATGCCCCAGGTGAACATCGTGAAGAAGACCGAGGTGCAGACCGGCGGCTTCAGCAAGGAGAGCATCCTGCCCAAGCGGAACAGCGACAAGCTGATCGCCCGGAAGAAGGACTGGGACCCCAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTACAGCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGAGCAAGAAGCTGAAGAGCGTGAAGGAGCTGCTGGGCATCACCATCATGGAGCGGAGCAGCTTCGAGAAGAACCCCATCGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTGAAGAAGGACCTGATCATCAAGCTGCCCAAGTACAGCCTGTTCGAGCTGGAGAACGGCCGGAAGCGGATGCTGGCCAGCGCCGGCGAGCTGCAGAAGGGCAACGAGCTGGCCCTGCCCAGCAAGTACGTGAACTTCCTGTACCTGGCCAGCCACTACGAGAAGCTGAAGGGCAGCCCCGAGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCAGCAAGCGGGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGAGCGCCTACAACAAGCACCGGGACAAGCCCATCCGGGAGCAGGCCGAGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCCCGCCGCCTTCAAGTACTTCGACACCACCATCGACCGGAAGCGGTACACCAGCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACCCGGATCGACCTGAGCCAGCTGGGCGGCGACGGCGGCGGCAGCCCCAAGAAGAAGCGGAAGGTGTGA |
| Sp. Cas9之胺基酸序列 | 48 | MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGGGSPKKKRKV |
| 具有HiBiT標籤之Cas9之開放閱讀框架 | 49 | AUGGACAAGAAGUACUCCAUCGGCCUGGACAUCGGCACCAACUCCGUGGGCUGGGCCGUGAUCACCGACGAGUACAAGGUGCCCUCCAAGAAGUUCAAGGUGCUGGGCAACACCGACCGGCACUCCAUCAAGAAGAACCUGAUCGGCGCCCUGCUGUUCGACUCCGGCGAGACCGCCGAGGCCACCCGGCUGAAGCGGACCGCCCGGCGGCGGUACACCCGGCGGAAGAACCGGAUCUGCUACCUGCAGGAGAUCUUCUCCAACGAGAUGGCCAAGGUGGACGACUCCUUCUUCCACCGGCUGGAGGAGUCCUUCCUGGUGGAGGAGGACAAGAAGCACGAGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAGGUGGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAAGAAGCUGGUGGACUCCACCGACAAGGCCGACCUGCGGCUGAUCUACCUGGCCCUGGCCCACAUGAUCAAGUUCCGGGGCCACUUCCUGAUCGAGGGCGACCUGAACCCCGACAACUCCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCGAGGAGAACCCCAUCAACGCCUCCGGCGUGGACGCCAAGGCCAUCCUGUCCGCCCGGCUGUCCAAGUCCCGGCGGCUGGAGAACCUGAUCGCCCAGCUGCCCGGCGAGAAGAAGAACGGCCUGUUCGGCAACCUGAUCGCCCUGUCCCUGGGCCUGACCCCCAACUUCAAGUCCAACUUCGACCUGGCCGAGGACGCCAAGCUGCAGCUGUCCAAGGACACCUACGACGACGACCUGGACAACCUGCUGGCCCAGAUCGGCGACCAGUACGCCGACCUGUUCCUGGCCGCCAAGAACCUGUCCGACGCCAUCCUGCUGUCCGACAUCCUGCGGGUGAACACCGAGAUCACCAAGGCCCCCCUGUCCGCCUCCAUGAUCAAGCGGUACGACGAGCACCACCAGGACCUGACCCUGCUGAAGGCCCUGGUGCGGCAGCAGCUGCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGUCCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCGCCUCCCAGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACCGAGGAGCUGCUGGUGAAGCUGAACCGGGAGGACCUGCUGCGGAAGCAGCGGACCUUCGACAACGGCUCCAUCCCCCACCAGAUCCACCUGGGCGAGCUGCACGCCAUCCUGCGGCGGCAGGAGGACUUCUACCCCUUCCUGAAGGACAACCGGGAGAAGAUCGAGAAGAUCCUGACCUUCCGGAUCCCCUACUACGUGGGCCCCCUGGCCCGGGGCAACUCCCGGUUCGCCUGGAUGACCCGGAAGUCCGAGGAGACCAUCACCCCCUGGAACUUCGAGGAGGUGGUGGACAAGGGCGCCUCCGCCCAGUCCUUCAUCGAGCGGAUGACCAACUUCGACAAGAACCUGCCCAACGAGAAGGUGCUGCCCAAGCACUCCCUGCUGUACGAGUACUUCACCGUGUACAACGAGCUGACCAAGGUGAAGUACGUGACCGAGGGCAUGCGGAAGCCCGCCUUCCUGUCCGGCGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACCAACCGGAAGGUGACCGUGAAGCAGCUGAAGGAGGACUACUUCAAGAAGAUCGAGUGCUUCGACUCCGUGGAGAUCUCCGGCGUGGAGGACCGGUUCAACGCCUCCCUGGGCACCUACCACGACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGACCCUGACCCUGUUCGAGGACCGGGAGAUGAUCGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCAGCUGAAGCGGCGGCGGUACACCGGCUGGGGCCGGCUGUCCCGGAAGCUGAUCAACGGCAUCCGGGACAAGCAGUCCGGCAAGACCAUCCUGGACUUCCUGAAGUCCGACGGCUUCGCCAACCGGAACUUCAUGCAGCUGAUCCACGACGACUCCCUGACCUUCAAGGAGGACAUCCAGAAGGCCCAGGUGUCCGGCCAGGGCGACUCCCUGCACGAGCACAUCGCCAACCUGGCCGGCUCCCCCGCCAUCAAGAAGGGCAUCCUGCAGACCGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCCGAGAACAUCGUGAUCGAGAUGGCCCGGGAGAACCAGACCACCCAGAAGGGCCAGAAGAACUCCCGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGGGCUCCCAGAUCCUGAAGGAGCACCCCGUGGAGAACACCCAGCUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAACGGCCGGGACAUGUACGUGGACCAGGAGCUGGACAUCAACCGGCUGUCCGACUACGACGUGGACCACAUCGUGCCCCAGUCCUUCCUGAAGGACGACUCCAUCGACAACAAGGUGCUGACCCGGUCCGACAAGAACCGGGGCAAGUCCGACAACGUGCCCUCCGAGGAGGUGGUGAAGAAGAUGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACCCAGCGGAAGUUCGACAACCUGACCAAGGCCGAGCGGGGCGGCCUGUCCGAGCUGGACAAGGCCGGCUUCAUCAAGCGGCAGCUGGUGGAGACCCGGCAGAUCACCAAGCACGUGGCCCAGAUCCUGGACUCCCGGAUGAACACCAAGUACGACGAGAACGACAAGCUGAUCCGGGAGGUGAAGGUGAUCACCCUGAAGUCCAAGCUGGUGUCCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGCGGGAGAUCAACAACUACCACCACGCCCACGACGCCUACCUGAACGCCGUGGUGGGCACCGCCCUGAUCAAGAAGUACCCCAAGCUGGAGUCCGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUGCGGAAGAUGAUCGCCAAGUCCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACUCCAACAUCAUGAACUUCUUCAAGACCGAGAUCACCCUGGCCAACGGCGAGAUCCGGAAGCGGCCCCUGAUCGAGACCAACGGCGAGACCGGCGAGAUCGUGUGGGACAAGGGCCGGGACUUCGCCACCGUGCGGAAGGUGCUGUCCAUGCCCCAGGUGAACAUCGUGAAGAAGACCGAGGUGCAGACCGGCGGCUUCUCCAAGGAGUCCAUCCUGCCCAAGCGGAACUCCGACAAGCUGAUCGCCCGGAAGAAGGACUGGGACCCCAAGAAGUACGGCGGCUUCGACUCCCCCACCGUGGCCUACUCCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGCAAGUCCAAGAAGCUGAAGUCCGUGAAGGAGCUGCUGGGCAUCACCAUCAUGGAGCGGUCCUCCUUCGAGAAGAACCCCAUCGACUUCCUGGAGGCCAAGGGCUACAAGGAGGUGAAGAAGGACCUGAUCAUCAAGCUGCCCAAGUACUCCCUGUUCGAGCUGGAGAACGGCCGGAAGCGGAUGCUGGCCUCCGCCGGCGAGCUGCAGAAGGGCAACGAGCUGGCCCUGCCCUCCAAGUACGUGAACUUCCUGUACCUGGCCUCCCACUACGAGAAGCUGAAGGGCUCCCCCGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUCUCCGAGUUCUCCAAGCGGGUGAUCCUGGCCGACGCCAACCUGGACAAGGUGCUGUCCGCCUACAACAAGCACCGGGACAAGCCCAUCCGGGAGCAGGCCGAGAACAUCAUCCACCUGUUCACCCUGACCAACCUGGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCACCAUCGACCGGAAGCGGUACACCUCCACCAAGGAGGUGCUGGACGCCACCCUGAUCCACCAGUCCAUCACCGGCCUGUACGAGACCCGGAUCGACCUGUCCCAGCUGGGCGGCGACGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUGA |
| 具有HiBiT標籤之Cas9之胺基酸序列 | 50 | MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGGGSPKKKRKVSESATPESVSGWRLFKKIS |
| 智人(H. sapiens) APOBEC3A脫胺酶(A3A)之胺基酸序列 | 151 | MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGN |
| 褐家鼠(R. norvegicus) Apobec1之胺基酸序列 | 152 | MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK |
| 胞苷脫胺酶之例示性胺基酸序列 | 153 | MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQNTSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLF |
| 胞苷脫胺酶之例示性胺基酸序列 | 154 | MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQNTSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLFIYIARLYH |
| 胞苷脫胺酶之例示性胺基酸序列 | 155 | MNWNALRSKAIEVSRHAYAPYSGFPVGAAALVDDGRTVTGCNVENVSYGLGLCAECAVVCALHSGGGGRLVALSCVGPDGGVLMPCGRCRQVLLEHGGPELLIDHAHGPRPLRELLPDAFGPDDLGRR |
| 胞苷脫胺酶之例示性胺基酸序列 | 156 | MTHHALIEAAKAAREKAYAPYSNFKVGAALVTNDGKVFHGCNVENASYGLCNCAERTALFSALAAGYRPGEFAAIAVVGETHGPIAPCGACRQVMIELGKPTLEVVLTNMQGDVRVTSAGDLLPDAFYLA |
| 胞苷脫胺酶之例示性胺基酸序列 | 157 | MPDIDWKQLRDKATQVAAGAYAPYSRFPVGAAALVDDGRVVTGCNVENVSYGLALCAECGVVCALHATGGGRLVALACVDGRGAPLMPCGRCRQLLFEHGGPELLVDHLAGPRRLGDLLPEPFHADLTGEPT |
| 胞苷脫胺酶之例示性胺基酸序列 | 158 | MNSKQLIQEAIEARKQAYVPYSKFQVGAALLTQDGKVYRGCNVENASYGLCNCAERTALFKAVSEGDKEFVAIAIVADTKRPVPPCGACRQVMVELCKQDTKVYLSNLHGDVQETTVGELLPGAFLAEDLHE |
| 胞苷脫胺酶之例示性胺基酸序列 | 159 | MPDVDWNMLRGNATQAAAGAYVPYSRFAVGAAALVDDGRVVTGCNVENVSYGLTLCAECAVVCALHSTGGGRLLALACVDGHGSVLMPCGRCRQVLLEHGGSELLIDHPVRPRRLGDLLPDAFGLDDLPRERR |
| 胞苷脫胺酶之例示性胺基酸序列 | 160 | MGDVNWDTLQKAAVAARANSYAPYSNFPVGVAGFVNDGRLITGVNVENASYGLALCAECSMISALYATGGGRLVAVYCVDGNGDSLMPCGRCRQLLYEHGGPELKIMTPKGVQTMAQLLPQAFNPQERIFGNDE |
| 胞苷脫胺酶之例示性胺基酸序列 | 161 | MNRQELITEALKARDMAYAPYSKFQVGAALLTKDGKVYRGCNIENAAYSMCNCAERTALFKAVSEGDTEFQMLAVAADTPGPVSPCGACRQVISELCTKDVIVVLTNLQGQIKEMTVEELLPGAFSSEDLHDERKL |
| 胞苷脫胺酶之例示性胺基酸序列 | 162 | MKVGGIEDRQLEALKRAALKACELSYSPYSHFRVGCSILTNNDVIFTGANVENASYSNCICAERSAMIQVLMAGHRSGWKCMVICGDSEDQCVSPCGVCRQFINEFVVKDFPIVMLNSTGSRSKVMTMGELLPMAFGPSHLN |
| 胞苷脫胺酶之例示性胺基酸序列 | 163 | MNIEQQLYDVVKQLIEQRYPNDWGGAAAIRVEDGTIYTSVAPDVINASTELCMETGAILEAHKFQKKVTHSICLARENEHSELKVLSPCGVCQERLFYWGPEVQCAITNAKQDIIFKPLKELQPYHWTEAYHDEMVKEWSTR |
| 胞苷脫胺酶之例示性胺基酸序列 | 164 | MAQERPSCAVEPEHVQRLLLSSREAKKSAYCPYSRFPVGAALLTGDGRIFSGCNIENACYPLGVCAERTAIQKAISEGYKDFRAIAISSDLQEEFISPCGACRQVMREFGTDWAVYMTKPDGTFVVRTVQELLPASFGPEDLQKIQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 165 | MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIFKGCNIENACYPLGICAERTAIQKAVSEGYKDFRAIAIASDMQDDFISPCGACRQVMREFGTNWPVYMTKPDGTYIVMTVQELLPSSFGPEDLQKTQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 166 | MVTGGMASKWDQKGMDIAYEEAALGYKEGGVPIGGCLINNKDGSVLGRGHNMRFQKGSATLHGEISTLENCGRLEGKVYKDTTLYTTLSPCDMCTGAIIMYGIPRCVVGENVNFKSKGEKYLQTRGHEVVVVDDERCKKIMKQFIDERPQDWFEDIGE |
| 胞苷脫胺酶之例示性胺基酸序列 | 167 | MTTTKANLTEFEQQLVDKAIGAMENAYCKYSNFKVGAALVCDDGEIIIGANHENASYGATICAERSAIVTALTKGHRKFKYIVVATELEAPCSPCGVCRQVLIEFGDYKVILGSSTSDQIIETTTYELLPYAFTPKSLDDHEKETEERKHHNDHNNKE |
| 胞苷脫胺酶之例示性胺基酸序列 | 168 | MAANSLPQDISDVELVHLARAAMKRAHCPYSKFPVGAALLTESGEIVQGCNVENASYGGTICAERSAIVSAVSQGYTKFRAIAVVTELSEPASPCGLCRQFLVEFGDYKVVVGTASNNKILITSTRALLPFAFTPESLDTFEQEKASEAKGLKQDDATEHNVTVVS |
| 胞苷脫胺酶之例示性胺基酸序列 | 169 | MNPQIRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSWKTGVFRNQVDSETHCHAERCFLSWFCDDILSPNTKYQVTWYTSWSPCPDCAGEVAEFLARHSNVNLTIFTARLYYFQYPCYQEGLRSLSQEGVAVEIMDYEDFKYCWENFVYNDNEPFKPWKGLKTNFRLLKRRLRESLQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 170 | MNPQIRNPMEAMYPHIFYFHFKNLLKACGRNESWLCFTMEVTKHHSAVFRKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGASVKIMGYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 171 | MNDALHIGLPPFLVQANNEPRVLAAPEARMGYVLELVRANIAADGGPFAAAVFERDSGLLIAAGTNRVVPGRCSAAHAEILALSLAQAKLDTHDLSADGLPACELVTSAEPCVMCFGAVIWSGVRSLVCAARSDDVEAIGFDEGPRPENWMGGLEARGITVTTGLLRDAACALLREYNACNGVIYNARCGVHK |
| 胞苷脫胺酶之例示性胺基酸序列 | 172 | MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL |
| 胞苷脫胺酶之例示性胺基酸序列 | 173 | MDSLLMKQKKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSCSLDFGHLRNKSGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAEFLRWNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIGIMTFKDYFYCWNTFVENRERTFKAWEGLHENSVRLTRQLRRILLPLYEVDDLRDAFRMLGF |
| 胞苷脫胺酶之例示性胺基酸序列 | 174 | MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGYFENKKKCHAEICFINEIKSMGLDETQCYQVTCYLTWSPCSSCAWELVDFIKAHDHLNLGIFASRLYYHWCKPQQKGLRLLCGSQVPVEVMGFPKFADCWENFVDHEKPLSFNPYKMLEELDKNSRAIKRRLERIKIPGVRAQGRYMDILCDAEV |
| 胞苷脫胺酶之例示性胺基酸序列 | 175 | MAQKEEAAVATEAASQNGEDLENLDDPEKLKELIELPPFEIVTGERLPANFFKFQFRNVEYSSGRNKTFLCYVVEAQGKGGQVQASRGYLEDEHAAAHAEEAFFNTILPAFDPALRYNVTWYVSSSPCAACADRIIKTLSKTKNLRLLILVGRLFMWEEPEIQAALKKLKEAGCKLRIMKPQDFEYVWQNFVEQEEGESKAFQPWEDIQENFLYYEEKLADILK |
| 胞苷脫胺酶之例示性胺基酸序列 | 176 | MAQKEEAAEAAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVNFFKFQFRNVEYSSGRNKTFLCYVVEVQSKGGQAQATQGYLEDEHAGAHAEEAFFNTILPAFDPALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLILVSRLFMWEEPEVQAALKKLKEAGCKLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK |
| 胞苷脫胺酶之例示性胺基酸序列 | 177 | MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQNTSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLFIYIARLYHHTDQRNRQGLRDLISSGVTIQIMTEQEYCYCWRNFVNYPPSNEAYWPRYPHLWVKLYVLELYCIILGLPPCLKILRRKQPQLTFFTITLQTCHYQRIPPHLLWATGLK |
| 胞苷脫胺酶之例示性胺基酸序列 | 178 | MNSKTGPSVGDATLRRRIKPWEFVAFFNPQELRKETCLLYEIKWGNQNIWRHSNQNTSQHAEINFMEKFTAERHFNSSVRCSITWFLSWSPCWECSKAIRKFLDHYPNVTLAIFISRLYWHMDQQHRQGLKELVHSGVTIQIMSYSEYHYCWRNFVDYPQGEEDYWPKYPYLWIMLYVLELHCIILGLPPCLKISGSHSNQLALFSLDLQDCHYQKIPYNVLVATGLVQPFVTWR |
| 胞苷脫胺酶之例示性胺基酸序列 | 179 | MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAIREFLSRHPGVTLVIYVARLFWHMDQQNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQNHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR |
| 胞苷脫胺酶之例示性胺基酸序列 | 180 | MASEKGPSNKDYTLRRRIEPWEFEVFFDPQELRKEACLLYEIKWGASSKTWRSSGKNTTNHVEVNFLEKLTSEGRLGPSTCCSITWFLSWSPCWECSMAIREFLSQHPGVTLIIFVARLFQHMDRRNRQGLKDLVTSGVTVRVMSVSEYCYCWENFVNYPPGKAAQWPRYPPRWMLMYALELYCIILGLPPCLKISRRHQKQLTFFSLTPQYCHYKMIPPYILLATGLLQPSVPWR |
| 胞苷脫胺酶之例示性胺基酸序列 | 181 | MKVSLAGQTVDVKKILNEIPKRTVTAALLEGGEIVAVEEADDEHAERKLVRRHDVEGKVVFVTARPCLYCARELAEAGVAGVVYLGRGRGLGPYYLARSGVEVVEVHPDEPLGYDPVDRLDVLLTFGGNPYLTEEDVAARVYCLLTGRGFDADIAPAPENLSGRVEIMVTRGDPDEAVELLKEELPVFRIRRFLISGEFDRDELRERILEDIEPRILDPFAVRARIARAGAFSSSREAEVFIGDVLTSVGREVNLNDPRTVVTVDVLGPRVSVGVEKR |
| 胞苷脫胺酶之例示性胺基酸序列 | 182 | MHPRFQTAFAQLADNLQSALEPILADKYFPALLTGEQVSSLKSATGLDEDALAFALLPLAAACARTPLSNFNVGAIARGVSGTWYFGANMEFIGATMQQTVHAEQSAISHAWLSGEKALAAITVNYTPCGHCRQFMNELNSGLDLRIHLPGREAHALRDYLPDAFGPKDLEIKTLLMDEQDHGYALTGDALSQAAIAAANRSHMPYSKSPSGVALECKDGRIFSGSYAENAAFNPTLPPLQGALILLNLKGYDYPDIQRAVLAEKADAPLIQWDATSATLKALGCHSIDRVLLA |
| 胞苷脫胺酶之例示性胺基酸序列 | 183 | MRNRIEQALQQMPASFAPYLRELVLAKDFDATFSAEQYQQLLTLSGLEDADLRVALLPIAAAYSYAPISEFYVGAIVRGISGRLYLGANMEFTGAQLGQTVHAEQCAISHAWMKGEKGVADITINFSPCGHCRQFMNELTTASSLKIQLPKRAAKTLQEYLPESFGPADLGIDSGLMSPVNHGKTSDDDEELIQQALRAMNISHSPYTQNFSGVALKMRSGAIYLGAYAENAAFNPSLPPLQVALAQAMMMGESFEDIEAAALVESATGKISHLADTQATLEVINPDIPLSYLSL |
| 胞苷脫胺酶之例示性胺基酸序列 | 184 | MSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 185 | MDKPSFVIQSKEAESAAKQLGVSVIQLLPSLVKPAQSYARTPISKFNVAVVGLGSSGRIFLGVNVEFPNLPLHHSIHAEQFLVTNLTLNGERHLNFFAVSAAPCGHCRQFLQEIRDAPEIKILITDPNNSADSDSAADSDGFLRLGSFLPHRFGPDDLLGKDHPLLLESHDNHLKISDLDSICNGNTDSSADLKQTALAAANRSYAPYSLCPSGVSLVDCDGKVYRGWYMESAAYNPSMGPVQAALVDYVANGGGGGYERIVGAVLVEKEDAVVRQEHTARLLLETISPKCEFKVFHCYEA |
| 胞苷脫胺酶之例示性胺基酸序列 | 186 | MVEPMDPRTFVSNFNNRPILSGLNTVWLCCEVKTKDPSGPPLDAKIFQGKVYSKAKYHPEMRFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANSVATFLAKDPKVTLTIFVARLYYFWKPDYQQALRILCQKRGGPHATMKIMNYNEFQDCWNKFVDGRGKPFKPRNNLPKHYTLLQATLGELLRHLMDPGTFTSNFNNKPWVSGQHETYLCYKVERLHNDTWVPLNQHRGFLRNQAPNIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFSCAQEMAKFISNNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI |
| 胞苷脫胺酶之例示性胺基酸序列 | 187 | MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQVYSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYSEGQPFMPWYKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE |
| 胞苷脫胺酶之例示性胺基酸序列 | 188 | MNPQIRNMVEQMEPDIFVYYFNNRPILSGRNTVWLCYEVKTKDPSGPPLDANIFQGKLYPEAKDHPEMKFLHWFRKWRQLHRDQEYEVTWYVSWSPCTRCANSVATFLAEDPKVTLTIFVARLYYFWKPDYQQALRILCQERGGPHATMKIMNYNEFQHCWNEFVDGQGKPFKPRKNLPKHYTLLHATLGELLRHVMDPGTFTSNFNNKPWVSGQRETYLCYKVERSHNDTWVLLNQHRGFLRNQAPDRHGFPKGRHAELCFLDLIPFWKLDDQQYRVTCFTSWSPCFSCAQKMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLHRDGAKIAVMNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI |
| 胞苷脫胺酶之例示性胺基酸序列 | 189 | MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFRGQVYFKPQYHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLSEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVTIMDYEEFAYCWENFVYNEGQQFMPWYKFDENYAFLHRTLKEILRYLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQNQGN |
| 胞苷脫胺酶之例示性胺基酸序列 | 190 | MKPQIRNMVEPMDPRTFVSNFNNRPILSGLDTVWLCCEVKTKDPSGPPLDAKIFQGKVYPKAKYHPEMRFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANSVATFLAKDPKVTLTIFVARLYYFWKPDYQQALRILCQKRDGPHATMKIMNYNEFQDCWNKFVDGRGKPFKPWNNLPKHYTLLQATLGELLRHLMDPGTFTSNFNNKPWVSGQHETYLCYKVERLHNDTWVPLNQHRGFLRNQAPNIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFSCAQEMAKFISNNEHVSLCIFAARIYDDQGRYQEGLRTLHRDGAKIAMMNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAILQNQGN |
| 胞苷脫胺酶之例示性胺基酸序列 | 191 | MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN |
| 胞苷脫胺酶之例示性胺基酸序列 | 192 | MKPHFRNPVERMYQDTFSDNFYNRPILSHRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSKLKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDVATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTSNFNNELWVRGRHETYLCYEVERLHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLHQDYRVTCFTSWSPCFSCAQEMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLAKAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLEEHSQALSGRLRAILQNQGN |
| 胞苷脫胺酶之例示性胺基酸序列 | 193 | MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFRGPVLPKRQSNHRQEVYFRFENHAEMCFLSWFCGNRLPANRRFQITWFVSWNPCLPCVVKVTKFLAEHPNVTLTISAARLYYYRDRDWRWVLLRLHKAGARVKIMDYEDFAYCWENFVCNEGQPFMPWYKFDDNYASLHRTLKEILRNPMEAMYPHIFYFHFKNLLKACGRNESWLCFTMEVTKHHSAVFRKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGASVKIMGYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 194 | MQPQRLGPRAGMGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESRSHAS |
| 胞苷脫胺酶之例示性胺基酸序列 | 195 | MQPQRLGPRAGMGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 196 | MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRPCYISVPSSSSSTLSNICLTKGLPETRFWVEGRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 197 | MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVEGRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 198 | MQPQRLGPRAGMGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRPCYISVPSSSSSTLSNICLTKGLPETRFWVEGRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKEVRTTLLQGPAS |
| 胞苷脫胺酶之例示性胺基酸序列 | 199 | MQPQRLGPRAGMGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRPCYISVPSSSSSTLSNICLTKGLPETRFWVEGRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 200 | MKETDQMQSLEGSGAERSVGTQTGSMTGQIPRLSKVNLFTLLSLWMELFPGVEAQGQKSQKTEEESRGPLGDNEELTRVSTEKKQVKKTGLVVVKNMKIIGLHCSSEDLHTGQIALIKHGSRLKNCDLYFSRKPCSACLKMIVNAGVNRISYWPSDPEISLLTEASSSEDAKLDAKAAERLKSNSRAHVCVLLQPLVCYMVQFVEETSYKCDFIQKTAKALPGADTDFYSECKQERIKEYEMLFLVSNEERHKQILMTIGLESLCEDPYFSNLRQNMKDLILLLATVASSVPNLKHFGFYCSSPEQINEIHNQSLPQEVARHCMVQARLLAYRTEDHKTGVGAVIWAEAKSRSCDGTGAMYFIGCGYNAFPVGSEYADFPHMDDKHKDREIRKFRYIIHAEQNALTFRCQDIKPEERSMIFVTKCPCDECVPLIKGAGIKQIYAGDVDVGKKKADISYMKFGELEGVRKFTWQLNPSEAYSLDPNEPERRENGVLRRRSAKDEQRSSKRPRLETRSAGSATTACF |
| 胞苷脫胺酶之例示性胺基酸序列 | 201 | MSNNALQTIINARLPGEEGLWQIHLQDGKISAIDAQSGVMPITENSLDAEQGLVIPPFVEPHIHLDTTQTAGQPNWNQSGTLFEGIERWAERKALLTHDDVKQRAWQTLKWQIANGIQHVRTHVDVSDATLTALKAMLEVKQEVAPWIDLQIVAFPQEGILSYPNGEALLEEALRLGADVVGAIPHFEFTREYGVESLHKTFALAQKYDRLIDVHCDEIDDEQSRFVETVAALAHHEGMGARVTASHTTAMHSYNGAYTSRLFRLLKMSGINFVANPLVNIHLQGRFDTYPKRRGITRVKEMLESGINVCFGHDDVFDPWYPLGTANMLQVLHMGLHVCQLMGYGQINDGLNLITHHSARTLNLQDYGIAAGNSANLIILPAENGFDALRRQVPVRYSVRGGKVIASTQPAQTTVYLEQPEAIDYKR |
| 胞苷脫胺酶之例示性胺基酸序列 | 202 | MALLTAKTFSLQFNNKRRVNKPYYPRKALLCYQLTPQNGSTPTRGHLKNKKKDHAEIRFINKIKSMGLDETQCYQVTCYLTWSPCPSCAGELVDFIKAHRHLNLRIFASRLYYHWRPNYQEGLLLLCGSQVPVEVMGLPEFTDCWENFVDHKEPPSFNPSEKLEELDKNSQAIKRRLERIKSRSVDVLENGLRSLQLGPVTPSSSIRNSR |
| 胞苷脫胺酶之例示性胺基酸序列 | 203 | MEKDINLKIFKGNLIFTKTSDKFTIMKDSYIVVIDGKIASVSSNLPDKYKGNPIIDFRNNIIIPGMNDLHAHASQYKNLGIGMDKELLPWLNNYTFPEEAKFLNVDYAKKTYGRLIKDLIKNGTTRVALFATLHKDSTIELFNMLIKSGIGAYVGKVNMDYNCPDYLTENYITSLNDTEEIILKYKDKSNIVKPIITPRFVPSCSNELMDGLGKLSYKYRLPVQSHLSENLDEIAVVKSLHKKSNFYGEVYDKFGLFGNTPTLMAHCIHSSKEEINLIKRNNVTIVHCPTSNFNLGSGMMPVRKYLNLGINVVLGSDISAGHTCSLFKVIAYAIQNSKIKWQESGKKDMFLSTSEAFYMATKKGGSFFGKVGSFEEGYDFDALVINDSNLYPEDYDLTERLERFIYLGDDRNIMKRYVCGNEIFGPKF |
| 胞苷脫胺酶之例示性胺基酸序列 | 204 | MKIINARLRRQEALFTLDLQDGIIHRITAQAAMQTADAGAIDAQGRLAIPPFVEPHIHLDATLTAGEPEWNRSGTLFEGITRWSQRKASITPEDTRQRALKTIGMLRDFGVQHVRTHVDVTDPSLAALQALLAVKQEAADLIDLQIVAFPQEGIESYPNGRELMTRAIEMGADVVGGIPHYENTRDKGVSSVMFLMDLAQRYGRLVDVHCDEIDDPQSRFLEVLAEEARVRGMGAQVTASHTCAMGSYDNAYCSKLFRLLKASGINFISCPTESIHLQGRFDSWPKRRGVTRVAELDRAGINVCFAQDSIQDPWYPLGNGNILRILDAGLHICHMLGYDDLQRCLDFVTDNSARALCLGDNYGLAEGRPANLLILDAENDYEAVRRQARVLTSIRHGKVILQREVEHIRYPA |
| 胞苷脫胺酶之例示性胺基酸序列 | 205 | MGRKLDPTKEKRGPGRKARKQKGAETELVRFLPAVSDENSKRLSSRARKRAAKRRLGSVEAPKTNKSPEAKPLPGKLPKGISAGAVQTAGKKGPQSLFNAPRGKKRPAPGSDEEEEEEDSEEDGMVNHGDLWGSEDDADTVDDYGADSNSEDEEEGEALLPIERAARKQKAREAAAGIQWSEEETEDEEEEKEVTPESGPPKVEEADGGLQINVDEEPFVLPPAGEMEQDAQAPDLQRVHKRIQDIVGILRDFGAQREEGRSRSEYLNRLKKDLAIYYSYGDFLLGKLMDLFPLSELVEFLEANEVPRPVTLRTNTLKTRRRDLAQALINRGVNLDPLGKWSKTGLVVYDSSVPIGATPEYLAGHYMLQGASSMLPVMALAPQEHERILDMCCAPGGKTSYMAQLMKNTGVILANDANAERLKSVVGNLHRLGVTNTIISHYDGRQFPKVVGGFDRVLLDAPCSGTGVISKDPAVKTNKDEKDILRCAHLQKELLLSAIDSVNATSKTGGYLVYCTCSITVEENEWVVDYALKKRNVRLVPTGLDFGQEGFTRFRERRFHPSLRSTRRFYPHTHNMDGFFIAKFKKFSNSIPQSQTGNSETATPTNVDLPQVIPKSENSSQPAKKAKGAAKTKQQLQKQQHPKKASFQKLNGISKGADSELSTVPSVTKTQASSSFQDSSQPAGKAEGIREPKVTGKLKQRSPKLQSSKKVAFLRQNAPPKGTDTQTPAVLSPSKTQATLKPKDHHQPLGRAKGVEKQQLPEQPFEKAAFQKQNDTPKGPQPPTVSPIRSSRPPPAKRKKSQSRGNSQLLLS |
| 胞苷脫胺酶之例示性胺基酸序列 | 206 | MGRRSRGRRLQQQQRPEDAEDGAEGGGKRGEAGWEGGYPEIVKENKLFEHYYQELKIVPEGEWGQFMDALREPLPATLRITGYKSHAKEILHCLKNKYFKELEDLEVDGQKVEVPQPLSWYPEELAWHTNLSRKILRKSPHLEKFHQFLVSETESGNISRQEAVSMIPPLLLNVRPHHKILDMCAAPGSKTTQLIEMLHADMNVPFPEGFVIANDVDNKRCYLLVHQAKRLSSPCIMVVNHDASSIPRLQIDVDGRKEILFYDRILCDVPCSGDGTMRKNIDVWKKWTTLNSLQLHGLQLRIATRGAEQLAEGGRMVYSTCSLNPIEDEAVIASLLEKSEGALELADVSNELPGLKWMPGITQWKVMTKDGQWFTDWDAVPHSRHTQIRPTMFPPKDPEKLQAMHLERCLRILPHHQNTGGFFVAVLVKKSSMPWNKRQPKLQGKSAETRESTQLSPADLTEGKPTDPSKLESPSFTGTGDTEIAHATEDLENNGSKKDGVCGPPPSKKMKLFGFKEDPFVFIPEDDPLFPPIEKFYALDPSFPRMNLLTRTTEGKKRQLYMVSKELRNVLLNNSEKMKVINTGIKVWCRNNSGEEFDCAFRLAQEGIYTLYPFINSRIITVSMEDVKILLTQENPFFRKLSSETYSQAKDLAKGSIVLKYEPDSANPDALQCPIVLCGWRGKASIRTFVPKNERLHYLRMMGLEVLGEKKKEGVILTNESAASTGQPDNDVTEGQRAGEPNSPDAEEANSPDVTAGCDPAGVHPPR^p |
| 胞苷脫胺酶之例示性胺基酸序列 | 207 | MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVEGRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 208 | MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLRYAIDRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQVLRFLATHHNLSLDIFSSRLYNIRDPENQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKKLLTNFRYQDSKLQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVERRRVHLLSEEEFYSQFYNQRVKHLCYYHGVKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVIITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFWPWKGLEIISRRTQRRLHRIKESWGLQDLVNDFGNLQLGPPMS |
| 胞苷脫胺酶之例示性胺基酸序列 | 209 | MVEPMDPRTFVSNFNNRPILSGLNTVWLCCEVKTKDPSGPPLDAKIFQGKVYSKAKYHPEMRFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANSVATFLAKDPKVTLTIFVARLYYFWKPDYQQALRILCQKRGGPHATMKIMNYNEFQDCWNKFVDGRGKPFKPRNNLPKHYTLLQATLGELLRHLMDPGTFTSNFNNKPWVSGQHETYLCYKVERLHNDTWVPLNQHRGFLRNQAPNIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFSCAQEMAKFISNNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI |
| 胞苷脫胺酶之例示性胺基酸序列 | 210 | MKPHFRNPVERMYQDTFSDNFYNRPILSHRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSKLKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDVATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTSNFNNELWVRGRHETYLCYEVERLHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLHQDYRVTCFTSWSPCFSCAQEMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLAKAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLEEHSQALSGRLRAILQNQGN |
| 胞苷脫胺酶之例示性胺基酸序列 | 211 | MNPQIRNMVEQMEPDIFVYYFNNRPILSGRNTVWLCYEVKTKDPSGPPLDANIFQGKLYPEAKDHPEMKFLHWFRKWRQLHRDQEYEVTWYVSWSPCTRCANSVATFLAEDPKVTLTIFVARLYYFWKPDYQQALRILCQERGGPHATMKIMNYNEFQHCWNEFVDGQGKPFKPRKNLPKHYTLLHATLGELLRHVMDPGTFTSNFNNKPWVSGQRETYLCYKVERSHNDTWVLLNQHRGFLRNQAPDRHGFPKGRHAELCFLDLIPFWKLDDQQYRVTCFTSWSPCFSCAQKMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLHRDGAKIAVMNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI |
| 胞苷脫胺酶之例示性胺基酸序列 | 212 | MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN |
| 胞苷脫胺酶之例示性胺基酸序列 | 213 | MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQVYSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYSEGQPFMPWYKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE |
| 胞苷脫胺酶之例示性胺基酸序列 | 214 | MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFRGQVYFKPQYHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLSEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVTIMDYEEFAYCWENFVYNEGQQFMPWYKFDENYAFLHRTLKEILRYLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQNQGN |
| 胞苷脫胺酶之例示性胺基酸序列 | 215 | MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLWDTGVFRGPVLPKRQSNHRQEVYFRFENHAEMCFLSWFCGNRLPANRRFQITWFVSWNPCLPCVVKVTKFLAEHPNVTLTISAARLYYYRDRDWRWVLLRLHKAGARVKIMDYEDFAYCWENFVCNEGQPFMPWYKFDDNYASLHRTLKEILRNPMEAMYPHIFYFHFKNLLKACGRNESWLCFTMEVTKHHSAVFRKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGASVKIMGYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ |
| 胞苷脫胺酶之例示性胺基酸序列 | 216 | MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVL ELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK |
| Nme1Cas9裂解酶之例示性胺基酸序列 | 220 | MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR |
| 編碼Nme1Cas9裂解酶之例示性編碼序列 | 221 | GCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme1Cas9裂解酶之例示性編碼序列 | 222 | GCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme1Cas9裂解酶之例示性編碼序列 | 223 | GCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme1Cas9裂解酶之例示性開放閱讀框架 | 224 | ATGGCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme1Cas9裂解酶之例示性開放閱讀框架 | 225 | ATGGCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme1Cas9裂解酶之例示性開放閱讀框架 | 226 | ATGGCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme1Cas9 dCas9之例示性胺基酸序列 | 227 | MAAFKPNSINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR |
| 編碼Nme1Cas9 dCas9之例示性編碼序列 | 228 | GCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme1Cas9 dCas9之例示性編碼序列 | 229 | GCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme1Cas9 dCas9之例示性編碼序列 | 230 | GCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme1Cas9 dCas9之例示性開放閱讀框架 | 231 | ATGGCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme1Cas9 dCas9之例示性開放閱讀框架 | 232 | ATGGCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme1Cas9 dCas9之例示性開放閱讀框架 | 233 | ATGGCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme1Cas9 RuvC切口酶之例示性胺基酸序列 | 234 | MAAFKPNSINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR |
| 編碼Nme1Cas9 RuvC切口酶之例示性編碼序列 | 235 | GCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme1Cas9 RuvC切口酶之例示性編碼序列 | 236 | GCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme1Cas9 RuvC切口酶之例示性編碼序列 | 237 | GCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme1Cas9 RuvC切口酶之例示性開放閱讀框架 | 238 | ATGGCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme1Cas9 RuvC切口酶之例示性開放閱讀框架 | 239 | ATGGCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme1Cas9 RuvC切口酶之例示性開放閱讀框架 | 240 | ATGGCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme1Cas9 HNH切口酶之例示性胺基酸序列 | 241 | MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR |
| 編碼Nme1Cas9 HNH切口酶之例示性編碼序列 | 242 | GCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme1Cas9 HNH切口酶之例示性編碼序列 | 243 | GCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme1Cas9 HNH切口酶之例示性編碼序列 | 244 | GCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme1Cas9 HNH切口酶之例示性開放閱讀框架 | 245 | ATGGCTGCTTTTAAGCCTAATTCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTACTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTAATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGGTAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTTCTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCTTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTCAGGGTAAGGATGAGGAGGATTGGCAGCTTATTGATGATTCTTTTAATTTTAAGTTTTCTCTTCATCCTAATGATCTTGTTGAGGTTATTACTAAGAAGGCTCGTATGTTTGGTTATTTTGCTTCTTGTCATCGTGGTACTGGTAATATTAATATTCGTATTCATGATCTTGATCATAAGATTGGTAAGAATGGTATTCTTGAGGGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme1Cas9 HNH切口酶之例示性開放閱讀框架 | 246 | ATGGCCGCCTTCAAGCCCAACTCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGACCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCAACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGGCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGTCCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCTGGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGCAGGGCAAGGACGAGGAGGACTGGCAGCTGATCGACGACTCCTTCAACTTCAAGTTCTCCCTGCACCCCAACGACCTGGTGGAGGTGATCACCAAGAAGGCCCGGATGTTCGGCTACTTCGCCTCCTGCCACCGGGGCACCGGCAACATCAACATCCGGATCCACGACCTGGACCACAAGATCGGCAAGAACGGCATCCTGGAGGGCATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme1Cas9 HNH切口酶之例示性開放閱讀框架 | 247 | ATGGCAGCATTCAAACCAAACTCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAACACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAAACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGGAAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGATCAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACTAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTACAAGGAAAAGACGAAGAAGACTGACAACTAATCGACGACTCATTCAACTTCAAATTCTCACTACACCCAAACGACCTAGTAGAAGTAATCACAAAAAAAGCACGAATGTTCGGATACTTCGCATCATGCCACCGAGGAACAGGAAACATCAACATCCGAATCCACGACCTAGACCACAAAATCGGAAAAAACGGAATCCTAGAAGGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme2Cas9裂解酶之例示性胺基酸序列 | 248 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 編碼Nme2Cas9裂解酶之例示性編碼序列 | 249 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme2Cas9裂解酶之例示性編碼序列 | 250 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme2Cas9裂解酶之例示性編碼序列 | 251 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAAACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCATCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAGTACAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGTACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAATGCAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCACATCCTACTAACAGGAAAAGGAAAACGACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAAAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGAGCACACAAAGACACACTACGATCAGCAAAACGATTCGTAAAACACAACGAAAAAATCTCAGTAAAACGAGTATGACTAACAGAAATCAAACTAGCAGACCTAGAAAACATGGTAAACTACAAAAACGGACGAGAAATCGAACTATACGAAGCACTAAAAGCACGACTAGAAGCATACGGAGGAAACGCAAAACAAGCATTCGACCCAAAAGACAACCCATTCTACAAAAAAGGAGGACAACTAGTAAAAGCAGTACGAGTAGAAAAAACACAAGAATCAGGAGTACTACTAAACAAAAAAAACGCATACACAATCGCAGACAACGGAGACATGGTACGAGTAGACGTATTCTGCAAAGTAGACAAAAAAGGAAAAAACCAATACTTCATCGTACCAATCTACGCATGACAAGTAGCAGAAAACATCCTACCAGACATCGACTGCAAAGGATACCGAATCGACGACTCATACACATTCTGCTTCTCACTACACAAATACGACCTAATCGCATTCCAAAAAGACGAAAAATCAAAAGTAGAATTCGCATACTACATCAACTGCGACTCATCAAACGGACGATTCTACCTAGCATGACACGACAAAGGATCAAAAGAACAACAATTCCGAATCTCAACACAAAACCTAGTACTAATCCAAAAATACCAAGTAAACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme2Cas9裂解酶之例示性開放閱讀框架 | 252 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme2Cas9裂解酶之例示性開放閱讀框架 | 253 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme2Cas9裂解酶之例示性開放閱讀框架 | 254 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAAACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCATCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAGTACAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGTACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAATGCAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCACATCCTACTAACAGGAAAAGGAAAACGACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAAAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGAGCACACAAAGACACACTACGATCAGCAAAACGATTCGTAAAACACAACGAAAAAATCTCAGTAAAACGAGTATGACTAACAGAAATCAAACTAGCAGACCTAGAAAACATGGTAAACTACAAAAACGGACGAGAAATCGAACTATACGAAGCACTAAAAGCACGACTAGAAGCATACGGAGGAAACGCAAAACAAGCATTCGACCCAAAAGACAACCCATTCTACAAAAAAGGAGGACAACTAGTAAAAGCAGTACGAGTAGAAAAAACACAAGAATCAGGAGTACTACTAAACAAAAAAAACGCATACACAATCGCAGACAACGGAGACATGGTACGAGTAGACGTATTCTGCAAAGTAGACAAAAAAGGAAAAAACCAATACTTCATCGTACCAATCTACGCATGACAAGTAGCAGAAAACATCCTACCAGACATCGACTGCAAAGGATACCGAATCGACGACTCATACACATTCTGCTTCTCACTACACAAATACGACCTAATCGCATTCCAAAAAGACGAAAAATCAAAAGTAGAATTCGCATACTACATCAACTGCGACTCATCAAACGGACGATTCTACCTAGCATGACACGACAAAGGATCAAAAGAACAACAATTCCGAATCTCAACACAAAACCTAGTACTAATCCAAAAATACCAAGTAAACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme2Cas9 dCas9之例示性胺基酸序列 | 255 | MAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 編碼Nme2Cas9 dCas9之例示性編碼序列 | 256 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme2Cas9 dCas9之例示性編碼序列 | 257 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme2Cas9 dCas9之例示性編碼序列 | 258 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| Nme2Cas9 dCas9之例示性開放閱讀框架 | 259 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme2Cas9 dCas9之例示性開放閱讀框架 | 260 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme2Cas9 dCas9之例示性開放閱讀框架 | 261 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUAA |
| Nme2Cas9 RuvC切口酶之例示性胺基酸序列 | 262 | MAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 編碼Nme2Cas9 RuvC切口酶之例示性編碼序列 | 263 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme2Cas9 RuvC切口酶之例示性編碼序列 | 264 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme2Cas9 RuvC切口酶之例示性編碼序列 | 265 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| Nme2Cas9 RuvC切口酶之例示性開放閱讀框架 | 266 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme2Cas9 RuvC切口酶之例示性開放閱讀框架 | 267 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme2Cas9 RuvC切口酶之例示性開放閱讀框架 | 268 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUAA |
| Nme2Cas9 HNH切口酶之例示性胺基酸序列 | 269 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR |
| 編碼Nme2Cas9 HNH切口酶之例示性編碼序列 | 270 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme2Cas9 HNH切口酶之例示性編碼序列 | 271 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme2Cas9 HNH切口酶之例示性編碼序列 | 272 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAAACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCATCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAGTACAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGTACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAATGCAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCACATCCTACTAACAGGAAAAGGAAAACGACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAAAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGAGCACACAAAGACACACTACGATCAGCAAAACGATTCGTAAAACACAACGAAAAAATCTCAGTAAAACGAGTATGACTAACAGAAATCAAACTAGCAGACCTAGAAAACATGGTAAACTACAAAAACGGACGAGAAATCGAACTATACGAAGCACTAAAAGCACGACTAGAAGCATACGGAGGAAACGCAAAACAAGCATTCGACCCAAAAGACAACCCATTCTACAAAAAAGGAGGACAACTAGTAAAAGCAGTACGAGTAGAAAAAACACAAGAATCAGGAGTACTACTAAACAAAAAAAACGCATACACAATCGCAGACAACGGAGACATGGTACGAGTAGACGTATTCTGCAAAGTAGACAAAAAAGGAAAAAACCAATACTTCATCGTACCAATCTACGCATGACAAGTAGCAGAAAACATCCTACCAGACATCGACTGCAAAGGATACCGAATCGACGACTCATACACATTCTGCTTCTCACTACACAAATACGACCTAATCGCATTCCAAAAAGACGAAAAATCAAAAGTAGAATTCGCATACTACATCAACTGCGACTCATCAAACGGACGATTCTACCTAGCATGACACGACAAAGGATCAAAAGAACAACAATTCCGAATCTCAACACAAAACCTAGTACTAATCCAAAAATACCAAGTAAACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme2Cas9 HNH切口酶之例示性開放閱讀框架 | 273 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTAATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTCTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTATTCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTGGTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATGCTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTTCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTGTTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGTTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGTGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCATATTCTTCTTACTGGTAAGGGTAAGCGTCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTAAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTGCTCATAAGGATACTCTTCGTTCTGCTAAGCGTTTTGTTAAGCATAATGAGAAGATTTCTGTTAAGCGTGTTTGGCTTACTGAGATTAAGCTTGCTGATCTTGAGAATATGGTTAATTATAAGAATGGTCGTGAGATTGAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTTATGGTGGTAATGCTAAGCAGGCTTTTGATCCTAAGGATAATCCTTTTTATAAGAAGGGTGGTCAGCTTGTTAAGGCTGTTCGTGTTGAGAAGACTCAGGAGTCTGGTGTTCTTCTTAATAAGAAGAATGCTTATACTATTGCTGATAATGGTGATATGGTTCGTGTTGATGTTTTTTGTAAGGTTGATAAGAAGGGTAAGAATCAGTATTTTATTGTTCCTATTTATGCTTGGCAGGTTGCTGAGAATATTCTTCCTGATATTGATTGTAAGGGTTATCGTATTGATGATTCTTATACTTTTTGTTTTTCTCTTCATAAGTATGATCTTATTGCTTTTCAGAAGGATGAGAAGTCTAAGGTTGAGTTTGCTTATTATATTAATTGTGATTCTTCTAATGGTCGTTTTTATCTTGCTTGGCATGATAAGGGTTCTAAGGAGCAGCAGTTTCGTATTTCTACTCAGAATCTTGTTCTTATTCAGAAGTATCAGGTTAATGAGCTTGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme2Cas9 HNH切口酶之例示性開放閱讀框架 | 274 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme2Cas9 HNH切口酶之例示性開放閱讀框架 | 275 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAAACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATCAGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAATCCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTAGGACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACGCAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCATCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAGTACAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGTACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAATGCAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCACATCCTACTAACAGGAAAAGGAAAACGACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAAAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGAGCACACAAAGACACACTACGATCAGCAAAACGATTCGTAAAACACAACGAAAAAATCTCAGTAAAACGAGTATGACTAACAGAAATCAAACTAGCAGACCTAGAAAACATGGTAAACTACAAAAACGGACGAGAAATCGAACTATACGAAGCACTAAAAGCACGACTAGAAGCATACGGAGGAAACGCAAAACAAGCATTCGACCCAAAAGACAACCCATTCTACAAAAAAGGAGGACAACTAGTAAAAGCAGTACGAGTAGAAAAAACACAAGAATCAGGAGTACTACTAAACAAAAAAAACGCATACACAATCGCAGACAACGGAGACATGGTACGAGTAGACGTATTCTGCAAAGTAGACAAAAAAGGAAAAAACCAATACTTCATCGTACCAATCTACGCATGACAAGTAGCAGAAAACATCCTACCAGACATCGACTGCAAAGGATACCGAATCGACGACTCATACACATTCTGCTTCTCACTACACAAATACGACCTAATCGCATTCCAAAAAGACGAAAAATCAAAAGTAGAATTCGCATACTACATCAACTGCGACTCATCAAACGGACGATTCTACCTAGCATGACACGACAAAGGATCAAAAGAACAACAATTCCGAATCTCAACACAAAACCTAGTACTAATCCAAAAATACCAAGTAAACGAACTAGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme3Cas9裂解酶之例示性胺基酸序列 | 276 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYADEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKEIRPCRLKKRPPVR |
| 編碼Nme3Cas9裂解酶之例示性編碼序列 | 277 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme3Cas9裂解酶之例示性編碼序列 | 278 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme3Cas9裂解酶之例示性編碼序列 | 279 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme3Cas9裂解酶之例示性開放閱讀框架 | 280 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme3Cas9裂解酶之例示性開放閱讀框架 | 281 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme3Cas9裂解酶之例示性開放閱讀框架 | 282 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme3Cas9 dCas9之例示性胺基酸序列 | 283 | MAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYADEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKEIRPCRLKKRPPVR |
| 編碼Nme3Cas9 dCas9之例示性編碼序列 | 284 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme3Cas9 dCas9之例示性編碼序列 | 285 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme3Cas9 dCas9之例示性編碼序列 | 286 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme3Cas9 dCas9之例示性開放閱讀框架 | 287 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme3Cas9 dCas9之例示性開放閱讀框架 | 288 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme3Cas9 dCas9之例示性開放閱讀框架 | 289 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme3Cas9 RuvC切口酶之例示性胺基酸序列 | 290 | MAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYADEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKEIRPCRLKKRPPVR |
| 編碼Nme3Cas9 RuvC切口酶之例示性編碼序列 | 291 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme3Cas9 RuvC切口酶之例示性編碼序列 | 292 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme3Cas9 RuvC切口酶之例示性編碼序列 | 293 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme3Cas9 RuvC切口酶之例示性開放閱讀框架 | 294 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGCTATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATCATGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUAA |
| Nme3Cas9 RuvC切口酶之例示性開放閱讀框架 | 295 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGCCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme3Cas9 RuvC切口酶之例示性開放閱讀框架 | 296 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGCAATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACCACGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| Nme3Cas9 HNH切口酶之例示性胺基酸序列 | 297 | MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYADEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKEIRPCRLKKRPPVR |
| 編碼Nme3Cas9 HNH切口酶之例示性編碼序列 | 298 | GCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGT |
| 編碼Nme3Cas9 HNH切口酶之例示性編碼序列 | 299 | GCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGG |
| 編碼Nme3Cas9 HNH切口酶之例示性編碼序列 | 300 | GCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGA |
| Nme3Cas9 HNH切口酶之例示性開放閱讀框架 | 301 | ATGGCTGCTTTTAAGCCTAATCCTATTAATTATATTCTTGGTCTTGATATTGGTATTGCTTCTGTTGGTTGGGCTATGGTTGAGATTGATGAGGAGGAGAATCCTATTCGTCTTATTGATCTTGGTGTTCGTGTTTTTGAGCGTGCTGAGGTTCCTAAGACTGGTGATTCTCTTGCTATGGCTCGTCGTCTTGCTCGTTCTGTTCGTCGTCTTACTCGTCGTCGTGCTCATCGTCTTCTTCGTGCTCGTCGTCTTCTTAAGCGTGAGGGTGTTCTTCAGGCTGCTGATTTTGATGAGAATGGTCTTATTAAGTCTCTTCCTAATACTCCTTGGCAGCTTCGTGCTGCTGCTCTTGATCGTAAGCTTACTCCTCTTGAGTGGTCTGCTGTTCTTCTTCATCTTATTAAGCATCGTGGTTATCTTTCTCAGCGTAAGAATGAGGGTGAGACTGCTGATAAGGAGCTTGGTGCTCTTCTTAAGGGTGTTGCTGATAATGCTCATGCTCTTCAGACTGGTGATTTTCGTACTCCTGCTGAGCTTGCTCTTAATAAGTTTGAGAAGGAGTGTGGTCATATTCGTAATCAGCGTGGTGATTATTCTCATACTTTTTCTCGTAAGGATCTTCAGGCTGAGCTTAATCTTCTTTTTGAGAAGCAGAAGGAGTTTGGTAATCCTCATGTTTCTGGTGGTCTTAAGGAGGGTATTGAGACTCTTCTTATGACTCAGCGTCCTGCTCTTTCTGGTGATGCTGTTCAGAAGATGCTTGGTCATTGTACTTTTGAGCCTGCTGAGCCTAAGGCTGCTAAGAATACTTATACTGCTGAGCGTTTTATTTGGCTTACTAAGCTTAATAATCTTCGTATTCTTGAGCAGGGTTCTGAGCGTCCTCTTACTGATACTGAGCGTGCTACTCTTATGGATGAGCCTTATCGTAAGTCTAAGCTTACTTATGCTCAGGCTCGTAAGCTTCTTTCTCTTGAGGATACTGCTTTTTTTAAGGGTCTTCGTTATGGTAAGGATAATGCTGAGGCTTCTACTCTTATGGAGATGAAGGCTTATCATACTATTTCTCGTGCTCTTGAGAAGGAGGGTCTTAAGGATAAGAAGTCTCCTCTTAATCTTTCTCCTGAGCTTCAGGATGAGATTGGTACTGCTTTTTCTCTTTTTAAGACTGATGAGGATATTACTGGTCGTCTTAAGGATCGTATTCAGCCTGAGATTCTTGAGGCTCTTCTTAAGCATATTTCTTTTGATAAGTTTGTTCAGATTTCTCTTAAGGCTCTTCGTCGTATTGTTCCTCTTATGGAGCAGGGTAAGCGTTATGATGAGGCTTGTGCTGAGATTTATGGTGATCATTATGGTAAGAAGAATACTGAGGAGAAGATTTATCTTCCTCCTATTCCTGCTGATGAGATTCGTAATCCTGTTGTTCTTCGTGCTCTTTCTCAGGCTCGTAAGGTTATTAATGGTGTTGTTCGTCGTTATGGTTCTCCTGCTCGTATTCATATTGAGACTGCTCGTGAGGTTGGTAAGTCTTTTAAGGATCGTAAGGAGATTGAGAAGCGTCAGGAGGAGAATCGTAAGGATCGTGAGAAGGCTGCTGCTAAGTTTCGTGAGTATTTTCCTAATTTTGTTGGTGAGCCTAAGTCTAAGGATATTCTTAAGCTTCGTCTTTATGAGCAGCAGCATGGTAAGTGTCTTTATTCTGGTAAGGAGATTAATCTTGGTCGTCTTAATGAGAAGGGTTATGTTGAGATTGATGCTGCTCTTCCTTTTTCTCGTACTTGGGATGATTCTTTTAATAATAAGGTTCTTGTTCTTGGTTCTGAGAATCAGAATAAGGGTAATCAGACTCCTTATGAGTATTTTAATGGTAAGGATAATTCTCGTGAGTGGCAGGAGTTTAAGGCTCGTGTTGAGACTTCTCGTTTTCCTCGTTCTAAGAAGCAGCGTATTCTTCTTCAGAAGTTTGATGAGGATGGTTTTAAGGAGCGTAATCTTAATGATACTCGTTATGTTAATCGTTTTCTTTGTCAGTTTGTTGCTGATCGTATGCGTCTTACTGGTAAGGGTAAGAAGCGTGTTTTTGCTTCTAATGGTCAGATTACTAATCTTCTTCGTGGTTTTTGGGGTCTTCGTAAGGTTCGTGCTGAGAATGATCGTCATCATGCTCTTGATGCTGTTGTTGTTGCTTGTTCTACTGTTGCTATGCAGCAGAAGATTACTCGTTTTGTTCGTTATAAGGAGATGAATGCTTTTGATGGTAAGACTATTGATAAGGAGACTGGTGAGGTTCTTCATCAGAAGACTCATTTTCCTCAGCCTTGGGAGTTTTTTGCTCAGGAGGTTATGATTCGTGTTTTTGGTAAGCCTGATGGTAAGCCTGAGTTTGAGGAGGCTGATACTCCTGAGAAGCTTCGTACTCTTCTTGCTGAGAAGCTTTCTTCTCGTCCTGAGGCTGTTCATGAGTATGTTACTCCTCTTTTTGTTTCTCGTGCTCCTAATCGTAAGATGTCTGGTCAGGGTCATATGGAGACTGTTAAGTCTGCTAAGCGTCTTGATGAGGGTGTTTCTGTTCTTCGTGTTCCTCTTACTCAGCTTAAGCTTAAGGATCTTGAGAAGATGGTTAATCGTGAGCGTGAGCCTAAGCTTTATGAGGCTCTTAAGGCTCGTCTTGAGGCTCATAAGGATGATCCTGCTAAGGCTTTTGCTGAGCCTTTTTATAAGTATGATAAGGCTGGTAATCGTACTCAGCAGGTTAAGGCTGTTCGTGTTGAGCAGGTTCAGAAGACTGGTGTTTGGGTTCGTAATCATAATGGTATTGCTGATAATGCTACTATGGTTCGTGTTGATGTTTTTGAGAAGGGTGATAAGTATTATCTTGTTCCTATTTATTCTTGGCAGGTTGCTAAGGGTATTCTTCCTGATCGTGCTGTTGTTGCTTATGCTGATGAGGAGGATTGGACTGTTATTGATGAGTCTTTTCGTTTTAAGTTTGTTCTTTATTCTAATGATCTTATTAAGGTTCAGCTTAAGAAGGATTCTTTTCTTGGTTATTTTTCTGGTCTTGATCGTGCTACTGGTGCTATTTCTCTTCGTGAGCATGATCTTGAGAAGTCTAAGGGTAAGGATGGTATGCATCGTATTGGTGTTAAGACTGCTCTTTCTTTTCAGAAGTATCAGATTGATGAGATGGGTAAGGAGATTCGTCCTTGTCGTCTTAAGAAGCGTCCTCCTGTTCGTUGA |
| Nme3Cas9 HNH切口酶之例示性開放閱讀框架 | 302 | ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCGACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTGCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGAACCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGTCCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACACCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCCCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGATCCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGGCCGGCTGAACGAGAAGGGCTACGTGGAGATCGACGCCGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGCGGAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCGGATGCGGCTGACCGGCAAGGGCAAGAAGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCGAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCCAGGGCCACATGGAGACCGTGAAGTCCGCCAAGCGGCTGGACGAGGGCGTGTCCGTGCTGCGGGTGCCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGATGGTGAACCGGGAGCGGGAGCCCAAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCCACAAGGACGACCCCGCCAAGGCCTTCGCCGAGCCCTTCTACAAGTACGACAAGGCCGGCAACCGGACCCAGCAGGTGAAGGCCGTGCGGGTGGAGCAGGTGCAGAAGACCGGCGTGTGGGTGCGGAACCACAACGGCATCGCCGACAACGCCACCATGGTGCGGGTGGACGTGTTCGAGAAGGGCGACAAGTACTACCTGGTGCCCATCTACTCCTGGCAGGTGGCCAAGGGCATCCTGCCCGACCGGGCCGTGGTGGCCTACGCCGACGAGGAGGACTGGACCGTGATCGACGAGTCCTTCCGGTTCAAGTTCGTGCTGTACTCCAACGACCTGATCAAGGTGCAGCTGAAGAAGGACTCCTTCCTGGGCTACTTCTCCGGCCTGGACCGGGCCACCGGCGCCATCTCCCTGCGGGAGCACGACCTGGAGAAGTCCAAGGGCAAGGACGGCATGCACCGGATCGGCGTGAAGACCGCCCTGTCCTTCCAGAAGTACCAGATCGACGAGATGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGUGA |
| Nme3Cas9 HNH切口酶之例示性開放閱讀框架 | 303 | ATGGCAGCATTCAAACCAAACCCAATCAACTACATCCTAGGACTAGACATCGGAATCGCATCAGTAGGATGAGCAATGGTAGAAATCGACGAAGAAGAAAACCCAATCCGACTAATCGACCTAGGAGTACGAGTATTCGAACGAGCAGAAGTACCAAAAACAGGAGACTCACTAGCAATGGCACGACGACTAGCACGATCAGTACGACGACTAACACGACGACGAGCACACCGACTACTACGAGCACGACGACTACTAAAACGAGAAGGAGTACTACAAGCAGCAGACTTCGACGAAAACGGACTAATCAAATCACTACCAAACACACCATGACAACTACGAGCAGCAGCACTAGACCGAAAACTAACACCACTAGAATGATCAGCAGTACTACTACACCTAATCAAACACCGAGGATACCTATCACAACGAAAAAACGAAGGAGAAACAGCAGACAAAGAACTAGGAGCACTACTAAAAGGAGTAGCAGACAACGCACACGCACTACAAACAGGAGACTTCCGAACACCAGCAGAACTAGCACTAAACAAATTCGAAAAAGAATGCGGACACATCCGAAACCAACGAGGAGACTACTCACACACATTCTCACGAAAAGACCTACAAGCAGAACTAAACCTACTATTCGAAAAACAAAAAGAATTCGGAAACCCACACGTATCAGGAGGACTAAAAGAAGGAATCGAAACACTACTAATGACACAACGACCAGCACTATCAGGAGACGCAGTACAAAAAATGCTAGGACACTGCACATTCGAACCAGCAGAACCAAAAGCAGCAAAAAACACATACACAGCAGAACGATTCATCTGACTAACAAAACTAAACAACCTACGAATCCTAGAACAAGGATCAGAACGACCACTAACAGACACAGAACGAGCAACACTAATGGACGAACCATACCGAAAATCAAAACTAACATACGCACAAGCACGAAAACTACTATCACTAGAAGACACAGCATTCTTCAAAGGACTACGATACGGAAAAGACAACGCAGAAGCATCAACACTAATGGAAATGAAAGCATACCACACAATCTCACGAGCACTAGAAAAAGAAGGACTAAAAGACAAAAAATCACCACTAAACCTATCACCAGAACTACAAGACGAAATCGGAACAGCATTCTCACTATTCAAAACAGACGAAGACATCACAGGACGACTAAAAGACCGAATCCAACCAGAAATCCTAGAAGCACTACTAAAACACATCTCATTCGACAAATTCGTACAAATCTCACTAAAAGCACTACGACGAATCGTACCACTAATGGAACAAGGAAAACGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACGGAAAAAAAAACACAGAAGAAAAAATCTACCTACCACCAATCCCAGCAGACGAAATCCGAAACCCAGTAGTACTACGAGCACTATCACAAGCACGAAAAGTAATCAACGGAGTAGTACGACGATACGGATCACCAGCACGAATCCACATCGAAACAGCACGAGAAGTAGGAAAATCATTCAAAGACCGAAAAGAAATCGAAAAACGACAAGAAGAAAACCGAAAAGACCGAGAAAAAGCAGCAGCAAAATTCCGAGAATACTTCCCAAACTTCGTAGGAGAACCAAAATCAAAAGACATCCTAAAACTACGACTATACGAACAACAACACGGAAAATGCCTATACTCAGGAAAAGAAATCAACCTAGGACGACTAAACGAAAAAGGATACGTAGAAATCGACGCAGCACTACCATTCTCACGAACATGAGACGACTCATTCAACAACAAAGTACTAGTACTAGGATCAGAAAACCAAAACAAAGGAAACCAAACACCATACGAATACTTCAACGGAAAAGACAACTCACGAGAATGACAAGAATTCAAAGCACGAGTAGAAACATCACGATTCCCACGATCAAAAAAACAACGAATCCTACTACAAAAATTCGACGAAGACGGATTCAAAGAACGAAACCTAAACGACACACGATACGTAAACCGATTCCTATGCCAATTCGTAGCAGACCGAATGCGACTAACAGGAAAAGGAAAAAAACGAGTATTCGCATCAAACGGACAAATCACAAACCTACTACGAGGATTCTGAGGACTACGAAAAGTACGAGCAGAAAACGACCGACACCACGCACTAGACGCAGTAGTAGTAGCATGCTCAACAGTAGCAATGCAACAAAAAATCACACGATTCGTACGATACAAAGAAATGAACGCATTCGACGGAAAAACAATCGACAAAGAAACAGGAGAAGTACTACACCAAAAAACACACTTCCCACAACCATGAGAATTCTTCGCACAAGAAGTAATGATCCGAGTATTCGGAAAACCAGACGGAAAACCAGAATTCGAAGAAGCAGACACACCAGAAAAACTACGAACACTACTAGCAGAAAAACTATCATCACGACCAGAAGCAGTACACGAATACGTAACACCACTATTCGTATCACGAGCACCAAACCGAAAAATGTCAGGACAAGGACACATGGAAACAGTAAAATCAGCAAAACGACTAGACGAAGGAGTATCAGTACTACGAGTACCACTAACACAACTAAAACTAAAAGACCTAGAAAAAATGGTAAACCGAGAACGAGAACCAAAACTATACGAAGCACTAAAAGCACGACTAGAAGCACACAAAGACGACCCAGCAAAAGCATTCGCAGAACCATTCTACAAATACGACAAAGCAGGAAACCGAACACAACAAGTAAAAGCAGTACGAGTAGAACAAGTACAAAAAACAGGAGTATGAGTACGAAACCACAACGGAATCGCAGACAACGCAACAATGGTACGAGTAGACGTATTCGAAAAAGGAGACAAATACTACCTAGTACCAATCTACTCATGACAAGTAGCAAAAGGAATCCTACCAGACCGAGCAGTAGTAGCATACGCAGACGAAGAAGACTGAACAGTAATCGACGAATCATTCCGATTCAAATTCGTACTATACTCAAACGACCTAATCAAAGTACAACTAAAAAAAGACTCATTCCTAGGATACTTCTCAGGACTAGACCGAGCAACAGGAGCAATCTCACTACGAGAACACGACCTAGAAAAATCAAAAGGAAAAGACGGAATGCACCGAATCGGAGTAAAAACAGCACTATCATTCCAAAAATACCAAATCGACGAAATGGGAAAAGAAATCCGACCATGCCGACTAAAAAAACGACCACCAGTACGAUAA |
| 編碼Nme2Cas9之例示性編碼序列 | 304 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA |
| 編碼Nme1Cas9之例示性編碼序列 | 305 | GGGUCCCGCAGUCGGCGUCCAGCGGCUCUGCUUGUUCGUGUGUGUGUCGUUGCAGGCCUUAUUCGGAUCCGCCACCAUGGCAGCAUUCAAGCCGAACUCGAUCAACUACAUCCUGGGACUGGACAUCGGAAUCGCAUCGGUCGGAUGGGCAAUGGUCGAAAUCGACGAAGAAGAAAACCCGAUCAGACUGAUCGACCUGGGAGUCAGAGUCUUCGAAAGAGCAGAAGUCCCGAAGACAGGAGACUCGCUGGCAAUGGCAAGAAGACUGGCAAGAUCGGUCAGAAGACUGACAAGAAGAAGAGCACACAGACUGCUGAGAACAAGAAGACUGCUGAAGAGAGAAGGAGUCCUGCAGGCAGCAAACUUCGACGAAAACGGACUGAUCAAGUCGCUGCCGAACACACCGUGGCAGCUGAGAGCAGCAGCACUGGACAGAAAGCUGACACCGCUGGAAUGGUCGGCAGUCCUGCUGCACCUGAUCAAGCACAGAGGAUACCUGUCGCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAACUGGGAGCACUGCUGAAGGGAGUCGCAGGAAACGCACACGCACUGCAGACAGGAGACUUCAGAACACCGGCAGAACUGGCACUGAACAAGUUCGAAAAGGAAUCGGGACACAUCAGAAACCAGAGAUCGGACUACUCGCACACAUUCUCGAGAAAGGACCUGCAGGCAGAACUGAUCCUGCUGUUCGAAAAGCAGAAGGAAUUCGGAAACCCGCACGUCUCGGGAGGACUGAAGGAAGGAAUCGAAACACUGCUGAUGACACAGAGACCGGCACUGUCGGGAGACGCAGUCCAGAAGAUGCUGGGACACUGCACAUUCGAACCGGCAGAACCGAAGGCAGCAAAGAACACAUACACAGCAGAAAGAUUCAUCUGGCUGACAAAGCUGAACAACCUGAGAAUCCUGGAACAGGGAUCGGAAAGACCGCUGACAGACACAGAAAGAGCAACACUGAUGGACGAACCGUACAGAAAGUCGAAGCUGACAUACGCACAGGCAAGAAAGCUGCUGGGACUGGAAGACACAGCAUUCUUCAAGGGACUGAGAUACGGAAAGGACAACGCAGAAGCAUCGACACUGAUGGAAAUGAAGGCAUACCACGCAAUCUCGAGAGCACUGGAAAAGGAAGGACUGAAGGACAAGAAGUCGCCGCUGAACCUGUCGCCGGAACUGCAGGACGAAAUCGGAACAGCAUUCUCGCUGUUCAAGACAGACGAAGACAUCACAGGAAGACUGAAGGACAGAAUCCAGCCGGAAAUCCUGGAAGCACUGCUGAAGCACAUCUCGUUCGACAAGUUCGUCCAGAUCUCGCUGAAGGCACUGAGAAGAAUCGUCCCGCUGAUGGAACAGGGAAAGAGAUACGACGAAGCAUGCGCAGAAAUCUACGGAGACCACUACGGAAAGAAGAACACAGAAGAAAAGAUCUACCUGCCGCCGAUCCCGGCAGACGAAAUCAGAAACCCGGUCGUCCUGAGAGCACUGUCGCAGGCAAGAAAGGUCAUCAACGGAGUCGUCAGAAGAUACGGAUCGCCGGCAAGAAUCCACAUCGAAACAGCAAGAGAAGUCGGAAAGUCGUUCAAGGACAGAAAGGAAAUCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAGCAGCAAAGUUCAGAGAAUACUUCCCGAACUUCGUCGGAGAACCGAAGUCGAAGGACAUCCUGAAGCUGAGACUGUACGAACAGCAGCACGGAAAGUGCCUGUACUCGGGAAAGGAAAUCAACCUGGGAAGACUGAACGAAAAGGGAUACGUCGAAAUCGACCACGCACUGCCGUUCUCGAGAACAUGGGACGACUCGUUCAACAACAAGGUCCUGGUCCUGGGAUCGGAAAACCAGAACAAGGGAAACCAGACACCGUACGAAUACUUCAACGGAAAGGACAACUCGAGAGAAUGGCAGGAAUUCAAGGCAAGAGUCGAAACAUCGAGAUUCCCGAGAUCGAAGAAGCAGAGAAUCCUGCUGCAGAAGUUCGACGAAGACGGAUUCAAGGAAAGAAACCUGAACGACACAAGAUACGUCAACAGAUUCCUGUGCCAGUUCGUCGCAGACAGAAUGAGACUGACAGGAAAGGGAAAGAAGAGAGUCUUCGCAUCGAACGGACAGAUCACAAACCUGCUGAGAGGAUUCUGGGGACUGAGAAAGGUCAGAGCAGAAAACGACAGACACCACGCACUGGACGCAGUCGUCGUCGCAUGCUCGACAGUCGCAAUGCAGCAGAAGAUCACAAGAUUCGUCAGAUACAAGGAAAUGAACGCAUUCGACGGAAAGACAAUCGACAAGGAAACAGGAGAAGUCCUGCACCAGAAGACACACUUCCCGCAGCCGUGGGAAUUCUUCGCACAGGAAGUCAUGAUCAGAGUCUUCGGAAAGCCGGACGGAAAGCCGGAAUUCGAAGAAGCAGACACACUGGAAAAGCUGAGAACACUGCUGGCAGAAAAGCUGUCGUCGAGACCGGAAGCAGUCCACGAAUACGUCACACCGCUGUUCGUCUCGAGAGCACCGAACAGAAAGAUGUCGGGACAGGGACACAUGGAAACAGUCAAGUCGGCAAAGAGACUGGACGAAGGAGUCUCGGUCCUGAGAGUCCCGCUGACACAGCUGAAGCUGAAGGACCUGGAAAAGAUGGUCAACAGAGAAAGAGAACCGAAGCUGUACGAAGCACUGAAGGCAAGACUGGAAGCACACAAGGACGACCCGGCAAAGGCAUUCGCAGAACCGUUCUACAAGUACGACAAGGCAGGAAACAGAACACAGCAGGUCAAGGCAGUCAGAGUCGAACAGGUCCAGAAGACAGGAGUCUGGGUCAGAAACCACAACGGAAUCGCAGACAACGCAACAAUGGUCAGAGUAGACGUCUUCGAAAAGGGAGACAAGUACUACCUGGUCCCGAUCUACUCGUGGCAGGUCGCAAAGGGAAUCCUGCCGGACAGAGCAGUCGUCCAGGGAAAGGACGAAGAAGACUGGCAGCUGAUCGACGACUCGUUCAACUUCAAGUUCUCGCUGCACCCGAACGACCUGGUCGAAGUCAUCACAAAGAAGGCAAGAAUGUUCGGAUACUUCGCAUCGUGCCACAGAGGAACAGGAAACAUCAACAUCAGAAUCCACGACCUGGACCACAAGAUCGGAAAGAACGGAAUCCUGGAAGGAAUCGGAGUCAAGACAGCACUGUCGUUCCAGAAGUACCAGAUCGACGAACUGGGAAAGGAAAUCAGACCGUGCAGACUGAAGAAGAGACCGCCGGUCAGAUCCGGAAAGAGAACAGCAGACGGAUCGGAAUUCGAAUCGCCGAAGAAGAAGAGAAAGGUCGAAUGAUAGCUAGCCAUCACAUUUAAAAGCAUCUCAGCCUACCAUGAGAAUAAGAGAAAGAAAAUGAAGAUCAAUAGCUUAUUCAUCUCUUUUUCUUUUUCGUUGGUGUAAAGCCAACACCCUGUCUAAAAAACAUAAAUUUCUUUAAUCAUUUUGCCUCUUUUCUCUGUGCUUCAAUUAAUAAAAAAUGGAAAGAACCUCGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG |
| 編碼具有HiBiT標籤之Nme2Cas9的例示性編碼序列 | 306 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUCGA |
| 編碼具有HiBiT標籤之Nme1Cas9的例示性編碼序列 | 307 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCAGCAUUCAAGCCAAACUCAAUCAAUUACAUCCUGGGACUGGACAUCGGCAUCGCAUCCGUCGGGUGGGCUAUGGUCGAAAUCGACGAGGAGGAGAACCCCAUCCGCCUGAUCGAUCUGGGCGUGCGCGUGUUUGAGAGGGCAGAGGUGCCUAAGACCGGCGACAGCCUGGCCAUGGCACGGAGACUGGCACGCUCCGUGAGGCGCCUGACCCGGAGAAGGGCCCACAGACUGCUGAGGACACGCCGGCUGCUGAAGAGGGAGGGCGUGCUGCAGGCCGCCAACUUCGAUGAGAAUGGCCUGAUCAAGUCCCUGCCCAAUACCCCUUGGCAGCUGAGGGCAGCCGCCCUGGACCGCAAGCUGACACCUCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCUCAGAGAAAGAACGAGGGCGAGACAGCCGAUAAGGAGCUGGGCGCCCUGCUGAAGGGAGUGGCAGGAAAUGCACACGCCCUGCAGACCGGCGACUUUCGCACACCAGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGAGCGGCCACAUCCGCAAUCAGCGGUCUGACUAUAGCCACACCUUCUCCCGGAAGGAUCUGCAGGCCGAGCUGAUCCUGCUGUUUGAGAAGCAGAAGGAGUUCGGCAACCCACACGUGUCUGGCGGCCUGAAGGAGGGCAUCGAGACACUGCUGAUGACACAGCGGCCCGCCCUGAGCGGCGACGCAGUGCAGAAGAUGCUGGGACACUGCACCUUUGAGCCAGCCGAGCCCAAGGCCGCCAAGAAUACCUACACAGCCGAGCGGUUCAUCUGGCUGACAAAGCUGAACAAUCUGAGGAUCCUGGAGCAGGGAAGCGAGCGCCCACUGACCGACACAGAGAGGGCCACCCUGAUGGAUGAGCCCUACCGCAAGUCCAAGCUGACAUAUGCACAGGCAAGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUUAAGGGCCUGAGAUACGGCAAGGAUAACGCCGAGGCCUCUACACUGAUGGAGAUGAAGGCCUAUCACGCCAUCAGCAGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCACUGAAUCUGUCUCCCGAGCUGCAGGAUGAGAUCGGCACCGCCUUUAGCCUGUUCAAGACCGACGAGGAUAUCACAGGCAGACUGAAGGACAGGAUCCAGCCAGAGAUCCUGGAGGCCCUGCUGAAGCACAUCAGCUUUGAUAAGUUCGUGCAGAUCAGCCUGAAGGCCCUGCGGAGGAUCGUGCCACUGAUGGAGCAGGGCAAGAGGUACGACGAGGCCUGCGCCGAAAUCUACGGCGAUCACUAUGGCAAGAAGAACACAGAGGAGAAAAUCUACCUGCCCCCUAUCCCCGCCGAUGAGAUCAGGAACCCUGUGGUGCUGCGCGCCCUGUCUCAGGCAAGAAAAGUGAUCAACGGAGUGGUGCGCCGGUACGGCAGCCCCGCCAGAAUCCACAUCGAGACAGCCAGGGAAGUGGGCAAGUCCUUUAAGGACAGAAAGGAGAUCGAGAAGAGGCAGGAGGAGAACAGAAAGGAUAGGGAGAAGGCCGCCGCCAAGUUCAGAGAGUACUUUCCUAAUUUCGUGGGCGAGCCAAAGUCCAAGGAUAUCCUGAAGCUGAGGCUGUACGAGCAGCAGCACGGCAAGUGUCUGUAUUCUGGCAAGGAGAUCAACCUGGGCCGCCUGAAUGAGAAGGGCUAUGUGGAGAUCGACCACGCCCUGCCUUUUUCUCGGACCUGGGACGAUAGCUUCAACAAUAAGGUGCUGGUGCUGGGCUCUGAGAACCAGAAUAAGGGCAACCAGACACCCUACGAGUAUUUCAACGGCAAGGACAAUAGCCGCGAGUGGCAGGAGUUUAAGGCAAGGGUGGAGACAAGCAGGUUCCCUCGGUCCAAGAAGCAGAGAAUCCUGCUGCAGAAGUUUGACGAGGAUGGCUUCAAGGAGAGGAACCUGAAUGACACCCGCUACGUGAAUCGGUUUCUGUGCCAGUUCGUGGCCGAUAGAAUGAGGCUGACCGGCAAGGGCAAGAAGAGAGUGUUUGCCUCCAACGGCCAGAUCACAAAUCUGCUGAGGGGCUUCUGGGGCCUGAGAAAGGUGAGGGCAGAGAACGACAGGCACCACGCACUGGAUGCAGUGGUGGUGGCAUGUUCUACCGUGGCCAUGCAGCAGAAGAUCACACGCUUUGUGCGGUAUAAGGAGAUGAAUGCCUUCGACGGCAAGACCAUCGAUAAGGAGACAGGCGAGGUGCUGCACCAGAAGACACACUUUCCUCAGCCAUGGGAGUUCUUUGCCCAGGAAGUGAUGAUCCGGGUGUUUGGCAAGCCUGACGGCAAGCCAGAGUUCGAGGAGGCCGAUACCCUGGAGAAGCUGAGAACACUGCUGGCAGAGAAGCUGAGCUCCAGGCCCGAGGCAGUGCACGAGUACGUGACCCCACUGUUCGUGUCUAGAGCCCCCAACAGGAAGAUGAGCGGCCAGGGCCACAUGGAGACAGUGAAGUCCGCCAAGAGACUGGACGAGGGCGUGUCUGUGCUGAGGGUGCCUCUGACACAGCUGAAGCUGAAGGAUCUGGAGAAGAUGGUGAAUCGCGAGCGGGAGCCAAAGCUGUAUGAGGCCCUGAAGGCAAGGCUGGAGGCACACAAGGACGAUCCUGCCAAGGCCUUUGCCGAGCCAUUCUACAAGUAUGAUAAGGCCGGCAACAGAACCCAGCAGGUGAAGGCCGUGAGGGUGGAGCAGGUGCAGAAGACAGGCGUGUGGGUGCGCAACCACAAUGGCAUCGCCGACAAUGCUACCAUGGUGCGGGUGGACGUGUUUGAGAAGGGCGAUAAGUACUAUCUGGUGCCCAUCUACAGCUGGCAGGUGGCCAAGGGCAUCCUGCCUGAUAGAGCCGUGGUGCAGGGCAAGGACGAGGAGGAUUGGCAGCUGAUCGACGAUUCCUUCAACUUUAAGUUCUCUCUGCACCCCAAUGACCUGGUGGAAGUGAUCACCAAGAAGGCCAGGAUGUUUGGCUACUUCGCCUCCUGCCACCGCGGCACAGGCAACAUCAAUAUCCGGAUCCACGACCUGGAUCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGAAGACAGCCCUGAGCUUCCAGAAGUAUCAGAUCGACGAGCUGGGCAAGGAGAUCAGACCUUGUAGGCUGAAGAAGCGCCCACCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUCGA |
| 編碼具有HiBiT標籤之Nme1Cas9的例示性編碼序列 | 308 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACUCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGACCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCAACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCGGCAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGUCCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCUGGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGCAGGGCAAGGACGAGGAGGACUGGCAGCUGAUCGACGACUCCUUCAACUUCAAGUUCUCCCUGCACCCCAACGACCUGGUGGAGGUGAUCACCAAGAAGGCCCGGAUGUUCGGCUACUUCGCCUCCUGCCACCGGGGCACCGGCAACAUCAACAUCCGGAUCCACGACCUGGACCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGAAGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUCGA |
| 編碼具有HiBiT標籤之Nme3Cas9的例示性編碼序列 | 309 | GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCGACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUGCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAACCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGUCCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACACCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGGCCUACGCCGACGAGGAGGACUGGACCGUGAUCGACGAGUCCUUCCGGUUCAAGUUCGUGCUGUACUCCAACGACCUGAUCAAGGUGCAGCUGAAGAAGGACUCCUUCCUGGGCUACUUCUCCGGCCUGGACCGGGCCACCGGCGCCAUCUCCCUGCGGGAGCACGACCUGGAGAAGUCCAAGGGCAAGGACGGCAUGCACCGGAUCGGCGUGAAGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGAUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG |
| Nme2Cas9之例示性胺基酸序列 | 310 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR* |
| Nme1Cas9之例示性胺基酸序列 | 311 | MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE* |
| 具有HiBiT標籤之Nme2Cas9之例示性胺基酸序列 | 312 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS* |
| 具有HiBiT標籤之Nme1Cas9之例示性胺基酸序列 | 313 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS* |
| 具有HiBiT標籤之Nme1Cas9之例示性胺基酸序列 | 314 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS* |
| 具有HiBiT標籤之Nme3Cas9之例示性胺基酸序列 | 315 | MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYADEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS* |
| Nme2Cas9之例示性開放閱讀框架 | 316 | augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCgccgccuucaagcccaaccccaucaacuacauccugggccuggacaucggcaucgccuccgugggcugggccaugguggagaucgacgaggaggagaaccccauccggcugaucgaccugggcgugcggguguucgagcgggccgaggugcccaagaccggcgacucccuggccauggcccggcggcuggcccgguccgugcggcggcugacccggcggcgggcccaccggcugcugcgggcccggcggcugcugaagcgggagggcgugcugcaggccgccgacuucgacgagaacggccugaucaagucccugcccaacacccccuggcagcugcgggccgccgcccuggaccggaagcugaccccccuggagugguccgccgugcugcugcaccugaucaagcaccggggcuaccugucccagcggaagaacgagggcgagaccgccgacaaggagcugggcgcccugcugaagggcguggccaacaacgcccacgcccugcagaccggcgacuuccggacccccgccgagcuggcccugaacaaguucgagaaggaguccggccacauccggaaccagcggggcgacuacucccacaccuucucccggaaggaccugcaggccgagcugauccugcuguucgagaagcagaaggaguucggcaacccccacguguccggcggccugaaggagggcaucgagacccugcugaugacccagcggcccgcccuguccggcgacgccgugcagaagaugcugggccacugcaccuucgagcccgccgagcccaaggccgccaagaacaccuacaccgccgagcgguucaucuggcugaccaagcugaacaaccugcggauccuggagcagggcuccgagcggccccugaccgacaccgagcgggccacccugauggacgagcccuaccggaaguccaagcugaccuacgcccaggcccggaagcugcugggccuggaggacaccgccuucuucaagggccugcgguacggcaaggacaacgccgaggccuccacccugauggagaugaaggccuaccacgccaucucccgggcccuggagaaggagggccugaaggacaagaaguccccccugaaccuguccuccgagcugcaggacgagaucggcaccgccuucucccuguucaagaccgacgaggacaucaccggccggcugaaggaccgggugcagcccgagauccuggaggcccugcugaagcacaucuccuucgacaaguucgugcagaucucccugaaggcccugcggcggaucgugccccugauggagcagggcaagcgguacgacgaggccugcgccgagaucuacggcgaccacuacggcaagaagaacaccgaggagaagaucuaccugccccccauccccgccgacgagauccggaaccccguggugcugcgggcccugucccaggcccggaaggugaucaacggcguggugcggcgguacggcucccccgcccggauccacaucgagaccgcccgggaggugggcaaguccuucaaggaccggaaggagaucgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaaguuccgggaguacuuccccaacuucgugggcgagcccaaguccaaggacauccugaagcugcggcuguacgagcagcagcacggcaagugccuguacuccggcaaggagaucaaccuggugcggcugaacgagaagggcuacguggagaucgaccacgcccugcccuucucccggaccugggacgacuccuucaacaacaaggugcuggugcugggcuccgagaaccagaacaagggcaaccagacccccuacgaguacuucaacggcaaggacaacucccgggaguggcaggaguucaaggcccggguggagaccucccgguucccccgguccaagaagcagcggauccugcugcagaaguucgacgaggacggcuucaaggagugcaaccugaacgacacccgguacgugaaccgguuccugugccaguucguggccgaccacauccugcugaccggcaagggcaagcggcggguguucgccuccaacggccagaucaccaaccugcugcggggcuucuggggccugcggaaggugcgggccgagaacgaccggcaccacgcccuggacgccguggugguggccugcuccaccguggccaugcagcagaagaucacccgguucgugcgguacaaggagaugaacgccuucgacggcaagaccaucgacaaggagaccggcaaggugcugcaccagaagacccacuucccccagcccugggaguucuucgcccaggaggugaugauccggguguucggcaagcccgacggcaagcccgaguucgaggaggccgacacccccgagaagcugcggacccugcuggccgagaagcuguccucccggcccgaggccgugcacgaguacgugaccccccuguucgugucccgggcccccaaccggaagauguccggcgcccacaaggacacccugcgguccgccaagcgguucgugaagcacaacgagaagaucuccgugaagcggguguggcugaccgagaucaagcuggccgaccuggagaacauggugaacuacaagaacggccgggagaucgagcuguacgaggcccugaaggcccggcuggaggccuacggcggcaacgccaagcaggccuucgaccccaaggacaaccccuucuacaagaagggcggccagcuggugaaggccgugcggguggagaagacccaggaguccggcgugcugcugaacaagaagaacgccuacaccaucgccgacaacggcgacauggugcggguggacguguucugcaagguggacaagaagggcaagaaccaguacuucaucgugcccaucuacgccuggcagguggccgagaacauccugcccgacaucgacugcaagggcuaccggaucgacgacuccuacaccuucugcuucucccugcacaaguacgaccugaucgccuuccagaaggacgagaaguccaagguggaguucgccuacuacaucaacugcgacuccuccaacggccgguucuaccuggccuggcacgacaagggcuccaaggagcagcaguuccggaucuccacccagaaccuggugcugauccagaaguaccaggugaacgagcugggcaaggagauccggcccugccggcugaagaagcggccccccgugcgguag |
| Nme1Cas9之例示性開放閱讀框架 | 317 | AUGGCAGCAUUCAAGCCGAACUCGAUCAACUACAUCCUGGGACUGGACAUCGGAAUCGCAUCGGUCGGAUGGGCAAUGGUCGAAAUCGACGAAGAAGAAAACCCGAUCAGACUGAUCGACCUGGGAGUCAGAGUCUUCGAAAGAGCAGAAGUCCCGAAGACAGGAGACUCGCUGGCAAUGGCAAGAAGACUGGCAAGAUCGGUCAGAAGACUGACAAGAAGAAGAGCACACAGACUGCUGAGAACAAGAAGACUGCUGAAGAGAGAAGGAGUCCUGCAGGCAGCAAACUUCGACGAAAACGGACUGAUCAAGUCGCUGCCGAACACACCGUGGCAGCUGAGAGCAGCAGCACUGGACAGAAAGCUGACACCGCUGGAAUGGUCGGCAGUCCUGCUGCACCUGAUCAAGCACAGAGGAUACCUGUCGCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAACUGGGAGCACUGCUGAAGGGAGUCGCAGGAAACGCACACGCACUGCAGACAGGAGACUUCAGAACACCGGCAGAACUGGCACUGAACAAGUUCGAAAAGGAAUCGGGACACAUCAGAAACCAGAGAUCGGACUACUCGCACACAUUCUCGAGAAAGGACCUGCAGGCAGAACUGAUCCUGCUGUUCGAAAAGCAGAAGGAAUUCGGAAACCCGCACGUCUCGGGAGGACUGAAGGAAGGAAUCGAAACACUGCUGAUGACACAGAGACCGGCACUGUCGGGAGACGCAGUCCAGAAGAUGCUGGGACACUGCACAUUCGAACCGGCAGAACCGAAGGCAGCAAAGAACACAUACACAGCAGAAAGAUUCAUCUGGCUGACAAAGCUGAACAACCUGAGAAUCCUGGAACAGGGAUCGGAAAGACCGCUGACAGACACAGAAAGAGCAACACUGAUGGACGAACCGUACAGAAAGUCGAAGCUGACAUACGCACAGGCAAGAAAGCUGCUGGGACUGGAAGACACAGCAUUCUUCAAGGGACUGAGAUACGGAAAGGACAACGCAGAAGCAUCGACACUGAUGGAAAUGAAGGCAUACCACGCAAUCUCGAGAGCACUGGAAAAGGAAGGACUGAAGGACAAGAAGUCGCCGCUGAACCUGUCGCCGGAACUGCAGGACGAAAUCGGAACAGCAUUCUCGCUGUUCAAGACAGACGAAGACAUCACAGGAAGACUGAAGGACAGAAUCCAGCCGGAAAUCCUGGAAGCACUGCUGAAGCACAUCUCGUUCGACAAGUUCGUCCAGAUCUCGCUGAAGGCACUGAGAAGAAUCGUCCCGCUGAUGGAACAGGGAAAGAGAUACGACGAAGCAUGCGCAGAAAUCUACGGAGACCACUACGGAAAGAAGAACACAGAAGAAAAGAUCUACCUGCCGCCGAUCCCGGCAGACGAAAUCAGAAACCCGGUCGUCCUGAGAGCACUGUCGCAGGCAAGAAAGGUCAUCAACGGAGUCGUCAGAAGAUACGGAUCGCCGGCAAGAAUCCACAUCGAAACAGCAAGAGAAGUCGGAAAGUCGUUCAAGGACAGAAAGGAAAUCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAGCAGCAAAGUUCAGAGAAUACUUCCCGAACUUCGUCGGAGAACCGAAGUCGAAGGACAUCCUGAAGCUGAGACUGUACGAACAGCAGCACGGAAAGUGCCUGUACUCGGGAAAGGAAAUCAACCUGGGAAGACUGAACGAAAAGGGAUACGUCGAAAUCGACCACGCACUGCCGUUCUCGAGAACAUGGGACGACUCGUUCAACAACAAGGUCCUGGUCCUGGGAUCGGAAAACCAGAACAAGGGAAACCAGACACCGUACGAAUACUUCAACGGAAAGGACAACUCGAGAGAAUGGCAGGAAUUCAAGGCAAGAGUCGAAACAUCGAGAUUCCCGAGAUCGAAGAAGCAGAGAAUCCUGCUGCAGAAGUUCGACGAAGACGGAUUCAAGGAAAGAAACCUGAACGACACAAGAUACGUCAACAGAUUCCUGUGCCAGUUCGUCGCAGACAGAAUGAGACUGACAGGAAAGGGAAAGAAGAGAGUCUUCGCAUCGAACGGACAGAUCACAAACCUGCUGAGAGGAUUCUGGGGACUGAGAAAGGUCAGAGCAGAAAACGACAGACACCACGCACUGGACGCAGUCGUCGUCGCAUGCUCGACAGUCGCAAUGCAGCAGAAGAUCACAAGAUUCGUCAGAUACAAGGAAAUGAACGCAUUCGACGGAAAGACAAUCGACAAGGAAACAGGAGAAGUCCUGCACCAGAAGACACACUUCCCGCAGCCGUGGGAAUUCUUCGCACAGGAAGUCAUGAUCAGAGUCUUCGGAAAGCCGGACGGAAAGCCGGAAUUCGAAGAAGCAGACACACUGGAAAAGCUGAGAACACUGCUGGCAGAAAAGCUGUCGUCGAGACCGGAAGCAGUCCACGAAUACGUCACACCGCUGUUCGUCUCGAGAGCACCGAACAGAAAGAUGUCGGGACAGGGACACAUGGAAACAGUCAAGUCGGCAAAGAGACUGGACGAAGGAGUCUCGGUCCUGAGAGUCCCGCUGACACAGCUGAAGCUGAAGGACCUGGAAAAGAUGGUCAACAGAGAAAGAGAACCGAAGCUGUACGAAGCACUGAAGGCAAGACUGGAAGCACACAAGGACGACCCGGCAAAGGCAUUCGCAGAACCGUUCUACAAGUACGACAAGGCAGGAAACAGAACACAGCAGGUCAAGGCAGUCAGAGUCGAACAGGUCCAGAAGACAGGAGUCUGGGUCAGAAACCACAACGGAAUCGCAGACAACGCAACAAUGGUCAGAGUAGACGUCUUCGAAAAGGGAGACAAGUACUACCUGGUCCCGAUCUACUCGUGGCAGGUCGCAAAGGGAAUCCUGCCGGACAGAGCAGUCGUCCAGGGAAAGGACGAAGAAGACUGGCAGCUGAUCGACGACUCGUUCAACUUCAAGUUCUCGCUGCACCCGAACGACCUGGUCGAAGUCAUCACAAAGAAGGCAAGAAUGUUCGGAUACUUCGCAUCGUGCCACAGAGGAACAGGAAACAUCAACAUCAGAAUCCACGACCUGGACCACAAGAUCGGAAAGAACGGAAUCCUGGAAGGAAUCGGAGUCAAGACAGCACUGUCGUUCCAGAAGUACCAGAUCGACGAACUGGGAAAGGAAAUCAGACCGUGCAGACUGAAGAAGAGACCGCCGGUCAGAUCCGGAAAGAGAACAGCAGACGGAUCGGAAUUCGAAUCGCCGAAGAAGAAGAGAAAGGUCGAAUGA |
| 具有HiBiT標籤之Nme2Cas9之例示性開放閱讀框架 | 318 | augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAG |
| 具有HiBiT標籤之Nme1Cas9之例示性開放閱讀框架 | 319 | augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCAGCAUUCAAGCCAAACUCAAUCAAUUACAUCCUGGGACUGGACAUCGGCAUCGCAUCCGUCGGGUGGGCUAUGGUCGAAAUCGACGAGGAGGAGAACCCCAUCCGCCUGAUCGAUCUGGGCGUGCGCGUGUUUGAGAGGGCAGAGGUGCCUAAGACCGGCGACAGCCUGGCCAUGGCACGGAGACUGGCACGCUCCGUGAGGCGCCUGACCCGGAGAAGGGCCCACAGACUGCUGAGGACACGCCGGCUGCUGAAGAGGGAGGGCGUGCUGCAGGCCGCCAACUUCGAUGAGAAUGGCCUGAUCAAGUCCCUGCCCAAUACCCCUUGGCAGCUGAGGGCAGCCGCCCUGGACCGCAAGCUGACACCUCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCUCAGAGAAAGAACGAGGGCGAGACAGCCGAUAAGGAGCUGGGCGCCCUGCUGAAGGGAGUGGCAGGAAAUGCACACGCCCUGCAGACCGGCGACUUUCGCACACCAGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGAGCGGCCACAUCCGCAAUCAGCGGUCUGACUAUAGCCACACCUUCUCCCGGAAGGAUCUGCAGGCCGAGCUGAUCCUGCUGUUUGAGAAGCAGAAGGAGUUCGGCAACCCACACGUGUCUGGCGGCCUGAAGGAGGGCAUCGAGACACUGCUGAUGACACAGCGGCCCGCCCUGAGCGGCGACGCAGUGCAGAAGAUGCUGGGACACUGCACCUUUGAGCCAGCCGAGCCCAAGGCCGCCAAGAAUACCUACACAGCCGAGCGGUUCAUCUGGCUGACAAAGCUGAACAAUCUGAGGAUCCUGGAGCAGGGAAGCGAGCGCCCACUGACCGACACAGAGAGGGCCACCCUGAUGGAUGAGCCCUACCGCAAGUCCAAGCUGACAUAUGCACAGGCAAGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUUAAGGGCCUGAGAUACGGCAAGGAUAACGCCGAGGCCUCUACACUGAUGGAGAUGAAGGCCUAUCACGCCAUCAGCAGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCACUGAAUCUGUCUCCCGAGCUGCAGGAUGAGAUCGGCACCGCCUUUAGCCUGUUCAAGACCGACGAGGAUAUCACAGGCAGACUGAAGGACAGGAUCCAGCCAGAGAUCCUGGAGGCCCUGCUGAAGCACAUCAGCUUUGAUAAGUUCGUGCAGAUCAGCCUGAAGGCCCUGCGGAGGAUCGUGCCACUGAUGGAGCAGGGCAAGAGGUACGACGAGGCCUGCGCCGAAAUCUACGGCGAUCACUAUGGCAAGAAGAACACAGAGGAGAAAAUCUACCUGCCCCCUAUCCCCGCCGAUGAGAUCAGGAACCCUGUGGUGCUGCGCGCCCUGUCUCAGGCAAGAAAAGUGAUCAACGGAGUGGUGCGCCGGUACGGCAGCCCCGCCAGAAUCCACAUCGAGACAGCCAGGGAAGUGGGCAAGUCCUUUAAGGACAGAAAGGAGAUCGAGAAGAGGCAGGAGGAGAACAGAAAGGAUAGGGAGAAGGCCGCCGCCAAGUUCAGAGAGUACUUUCCUAAUUUCGUGGGCGAGCCAAAGUCCAAGGAUAUCCUGAAGCUGAGGCUGUACGAGCAGCAGCACGGCAAGUGUCUGUAUUCUGGCAAGGAGAUCAACCUGGGCCGCCUGAAUGAGAAGGGCUAUGUGGAGAUCGACCACGCCCUGCCUUUUUCUCGGACCUGGGACGAUAGCUUCAACAAUAAGGUGCUGGUGCUGGGCUCUGAGAACCAGAAUAAGGGCAACCAGACACCCUACGAGUAUUUCAACGGCAAGGACAAUAGCCGCGAGUGGCAGGAGUUUAAGGCAAGGGUGGAGACAAGCAGGUUCCCUCGGUCCAAGAAGCAGAGAAUCCUGCUGCAGAAGUUUGACGAGGAUGGCUUCAAGGAGAGGAACCUGAAUGACACCCGCUACGUGAAUCGGUUUCUGUGCCAGUUCGUGGCCGAUAGAAUGAGGCUGACCGGCAAGGGCAAGAAGAGAGUGUUUGCCUCCAACGGCCAGAUCACAAAUCUGCUGAGGGGCUUCUGGGGCCUGAGAAAGGUGAGGGCAGAGAACGACAGGCACCACGCACUGGAUGCAGUGGUGGUGGCAUGUUCUACCGUGGCCAUGCAGCAGAAGAUCACACGCUUUGUGCGGUAUAAGGAGAUGAAUGCCUUCGACGGCAAGACCAUCGAUAAGGAGACAGGCGAGGUGCUGCACCAGAAGACACACUUUCCUCAGCCAUGGGAGUUCUUUGCCCAGGAAGUGAUGAUCCGGGUGUUUGGCAAGCCUGACGGCAAGCCAGAGUUCGAGGAGGCCGAUACCCUGGAGAAGCUGAGAACACUGCUGGCAGAGAAGCUGAGCUCCAGGCCCGAGGCAGUGCACGAGUACGUGACCCCACUGUUCGUGUCUAGAGCCCCCAACAGGAAGAUGAGCGGCCAGGGCCACAUGGAGACAGUGAAGUCCGCCAAGAGACUGGACGAGGGCGUGUCUGUGCUGAGGGUGCCUCUGACACAGCUGAAGCUGAAGGAUCUGGAGAAGAUGGUGAAUCGCGAGCGGGAGCCAAAGCUGUAUGAGGCCCUGAAGGCAAGGCUGGAGGCACACAAGGACGAUCCUGCCAAGGCCUUUGCCGAGCCAUUCUACAAGUAUGAUAAGGCCGGCAACAGAACCCAGCAGGUGAAGGCCGUGAGGGUGGAGCAGGUGCAGAAGACAGGCGUGUGGGUGCGCAACCACAAUGGCAUCGCCGACAAUGCUACCAUGGUGCGGGUGGACGUGUUUGAGAAGGGCGAUAAGUACUAUCUGGUGCCCAUCUACAGCUGGCAGGUGGCCAAGGGCAUCCUGCCUGAUAGAGCCGUGGUGCAGGGCAAGGACGAGGAGGAUUGGCAGCUGAUCGACGAUUCCUUCAACUUUAAGUUCUCUCUGCACCCCAAUGACCUGGUGGAAGUGAUCACCAAGAAGGCCAGGAUGUUUGGCUACUUCGCCUCCUGCCACCGCGGCACAGGCAACAUCAAUAUCCGGAUCCACGACCUGGAUCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGAAGACAGCCCUGAGCUUCCAGAAGUAUCAGAUCGACGAGCUGGGCAAGGAGAUCAGACCUUGUAGGCUGAAGAAGCGCCCACCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAG |
| 具有HiBiT標籤之Nme1Cas9之例示性開放閱讀框架 | 320 | augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACUCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGACCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCAACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCGGCAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGUCCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCUGGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGCAGGGCAAGGACGAGGAGGACUGGCAGCUGAUCGACGACUCCUUCAACUUCAAGUUCUCCCUGCACCCCAACGACCUGGUGGAGGUGAUCACCAAGAAGGCCCGGAUGUUCGGCUACUUCGCCUCCUGCCACCGGGGCACCGGCAACAUCAACAUCCGGAUCCACGACCUGGACCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGAAGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAG |
| 具有HiBiT標籤之Nme3Cas9之例示性開放閱讀框架 | 321 | augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCGACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUGCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAACCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGUCCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACACCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGGCCUACGCCGACGAGGAGGACUGGACCGUGAUCGACGAGUCCUUCCGGUUCAAGUUCGUGCUGUACUCCAACGACCUGAUCAAGGUGCAGCUGAAGAAGGACUCCUUCCUGGGCUACUUCUCCGGCCUGGACCGGGCCACCGGCGCCAUCUCCCUGCGGGAGCACGACCUGGAGAAGUCCAAGGGCAAGGACGGCAUGCACCGGAUCGGCGUGAAGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGAUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAG |
| 描述 | SEQ ID NO | 序列 |
| 例示性XTEN | 58 | SGSETPGTSESATPES |
| 例示性XTEN | 59 | SGSETPGTSESA |
| 例示性XTEN | 60 | SGSETPGTSESATPEGGSGGS |
| 例示性連接子之胺基酸序列 | 61 | GGS |
| 例示性連接子之胺基酸序列 | 62 | GGGGS |
| 例示性連接子之胺基酸序列 | 63 | EAAAK |
| 例示性連接子之胺基酸序列 | 64 | SEGSA |
| 例示性連接子之胺基酸序列 | 65 | SEGSAGTST |
| 例示性連接子之胺基酸序列 | 66 | GGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 67 | GGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 68 | EAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 69 | EAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 70 | SEGSAGTSTESEGSA |
| 例示性連接子之胺基酸序列 | 71 | GGGGSGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 72 | GGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 73 | GGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 74 | EAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 75 | EAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 76 | SEGSAGTSTESEGSAGTSTE |
| 例示性連接子之胺基酸序列 | 77 | GGGGSGGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 78 | GGGGSGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 79 | GGGGSEAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 80 | GGGGSEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 81 | GGGGSEAAAKEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 82 | EAAAKGGGGSGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 83 | EAAAKGGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 84 | EAAAKGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 85 | EAAAKGGGGSEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 86 | EAAAKEAAAKGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 87 | EAAAKEAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 88 | EAAAKEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 89 | SEGSAGTSTESEGSAGTSTESEGSA |
| 例示性連接子之胺基酸序列 | 90 | GGGGSGGGGSGGGGSGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 91 | GGGGSGGGGSGGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 92 | GGGGSGGGGSGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 93 | GGGGSGGGGSGGGGSEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 94 | GGGGSGGGGSEAAAKGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 95 | GGGGSGGGGSEAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 96 | GGGGSGGGGSEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 97 | GGGGSGGGGSEAAAKEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 98 | GGGGSEAAAKGGGGSGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 99 | GGGGSEAAAKGGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 100 | GGGGSEAAAKGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 101 | GGGGSEAAAKGGGGSEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 102 | GGGGSEAAAKEAAAKGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 103 | GGGGSEAAAKEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 104 | GGGGSEAAAKEAAAKEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 105 | EAAAKGGGGSGGGGSGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 106 | EAAAKGGGGSGGGGSGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 107 | EAAAKGGGGSGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 108 | EAAAKGGGGSGGGGSEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 109 | EAAAKGGGGSEAAAKGGGGSGGGGS |
| 例示性連接子之胺基酸序列 | 110 | EAAAKGGGGSEAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 111 | EAAAKGGGGSEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 112 | EAAAKGGGGSEAAAKEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 113 | EAAAKEAAAKGGGGSEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 114 | EAAAKEAAAKGGGGSEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 115 | EAAAKEAAAKEAAAKGGGGSEAAAK |
| 例示性連接子之胺基酸序列 | 116 | EAAAKEAAAKEAAAKEAAAKGGGGS |
| 例示性連接子之胺基酸序列 | 117 | EAAAKEAAAKEAAAKEAAAKEAAAK |
| 例示性連接子之胺基酸序列 | 118 | GTKDSTKDIPETPSKD |
| 例示性連接子之胺基酸序列 | 119 | GRDVRQPEVKEEKPES |
| 例示性連接子之胺基酸序列 | 120 | EGKSSGSGSESKSTAG |
| 例示性連接子之胺基酸序列 | 121 | TPGSPAGSPTSTEEGT |
| 例示性連接子之胺基酸序列 | 122 | GSEPATSGSETPGTST |
| 123-129 | ||
| G000502 | 130 | mA*mC*mA*CAAAUACCAGUCCAGCGGUUUUAGAmGmCmUmAmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU |
| G017564 | 131 | mG*mG*mC*CUGGCUGAUGAGGCCGCACAUGUUGUAGCUCCCU*mG*mA*mA*mA*CCGUUGCUACAAUAAGGCCGUmC*mU*mG*mA*mA*mA*mA*mGAUGUGCCGCAACGCUCUGCCG*mC*mU*mU*mC*mU*mG*CGGCAUCGUUU*mA*mU*mC |
| G017565 | 132 | mG*mG*mC*CUGGCUGAUGAGGCCGCACAUGUUGUAGCUCCCU*mG*mA*mA*mA*CCGUUGCUACAAUAAGGCCGUmC*mU*mG*mA*mA*mA*mA*mGAUGUGCCGCAACGCUCUGCCmU*mU*mC*mUGGCAUCGUUU*mA*mU*mC |
| G017566 | 133 | mG*mG*mC*CUGGCUGAUGAGGCCGCACAUGUUGUAGCUCCCU*mG*mA*mA*mA*CCGUUGCUACAAUAAGGCCGUmC*mG*mA*mA*mA*mGAUGUGCCGCAACGCUCUGCCmU*mU*mC*mUGGCAUCGUUU*mA*mU*mC |
| G020055 | 134 | mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGUUUAmU*mU |
| G020361 | 135 | mG*mGC*CUGGCUmGAUmGAGGCCGCACAUmGUUGmUmAmGmCUCCCUmCmGmAmAmAmGCCGUUmGmCUAmCAAU*A*AGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGUUU*AmU*mU |
| G020848 | 136 | mU*mGA*GGACCGmCCCmUGGGCCUGGGAGmGUUGmUmAmGmCUCCCUmCmGmAmAmAmGCCGUUmGmCUAmCAAU*A*AGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGUUU*AmU*mU |
| G021256 | 137 | mC*mCAAGUGUCmUUCmCAGUACGAUUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| G021320 | 138 | mC*mUUCACCAGmGAGmAAGCCGUCACACmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| G021536 | 139 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 140 | 未使用 | |
| G021844 | 141 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmC(L1)mGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G021845 | 142 | mC*mU*mU*mCmACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G021846 | 143 | mC*mU*mU*mCmACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmUmUmC(L1)mGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G023413 | 144 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmG(L1)mCmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023414 | 145 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmG(L1)mCmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023415 | 146 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmG(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023416 | 147 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCmG(L1)mCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023417 | 148 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCC(L1)GUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023418 | 149 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmG(L1)mCmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmU(L1)mAmGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCGmU*mU |
| G023419 | 150 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmG(L1)mCmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCCmU(L1)mAGGCAUCGmU*mU |
| 322-350 | 未使用 | |
| G029377 | 351 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029378 | 352 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029379 | 353 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAmAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029380 | 354 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029381 | 355 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAdTAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029382 | 356 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029383 | 357 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029384 | 358 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029385 | 359 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029386 | 360 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G029387 | 361 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGmCmCmUmUmCmUGGCAUCG*mU*mU |
| G029388 | 362 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUmCmG*mU*mU |
| G029389 | 363 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCmAmUmCmG*mU*mU |
| G029390 | 364 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGmCmCmUmUmCmUGGCmAmUmCmG*mU*mU |
| G029391 | 365 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGmCmCmUmUmCmUGGCAUmCmG*mU*mU |
| G029392 | 366 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCCmUmUmCmUGGCAUmCmG*mU*mU |
| 367-382 | 未使用 | |
| SV40 NLS | 383 | PKKKRKVE |
| SV40 NLS | 384 | KKKRKVE |
| 雙聯NLS | 385 | KRTADGSEFESPKKKRKVE |
| c-myc樣NLS | 386 | PAAKKKKLD |
| SV40 NLS之核酸序列 | 387 | CCCAAGAAGAAGAGGAAAGTC |
| 用於SV40 NLS之胺基酸序列 | 388 | PKKKRKV |
| U6啟動子 | 389 | TTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACG |
| CMV啟動子 | 390 | ATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTGCGATCGCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC |
| 例示性5' UTR | 391 | ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC |
| 例示性5' UTR | 392 | CATAAACCCTGGCGCGCTCGCGGCCCGGCACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACC |
| 例示性5' UTR | 393 | AAGCTCAGAATAAACGCTCAACTTTGGCC |
| 例示性5' UTR | 394 | CAGGGTCCTGTGGACAGCTCACCAGCT |
| 例示性5' UTR | 395 | TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTTATTC |
| 例示性5' UTR | 396 | CAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCAT |
| 例示性5' UTR | 397 | AGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGG |
| 例示性5' UTR | 398 | TGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACTCACCG |
| 例示性3' UTR | 399 | GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGC |
| 例示性3' UTR | 400 | GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC |
| 例示性3' UTR | 401 | ACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATAATACCAACTTACACTTTACAAAATGTTGTCCCCCAAAATGTAGCCATTCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACATTCT |
| 例示性3' UTR | 402 | TTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCA |
| 例示性3' UTR | 403 | GCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTCTCCCTTGCACCTGTACCTCTTGGTCTTTGAATAAAGCCTGAGTAGGAAG |
| 例示性3' UTR | 404 | CTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCCCAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACC |
| 例示性3' UTR | 405 | CAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACCCTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCC |
| 例示性3' UTR | 406 | ACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATAATACCAACTTACACTTTACAAAATGTTGTCCCCCAAAATGTAGCCATTCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACATTCTACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATAATACCAACTTACACTTTACAAAATGTTGTCCCCCAAAATGTAGCCATTCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACATTCT |
| 例示性Kozak序列 | 407 | GCCRCCAUGG |
| 例示性Kozak序列 | 408 | GCCGCCRCCAUGG |
| 例示性poly-A序列 | 409 | AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA |
| 例示性NLS 1 | 410 | LAAKRSRTT |
| 例示性NLS 2 | 411 | QAAKRSRTT |
| 例示性NLS 3 | 412 | PAPAKRERTT |
| 例示性NLS 4 | 413 | QAAKRPRTT |
| 例示性NLS 5 | 414 | RAAKRPRTT |
| 例示性NLS 6 | 415 | AAAKRSWSMAA |
| 例示性NLS 7 | 416 | AAAKRVWSMAF |
| 例示性NLS 8 | 417 | AAAKRSWSMAF |
| 例示性NLS 9 | 418 | AAAKRKYFAA |
| 例示性NLS 10 | 419 | RAAKRKAFAA |
| 例示性NLS 11 | 420 | RAAKRKYFAV |
| 替代SV40 NLS | 421 | PKKKRRV |
| 核質蛋白NLS | 422 | KRPAATKKAGQAKKKK |
| 用於SV40 NLS之例示性編碼序列 | 423 | CCGAAGAAGAAGAGAAAGGTC |
| 用於NLS1之例示性編碼序列 | 424 | CTGGCAGCAAAGAGAAGCAGAACAACA |
| 用於NLS2之例示性編碼序列 | 425 | CAGGCAGCAAAGAGAAGCAGAACAACA |
| 用於NLS3之例示性編碼序列 | 426 | CCGGCACCGGCAAAGAGAGAAAGAACAACA |
| 用於NLS4之例示性編碼序列 | 427 | CAGGCAGCAAAGAGACCGAGAACAACA |
| 用於NLS5之例示性編碼序列 | 428 | AGAGCAGCAAAGAGACCGAGAACAACA |
| 用於NLS6之例示性編碼序列 | 429 | GCAGCAGCAAAGAGAAGCTGGAGCATGGCAGCA |
| 用於NLS7之例示性編碼序列 | 430 | GCAGCAGCAAAGAGAGTCTGGAGCATGGCATTC |
| 用於NLS8之例示性編碼序列 | 431 | GCAGCAGCAAAGAGAAGCTGGAGCATGGCATTC |
| 用於NLS9之例示性編碼序列 | 432 | GCAGCAGCAAAGAGAAAGTACTTCGCAGCA |
| 用於NLS10之例示性編碼序列 | 433 | AGAGCAGCAAAGAGAAAGGCATTCGCAGCA |
| 用於NLS11之例示性編碼序列 | 434 | AGAGCAGCAAAGAGAAAGTACTTCGCAGTC |
| 用於替代SV40 NLS之例示性編碼序列 | 435 | CCGAAGAAGAAGAGAAGAGTC |
| G024103 | 436 | mC*mA*mA*mGmUCUmGmUCmUGmCCUAUmUCACmCGAmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCCGGCAUCG*mU*mU |
| G024104 | 437 | mG*mG*mU*mGmAAUmAmGGmCAmGACAGmACUUmGUCmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024108 | 438 | mG*mA*mU*mUmAAAmCmCCmGGmCCACUmUUCAmGGAmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024109 | 439 | mC*mA*mG*mUmGACmAmAGmUCmUGUCUmGCCUmAUUmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024110 | 440 | mG*mU*mU*mGmAAGmGmCGmUUmUGCACmAUGCmAAAmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024111 | 441 | mU*mC*mC*mUmGUGmAmUGmUCmAAGCUmGGUCmGAGmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024112 | 442 | mC*mA*mG*mGmUUUmUmGAmAAmGUUUAmGGUUmCGUmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024113 | 443 | mA*mU*mC*mAmGAAmUmCCmUUmACUUUmGUGAmCACmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G024114 | 444 | mG*mA*mA*mGmUCCmAmUAmGAmCCUCAmUGUCmUAGmGUUGmUmAmGmCUCCCmU(L1)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| G028844 | 445 | mU*mG*mU*mCmUGCmCmUAmUUmCACCGmAUUUmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028845 | 446 | mU*mG*mC*mCmUAUmUmCAmCCmGAUUUmUGAUmUCUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028846 | 447 | mC*mG*mA*mUmUUUmGmAUmUCmUCAAAmCAAAmUGUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028847 | 448 | mG*mU*mA*mAmGGAmUmUCmUGmAUGUGmUAUAmUCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028848 | 449 | mA*mG*mA*mGmCAAmCmAGmUGmCUGUGmGCCUmGGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028849 | 450 | mU*mG*mG*mAmGCAmAmCAmAAmUCUGAmCUUUmGCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028850 | 451 | mA*mU*mG*mCmUGUmUmGUmUGmAAGGCmGUUUmGCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028851 | 452 | mU*mU*mU*mUmGAAmAmGUmUUmAGGUUmCGUAmUCUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028852 | 453 | mU*mU*mA*mCmUUUmGmUGmACmACAUUmUGUUmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G028853 | 454 | mG*mA*mU*mUmAAAmCmCCmGGmCCACUmUUCAmGGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G021469 | 455 | mA*mU*mA*mUmCCAmGmAAmCCmCUGACmCCUGmCCGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G024739 | 456 | mA*mG*mG*mAmCCAmGmCCmUCmAGACAmCAAAmUACmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G024741 | 457 | mC*mU*mG*mCmCUCmGmGAmCGmGCAUCmUAGAmACUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G024743 | 458 | mA*mG*mG*mCmAGAmGmGAmGGmAGCAGmACGAmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 459-499 | 未使用 | |
| 野生型NmeCas9引導RNA | 500 | NNNNNNNNNNNNNNNNNNNNNNNNGUUGUAGCUCCCUUUCUCAUUUCGGAAACGAAAUGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCCUUAAAGCUUCUGCUUUAAGGGGCAUCGUUUA |
| 縮短/未經修飾之NmeCas9引導RNA | 501 | (N) 20-25GUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| 縮短/未經修飾之NmeCas9引導RNA | 502 | (N) 20-25GUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUUAUU |
| 縮短/未經修飾之NmeCas9引導RNA | 503 | (N) 20-25GUUGUAGCUCCCUGGAAACCCGUUGCUACAAUAAGGCCGUCGAAAGA UGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUUAUU |
| 僅Mod-N77保守部分 | 504 | mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| 僅Mod-N78保守部分 | 505 | mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 包含連接子之縮短/未經修飾之NmeCas9引導RNA | 506 | (N) 20-25mGUUGUAGCUCCCUUC(L1)GACCGUUGCUACAAUAAGGCCGUC(L1)GAUGUGCCGCAACGCUCUGCC(L1)GGCAUCGUU |
| 包含連接子之縮短/經修飾NmeCas9引導RNA | 507 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmC(L1)mGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(L1)mGmAmUGUGCmCGmCAAmCGCUCUmGmCC(L1)GGCAUCG*mU*mU |
| 縮短/經修飾之NmeCas9引導RNA | 508 | mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| G024739未經修飾之序列 | 509 | AGGACCAGCCUCAGACACAAAUACGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| G024741未經修飾之序列 | 510 | CUGCCUCGGACGGCAUCUAGAACUGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| G024743未經修飾之序列 | 511 | AGGCAGAGGAGGAGCAGACGAUGAGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| G021536 Mod-N78 Nme Cas9引導RNA (101) | 512 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027492經縮短之Nme Cas9 引導RNA (105)僅保守部分 | 513 | GUUGUAGCUCCCUUCGAAAGACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| G027492 經縮短之Cas9引導RNA (105) | 514 | (N) 20-25GUUGUAGCUCCCUUCGAAAGACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU |
| G027492 Mod-N78 Nme Cas9引導RNA (105)僅保守部分 | 515 | mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027492 Mod-N78 Nme Cas9引導RNA (105) | 516 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 517 | mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| 例示性sgRNA | 518 | mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmCmUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| 例示性sgRNA | 519 | mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmCmUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| 例示性sgRNA | 520 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 521 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 522 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 523 | (N) 20-25mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmCmUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU |
| 例示性sgRNA | 524 | (N) 20-25mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 525 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 526 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA | 527 | mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| 例示性sgRNA (G032572；如圖34中所示之101聚體) | 528 | Mc*Mc*Ma*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*Mu*Mu |
| 例示性sgRNA (G031771；如圖35中所示之105聚體) | 529 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G020073 | 530 | mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU*mU |
| G027492 | 531 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027493 | 532 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmGmAmAmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027494 | 533 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmGmAmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027495 | 534 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmAmAmAGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
| G027496 | 535 | mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmAmAmAGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU |
圖1顯示在增加劑量之Nme2Cas9 mRNA及化學修飾之sgRNA下，PMH中TTR基因座處之平均編輯百分比。
圖2A顯示使用不同比率之sgRNA及Nme2Cas9 mRNA時PMH中TTR基因座處之平均編輯百分比。
圖2B顯示使用不同比率之pgRNA及Nme2Cas9 mRNA時PMH中TTR基因座處之平均編輯百分比。
圖3針對pgRNA及Nme2Cas9 mRNA顯示PMH中TTR基因座處之平均編輯百分比。
圖4顯示PMH中PCSK9基因座處之平均編輯百分比。
圖5A顯示用mRNA C處理之HEK細胞中VEGFA基因座處之平均編輯結果。
圖5B顯示用mRNA I處理之HEK細胞中VEGFA基因座處之平均編輯結果
圖5C顯示用mRNA J處理之HEK細胞中VEGFA基因座處之平均編輯結果
圖5D顯示用mRNA C處理之PHH細胞中VEGFA基因座處之平均編輯結果
圖5E顯示用mRNA I處理之PHH細胞中VEGFA基因座處之平均編輯結果
圖5F顯示用mRNA J處理之PHH細胞中VEGFA基因座處之平均編輯結果
圖6顯示用被設計成具有1或2個核定位序列之NmeCas9構築體處理之PMH細胞中小鼠TTR基因座處之平均編輯百分比。
圖7展示用pgRNA及各種Nme2Cas9 mRNA處理的PMH細胞中之小鼠TTR基因座處的平均編輯百分比。
圖8顯示與PMH、PRH、PCH及PHH細胞中之SpyCas9蛋白表現相比，Nme2Cas9蛋白表現的倍數變化。
圖9A-9F顯示與來自治療後24小時、48小時及72小時分析之2個供體的T細胞中之SpyCas9蛋白表現相比，Nme2Cas9蛋白表現的倍數變化。
圖10顯示用sgRNA及Nme2Cas9處理之小鼠肝臟中TTR基因座處之平均編輯百分比。
圖11A顯示用pgRNA及Nme2Cas9處理之後小鼠肝臟中TTR基因座處之平均編輯百分比。
圖11B顯示用pgRNA及Nme2Cas9處理之後的平均血清TTR蛋白。
圖11C顯示用pgRNA及Nme2Cas9處理之後的平均TTR減弱百分比。
圖11D顯示用pgRNA及各種Nme2Cas9處理之後小鼠肝臟中TTR基因座處之平均編輯百分比。
圖11E顯示用pgRNA及各種Nme2Cas9處理之後的血清TTR蛋白減弱。
圖12顯示用各種Nme2Cas9構築體處理後小鼠肝臟中之平均編輯百分比。
圖13顯示用pgRNA及各種Nme2Cas9處理後小鼠肝臟中之平均編輯百分比。
圖14顯示用各種鹼基編輯劑處理後小鼠肝臟中之平均編輯百分比。
圖15顯示呈可能的二級結構之Nme2 sgRNA之例示性示意圖，該二級結構包括重複/反重複區及髮夾區(其包括髮夾1及髮夾2區)，且進一步指示引導區(或靶向區) (用帶虛線輪廓之灰色填充指示)、不適合單一或配對缺失之鹼基(用帶實線輪廓之灰色填充指示)、適合單一或配對缺失之鹼基(空心圓)。
圖16顯示用Nme1Cas9進行TRAC編輯之後的平均CD3陰性T細胞百分比。
圖17顯示用Nme3Cas9進行TRAC編輯之後的平均CD3陰性T細胞百分比。
圖18顯示24小時處T細胞中Nme-HiBiT構築體之表現。
圖19顯示作為NmeCas9 mRNA量之函數的CD3陰性細胞群體。
圖20顯示PCH中所選gRNA之劑量反應曲線。
圖21顯示PCH中LNP稀釋系列之劑量反應曲線。
圖22顯示小鼠中之血清TTR含量。
圖23顯示小鼠肝臟樣品中TTR基因座處之編輯百分比。
圖24顯示PMH中所選gRNA之劑量反應曲線。
圖25顯示PMH中所選gRNA之劑量反應曲線。
圖26顯示在具有經修飾sgRNA之PMH中PCSK9基因座處之平均編輯百分比。
圖27顯示若干Nme2Cas9 mRNA與經修飾sgRNA之PMH中之平均編輯百分比。
圖28顯示原代小鼠肝細胞中TTR基因座處之編輯百分比。
圖29顯示小鼠中之血清TTR含量。
圖30顯示小鼠肝臟樣品中TTR基因座處之編輯百分比。
圖31顯示小鼠中處理之後的血清TTR量測結果。
圖32顯示小鼠肝臟樣品中TTR基因座處之編輯百分比。
圖33顯示呈可能的二級結—構之例示性sgRNA (G021536；SEQ ID NO: 139)。甲基化以粗體顯示；硫代磷酸酯鍵由『*』指示。沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『—』指示。非沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『•』指示。
圖34顯示呈可能的二級結構之例示性sgRNA (G032572；SEQ ID NO: 528)。未經修飾之核苷酸以粗體顯示且甲基化以淺色字體顯示；硫代磷酸酯鍵由『*』指示。沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『—』指示。非沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『•』指示。
圖35顯示呈可能的二級結構之例示性sgRNA (G031771；SEQ ID NO: 529)。未經修飾之核苷酸以粗體顯示且甲基化以淺色字體顯示；硫代磷酸酯鍵由『*』指示。沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『—』指示。非沃森-克里克鹼基配對由雙螺旋部分中核苷酸之間的『•』指示。
TW202325848A_111141875_SEQL.xml
Claims (84)
- 一種包含開放閱讀框架(ORF)之多核苷酸，該ORF包含： 編碼C端奈瑟氏腦膜炎菌( N. meningitidis) (Nme) Cas9多肽之核苷酸序列，其與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中之任一者至少90%一致，其中該Nme Cas9為Nme2 Cas9、Nme1 Cas9或Nme3 Cas9；及 編碼第一核定位信號(NLS)之核苷酸序列。
- 如請求項1之多核苷酸，其中該ORF進一步包含編碼第二NLS之核苷酸序列。
- 如請求項1之多核苷酸，其中該第一及第二NLS獨立地選自SEQ ID NO: 388及410-422。
- 如請求項1至3中任一項之多核苷酸，其中該多核苷酸進一步包含poly-A序列或聚腺苷酸化信號序列。
- 如請求項4之多核苷酸，其中該poly-A序列包含非腺嘌呤核苷酸。
- 如請求項4至5中任一項之多核苷酸，其中該poly-A序列包含100-400個核苷酸。
- 如請求項4至6中任一項之多核苷酸，其中該poly-A序列包含SEQ ID NO: 409之序列。
- 如請求項1至7中任一項之多核苷酸，其中該ORF進一步包含編碼該第一NLS與該第二NLS之間的連接子序列之核苷酸序列。
- 如請求項1至8中任一項之多核苷酸，其中該ORF進一步包含編碼Nme Cas9編碼序列與接近該Nme Cas9編碼序列之NLS之間的連接子間隔序列的核苷酸序列。
- 如請求項8至9中任一項之多核苷酸，其中該連接子包含至少1個、至少2個、至少3個、至少4個、至少5個、至少6個、至少7個、至少8個、至少9個或至少10個胺基酸。
- 如請求項8至10中任一項之多核苷酸，其中該連接子序列包含GGG或GGGS，視情況其中該GGG或GGGS序列位於該間隔序列之N端。
- 如請求項8至11中任一項之多核苷酸，其中該連接子序列包含SEQ ID NO: 61-122中任一者之序列。
- 如請求項1至12中任一項之多核苷酸，其中該ORF進一步包含一或多個另外異源功能域。
- 如請求項1至13中任一項之多核苷酸，其中該Nme Cas9具有雙股核酸內切酶活性。
- 如請求項1至14中任一項之多核苷酸，其中該Nme Cas9具有切口酶活性。
- 如請求項1至14中任一項之多核苷酸，其中該Nme Cas9包含dCas9 DNA結合域。
- 如請求項1至16中任一項之多核苷酸，其中該NmeCas9包含與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315中任一者具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%之胺基酸序列。
- 如請求項1至17中任一項之多核苷酸，其中該NmeCas9包含SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290、297或310-315之胺基酸序列。
- 如請求項1至18中任一項之多核苷酸，其中編碼該NmeCas9之序列包含與SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中任一者之核苷酸序列具有至少91%、92%、93%、94%、95%、96%、97%、98%或99%一致性之核苷酸序列。
- 如請求項1至19中任一項之多核苷酸，其中編碼該NmeCas9之序列包含SEQ ID NO: 15、18-27、29、32-41、221-226、228-233、235-240、242-247、249-254、256-261、263-268、270-275、277-282、284-289、291-296、298-303、304-309或316-321中任一者之核苷酸序列。
- 一種多核苷酸，其包含編碼多肽之開放閱讀框架(ORF)，該多肽包含： 胞苷脫胺酶，其視情況為APOBEC3A脫胺酶； 編碼C端奈瑟氏腦膜炎菌(Nme) Cas9切口酶多肽之核苷酸序列，其與SEQ ID NO: 1及4-13、220、227、234、241、248、255、262、269、276、283、290或297中任一者至少90%一致，其中該Nme Cas9切口酶為Nme2 Cas9切口酶、Nme1 Cas9切口酶或Nme3 Cas9切口酶；及 編碼第一核定位信號(NLS)之核苷酸序列； 其中該多肽不包含尿嘧啶醣苷酶抑制劑(UGI)。
- 如請求項21之多核苷酸，其中該ORF進一步包含編碼第二NLS之核苷酸序列。
- 如請求項21至22中任一項之多核苷酸，其中該脫胺酶位於該多肽中之NLS的N端。
- 如請求項21至23中任一項之多核苷酸，其中該胞苷脫胺酶位於該多肽中之第一NLS及第二NLS之N端。
- 如請求項21至22中任一項之多核苷酸，其中該胞苷脫胺酶位於該多肽中之NLS的C端。
- 如請求項23至25中任一項之多核苷酸，其中該胞苷脫胺酶位於該多肽中之第一NLS及第二NLS之C端。
- 如請求項21至26中任一項之多核苷酸，其中該ORF不包含位於編碼該Nme Cas9之ORF之C端的NLS之編碼序列。
- 如請求項21至26中任一項之多核苷酸，其中該ORF不包含位於編碼該Nme Cas9之ORF之C端的編碼序列。
- 如請求項1至28中任一項之多核苷酸，其中該胞苷脫胺酶包含與SEQ ID NO: 151具有至少87%一致性之胺基酸序列。
- 如請求項1至28中任一項之多核苷酸，其中該胞苷脫胺酶包含與SEQ ID NO: 152-216具有至少80%一致性之胺基酸序列。
- 如請求項1至28中任一項之多核苷酸，其中該胞苷脫胺酶包含與SEQ ID NO: 14具有至少80%一致性之胺基酸序列。
- 如請求項1至31中任一項之多核苷酸，該ORF包含與SEQ ID NO: 42至少80%一致之核苷酸序列。
- 如請求項1至32中任一項之多核苷酸，其中該多核苷酸包含與SEQ ID NO: 391-398中任一者具有至少90%一致性之5' UTR。
- 如請求項1至33中任一項之多核苷酸，其中該多核苷酸含有包含SEQ ID NO: 391-398中任一者之5' UTR。
- 如請求項1至34中任一項之多核苷酸，其中該多核苷酸包含與SEQ ID NO: 399-406中任一者具有至少90%一致性之3' UTR。
- 如請求項1至35中任一項之多核苷酸，其中該多核苷酸含有包含SEQ ID NO: 399-306中任一者之3' UTR。
- 如請求項1至36中任一項之多核苷酸，其中該多核苷酸包含來自相同來源之5' UTR及3' UTR。
- 如請求項1至37中任一項之多核苷酸，其中多核苷酸包含5'帽，視情況其中該5'帽為Cap0、Cap1或Cap2。
- 如請求項1至38中任一項之多核苷酸，其中該ORF之至少75%、80%、85%、90%、95%、98%、99%或100%的密碼子為最小腺嘌呤密碼子或最小尿苷密碼子。
- 如請求項1至39中任一項之多核苷酸，其中該ORF包含增加哺乳動物中mRNA之轉譯的密碼子或由其組成。
- 如請求項1至40中任一項之多核苷酸，其中該ORF包含增加人類中mRNA之轉譯的密碼子或由其組成。
- 如請求項1至41中任一項之多核苷酸，其中該多核苷酸為mRNA。
- 如請求項42之多核苷酸，其中該ORF包含與SEQ ID NO: 29、32-41、224-226、231-233、238-240、245-247、252-254、259-261、266-268、273-275、280-282、287-289、294-296、301-303或316-321中任一者具有至少90%、95%、98%或100%一致性之序列。
- 如請求項42至43中任一項之多核苷酸，其中該mRNA中至少10%之尿苷由經修飾之尿苷取代。
- 如請求項42至43中任一項之多核苷酸，其中該mRNA中小於10%之尿苷由經修飾之尿苷取代。
- 如請求項45之多核苷酸，其中該經修飾之尿苷為N1-甲基-假尿苷、假尿苷、5-甲氧基尿苷或5-碘尿苷中之一或多者。
- 如請求項45之多核苷酸，其中該經修飾之尿苷為N1-甲基-假尿苷或5-甲氧基尿苷中之一或兩者。
- 如請求項45至47中任一項之多核苷酸，其中該經修飾之尿苷為N1-甲基-假尿苷。
- 如請求項45至47中任一項之多核苷酸，其中該經修飾之尿苷為5-甲氧基尿苷。
- 如請求項44及46至49中任一項之多核苷酸，其中15%至45%之尿苷由該經修飾之尿苷取代。
- 如請求項50之多核苷酸，其中至少20%或至少30%之尿苷由該經修飾之尿苷取代。
- 如請求項51之多核苷酸，其中至少80%或至少90%之尿苷由該經修飾之尿苷取代。
- 如請求項52之多核苷酸，其中100%之尿苷由該經修飾之尿苷取代。
- 如請求項42之多核苷酸，其中該mRNA中小於10%之核苷酸由經修飾之核苷酸取代。
- 一種組合物，其包含如請求項1至54中任一項之多核苷酸及至少一種引導RNA (gRNA)。
- 一種組合物，其包含第一多核苷酸，該第一多核苷酸包含編碼包含胞苷脫胺酶、視情況APOBEC3A脫胺酶及NmeCas9切口酶之多肽的第一開放閱讀框架(ORF)，及第二多核苷酸，該第二多核苷酸包含編碼尿嘧啶醣苷酶抑制劑(UGI)之第二開放閱讀框架，其中該第二多核苷酸不同於該第一多核苷酸，且視情況進一步包含引導RNA (gRNA)。
- 如請求項55或56之組合物，其中該gRNA為單引導RNA。
- 如請求項55或56之組合物，其中該gRNA為雙引導RNA。
- 一種組合物，其包含如請求項1至57中任一項之多核苷酸，進一步包含單引導RNA，其中該單引導RNA包含引導區及保守區，其中該保守區包含以下一或多者： (a)經縮短之重複/反重複(anti-repeat)區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸37-48及53-64中之一或多者缺失，且視情況核苷酸37-64中之一或多者經取代；及 (ii)核苷酸36藉由至少2個核苷酸連接至核苷酸65；或 (b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸82-86及91-95中之一或多者缺失，且視情況位置82-96中之一或多者經取代；且 (ii)核苷酸81藉由至少4個核苷酸連接至核苷酸96；或 (c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸113-121及126-134中之一或多者缺失，且視情況核苷酸113-134中之一或多者經取代；且 (ii)核苷酸112藉由至少4個核苷酸連接至核苷酸135； 其中相對於SEQ ID NO: 500，核苷酸144-145中之一或兩者視情況缺失； 其中至少10個核苷酸為經修飾之核苷酸。
- 一種組合物，其包含如請求項1至57中任一項之多核苷酸，進一步包含單引導RNA，其中該單引導RNA包含引導區及保守區，其中該保守區包含以下一或多者： (a)經縮短之重複/反重複區，其中該經縮短之重複/反重複區缺少2-24個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸37-64中之一或多者缺失且視情況經取代；且 (ii)核苷酸36連接至核苷酸65藉由：(i)第一內部連接子，其單獨或與核苷酸組合取代4個核苷酸，或(ii)至少4個核苷酸；或 (b)經縮短之髮夾1區，其中該經縮短之髮夾1缺少2-10個、視情況2-8個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸82-95中之一或多者缺失且視情況經取代；且 (ii)核苷酸81連接至核苷酸96藉由：(i)第二內部連接子，其單獨或與核苷酸組合取代4個核苷酸，或(ii)至少4個核苷酸；或 (c)經縮短之髮夾2區，其中該經縮短之髮夾2缺少2-18個、視情況2-16個核苷酸，其中 (i)相對於SEQ ID NO: 500，核苷酸113-134中之一或多者缺失且視情況經取代；且 (ii)核苷酸112連接至核苷酸135藉由：(i)第三內部連接子，其單獨或與核苷酸組合取代4個核苷酸，或(ii)至少4個核苷酸； 其中相比於SEQ ID NO: 500，核苷酸144-145中之一者或兩者視情況缺失； 其中該gRNA包含該第一內部連接子、該第二內部連接子及該第三內部連接子中之至少一者。
- 一種多肽，其由如請求項1至60中任一項之多核苷酸編碼。
- 一種載體，其包含如請求項1至60中任一項之多核苷酸。
- 一種表現構築體，其包含啟動子可操作地連接於編碼如請求項1至60中任一項之多核苷酸之序列。
- 如請求項63之表現構築體，其中該啟動子為RNA聚合酶啟動子，視情況為細菌RNA聚合酶啟動子。
- 如請求項63或64之表現構築體，其進一步包含poly-A尾序列或聚腺苷酸化信號序列。
- 如請求項65之表現構築體，其中該poly-A尾序列為編碼poly-A尾序列。
- 一種質體，其包含如請求項63至66中任一項之表現構築體。
- 一種宿主細胞，其包含如請求項62之載體、如請求項63至66中任一項之表現構築體或如請求項67之質體。
- 一種醫藥組合物，其包含如請求項1至61中任一項之多核苷酸、組合物或多肽及醫藥學上可接受之載劑。
- 一種套組，其包含如請求項1至61中任一項之多核苷酸、組合物或多肽。
- 一種如請求項1至61中任一項之多核苷酸、組合物或多肽之用途，其用於修飾細胞中之目標基因。
- 一種如請求項1至61中任一項之多核苷酸、組合物或多肽之用途，其用於製造修飾細胞中之目標基因之藥劑。
- 如請求項1至60中任一項之多核苷酸或組合物，其中該多核苷酸或組合物調配為脂質核酸組裝組合物，視情況脂質奈米粒子。
- 一種修飾目標基因之方法，其包含向細胞遞送如請求項1至61中任一項之多核苷酸、多肽或組合物。
- 一種修飾目標基因之方法，其包含向細胞遞送一或多種包含如請求項1至60項中任一項之多核苷酸及一或多種引導RNA之脂質核酸組裝組合物，視情況脂質奈米粒子。
- 如請求項74至75中任一項之方法，其中至少一種脂質核酸組裝組合物包含脂質奈米粒子(LNP)，視情況其中所有脂質核酸組裝組合物包含LNP。
- 如請求項74至75中任一項之方法，其中至少一種脂質核酸組裝組合物為脂複合體(lipoplex)組合物。
- 如請求項75至77中任一項之組合物或方法，其中該脂質核酸組裝組合物包含可離子化脂質。
- 一種產生如請求項1至54中任一項之多核苷酸之方法，其包含使如請求項63至66之表現構築體與RNA聚合酶及包含至少一個經修飾之核苷酸的NTP接觸。
- 如請求項79之方法，其中NTP包含一個經修飾之核苷酸。
- 如請求項79或80之方法，其中該經修飾之核苷酸包含經修飾之尿苷。
- 如請求項81之方法，其中至少80%或至少90%或100%之尿苷位置為經修飾之尿苷。
- 如請求項81或82之方法，其中該經修飾之尿苷包含或為經取代之尿苷、假尿苷，或經取代之假尿苷，視情況N1-甲基-假尿苷。
- 如請求項79至83中任一項之方法，其中該表現構築體包含編碼之poly-A尾序列。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275425P | 2021-11-03 | 2021-11-03 | |
| US63/275,425 | 2021-11-03 | ||
| US202263352158P | 2022-06-14 | 2022-06-14 | |
| US63/352,158 | 2022-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202325848A true TW202325848A (zh) | 2023-07-01 |
Family
ID=84537879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111141875A TW202325848A (zh) | 2021-11-03 | 2022-11-02 | 用於基因體編輯之多核苷酸、組合物及方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240301377A1 (zh) |
| EP (1) | EP4426822A2 (zh) |
| KR (1) | KR20240114296A (zh) |
| AU (1) | AU2022382975A1 (zh) |
| CA (1) | CA3237303A1 (zh) |
| CO (1) | CO2024007019A2 (zh) |
| IL (1) | IL312508A (zh) |
| MX (1) | MX2024005242A (zh) |
| TW (1) | TW202325848A (zh) |
| WO (1) | WO2023081689A2 (zh) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| AU669353B2 (en) | 1991-12-24 | 1996-06-06 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| MY170059A (en) | 2012-12-17 | 2019-07-02 | Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| KR102271292B1 (ko) | 2013-03-15 | 2021-07-02 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도 |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| WO2015095340A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| HUE055458T2 (hu) | 2015-09-21 | 2021-11-29 | Trilink Biotechnologies Llc | Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére |
| WO2017173054A1 (en) | 2016-03-30 | 2017-10-05 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
| WO2018067447A1 (en) | 2016-10-03 | 2018-04-12 | Itellia Therapeutics, Inc. | Improved methods for identifying double strand break sites |
| KR102687373B1 (ko) * | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| MX2020003602A (es) | 2017-09-29 | 2020-09-22 | Intellia Therapeutics Inc | Polinucleotidos, composiciones y metodos para la edicion del genoma. |
| RS65493B1 (sr) | 2017-09-29 | 2024-05-31 | Intellia Therapeutics Inc | Formulacije |
| AU2018364993B2 (en) | 2017-11-10 | 2022-10-06 | University Of Massachusetts | Targeted CRISPR delivery platforms |
| WO2020051562A2 (en) * | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| EA202190916A1 (ru) | 2018-10-02 | 2021-07-09 | Интеллиа Терапьютикс, Инк. | Ионизируемые аминолипиды |
| EA202191033A1 (ru) * | 2018-10-15 | 2021-12-21 | Юниверсити Оф Массачусетс | Программируемое редактирование оснований днк посредством слитых белков nme2cas9-дезаминаза |
| BR112021010853A2 (pt) | 2018-12-05 | 2021-08-31 | Intellia Therapeutics, Inc. | Lipídios de amina modificados |
| KR20220004649A (ko) | 2019-03-28 | 2022-01-11 | 인텔리아 테라퓨틱스, 인크. | 폴리펩티드 발현을 위한 폴리뉴클레오티드, 조성물 및 방법 |
| EP3959191A1 (en) | 2019-04-25 | 2022-03-02 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| CA3143029A1 (en) * | 2019-06-11 | 2020-12-17 | Pairwise Plants Services, Inc. | Methods of producing plants with altered fruit development and plants derived therefrom |
| CN114616002A (zh) * | 2019-09-13 | 2022-06-10 | 瑞泽恩制药公司 | 使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控 |
| TW202237845A (zh) * | 2020-12-11 | 2022-10-01 | 美商英特利亞醫療公司 | 用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法 |
-
2022
- 2022-11-02 TW TW111141875A patent/TW202325848A/zh unknown
- 2022-11-02 MX MX2024005242A patent/MX2024005242A/es unknown
- 2022-11-02 KR KR1020247018182A patent/KR20240114296A/ko unknown
- 2022-11-02 WO PCT/US2022/079124 patent/WO2023081689A2/en active Application Filing
- 2022-11-02 AU AU2022382975A patent/AU2022382975A1/en active Pending
- 2022-11-02 IL IL312508A patent/IL312508A/en unknown
- 2022-11-02 CA CA3237303A patent/CA3237303A1/en active Pending
- 2022-11-02 EP EP22826533.6A patent/EP4426822A2/en active Pending
-
2024
- 2024-05-01 US US18/652,180 patent/US20240301377A1/en active Pending
- 2024-05-31 CO CONC2024/0007019A patent/CO2024007019A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240301377A1 (en) | 2024-09-12 |
| CA3237303A1 (en) | 2023-05-11 |
| IL312508A (en) | 2024-07-01 |
| WO2023081689A3 (en) | 2023-06-08 |
| KR20240114296A (ko) | 2024-07-23 |
| EP4426822A2 (en) | 2024-09-11 |
| MX2024005242A (es) | 2024-07-02 |
| WO2023081689A2 (en) | 2023-05-11 |
| AU2022382975A1 (en) | 2024-05-02 |
| CO2024007019A2 (es) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI839337B (zh) | 用於基因組編輯之多核苷酸、組合物及方法 | |
| TW201924724A (zh) | 調配物 | |
| US20230044994A1 (en) | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | |
| US20240002820A1 (en) | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | |
| TW202102529A (zh) | 用於多肽表現之多核苷酸、組合物及方法 | |
| US20230383253A1 (en) | Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy | |
| US20230374456A1 (en) | T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy | |
| TW202325848A (zh) | 用於基因體編輯之多核苷酸、組合物及方法 | |
| CN118660960A (zh) | 用于基因组编辑的多核苷酸、组合物和方法 | |
| US20240228577A1 (en) | Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy | |
| US20230383252A1 (en) | Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy | |
| WO2024138115A1 (en) | Systems and methods for genomic editing | |
| TW202413631A (zh) | 用於基因體編輯之組成物及方法 | |
| TW202428878A (zh) | 用於基因體編輯之系統及方法 |